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Abstract 
This thesis describes the use of direct imine acylation (DIA) methodology in a range of 
different applications. Firstly, the attempted synthesis of (±)-cytisine is described 
(Chapter 2). The use of DIA methodology in the formation of the pyridone ring 
scaffold of (±)-cytisine has been explored. In the most advanced synthesis towards (±)-
cytisine achieved in this project, the generation of N-acyliminium ions from imine A 
and subsequent nucleophilic addition of organometallic allyl reagents was developed 
to give diene B. 
 
DIA methodology has also been utilised in the synthesis of spirocyclic products from 
simple indole acids C and imines D (Chapter 3). The reaction provides a broad range 
of products E in good yields and the indole acid starting materials C are readily 
synthesised using Fischer indole methodology. The stereoselectivity of the reaction, 
derivatisation of the products E and 3D shape analysis are also described.  
 
Finally, work towards the synthesis of (±)-aspidospermidine, using the spirocyclisation 
methodology developed in this project, is introduced (Chapter 4). Two strategies are 
proposed utilising an intramolecular Heck reaction or a ring-closing metathesis to 
complete the polycyclic scaffold. A key DIA reaction between the synthesised acid F 
and imine G is reported and shows formation of the spirocyclic scaffold H.  
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1. Introduction 
1.1. Introduction to N-Acyliminium Ions 
1.1.1. Structure and Reactivity of N-Acyliminium Ions 
Iminium ions 1 and N-acyliminium ions 2 are important, reactive species in organic 
synthesis (Figure 1.1). They are very useful in the construction of carbon-carbon and 
carbon-heteroatom bonds.1 N-acyliminium ions are particularly important due to their 
increased reactivity compared to iminium ions. The carbonyl group on the nitrogen is 
electron-withdrawing both inductively and mesomerically so that the iminium carbon 
atom is more electron deficient with more cationic character.1   
 
Figure 1.1 – Structure of iminium ion 1 and N-acyliminium ion 2 
Nucleophiles that are relatively unreactive towards N-alkyliminium ions can be 
effectively used in the reaction with N-acyliminium ions.1 This was exhibited in 
Belleau’s early synthesis of the tetrahydroisoquinoline scaffolds of the erythrina 
alkaloids.2,3 The poor reactivity of the iminium ion intermediates, used in the Pictet-
Spengler approach to tetrahydroisoquinolines, was demonstrated by the failure of 
iminium ion 3 to cyclise to 4 under various conditions (Scheme 1.1).3 Successful 
cyclisation of N-acyliminium ion 6 (prepared from 5) to give the product 7 (Scheme 1.2) 
confirmed the expectation that the acyl component would increase electrophilic 
reactivity.1,3  
 
Scheme 1.1 – Unsuccessful nucleophilic addition onto iminium ion 33 
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Scheme 1.2 – Successful cyclisation onto N-acyliminium ion 63 
The mechanistic scheme for the majority of amidoalkylation reactions is shown in 
Scheme 1.3. It has been observed that the intermediate N-acyliminium ion 9 is not 
generated stoichiometrically throughout the course of a reaction, as it can exist in 
equilibrium with a covalent adduct 8 (Scheme 1.3).1 An irreversible nucleophilic 
reaction into the iminium carbon gives product 10. In the synthesis of β-lactams, tertiary 
imines can be treated with acid chlorides to generate intermediate N-acyliminium 
species 9 with the ionic structure shown in Scheme 1.3 (where X = Cl). However, NMR 
spectroscopic studies have shown that the adducts of the reaction exist mainly as the α-
chloroamides 8 (where X = Cl).4 α-Alkoxycarbamates 8 (where X = OR) are a common 
precursor to N-acyliminium ions and have been shown to generate intermediate 9 on 
treatment with a Lewis acid. Yamamoto et al. have reported the existence of this type of 
equilibrium in solution and shown that the proportion of the ionic form 9 and covalent 
form 8 varies depending on the Lewis acid used.5 
 
Scheme 1.3 – Mechanism for amidoalkylation reactions 
The mechanistic pathway of a reaction involving an N-acyliminium ion will always go 
through a planar intermediate and therefore direct control of the stereochemistry is not 
possible. For example, the optically pure compound (+)-11 (configuration unknown) 
formed racemic products when reacted with various nucleophiles (e.g. 
allyltrimethylsilane and furan) in the presence of a Lewis acid (Figure 1.2).6 However, 
stereoselectivity can be induced in these reactions through the use of chiral auxiliaries,7 
or chiral acid catalysts as demonstrated by Muratore et al.8 
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Figure 1.2 – Enantioenriched precursor of N-acyliminium ion 
 
1.1.2. Synthesis of N-Acyliminium Ions 
N-acyliminium ions can be generated in many different ways but owing to their 
reactivity they are almost always generated in situ.1 The most common synthetic 
approaches to generate N-acyliminiums are shown in Scheme 1.4. These methods 
include: (i) acylation of imines, (ii) N-protonation of N-acylimines, (iii) electrophilic 
addition to enamides, (iv) oxidation of amides, and (v) heterolysis of amides bearing a 
leaving group ‘X’ on the carbon α to nitrogen.5,9 These methods have been well 
documented but selected methods will be briefly discussed here.9 
 
Scheme 1.4 – Methods for the synthesis of N-acyliminium ions 
The preparation of N-acyliminium ions by the reaction of acid chlorides and imines 
(Scheme 1.4, (i)) was first reported in 1914 by James and Judd.10 This methodology has 
since been used in a number of applications, such as the synthesis of β-lactams.4 N-
acyliminium ions can also be generated by the acylation of an imine with an anhydride. 
Castagnoli et al. demonstrated that use of a cyclic anhydride can enable subsequent 
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 4 
intramolecular nucleophilic trapping (Scheme 1.5).11 Refluxing 
benzylidenemethylamine 12 and succinic anhydride 13 in benzene afforded an 82% 
yield of the stable pyrrolidone 14 via the two N-acyliminium ions 15 and 16 shown in 
Scheme 1.5. This methodology was then extended by other groups to include more 
complex imine and anhydride examples.12 
 
Scheme 1.5 – Synthesis of lactam 14 via intramolecular trapping11 
Electrophilic addition to enamides can also be used to access N-acyliminium ions 
(Scheme 1.4, (iii)). Enamides are easily accessible through the acylation of an imine 
with an acid chloride or anhydride, followed by elimination of HX. They are stable 
under neutral and basic conditions but under acidic conditions enamides 17 will be 
protonated or alkylated at the β-carbon to the nitrogen and form an N-acyliminium ion 
18  (Scheme 1.6). These intermediates can be trapped with a nucleophile to form 
product 19.9 Generation of an N-acyliminium ion in this way has been exploited in the 
synthesis of the natural product nakadomarin A.13 
 
Scheme 1.6 – Generation of N-acyliminium ions via enamides13 
Of all the methods to generate N-acyliminium ions, the most frequently used is the 
heterolysis of α-substituted amides (Scheme 1.4, (v)). Most of the examples contain an 
oxygen substituent as the ‘X’ group, although nitrogen, sulfur and phosphorus can also 
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 5 
be used.9 Where X = OR, Brönstead or Lewis acids are used to generate the N-
acyliminium ion. If R is alkyl or hydrogen then an acid is required but when R is acetyl 
or methanesulfonyl heat is sufficient for the elimination (Scheme 1.7).9 
 
Scheme 1.7 – Generation of N-acyliminium ions via α-substituted amides 
There are numerous ways to synthesise the precursor 20 that upon heterolysis will 
generate the N-acyliminium ion 21 in situ. Addition of oxygen nucleophiles to N-
acyliminium ions, reaction of amides with aldehydes or ketones and addition of 
nucleophiles (e.g. organolithium and Grignard reagents) to cyclic imides have all been 
extensively documented as a route to N-acyliminium ion precursors.1,9,14 The selective 
reduction of one carbonyl on a cyclic imide could be considered as the most successful 
and versatile technique.1 This strategy has been demonstrated by Marson et al. in the 
enantioselective synthesis of a polycyclic 5,7,6-fused ring system 24 present in a 
number of biologically important compounds including the cephalotaxus alkaloids that 
exhibit anti-leukaemic activity.15 Partial reduction of the cyclic imide 22 with NaBH4 
afforded the hemiaminal 23 (Scheme 1.8). Generation of the N-acyliminium ion was 
accomplished by reaction with triflic acid and cyclisation provided the tricyclic lactams 
as a mixture of diastereoisomers and regioisomers with the major isomer 24 isolated in 
55% yield (Scheme 1.8). 
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Scheme 1.8 – Reduction of a cyclic imide and intramolecular cyclisation15 
 
An alternative method for the synthesis of precursor 21 for use in the generation of an 
N-acyliminium ion is the α-oxidation of amides (Scheme 1.4, (iv)). Shono et al. 
demonstrated the first direct electrochemical oxidation of the α-methylene group of an 
amide.16-18 The reaction proceeds via an aniodic oxidation and methoxylation step to 
give the precursor 25 (Scheme 1.9).17 This key aniodic oxidation step is operationally 
simple and requires a standard electrochemical reaction set up.16,19 Subsequent Lewis 
acid-catalysed heterolysis generated the N-acyliminium ion 26 in situ and trapping with 
a silyl enol ether gave the product 27 in 74% yield (Scheme 1.9).18 
 
Scheme 1.9 – Generation of an N-acyliminium 26 via electrochemical oxidation17 
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1.1.3. Direct Imine Acylation 
Direct Imine Acylation (DIA) is methodology developed by the Taylor group that has 
been shown to be useful in a number of interesting and novel cyclisation reactions.20-22 
The concept is built upon the direct acylation of imines using carboxylic acids rather 
than their activated derivatives.21 Direct acylation onto imine structures using acid 
chlorides and anhydrides have previously been discussed and are well known methods 
to generate N-acyliminium ions, but acylation using carboxylic acids is much less 
common. The advantage of this method is that it allows the inclusion of an internal 
nucleophile, which would otherwise be incompatible with the activated carboxylic acid 
derivative, allowing subsequent trapping of the N-acyliminium ion intermediate to 
provide cyclised heterocyclic products.  
 
Scheme 1.10 shows the general conditions used the originally developed DIA reactions 
in the Taylor group. An imine 28 is directly acylated by a carboxylic acid 29, containing 
an internal nucleophile, in the presence of a coupling agent and a base (DIPEA). This 
generates the N-acyliminium ion 30 that can undergo in situ cyclisation with the built-in 
nucleophile to give heterocycle 31. Acid-promoted cyclisation or protecting group 
cleavage is sometimes required. 
 
Scheme 1.10 – General scheme for a DIA reaction 
The mechanistic pathway for the formation of the N-acyliminium ion under DIA 
conditions is shown in Scheme 1.11. The reaction begins by activation of the 
carboxylate 32 with T3P to give coupling reagent 33. On coupling with imine 28, the 
T3P byproduct is released and has the advantage of being easily removed by aqueous 
extraction during the work-up. The N-acyliminium ion 34 formed undergoes cyclisation 
with the internal nucleophile to provide the cyclised product 35. In theory, an alternative 
route where the nucleophile attacks the imine first and then intramolecular acylation 
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 8 
occurs would give the same product. Therefore, a mechanistic study using in situ 
ReactIR was carried out in the Taylor group to probe the reaction mechanism in detail 
and to confirm the mechanism.21,23 The results confirmed that the N-acyliminium ion 34 
is formed first. As expected, the N-acyliminium ion 34 was found to be short-lived and 
instead an alternative intermediate was observed. It was believed that this second 
intermediate was an ammonium salt 36, formed from trapping with the excess DIPEA in 
the reaction mixture. However, this reaction would be reversible and it was observed 
that the N-acyliminium ion 34 was regenerated by elimination of the amine and 
intramolecular trapping of the nucleophile formed the product 35 (Scheme 1.11).21,23 
 
Scheme 1.11 – Mechanism for a DIA reaction 
The initial publication from the Taylor group reporting this methodology showed DIA 
reactions of different functionalised benzoic acids and a variety of imines which 
highlighted the scope and potential of the method.21 For example, the reaction of 
aromatic imine 37 and N-methylanthranilic acid 38 proceeded well under the DIA 
conditions shown to give the cyclised product 39 in 94% yield (Scheme 1.12). The 
methodology was shown to be a robust and useful technique with yields >90% for the 
majority of substrates, and a variety of internal nucleophiles were used.21 A subsequent 
paper showcased the methodology with the synthesis of a natural product, Upenamide, 
where one of the key steps in the route was the efficient use of DIA methodology.22  
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Scheme 1.12 – DIA reaction of N-methylanthranilic acid 38 and imine 3721 
DIA methodology was then shown to be compatible with aliphatic carboxylic acids 
containing oxygen, nitrogen and sulfur nucleophiles.20 A wide range of nucleophiles and 
imine substrates were showcased and demonstrated the wide scope of this methodology. 
Particularly noteworthy reactions in this report involved the use of acids containing 
carbon pro-nucleophiles such as aromatic groups and alkenes which allowed the 
formation of carbon-carbon bonds in the cylisation products.20 An example of this is the 
reaction between aromatic imine 37 and 3-methyl-3-butenoic acid 40 under the 
conditions shown in Scheme 1.13 to provide the cyclised product 41 in 78% yield.  
 
Scheme 1.13 – DIA reaction of 3-methyl-3-butenoic acid 40 and imine 3720 
It was found that the methodology was also suitable for the synthesis of β-lactams, an 
example of which is shown in Scheme 1.14.24 A good range of β-lactams were 
synthesised in high yield from acyclic imines and aryl-substituted acetic acids, with the 
trans isomer being the major product in most cases.24 The lack of an acidic additive is 
important to avoid formation of the Friedel-Crafts type products seen when reacted with 
carbon pro-nucleophiles.23 
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Scheme 1.14 – Synthesis of β-lactams using DIA methodology24 
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1.2. Brief Outline of the Project 
The overall aim of the work described in this thesis was to utilise DIA methodology in a 
range of different applications, and our three main target compounds are shown in 
Figure 1.3. It was hoped that development of a DIA cyclisation reaction would afford 
the pyridone ring scaffold present in the natural product (−)-cytisine (Chapter 2). DIA 
methodology would also be utilised in a novel route to spirocyclic scaffolds (Chapter 3). 
As an extension of this route to spirocycles, the DIA methodology would then be tested 
in an attempted synthesis of the natural product (±)-aspidospermidine (Chapter 4). The 
specific aims of each project will be discussed in more detail in each chapter, each 
accompanied with an associated introductory section. 
 
Figure 1.3 – Structure of target compounds of the projects in this thesis 
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2. Attempted Synthesis of (±)-Cytisine using Direct Imine 
Acylation Methodology 
2.1. Introduction to Cytisine 
2.1.1. Biological Activity and the Use of (−)-Cytisine 
(−)-Cytisine 42 (Figure 2.1) is a naturally occurring lupin alkaloid prevalent in the 
plants and seeds of the Leguminosae family.25 It shows significant biological activity at 
neuronal nicotinic acetylcholine receptors (nAChRs), which are found in the peripheral 
and central nervous systems.26  
 
Figure 2.1 – Structure of (−)-cytisine, (−)-nicotine and Varenicline 
nAChRs are pentameric ligand-gated ion channels that consist of 17 known receptor 
subunits. Of these, the α4β2, α3β4 and α7 are the most important in the central nervous 
system.26 It is known that the α4β2 nAChR subtype receptor plays a major role in 
reinforcing the addictive effects of (−)-nicotine 43 (Figure 2.1), through binding 
activation and the subsequent release of dopamine.27 While (−)-nicotine 43 displays a 
full agonist profile at the α4β2 nAChR subtype receptor,  (−)-cytisine 42 has also been 
shown to have a potent affinity for the receptor and acts as a partial agonist,28 preventing 
(−)-nicotine 43 from binding and providing a reduced dopaminergic response 
comparatively. In this way, (−)-cytisine 42 can be used as a smoking cessation drug. 
This has been confirmed in a placebo controlled trial of (−)-cytisine 42 for smoking 
cessation29 and it is a key ingredient in the smoking cessation drug Tabex® used since 
the 1960s throughout Eastern and Central Europe to treat nicotine addiction.30 However, 
studies have shown that (−)-cytisine 42 has poor efficacy in vivo due to poor absorption 
and poor penetration at the blood brain barrier.26,31,32 Due to the lack of bioavailability 
of (−)-cytisine 42, recent work has revolved around developing analogues of (−)-
cytisine 42 that maintain the significant in vitro activity but improve the in vivo 
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availability. Coe et al. at Pfizer developed Varenicline 44 (Figure 2.1) in 2005 using 
(−)-cytisine 42 as their starting point, which demonstrates the desired dopaminergic 
profile for the α4β2 nAChR receptor with high affinity.26 It has since been approved as a 
smoking cessation drug, with studies highlighting its favourable pharmacokinetic 
profile.33  
 
(−)-Cytisine 42 was first isolated in its pure form in 1862 by Husemann and Marmé.34 It 
is commercially available but expensive. However, the naturally occurring compound 
can be extracted on a multigram scale from Laburnum anagyroides seeds.31 Yields of 
isolation vary, but a reproducible process has been developed by the Rouden group and 
the O’Brien group, which usually provides up to 1.5 g of (−)-cytisine 42 for every 100 g 
of seeds used in the extraction.35,36 This is put into synthetic use by the O’Brien group in 
the synthesis of a (+)-sparteine surrogate 45, an analogue of the naturally occurring 
lupin alkaloid (−)-sparteine 46, which is used as a chiral diamine ligand in the group’s 
lithiation methodology.37 The diamine surrogate 45 can be obtained via a simple, three-
step procedure (Scheme 2.1) in 79% overall yield from the extracted (−)-cytisine 1.37  
 
Scheme 2.1 – Synthesis of the (+)-sparteine surrogate 45 
 
2.1.2. Previous Syntheses of Cytisine 
There have been numerous syntheses of cytisine 42 published.25,31 The first total 
synthesis of (±)-cytisine 42 was completed in 1955 by van Tamelen,38,39 and was 
followed by Bohlmann40 and Govindachari41 in 1956 and 1957 respectively. Following 
the recognition of the significant biological activity of the natural compound other 
syntheses were reported. A summary of the different approaches, with the key 
intermediates highlighted, is shown in Scheme 2.2. Syntheses of (±)-cytisine 42 are 
more common as asymmetric syntheses have proved to be more challenging. 
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Scheme 2.2 – Various approaches to cytisine 42 showing key intermediates 
 
As shown in Scheme 2.2, cytisine 42 contains three connected rings, A, B, and C. The 
first route completed in 1955 by van Tamelen,38,39 approached the synthesis using a 
pyridine-derived A ring and required a late-stage oxidation to obtain the desired 
pyridone ring. O’Neill revisited this approach in 2000,42 a key difference being the 
introduction of the methoxy group on the A ring to remove the need for oxidation. This 
resulted in the shortest and highest yielding route to date (5 steps and 25% overall 
yield). Plaquevent reported a formal synthesis of (±)-cytisine 4243 using O’Neill’s route 
but utilised a Negishi cross-coupling protocol to improve the yield of the key bis-
pyridine intermediate. The combination of O’Neill’s and Plaquevent’s synthetic routes 
provided the most efficient synthesis of (±)-cytisine 42. Coe44 and Gallagher45 used 
glutarimide- or pyridone-derived A rings as the key intermediates in their different 
approaches. Coe’s synthesis was particularly attractive, as it avoided the need for any 
protecting groups.44 Gallagher achieved a synthesis where the pyridone A-ring was 
intact throughout.45 
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One of the more recent syntheses of (±)-cytisine 42, from the O’Brien group in 2005,46 
took a novel approach to the bispidine core structure compared to previous syntheses 
(Scheme 2.3). The B and C rings, i.e. the bispidine core, were initially constructed. 
Starting with a cheap commercially available starting material, N-Boc piperidone 47, a 
double Mannich reaction was performed to give bispidone 48 followed by a Wolff-
Kishner-style reduction providing protected bispidine 49 in 46% yield over the two 
steps. The pyridone A ring was then constructed, starting with allylation of the bispidine 
by lithiation and subsequent trapping to give substituted bispidine 50. Highly efficient 
deprotection and acylation followed to give diene 51, which underwent Grubbs ring-
closing metathesis to give the dihydropyridone 52. A simultaneous deprotection and 
aromatisation gave the desired product and this led to one of the most efficient syntheses 
of (±)-cytisine 42 to date, with 19% overall yield achieved in six steps.  
 
Scheme 2.3 – Synthesis of (±)-cytisine by initial construction of the B and C rings46 
There have been relatively few asymmetric syntheses of cytisine 42. The first 
asymmetric synthesis of (+)-cytisine 42 was accomplished by Honda in 2004, using an 
enantioenriched starting material and maintaining it through to the final product.47 
Gallagher developed a second-generation synthesis in 2006,48 which utilised previous 
methodology of an intramolecular 1,6-addition of a lactam enolate to a pendant 2-
pyridone, and incorporated enzymatic resolution of an early-stage intermediate to induce 
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enantioselectivity. This resulted in an 11-step synthesis of (+)-cytisine 42 in 4% overall 
yield.  
 
The first total synthesis of (−)-cytisine 42 was completed in 2004 by Lesma49 and the 
retrosynthetic analysis is shown in Scheme 1.4. The approach relies on efficient 
enzymatic acetylation of diol cis-53 using Pseudomonas fluorescens lipase (PFL) to 
piperidine 3,5-dimethanol monoacetate cis-54, which proceeds in 78% yield with >98% 
ee.31 Following this, six steps were needed to access diene 55 and Grubbs ring-closing 
metathesis produced dihydropyridone 56. The bispidine core 57 was then synthesised by 
acetate hydrolysis, mesylate activation and cyclisation using NaH. Aromatisation was 
achieved using DDQ, and deprotection gave the desired product (−)-cytisine 42 in 13 
steps and 7% overall yield.  
 
Scheme 2.4 – Retrosynthetic analysis of (−)-cytisine49 
More recently, Hirschhäuser and Struth published an approach to (−)-cytisine 42 
utilising methodology developed by Gallagher et al. in 2011.50,51 The route focused on 
accessing the enantiomerically pure benzyl ether 63 and then utilised Gallagher’s high 
yielding final steps to generate (−)-cytisine 42. The chiral allylboronate 58 was accessed 
in 5 steps from a pinacol boronate and (−)-pinanediol. Alcohol 59 was obtained via 
reaction of the allylboronate 58 with a carbenoid and subsequent oxidation. 
Optimisation of this reaction to avoid the formation of stable borate ester side-products 
gave the desired product 59 in 81% yield. Conversion to the benzyl protected amine and 
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subsequent N-acylation gave diene 60 (73% yield), which was subjected to Grubbs’ 2nd 
generation catalyst to effect ring-closing metathesis and give lactam 61 in 74% yield. α-
Bromination and subsequent Stille coupling gave precursor 62, which was converted 
into (−)-cytisine 42 using Gallagher’s established route (Scheme 2.5).  
 
Scheme 2.5 – Synthesis of (−)-cytisine via pyridine-derived C ring51 
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2.2. Project Outline 
The aim of this part of the project was to utilise Taylor’s direct imine acylation (DIA) 
methodology to develop a new synthesis of (±)-cytisine 42 that may also have potential 
for further modification to an asymmetric synthesis. The proposed route is shown in 
Scheme 2.6. The conversion of N-Boc piperidone 47 into bispidine 49 is known.46 
Following deprotection to mono-protected bispidine 63, N-bromination and elimination 
should give bispidine imine 64. The key novel step in the synthesis will utilise Taylor 
group DIA methodology20,21 on imine 64; this requires the development of 
unprecedented chemistry in this area, using an acid 65 containing a ‘X’ group that is 
electron-withdrawing or stabilising to the charge developed through the reaction. The 
DIA reaction of imine 64 with acid 65 should give 66. Subsequent elimination of the 
‘X’ group in 66 is required to form the pyridone ring observed in the desired scaffold. 
Following this, deprotection of the Boc protecting group would give (±)-cytisine 42.  
 
Scheme 2.6 – Proposed route towards (±)-cytisine 
In this chapter, our efforts to implement the synthetic strategy shown in Scheme 2.6 (or 
variants thereof) are described.  
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2.3. Results and Discussion 
2.3.1. Direct Imine Acylation followed by Intramolecular 
Nucleophilic Addition of an Internal Carbon Nucleophile  
The first priority was to develop an efficient annelation procedure for the synthesis of 
the pyridone scaffold present in (±)-cytisine 42 using DIA methodology. Previous 
examples of carbon nucleophiles in DIA methodology have involved a benzoic acid 
moiety, such as the reaction between benzoic acid 67 and imine 37 to give the cyclised 
product 68 in 69% yield (Scheme 2.7).20,21 Aliphatic examples have also been 
demonstrated but the use of a Lewis acid was required to promote the cyclisation. 
Reaction of imine 37 and acid 69 in the presence of AlCl3 gave lactam 70 in 76% yield 
(Scheme 2.7).20 Investigations within the Taylor group showed that if only one ester 
group was present the reaction did not proceed. 
 
Scheme 2.7 – Examples of DIA reactions that form a carbon-carbon bond20,21 
The original proposed route involved the use of a carboxylic acid 65 containing a 
stabilising ‘X’ group that could be eliminated in a subsequent step to give (±)-cytisine 
42 (Scheme 2.8). Potential groups that could act as a stabilising group, but also allow for 
elimination to the pyridone, include a sulfone, halogen or ester.  
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Scheme 2.8 – Key step in the proposed route to cytisine 
The proposed mechanism for the DIA reaction can explain the required stabilising 
property of the ‘X’ group (Scheme 2.9). After formation of the N-acyliminium ion 71, 
the most acidic position α to the stabilising ‘X’ group would be deprotonated to give 
intermediate enolate 72. Rotation of the enolate 72 about the single bond provides the 
reactive cyclisation conformer 73. The mechanism therefore suggests that the cis- or 
trans-alkene of the acid would work, as during the reaction the more reactive conformer 
can be accessed. Cyclisation of enolate 73 would then occur to provide the targeted ring 
system 74 (Scheme 2.9). The suggested formation of enolate 72 could mean that the 
cyclisation does not require the presence of a Lewis acid, which has been shown to be 
necessary in other DIA reactions containing an aliphatic carbon nucleophile. 
 
Scheme 2.9 – Proposed mechanism for the DIA cyclisation reaction 
In order to investigate DIA methodology, an aromatic imine 37 was selected for our 
initial studies as this is a known stable imine, providing ease of handling, and had been 
successful in precedented DIA methodology.21 In addition, this imine is unable to 
tautomerise to the enamine, which is known to improve the yield of DIA reactions.23 
Treatment of amine 75 with NBS and then base-mediated elimination gave imine 37 in 
86% yield following a literature procedure (Scheme 2.10).52 
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Scheme 2.10 – Synthesis of aromatic imine 37 
This imine was used in the following reactions as a model substrate. The plan was that 
once a successful annelation procedure was developed, the bispidine imine substrate 
could be synthesised and the reaction tested to generate the desired scaffold in cytisine 
42.  
 
Bromine was first considered as a suitable ‘X’ group as it could stabilise the charge 
formed throughout the reaction and could be eliminated as HBr in the final step. Thus, 
4-bromocrotonic acid 77 was synthesised in 66% yield via bis(tributyltin)oxide 
demethylation of the methyl ester 76 (Scheme 2.11).53 However, reaction of the 4-
bromocrotonic acid 77 with the aromatic imine 37 under non-acidic DIA conditions 
(refluxed in toluene with T3P and DIPEA) was unsuccessful and no product was 
isolated.  
 
Scheme 2.11 – Synthesis and reaction of 4-bromocrotonic acid 77  
Next, it was considered that a sulfone group may be suitable as both an anion stabilising 
group and a leaving group. Therefore, the sulfonyl acid 79 was synthesised using a 
literature procedure.54 (Allylsufonyl)benzene 78 was treated with n-BuLi and trapped 
with CO2 to give a 12% yield of 4-phenylsulfonylcrotonic acid 79 (Scheme 2.12). The 
(E)-alkene in 79 was confirmed using the 3J-value (15.5 Hz). 
 
Scheme 2.12 – Synthesis of sulfonyl acid 79 via lithiation of allyl phenyl sulfone 78 
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Initial studies on 4-phenylsulfonylcrotonic acid 79 under standard DIA conditions with 
imine 37 in toluene at 90 °C (T3P, DIPEA) were unsuccessful (Table 2.1, Entry 1). 
Instead of the desired cyclised product 80, an interesting complex heterocyclic scaffold 
82 was observed (31% yield) where a second molecule of imine has quenched the initial 
N-acyliminium ion followed by cyclisation from the internal nucleophile (full 
mechanism is discussed later). Other conditions were investigated in an attempt to form 
the desired product 80 (Table 2.1). Under DIA conditions at 70 °C with AlCl3, the 
undesired product 82 was formed (Entry 2). A single diastereoisomer of product 82 with 
undefined relative stereochemistry was isolated following column chromatography. 
Other possible diastereoisomers were observed by 1H NMR spectroscopy of the crude 
product but these were not isolated cleanly by column chromatography. A reaction was 
performed at rt with no Lewis acid to determine whether the suggested enolate pathway, 
shown in Scheme 2.9, would proceed. It was also suggested that if the N-acyliminium 
ion formed, but no cyclisation occurred, an aldehyde 81 would be observed following 
hydrolysis in the aqueous work-up (Entry 3). However, observation of 82 in the 1H 
NMR spectrum of the crude product suggested that this product forms very readily, with 
no activation from temperature or Lewis acid being required. As a result, this substrate 
was not taken any further.  
 
a) Analysis of the 1H NMR spectrum of the unpurified reaction mixture showed 
formation of 82 as the major product. 
Table 2.1 – DIA reaction of imine 37 and acid 79 
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Entry Solvent Lewis acid Temp 80 (%) 81 (%) 82 (%) 
1 Toluene - 90 °C - - 31 
2 CHCl3 AlCl3 70 °C - - 29 
3 CH2Cl2 - rt - - -a 
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The proposed mechanism for the formation of the actual observed product 82 is shown 
in Scheme 2.13. It was believed that the desired N-acyliminium ion 83 did indeed form. 
However, rather than being deprotonated and cyclising (see Scheme 2.9), a second 
imine 37 added to give a different N-acyliminium ion intermediate 84. Deprotonation of 
the allyl sulfone either at this point, or before addition of the second imine, would give 
enolate 85. Next, addition to the N-acyliminium ion can occur through the carbon α to 
the carbonyl in order to form a six-membered ring and give product 86. Finally, 
formation of product 82 is suggested to be as a result of tautomerisation of the vinylic 
sulfone to be in conjugation with the carbonyl bond of the central ring system (Scheme 
2.13). 
 
Scheme 2.13 – Proposed mechanism for the formation of 82 
On inspection of the 1H NMR and related 2D spectra of the product formed from the 
mechanism shown in Scheme 2.13, it was confirmed that the isolated product was not 
86. It became clear that the sulfone substituent was allylic and the structure of the 
product was 82. Key signals in the 1H NMR spectrum of 82 that suggested the allylic 
product structure were the two singlet peaks at 5.92 and 4.95 ppm for the NCHN proton 
and NCHC=C, rather than the expected single singlet that would be present in product 
86. Two signals at 5.02 and 4.57 ppm were more downfield than usually observed in 
this type of compound (for the NCH2 peaks) and correlated to the CH2 protons situated 
between the alkene and sulfone. This was confirmed by the 13C/DEPT spectrum that 
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revealed five CH2 peaks (four CH2 peaks in 86). These protons also showed a strong 
correlation by COSY NMR, providing sufficient evidence for the allylic sulfone 
tautomer 82 rather than the vinylic sulfone tautomer 86.  
 
Another approach was investigated, utilising an alkene as the nucleophile for attack onto 
the N-acyliminium ion intermediate. It had been shown in the Taylor group that reaction 
of 3-methyl-3-butenoic acid 40 and aromatic imine 37 under DIA conditions afforded 
the cyclised product 41 in 78% yield.20 The reaction was repeated in our hands and 
confirmed that the cyclised product 41 could be formed and isolated in 50% yield 
(Scheme 2.14).  
 
Scheme 2.14 – DIA reaction to give dihydropyridone 41 
The suggested mechanism for this reaction is shown in Scheme 2.15. After formation of 
the N-acyliminium ion 87, nucleophilic attack from the alkene would form the cyclised 
carbocation intermediate 88. Deprotonation would give the cyclised product 89. The 
presence of the methyl group in this reaction is the key to its success as it stabilises the 
carbocation formed via inductive effects. For example, reaction of 3-butenoic acid 
(which lacks the methyl group) did not give any cyclised product. 
 
Scheme 2.15 – Mechanism for the cyclisation of N-acyliminium ion 87  
An alternative mechanistic pathway can be envisaged for the cyclisation of N-
acyliminium ion 87 involving an enolate intermediate (Scheme 2.16). This reaction 
pathway suggests that a Lewis acid is not needed for cylisation, but previous 
investigations within the Taylor group have confirmed that a Lewis acid is necessary for 
this substrate. In addition, if this reaction pathway was correct, the DIA reaction of 3-
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butenoic acid (lacking the methyl group) may have been successful but no product was 
observed. 
 
Scheme 2.16 – Alternative mechanism for cyclisation of N-acyliminium 87 
Knowing that the cyclisation reaction of the alkene required functionality that could 
stabilise the carbocation formed in the reaction pathway, two iodo-substituted alkenes 
90 and 91 were devised (Figure 2.2).  
 
Figure 2.2 – Structure of iodo-substituted alkene substrates 90 and 91 
It was thought that inclusion of an iodine substituent could provide suitable stabilisation 
for the generated carbocation via an iodonium ion 92, and access to the cyclised product 
93 (Scheme 2.17). Furthermore, subsequent elimination of HI would provide access to 
the pyridone ring scaffold and result in product 194. The reaction of acid 90 would first 
be attempted to ensure that the presence of the iodine did not affect the cyclisation, then 
acid 91 would determine whether iodonium formation provided sufficient stabilisation 
for the carbocation intermediate. 
 
Scheme 2.17 – Stabilisation of carbocation intermediate by an iodonium ion  
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Acid 90 was synthesised using Negishi’s Zr-catalysed carboalumination of 3-butyn-1-ol 
95 to give alkene 96,55,56 followed by subsequent Jones oxidation (Scheme 2.18). The 
carboalumination reaction occurs by syn-addition of the C-Al species across the terminal 
alkyne, with the aluminium adding at the least sterically hindered end. Subsequent 
reaction with an electrophile, e.g. I2, into the alkenylaluminium bond proceeds with 
retention of configuration and results in formation of the (E)-alkene product.57 
 
Scheme 2.18 – Synthesis of iodo-substituted alkene acid 90 
Subjecting acid 90 to the previously successful DIA conditions used for alkene addition, 
involving heating to 45 °C and addition of TFA, resulted in only an 11% yield of 97 
after column chromatography (Scheme 2.22). A second compound was isolated but 
analysis of the 1H NMR spectrum did not conclusively determine the structure. Mass 
spectrometry suggested that this was the pyridone 98, formed by elimination of HI, 
although this result is not conclusive as this could be as a result of elimination within the 
mass spectrometer.   
 
Scheme 2.19 – DIA reaction of imine 37 and iodo acid 90 
Despite only obtaining a poor yield of the cyclised product 97 using acid 90, (E)-4-
iodobut-3-enoic acid 91 was synthesised as the ideal annelation procedure would 
provide an unsubstituted pyridone ring scaffold. Synthesis of the iodo-substituted alkene 
91 could be achieved using hydrozirconation chemistry originally developed by 
Schwartz in 1976.58 Schwartz reagent, HZrCp2Cl, is commercially available but has a 
short shelf-life and is expensive but can be generated in situ by treatment of ZrCp2Cl2 
with a source of hydride. In order to synthesise (E)-4-iodobut-3-enoic acid 91, 3-butyn-
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1-ol 95 was initially protected to avoid deprotonation of the alcohol (Scheme 2.20).59 
Use of Lipshutz’s mild in situ generation of HZrCp2Cl, hydrozirconation and 
subsequent addition of iodine resulted in the formation of iodo-substituted alkene 100.60 
Subsequent deprotection of the TBDMS group to the alcohol 101, followed by Jones 
oxidation afforded the desired acid 91 in 22% yield over the four steps (Scheme 2.20).  
 
Scheme 2.20 – Synthesis of iodo-substituted alkene acid 91 
In a potentially shorter route, hydrozirconation was also carried out on the unprotected 
alcohol 95 (Scheme 2.21). Pretreating the alcohol with an equivalent of LiEt3BH was 
necessary for the reaction to proceed. Analysis of the 1H NMR spectrum of the 
unpurified reaction mixture showed a more complex mixture of products compared with 
reaction on the TBDMS protected alcohol, presumably because of the deprotonated 
hydroxyl group initiating unwanted side reactions. This made purification more difficult 
and the desired alkene product 101 was isolated in 36% yield. Subsequent Jones 
oxidation provided the acid 91 in 26% overall yield (Scheme 2.21).  
 
Scheme 2.21 – Synthesis of iodo alkene acid 91 without alcohol protection  
On reacting the iodo-alkenyl acid 91 under DIA conditions with imine 37 (Scheme 
2.22), none of the desired cyclised product 102 or cyclised/eliminated product 103 was 
observed. Instead, a small amount of the fused pentacyclic product 104 was isolated. A 
single diastereoisomer of 104 (16% yield) was isolated after chromatography, with 
undefined relative stereochemistry. This reaction sequence is analogous to the pathway 
described in Scheme 2.13. Unlike the product formed when sulfone acid 79 was used, 
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the product 104 did not tautomerise to be in conjugation with the carbonyl of the central 
ring. The two hydrogens on the central ring have a 3J coupling constant of 9.5 Hz. This 
suggests that they are positioned diaxially, making the ring and vinyl iodide substituents 
trans to each other. The result of this reaction suggests that, without the presence of the 
methyl group, the iodine substituent was not sufficiently stabilising of the carbocation 
that was formed during the reaction pathway. Therefore, the alkene did not attack and 
this allowed a second molecule of imine to be added into the N-acyliminium ion.   
 
Scheme 2.22 – DIA reaction of imine 37 and iodo-substituted alkene acid 91 
Finally, it was considered whether an appropriately placed trimethylsilyl group could 
stabilise the carbocation through the β-silicon effect.61 Use of allyl trimethylsilane acid 
106 may provide sufficient stabilisation of the intermediate carbocation formed on 
nucleophilic attack of the alkene into the N-acyliminium ion. This is analogous to the 
reaction pathway shown in Scheme 2.15, but the silicon group would be in the β-
position to the carbocation that is formed. Allyl trimethylsilane acid 106 was 
synthesised by lithiation of allyl trimethylsilane 105 and subsequent in situ generation of 
an allylic aluminate complex, followed by trapping with CO2.62 Use of these conditions 
gave a 4:1 mixture of carboxylated products α-106:γ-107 in the crude product mixture 
by 1H NMR spectroscopy (Scheme 2.23). Purification by column chromatography gave 
a clean sample of α-106 that was isolated in 27% yield and this sample was taken on to 
test under DIA conditions.  
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Scheme 2.23 – Synthesis of allyl trimethylsilane acid 106 
Reaction of α-allyl trimethylsilane 106 with imine 37 under DIA conditions with 
BF3OEt2 at rt resulted in none of the expected cyclised product 108 being observed 
(Table 2.2, Entry 1). As with other examples, a fused pentacyclic product 110 was 
isolated. The reaction was attempted with no acid activation at rt but product 110 was 
observed in the unpurified reaction mixture by 1H NMR spectroscopy (Entry 2), 
showing that this product formed too readily to be prevented. The product 110 was 
isolated as a single diastereoisomer with undefined relative stereochemistry. The 3J 
coupling constant for the hydrogens on the central ring system was 9.5 Hz indicating the 
trans stereochemistry of the ring and allyl substituents.  
 
Entry Solvent Lewis acid Temp 108  (%) 109 (%) 110 (%) 
1 CH2Cl2 BF3OEt2 rt - - 25 
2 CH2Cl2 - rt - - -a 
a) Analysis of the 1H NMR spectrum of the unpurified reaction mixture showed    
formation of 110 as the major product. 
Table 2.2 – DIA reaction of allyl trimethylsilane acid 106 and imine 37 
A mechanism for formation of product 110 is shown in Scheme 2.24. After formation of 
the N-acyliminium ion and attack by a second imine molecule, iminium ion 111 could 
form. Acid 107 has been shown to be unstable by loss of the TMS group, as reported by 
Uno et al.63 Therefore, a suggested route could involve the removal of TMS (possibly 
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by the T3P byproduct) and enolate formation to give 112. Subsequent cyclisation onto 
the N-acyliminium ion would provide the observed fused pentacyclic ring structure 110.  
 
Scheme 2.24 – Proposed reaction mechanism for the formation of product 110 
Use of a more stable α-silyl acid 113 that should not lose the silyl group so readily was 
also briefly explored. Dimethylphenylsilyl acid 113 was synthesised using Uno’s 
conditions,63 and was then reacted under DIA conditions with imine 37. Initial reaction 
in CH2Cl2 at rt, followed by addition of BF3OEt2 gave a complex mixture of products 
(Scheme 2.25). Attempted purification suggested that a small amount of the 
dihydropyridone 108 was isolated, but as a mixture with the polycyclic product 110. 
Mass spectrometry confirmed that the dihydropyridone 108 was present. Increasing the 
temperature of the reaction resulted in a mixture where the dihydropyridone 108 was not 
observed. Reaction without addition of the Lewis acid gave the polycyclic product 
suggesting the preference for this product to form over the cyclisation of the alkene 
nucleophile. Following these results, this route was abandoned.  
 
Scheme 2.25 – Attempted synthesis of dihydropyridone using a more stable silane 
Unfortunately, attempts to initiate intramolecular nucleophilic addition of various 
carbon nucleophiles into N-acyliminium ions were unsuccessful. A fused pentacyclic 
ring scaffold was observed where a sulfone, alkene or iodo-substituted alkene was 
present. The electron-withdrawing nature of these substituents appears to lead to 
formation of the complex heterocyclic structure. As shown in Scheme 2.26, it was 
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proposed that if ‘X’ is electron-withdrawing then imine 37 attacks the N-acyliminium 
ion 114 first and forms iminium ion 115. Once this has happened, the reaction goes on 
to form the pentacyclic product.  
 
Scheme 2.26 – Nucleophilic addition of imine 37 into the N-acyliminium ion 114 
Despite the pentacyclic ring structure not being the desired product that was wanted for 
a pyridone annelation procedure, it is a rapid and efficient way of building up a complex 
heterocyclic molecule. To demonstrate this, imine 37 (2 eq) and cyanoacetic acid 116 (1 
eq) were subjected to standard DIA conditions and the pentacyclic product 117 was 
formed (Scheme 2.27). The 1H NMR spectrum of the unpurified reaction mixture 
showed a 5:1 mixture of diastereoisomers and the major diastereoisomer was isolated in 
77% yield following column chromatography. The 3J-value for the hydrogens on the 
central ring was 10.5 Hz, indicating the trans stereochemistry of the ring and nitrile 
substitutents. It has been demonstrated within the Taylor group that the nature of the ‘X’ 
group is important, as a phenyl substituent results in formation of a β-lactam product, 
rather than the fused pentacyclic ring structure.24 Interestingly, the formation of the β-
lactam ring is not allowed by Baldwin’s rules as it is defined as a 4-endo-trig 
cyclisation.64 However, Baldwin followed up this publication with alternative rules for 
cyclisations involving an enolate intermediate,65 which may explain the formation of the 
β-lactam products. 
 
Scheme 2.27 – Selective formation of polycyclic product 117 
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2.3.2. Direct Imine Acylation followed by Intermolecular 
Nucleophilic Addition of an External Carbon Nucleophile  
An alternative approach to the synthesis of cytisine using DIA methodology was needed 
to advance the project. In the O’Brien synthesis of (±)-cytisine 42, the dihydropyridone 
ring structure was synthesised via formation of a diene, followed by Grubbs ring-closing 
metathesis (Scheme 2.3).46 We envisaged that, using DIA methodology, a diene could 
be constructed using intermolecular nucleophilic addition. The N-acyliminium ion 
would be formed using the standard DIA conditions with an acid containing a suitable 
alkene substituent, and an external nucleophile would be added at a later stage in the 
reaction, to install the second alkene of the diene for subsequent ring-closing metathesis.  
 
A DIA reaction between the aromatic imine 37 and trans-cinnamic acid 118 was carried 
out to form the N-acyliminium ion intermediate. The external nucleophile, allylsilane 
105, and BF3OEt2 were introduced into the reaction for addition into the N-
acyliminium ion. This intermolecular nucleophilic addition DIA approach was 
successful and provided diene 119 in 52% yield (Scheme 2.28). Subsequent ring-closing 
metathesis of diene 119 gave dihydropyridone 108 in 72% yield after 2 h at rt. This was 
a promising result as it gave a synthetically simple entry to an unsubstituted 
dihydropyridone scaffold, which upon oxidation would give the desired pyridone, as 
needed for a synthesis of (±)-cytisine 42.  
 
Scheme 2.28 – Synthesis of a dihydropyridone via direct imine acylation and 
addition of an external carbon nucleophile, followed by ring-closing metathesis 
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2.3.3. Synthesis and Reactions of Novel Bispidine Imines 
Following the successful synthesis of a dihydropyridone scaffold via direct imine 
acylation and subsequent addition of an external carbon nucleophile (Scheme 2.28), it 
became a priority to synthesise a bispidine imine in order to trial this chemistry on the 
relevant scaffold.  A known intermediate 48 (where R = t-Bu) from the O’Brien 
synthesis of (±)-cytisine 42 was used as a starting point for the synthesis of a bispidine 
imine. It was envisaged that deprotection of the benzyl group and oxidation would give 
the imines 64 and 121 (Scheme 2.29). The use of Boc- and ethyl carbamate-protecting 
groups would be explored as Boc is more acid-labile, whereas it was thought that the 
ethyl carbamate would be more stable to the acidic conditions used in DIA 
methodology. 
 
Scheme 2.29 – Planned synthesis of bispidine imines 
The syntheses of the Boc- and ethyl carbamate-protected bisipidine imines 64 and 121 
were completed in 4 steps (Scheme 2.30). The known protected bispidine 48 was first 
synthesised using a literature procedure previously used in the O’Brien synthesis of (±)-
cytisine 1.46 Using the cheap, commercially available N-Boc piperidone 47 as starting 
material, a double Mannich reaction provided the protected bispidinone 48 in 76% yield. 
A milder version of the Wolff-Kishner reduction was then used to reduce the carbonyl 
and provide the protected bispidine 49 in 62% yield. This method was preferable as a 
mild hydride reduction of the hydrazide formed in the first step maintained the Boc 
protecting group for subsequent steps. Hydrogenation of the benzyl group was 
unsuccessful using 10% Pd/C, but was accomplished with Pearlmann’s catalyst (20% 
Pd(OH)2/C) to give the amine 63 in 98% yield. Oxidation conditions previously used to 
synthesise aromatic imine 37,52  using NBS bromination followed by base-mediated 
elimination, were also successful on the bispidine scaffold and imine 64 was isolated in 
75% yield. This was a pleasing result as it was the most unexplored reaction and the 
DIA methodology relied on the successful isolation of a bispidine imine. The same 
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sequence of reactions was performed on the N-ethyl carbamate piperidone 122 to give 
ethyl carbamate-protected bispidine imine 121, with similar yields achieved in each step 
(Scheme 2.30). Scaling up of the oxidation step to the imine 121 proved to be 
detrimental to the yield, which appeared to be due to poor conversion of the starting 
material.  
 
Scheme 2.30 – Synthesis of bispidine imines 64 and 121 
Some imines are known to form trimers,66 particularly if they are not sterically hindered 
such as 2,3,4,5-tetrahydropyridine 125 (Scheme 2.31). Three of the monomer molecules 
125 react to form a trimer 126 and this reaction is an equilibrium process. Analysis of 
the 1H NMR spectrum of the ethyl carbamate-protected imine 121 suggested that it 
existed as a mixture of monomer and trimer. Integration of the signal at 7.84 ppm could 
be assigned to the monomer only for 1H (the imine proton), whereas other signals in the 
bispidine structure integrate for monomer and trimer, such as the CH2CH3 of the ethyl 
group. Using these signals, it was calculated that approximately 17% of trimer was 
present, although it is possible that the percentage of trimer depends on the 
concentration of the product in the NMR sample. In contrast, Boc imine 64 did not 
appear to trimerise. 
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Scheme 2.31 – Known trimerisation of imines66 
Following the successful synthesis of bispidine imines 64 and 121, a known DIA 
reaction using N-methyl anthranilic acid 38 was investigated.21 The DIA reactions 
between N-methyl anthranilic acid 38 and imines 64 and 121 were completed in 28% 
and 65% yield respectively (Scheme 2.32). These results were pleasing as they indicated 
that the bispidine imines were able to undergo DIA reactions. 1H NMR spectroscopy 
indicated that one diastereoisomer had been isolated in both examples, as only one 
signal (at 4.63 ppm in both products 127 and 128) was observed for the bridgehead 
proton between the two nitrogen atoms.  
 
Scheme 2.32 – DIA reaction of bispidine imines 64 and 121 d 
Trial of the intermolecular DIA methodology with N-Boc imine 64 provided an 
interesting result (Scheme 2.33). None of the desired product 129 was isolated but 
substituted bispidine 130 was isolated in 16% yield. 1H NMR spectroscopy indicated 
that the Boc group had been removed and the mass spectrum clearly featured the 
corresponding (M + H)+ peak for the product 130. This suggested that the desired 
nucleophilic addition into the N-acyliminium ion had occurred. However, additional 
Boc deprotection and acylation of the second amine had also occurred. This was not an 
unexpected result as BF3•OEt2 has previously been shown to be effective and mild 
deprotection conditions for the Boc group.67  
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 Scheme 2.33 – Direct imine acylation of bispidine imine 64  
Pleasingly, the intermolecular nucleophilic addition approach on the ethyl carbamate 
bispidine imine 121 was successful (Scheme 2.34). Using DIA conditions to form the N-
acyliminium ion, followed by introduction of the external nucleophile and Lewis acid, 
diene 131 was isolated in 63% yield. Grubbs ring-closing metathesis efficiently gave 
dihydropyridone 132 in 93% yield. Overall yields were reduced when crude diene was 
taken through so column chromatography of diene 131 is recommended.  
 
Scheme 2.34 – Synthesis of dihydropyridone 132 via direct imine acylation  
It was assumed that the product 132 had the stereochemistry shown in Scheme 2.34. 
This was based upon previous investigations of nucleophilic addition to N-acyliminium 
bispidine structures, which showed that attack proceeded through the more exposed exo 
face.68,69,70 This assumption was confirmed and will be discussed later. 1H NMR 
spectroscopy showed that one diastereoisomer of dihydropyridinone 132 was formed. 
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This was indicated by the single signal observed for the highlighted bridgehead proton 
(Scheme 2.34). This result confirmed that under the acidic conditions of this reaction the 
ethyl carbamate-protected imine 121 is a more suitable substrate than imine 64. 
 
2.3.4. Development of Lewis Acid-Free Conditions for the DIA 
Reaction with Addition of Intermolecular Nucleophile 
In the DIA reactions with addition of an intermolecular nucleophile, the best results 
were obtained using the ethyl carbamate-protected bispidine imine 121. However, the 
Boc protecting group is a more readily removed and more versatile protecting group, so 
an approach that could work with the N-Boc bispidine imine 64 was explored. 
 
Addition of an organometallic nucleophile into N-acyliminium ions has previously been 
demonstrated in the synthesis of nitrogen heterocycles.71 An example of this is shown in 
Scheme 2.35 where combination of the allyl amine and aromatic aldehyde 133 provided 
an allyl imine. Generation of the N-acyliminium intermediate by acylation with benzyl 
chloroformate was carried out at 60 °C to ensure complete formation of the intermediate 
N-acyliminium ion. Subsequent addition of the organometallic reagent facilitated 
nucleophilic attack into the N-acyliminium ion and afforded the product 135 in 85% 
yield (Scheme 2.35).71 
 
Scheme 2.35 – Synthesis of diene 135 via addition of an organometallic 
nucleophile71 
It was envisaged that this methodology, consisting of nucleophilic addition into an 
iminium ion without the need for a Lewis acid, could be exploited in the synthesis of a 
Boc-protected diene as a key intermediate in the synthesis of (±)-cytisine 42. In 
accordance with the literature, an acid chloride would be used to acylate the imine 
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precursor. Both allylzinc bromide 134 and allylmagnesium bromide 137 have been used 
in similar additions into N-acyliminium ions,71,72 with allylzinc bromide having the 
advantage of better functional group tolerance. However, the Grignard reagent 137 is 
commercially available whereas the allylzinc bromide 134 reagent had to be freshly 
synthesised.73 
 
Addition of the allylmagnesium bromide 137 into the N-acyliminium ion was attempted 
first (Table 2.3, Entries 1-3). Initially, the aromatic imine 37 and acid chloride 136 were 
reacted in either THF or CH2Cl2. Ethereal solvents are typically used in this type of 
addition reaction71 but there is some precedent for CH2Cl2 increasing the yield of 
Grignard additions into similar imine derivatives.72 In THF, the reaction of the acid 
chloride and imine required heating to solubilise the reaction mixture. Once the N-
acyliminium ion had been generated, the reaction was cooled to −78 °C and the 
organometallic reagent was added. Addition of 2 equivalents of Grignard reagent 
resulted in no product (Entry 1). The byproduct 138 was observed but not isolated. 
Using only 1.2 equivalents of Grignard reagent in THF or CH2Cl2 resulted in a low yield 
of product 119 (Entries 2 and 3). In all cases where the Grignard reagent was used some 
of the unwanted byproduct 138 was observed, which suggested that the Grignard 
reagent preferred to react with the C=O of the N-acyliminium ion. Hence, a softer 
nucleophile, allylzinc bromide 134, was tried instead and provided improved yields of 
diene 119 in THF at low temperature (Entries 4 and 5). Use of CH2Cl2 resulted in a 37% 
yield and a messier reaction profile (Entry 6). The best yield was achieved if the reaction 
was allowed to warm to rt following addition of the allylzinc bromide at −78 °C, 
providing the diene 119 in 76% yield (Entry 7). 
 
 
 
 
 39 
 
Entry Solvent Organometallic reagent Scale 
(mmol) 
Yield 
119 (%) 
1 THF AllylMgBr 137 (2.0 eq) 0.76 0 
2 THF AllylMgBr 137 (1.2 eq) 0.84 17 
3 CH2Cl2
a AllylMgBr 137 (1.2 eq) 0.76 24 
4 THF AllylZnBr 134 (1.2 eq) 0.76 59 
5 THF AllylZnBr 134 (1.2 eq) 2.00 70 
6 CH2Cl2
a AllylZnBr 134 (1.2 eq) 2.00 37 
7 THF AllylZnBr 134 (1.2 eq)b 1.52 76 
a) Reaction performed at rt in CH2Cl2. b) Reaction allowed to warm 
to rt after addition of organometallic at −78 °C. 
Table 2.3 – Addition of organometallic reagents into an N-acyliminium ion 
An alternative route to the same diene product 119 is by addition of the organometallic 
nucleophile first and subsequent trapping of the amine with the acid chloride 136. The 
results of these reactions are shown in Table 2.4. Initial addition of the Grignard reagent 
137 resulted in a 43% of diene 119 (Entry 1), which was higher than the yields obtained 
when the Grignard was added into the reaction mixture after formation of the N-
acyliminium ion. This could be because the N-acyliminium ion carbonyl functionality is 
not present in the molecule, reducing the possibility of side reactions. Addition of the 
allylzinc bromide 134 reagent first resulted in a 64% yield of diene 119 (Entry 2). This 
was a slight decrease in yield compared to addition of the allylzinc bromide after 
formation of the N-acyliminium ion, and could possibly be due to the less electrophilic 
nature of the imine compared to the N-acyliminium ion.  
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Entry Organometallic reagent Scale (mmol) 119 Yield (%) 
1 AllylMgBr 137 0.76 43 
2 AllylZnBr 134 0.76 64 
Table 2.4 – Synthesis of diene 119 via initial addition of organometallic reagent  
The optimum conditions developed in this process were initial formation of the N-
acyliminium ion and subsequent addition of the allylzinc bromide 134 at −78 °C, then 
allowing to warm to rt (Table 2.3, Entry 7). Therefore, these conditions were attempted 
on N-Boc bispidine imine 64 as a key step in the synthesis of (±)-cytisine 42 (Table 2.5). 
It was anticipated that these conditions would be compatible with the Boc protecting 
group. Following purification by column chromatography, the desired diene 129 was 
isolated. However, the isolated fractions contained a mixture of product 129 and a 
cinnamic acid impurity, formed from excess cinnamoyl chloride hydrolysed in the 
aqueous work-up. The cinnamic acid was removed by a basic wash with 10% NaOH(aq) 
to give the clean product 129 in 17% yield (Entry 1). The reaction was also tried using 
the Grignard reagent 137 but this was unsuccessful, likely due to the competing reaction 
with the carbonyl of the N-acyliminium ion intermediate (Entry 2). Initial addition of the 
Grignard reagent into the bispidine imine 64 in CH2Cl2, followed by trapping with the 
acid chloride was also attempted. It was thought that this would ensure all the Grignard 
had added to the imine prior to addition of the acid chloride, therefore avoiding the 
presence of the N-acyliminium ion carbonyl for side reactions to occur. However, the 
crude reaction mixture showed a complex mixture of products and upon purification by 
column chromatography none of the diene 129 was isolated. 
N
Cl
O
Ph
2 h, −78 °C - rt
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THF, 2.5 h, −78 °C - rt
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Ph
37
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Entry Organometallic 129 Yield (%) 
1 AllylZnBr 17 
2 AllylMgBr 0 
Table 2.5 – DIA reaction and addition of intermolecular nucleophile 
In summary, the DIA reaction involving addition of an intermolecular nucleophile was 
successfully developed on the aromatic imine 37 and ethyl carbamate-protected 
bispidine imine 121 but proved more challenging on the N-Boc bispidine imine 64.  
 
2.3.5. Reaction of Glutaconic Anhydride and Imidates as an 
Annelation Procedure 
An alternative approach to the synthesis of the pyridone scaffold in (±)-cytisine 35 has 
also been explored. This very different approach was based on the reaction of cyclic 
anhydrides and imines to form various heterocylic molecules.74 Early studies into new 
routes to benzo[α]quinolizines 143 in 1976, showed that the reaction of 3,4-dihydro-1-
methylisoquinoline 140 with glutaconic anhydride 141 at 100 °C in pyridine formed the 
cyclised product 143 in 56% yield, via the intermediate shown in Scheme 2.36.75 It was 
suggested that nucleophilic attack of the deprotonated methylene carbon in glutaconic 
anhydride 141 onto the imine would form 142, which would be followed by cyclisation 
of the anhydride and decarboxylation to give the product 143 in 56% yield.  
Cl
O
Ph
THF, 65 °C, 3 h
1.
2. BrZn
16 h, –78 °C-rt
N
N
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N
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134
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Scheme 2.36 – Reaction of glutaconic anhydride 141 and imine 14075 
Following on from this preliminary work, Cushman76 and Haimova12 demonstrated the 
use of homophthalic anhydrides in formal cycloaddition reactions with cyclic imine 
substrates. Haimova77 and Coppola78 subsequently showed that chloroimine and alkyl 
imidates react readily with homophthalic anhydride and form unsaturated lactam 
products following spontaneous decarboxylation.74 For example, reaction of 
homophthalic anhydride 144 with cyclic imidate 145 at high temperature provided the 
cyclised product 146 in 51% yield (Scheme 2.37). The proposed mechanistic pathway 
that Coppola suggested is given in Scheme 2.37. Deprotonation of the anhydride 144 by 
the imidate 145 forms an enolate 147 that attacks the resulting iminium ion 148 to 
generate intermediate 149. Internal nucleophilic attack of the amine 149 onto the 
carbonyl may generate 150, which could lose carbon dioxide and ethoxide to give the 
product 146.78 An alternative mechanism involving initial acylation of the imine, 
through nucleophilic attack onto the carbonyl of the anhydride, has also been 
suggested.74 
MeO
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Scheme 2.37 – Reaction between anhydride 144 and imidate 14578 
The product of the reaction of homophthalic anhydride 144 with the imidate 145 
contained a pyridone ring-type scaffold, with additional aromatic functionality as a 
result of the anhydride used. If glutaconic anhydride 141 was used, it could be possible 
to form a pyridone ring with no additional substitution around it. Indeed, the reaction of 
1-chloroisoquinoline 151 with glutaconic anhydride 141 has been shown to give the 
pyridone ring present in the product 152 (Scheme 2.38).79  
 
Scheme 2.38 – Synthesis of pyridone 152 by reaction of 1-chloroisoquinoline 15179 
This precedent for the formation of pyridone scaffolds via cyclisation of cyclic 
anhydrides and imidate-type structures presented an interesting possibility for this 
project. It was envisaged that the reaction of glutaconic anhydride 141 and a cyclic 
imidate 145 (where X = OEt or Cl) might form a simple pyridone ring scaffold 153 
(Scheme 2.39). Loss of carbon dioxide and elimination of ‘X’ might give a pyridone 
ring scaffold with no additional aromatic rings or substituents, and a synthetically 
simple procedure that could ultimately be used in synthesis of (±)-cytisine 42.  
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Scheme 2.39 – Proposed reaction for the synthesis of pyridone 153 
In a model study, the synthesis of pyridone 153 was investigated. The cyclic imidate 
145 (where X = OEt) was synthesised by alkylation of piperidin-2-one 154 using 
Meerwein’s reagent 155 in 82% yield (Scheme 2.40).22  
 
Scheme 2.40 – Synthesis of imidate 145 
The glutaconic anhydride 141 starting material was synthesised by refluxing trans-
glutaconic acid 156 in acetic anhydride following a literature procedure (Scheme 
2.41).80 Attempted purification of the crude glutaconic anhydride material by column 
chromatography resulted in decomposition. However, the 1H NMR spectrum of the 
unpurified material suggested complete conversion to the glutaconic anhydride 141 and 
was clean enough to be carried straight through to the subsequent reaction (Scheme 
2.41). Subjecting the glutaconic anhydride 141 and cyclic imidate 145 to the 
precedented conditions for this type of cycloaddition resulted in the α-condensation 
product 157 in 38% yield and none of the desired cyclised product 153 (Scheme 2.41). 
The suggested mechanistic pathway for formation of product 157 was generation of the 
anhydride enolate 159 and subsequent nucleophilic attack onto the iminium ion 158 
(Scheme 2.41). Rather than the desired internal cyclisation by nucleophilic attack onto 
the carbonyl, loss of ethoxide from 160 would have formed enamine 161. 
Tautomerisation to the product 157 creates a conformationally restricted compound that 
would be unlikely to cyclise due to steric hindrance.  
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Scheme 2.41 – Synthesis of glutaconic anhydride and reaction with imidate 145 
The product 157 was subjected to heating in the presence of catalytic DMAP in an 
attempt to facilitate cyclisation but only starting material was recovered. This type of α-
condensation product had been observed in the literature and provides evidence for the 
reaction pathway shown in Scheme 2.41 rather than the alternative imine acylation 
pathway.79 Conversion of these α-condensation products to the cyclised products had 
been shown to occur at high temperatures with acidic catalysts,79 in particular heating in 
the presence of POCl3.81 However, due to the lack of literature precedent concerning this 
transformation and the fact that the specific reaction of glutaconic anhydride 141 and 
cyclic imidate 145 appeared to be novel, work on this annelation approach was stopped. 
At the time, this approach appeared to be the least promising and given that the 
cyclisation was unsuccessful on a model imine it was thought that there was less chance 
of success on the more complicated bispidine imine 64.  
 
2.3.6. Towards the Synthesis of (±)-Cytisine: Oxidation of the 
Dihydropyridone Ring 
Development of the annelation procedure on the Boc-protected bispidine compound had 
proven challenging. The most advanced route in the synthesis of cytisine 42 could 
provide access to the ethyl-carbamate protected diyhydropyridone 132. For a successful 
racemic synthesis of (±)-cytisine, oxidation conditions for transformation of the 
dihydropyridone to the pyridone 164 were required.  
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Lesma had successfully employed DDQ conditions to oxidise a Cbz protected bispidine 
162 to give 163 in 50% yield (Scheme 2.42).49 Previous attempts within the O’Brien 
group on a benzyl-protected dihydropyridone similar in structure to 162 had been 
unsuccessful. Subjecting dihydropyridone 132 to Lesma’s DDQ conditions resulted in 
none of the desired pyridone 164 being isolated. Starting material was consistently 
observed using 1H NMR spectroscopy of the crude reaction mixture after 18 h, despite 
the similarity of the bispidine structure used in Lesma’s synthesis and the scaffold in 
this project (Scheme 2.42). Oxidation using MnO2 was also attempted, using conditions 
previously used by Coe et al. in the syntheses of (±)-cytisine, but none of the desired 
pyridone 164 was isolated.44,46 
 
Scheme 2.42 – Lesma’s oxidation of dihydropyridone 
O’Brien has reported that reacting a benzyl-protected dihydropyridone 165 with 10% 
Pd/C in 3:1 1,4-dioxane-cyclohexene resulted in oxidation of the ring and left the benzyl 
group intact. Benzyl-protected cytisine 166 was obtained in 41% yield (Scheme 2.43).46 
The purpose of cyclohexene in this reaction is as a hydrogen acceptor to regenerate the 
catalyst, as the double bond of cyclohexene should be easily reduced. Following the 
reasonably low 41% yield, it was suggested that 1,4-dioxane could be acting as a 
hydrogen source and limiting how far the reaction could proceed. This problem was 
overcome by using toluene rather than 1,4-dioxane, which successfully gave the 
dihydropyridone and advantageously removed the benzyl group to give (±)-cytisine 42 
in 76% yield (Scheme 2.43).46  
 
Scheme 2.43 – Precedented oxidation of dihydropyridone 165 using Pd/C46 
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Subjecting dihydropyridone 132 to 10% Pd/C in 1,4-dioxane and cyclohexene, in the 
hope that the ring would be oxidised, resulted in none of the desired protected cytisine 
164; instead a tetrahydropyridone 167 was isolated in 96% yield (Scheme 2.44). On 
swapping the solvent from 1,4-dioxane to toluene, the same undesired 
tetrahydropyridone 167 observed previously was isolated. 
 
Scheme 2.44 – Attempted oxidation of dihydropyridine 132 using Pd/C 
Although the oxidation conditions did not provide the desired pyridone product 164, the 
tetrahydropyridone 167 was viewed as a useful tool for determining the stereochemistry 
observed when DIA reaction conditions were used. Following a LiAlH4 reduction 
procedure previously used in the O’Brien synthesis of the sparteine surrogate 45,37 it 
was possible to convert the tetrahydropyridone 167 into a tricyclic diamine 168 (Scheme 
2.45). Tricyclic diamines (1S,5R,11aS)-168 and (1S,5R,11aR)-168 had been previously 
synthesised within the O’Brien group (Scheme 2.45) and provided 13C NMR 
spectroscopy data that allowed direct comparison with the data collected for the tricyclic 
diamine synthesised in this project.69 The two diastereoisomers show different chemical 
shifts at the carbon groups indicated in Scheme 2.45. Analysis of the 13C NMR spectrum 
of unpurified tricyclic diamine synthesised confirmed that the reduced product was 
tricyclic amine (1S,5R,11aR)-168. This showed that the earlier assumption that 
nucleophilic attack had occurred on the more exposed exo face during the 
intermolecular DIA nucleophilic addition was correct. 
 
N
N
O
O
OEt
H N
N
O
O
OEt
96%0%
N
N
O
O
OEt
Pd/C (10% w/w) 
(20 mol%)
H
132 164 167
1,4-dioxane-
cyclohexene (3:1)
100 °C, 20 h
 48 
 
Scheme 2.45 – Reduction of tetrahydropyridone 167 and diagnostic 13C NMR 
signals of tricyclic amine 168 
Unfortunately, we were unable to progress ethyl carbamate imine 121 into (±)-cytisine 
42. All of our attempted oxidation conditions on dihydropyridone 132 were 
unsuccessful.  
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2.4. Conclusions and Future Work 
The use of DIA methodology for the formation of a pyridone ring scaffold has proved 
unsuccessful in the route towards (±)-cytisine 42. In the intramolecular DIA approach, 
none of the designed carboxylic acid substrates provided the desired cyclised 
dihydropyridone product. For a number of the substrates, an alternative fused 
pentacyclic product was observed and isolated as a single diastereoisomer of undefined 
relative stereochemistry in low yields. This product was a result of the addition of a 
second imine molecule into the initial N-acyliminium ion, followed by cyclisation as 
shown in Scheme 2.26. The selective and deliberate synthesis of this product using the 
appropriate reagent stoichiometry provided the fused pentacyclic product in high yield 
(Scheme 2.27).  
 
The most advanced route that was developed towards a racemic synthesis of (±)-cytisine 
42 is shown in Scheme 2.46. An ethyl carbamate-protected dihydropyridone 132 was 
synthesised in 6 steps.  
 
Scheme 2.46 – Most advanced route towards (±)-cytisine 42 
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Both the ethyl carbamate-protected bispidine imine 121 and the N-Boc-protected 
bispidine imine 64 were synthesised using the same routes with similar yields. However, 
during development of the subsequent key DIA reaction it was found that the N-Boc 
imine 64 was not suitable due to the instability of the Boc group under the acidic 
conditions. Attempts to develop an acid-free process were partially successful but 
inefficient and low yielding. The key step of the route involved the direct imine 
acylation of ethyl carbamate-protected bispidine imine 121 with trans-cinnamic acid 
118 to form the N-acyliminium ion intermediate. Subsequent addition of an external 
nucleophile and Lewis acid resulted in intermolecular addition to the N-acyliminium ion 
and formation of the diene 131 (Scheme 2.46). Ring-closing metathesis was used to 
provide the dihydropyridone 132. Various precedented oxidation techniques were 
attempted but none gave the desired pyridone scaffold 164. Completion of this racemic 
synthesis requires development of a successful oxidation route from the 
dihydropyridone 132 to the corresponding pyridone and subsequent deprotection to give 
(±)-cytisine 42. 
 
Future work could focus on developing an asymmetric synthesis of (−)-cytisine 42. 
Preliminary thoughts are to investigate enantioselective enzyme-catalysed 
desymmetrisation of the mono-protected bispidines 63 and 124 to imines 64 and 121 
(Scheme 2.47), which would be the first chiral intermediates in the proposed route to 
(−)-cytisine 42. Turner has demonstrated this chemistry on a range of unprotected 
pyrrolidines, with related scaffolds to the bispidine structure of cytisine (Scheme 
2.47).82 
 
 
Scheme 2.47 – Proposed enantioselective enzyme-catalysed desymmetrisation82 
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3. Synthesis of Spirocyclic Compounds using Direct Imine 
Acylation Methodology 
3.1. Introduction  
Recently, spirocyclic compounds have been attracting a significant amount of interest 
due to their three-dimensional, rigid scaffolds, which allow them to be used to probe 
areas of chemical space that are currently under-explored.83,84 Access to new areas of 
chemical space could provide the opportunity to develop novel pharmaceutical 
compounds with interesting biological activities. Nitrogen-containing heterocycles are 
prevalent in medicinal chemistry and make up a significant proportion of FDA approved 
small molecule drugs.85 Spirocyclic compounds containing nitrogen heterocycles are 
therefore attractive targets for synthesis as they have the potential to be interesting 
biologically active compounds which occupy undiscovered areas of chemical space. 
3.1.1. Spirocyclic Scaffolds in Biologically Active Natural Products 
and Pharmaceutical Compounds 
Spirocyclic scaffolds are important due to their presence in a large number of 
biologically active natural products and pharmaceutical compounds.84 A number of 
alkaloid natural products contain a spirocyclic scaffold at their core. Examples include 
the aspidosperma and strychnos alkaloid families. The structures of aspidospermidine 
169 and strychnine 170 (Figure 3.1) have been widely used to showcase synthetic 
methodologies aimed at rapidly assembling polycyclic structures.86,87 Aspidospermidine 
169 has been shown to possess some adrenergic receptor inhibitor activity but these 
natural products are more attractive as targets for total synthesis.87,88 Some members of 
the vinca alkaloid family, vinblastine and vincristine, are clinically useful oncolytic 
agents whose structures are very closely related to the natural product vindoline 171 
(Figure 3.1).89,90 The spiroindolenine scaffold is present in a number of natural products 
including koumine 172 and spirobacillene 173, with the former possessing analgesic and 
anti-cancer activity (Figure 3.1).91-93 The spiroindoline scaffold occurs in 
pharmaceutically active compounds, such as the Sky kinase inhibitor 174, further 
highlighting the importance of these spirocyclic motifs and their use as potential 
therapeutics (Figure 3.1).94,95 
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Figure 3.1 – Biologically active and naturally occurring spirocycles 
A scaffold that shows a wide range of pharmacological activities is the spirooxindole 
scaffold.96 The natural product (−)-horsifiline 175, isolated from Horsfieldia superba, 
contains a simple spirooxindole scaffold and is used as an indigenous medicine (Figure 
3.2).96,97 Mitraphylline 176 was isolated from Unicaria tomentosa and shows anti-
tumour activity against human brain cancer cell lines (Figure 3.2).96,98 Spirotryprostatin 
A 177 and spirotryprostatin B 178 were both isolated from Aspergillus fumigatus and 
show powerful bioactivity in cell cycle modulation, with spirotryprostatin B 178 also 
showing cytotoxic activity on the growth of human leukemia cell lines.99,100 In general, 
spirooxindole compounds display anti-tumour, anti-microbial, anti-proliferative and 
anti-fungal properties.96 Due to the biological importance associated with the 
spirooxindole scaffold, there are many reports on the synthesis of such compounds. 
Transition-metal-mediated routes to 3,3-disubstituted oxindole compounds are widely 
used,101,102 but other methodologies such as 1,3-dipolar cycloaddition of azomethine 
ylides have been developed to access these important compounds.96 
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Figure 3.2 – Natural products with oxindole core scaffolds 
 
3.1.2. Synthesis of Spirocyclic Indolenines via Interrupted Fischer 
Indole Reactions 
As outlined in a recent review from our group,103 the synthesis of spirocyclic indolenine 
scaffolds can be separated into three main categories: interrupted Fischer indole 
reactions, condensation reactions and dearomatisation of indoles. The interrupted 
Fischer indole reaction is the oldest methodology for the synthesis of spirocyclic 
indolenines. In 1951, Wiktop and Patrick demonstrated the synthesis of simple 
cyclopentyl spirocyclic indolenines containing a group in the 2-position (Scheme 
3.1).104 The hydrazine intermediate 180 was generated by condensation of an aldehyde 
179 and phenyl hydrazine, followed by an acid-catalysed interrupted Fischer indole 
reaction to give indole 181 (Scheme 3.1, no yields were given).  
 
Scheme 3.1 – An interrupted Fischer indole reaction route to spiroindolenines104 
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The inclusion of a group in the 2-position of the spiroindolenine products is commonly 
used as a method to prevent a potential 1,2-migration reaction from occurring, which 
has been observed under acidic conditions.105-107 This process was recently studied 
mechanistically by You et al. who reported the first selective migration of optically 
active chiral spiroindolenines (Scheme 3.2).107 Previous work had demonstrated the 
synthesis of chiral spiroindolenines by an Ir-catalysed intramolecular asymmetric allylic 
dearomatisation reaction.108 Upon treatment with catalytic TsOH, spiroindolenine 182 
was converted into the tetrahydracarbazole 183 with the absolute configuration of the 
chiral centre at the allylic position conserved (Scheme 3.2).107 It was shown that the 
migration reaction proceeded by a concerted mechanism, which involves a “three-
centre-two-electron”-type transition state without formation of a free carbocation and 
therefore no racemisation occurs. The formation of the aromatic indole 183 can drive 
the rearrangement through formation of the more thermodynamically stable product 
(Scheme 3.2).107  
 
Scheme 3.2 – Stereoselective 1,2-migration of chiral spiroindolenines107 
Interrupted Fischer indole chemistry has been demonstrated as a powerful method in the 
synthesis of spirocyclic indolenines and has been showcased in the synthesis of natural 
products. Tokuyama et al. were able to utilise this methodology in the synthesis of (−)-
aspidophytine and related alkaloids (+)-cimicidine and (+)-cimicine. Hydrazone 184 
was treated with neat AcOH at 95 °C to afford the spiroindolenine 185 in 41% yield, 
which could be converted into (+)-cimicine 186 in subsequent steps (Scheme 3.3).109 
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Scheme 3.3 – Synthesis of (+)-cimicine via interrupted Fischer indole reaction109 
 
3.1.3. Synthesis of Spirocyclic Indolenines via Dearomatisation of 
Indoles 
The dearomatisation reaction of indoles is a popular method for the synthesis of 
spirocyclic indolenines.103 The reaction provides a powerful method for the introduction 
of substituents onto aromatic compounds and leads to a variety of heterocyclic 
skeletons.110 The generation of stereogenic quaternary centres is achievable and 
particularly useful in the synthesis of complex natural products.111 In this broad 
synthetic field, there are many different variations of this dearomatisation process such 
as alkylation reactions, oxidative coupling reactions and conjugate additions as well as 
many more.103,110,111 It is well known that the 3-position of an indole is the most reactive 
position with electrophiles. Electrophilic substitution at the 2-position of a 3-substituted 
indole is energetically unfavourable due to the formation of an intermediate 187 in 
which the aromatic ring system has been disturbed (Figure 3.3). In contrast, electrophilic 
substitution at the 3-position allows the aromatic ring to stay intact, forming an 
intermediate 188 (Figure 3.3).112 This electronic character can be exploited to generate 
spirocyclic centres at the 3-position of an indole.  
 
Figure 3.3 – Effects of electrophilic substitution at 2- and 3-position of indole 
A recent example developed in the Taylor group focused on the electrophilic activation 
of alkynes using Ag(I) and Cu(II) catalysts to generate spirocyclic indolenine products 
N
N
H CO2Me
AcOH
95 °C
OMe
N
N
H CO2Me
41%
OH
N
N
O
O
H
COEt
(+)-cimicine 186185184
HNMeO
187 188
N
H
R2
R1
H
N
H
R1
R2
 56 
190 in 75-100% yield (Scheme 3.4).113 The reaction proceeds through an intermediate 
189, which undergoes protodemetallation to give the spiroindolenine product 190. It was 
noted that the ynone functionality was necessary as the carbonyl group reduces the 
migratory aptitude of the alkene and therefore prevents the possible 1,2-migration 
reaction. An asymmetric variant was also developed, through the use of Ag(I) salts of 
chiral phosphoric acids. Conducting the reaction at −10 °C gave a range of 
enantioenriched products between 75-100% yield and up to 86:14 er.113 
 
Scheme 3.4 – Synthesis of spiroindolenines via electrophilic activation of alkynes113 
The dearomatisation of indoles involving nucleophilic addition into iminium ions most 
closely relates to the methodology developed in this project. The mechanism of this 
reaction is similar to that of the Pictet-Spengler reaction, which is often thought to 
proceed via a spirocyclic intermediate.107 Following a condensation reaction to give the 
iminium ion intermediate 191, nucleophilic attack can occur either through the 2- or 3-
position of the indole (Scheme 3.5).114,115 After formation of the spiroindolenine 
intermediate 192, the tetrahydro-β-carboline product 194 can be formed either by a 1,2-
migration reaction and rearomatisation of 193, or ring-opening to reform the iminium 
ion 192 and direct attack through the 2-position (Scheme 3.5).107 Therefore, in the 
synthesis of spirocyclic indolenine products via attack of an iminium ion, the potential 
1,2-migration reaction should be prevented.  
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Scheme 3.5 – Possible reaction pathways in the Pictet-Spengler reaction 
Woodward et al. demonstrated this dearomatisation strategy in their seminal work on 
the total synthesis of strychnine 170.116,117  In the dearomatisation process, the imine 195 
was activated by TsCl to form an N-sulfonyliminium ion. The increased electrophilicity 
initiates subsequent attack of the indole through the 3-position to give the 
spiroindolenine product 196 in 65% yield (Scheme 3.6).117 
 
Scheme 3.6 – Synthesis of a spirocyclic indolenine by nucleophilic attack117 
This method has commonly been used in transannular spirocyclisation reactions, where 
larger ring systems are converted into a polycyclic scaffold.103 An elegant example of 
this is in the formation of an important precursor in the synthesis of (−)-aspidophytine 
by Fukuyama et al. (Scheme 3.7).118 Initital deprotection of the nosyl group on indole 
197 and subsequent TFA-catalysed condensation of the amine and aldehyde produced 
the reactive iminium ion intermediate. Following this, deprotection of the Boc group 
enabled attack through the 3-position to give the complex polycyclic scaffold 198 in 
84% yield over two steps (Scheme 3.7).118 
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Scheme 3.7 – Synthesis of spirocyclic indolenine by transannular spirocyclisation118 
Activation of the iminium ion can also be accomplished by acylation of the nitrogen to 
give an N-acyliminium ion with increased electrophilic character. Van Vranken et al. 
demonstrated an example of this in their synthesis of indolo[2,3-a]carbazoles.119 
Reaction of ditryptophan 199 with TFA afforded the spirocyclic indolenine 200 in 56% 
yield, through elimination of the carbamide and subsequent transannular 
spirocyclisation onto the reactive N-acyliminium species (Scheme 3.8). 
 
Scheme 3.8 - Synthesis of spirocyclic indolenine by transannular spirocyclisation119  
 
3.1.4. Spirocyclic Indolenines as Precursors for Other Privileged 
Hetereocycles 
Spirocyclic indolenine scaffolds are primed to undergo further transformations and they 
can therefore be useful precursors to other privileged heterocycles, such as oxindoles, 
indolines, indoles and polycyclic frameworks.103,120 The formation of spirocyclic 
indoline products can be achieved through reduction of an indolenine intermediate. A 
recent synthesis of the spirocyclic indoline scaffolds found in the structures of the 
aspidosperma and strychnos alkaloid families demonstrates this, using an interrupted 
Bischler-Napieralski reaction.94 Movassaghi et al. noted that spiropyrrolidino-
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indoleninium intermediates 202 in the Bischler-Napieralski reaction underwent a 1,2-
migration to give the fused cyclic product 204 (Scheme 3.9). This rearrangement occurs 
unless there is a strongly nucleophilic trap present in the reaction.94 Using a reagent 
combination of Tf2O and 2-ClPy to induce the Bischler-Napieralski reaction of 
secondary amides 201, the product 204 was isolated in 76% yield and an unexpected 
spirocyclic side product 205 was isolated in 5% yield (Scheme 3.9). The yield of the 
spirocyclic product 205 could be increased to 30% by use of excess Tf2O and 2-Cl-Py 
and was rationalised by interception of the expected spirocyclic indoleninium 
intermediate 202. In comparison to the normal Bischler-Napieralski reaction, which 
goes via an iminium ion intermediate, formation of product 203 may go via a nitrilium 
ion instead to allow for trapping of the resulting imine with triflate (tautomerisation 
gives the enamine product 203). Deuterium-labelling experiments demonstrated that the 
intermediate 203 was persisting until addition of an exogeneous hydride source, from 
the Et3N added to the reaction, afforded reduction at the C-2 position (Scheme 3.9).94 
 
Scheme 3.9 – Interruption of the Bischler-Napieralski reaction94 
The group concluded that these results suggested that the N-trifluoromethanesulfonyl 
indoleninium 203 was electrophilic at C-2 but did not undergo the 1,2-migration due to 
deactivation of the trifluoromethane-sulfonamide nitrogen lone pair.94 Optimisation of 
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the reaction conditions provided high yields of the spiropyrrolidinoindoline products, an 
example of which is shown in Scheme 3.10 using a less potent hydride source (Et3SiH). 
Dehydrosulfination of 205 was achieved using DBU to afford the product 206 (Scheme 
3.10).  
 
Scheme 3.10 – Optimisation of the interrupted Bischler-Napieralski reaction94 
Polycyclic spirocyclic compounds can also be accessed via a spirocyclic indolenine 
intermediate. Many syntheses of compounds containing spirocyclic indole cores set the 
stereocentre of the spirocycle early in the synthesis, as Woodward did in his original 
synthesis of strychnine 170.116 A more recent report on the synthesis of tetracyclic 
frameworks present in the Strychnos alkaloids takes the same approach and the 
spirocyclic scaffold was constructed early on at the 3-position.86 In the synthesis, the 
key spirocyclic scaffold 208 was afforded in high yield and stereoselectivity in the 
presence of AgOTf and base from the substituted indole 207 (Scheme 3.11). Subsequent 
intramolecular aza-Baylis-Hillman reaction with DBU gave the tetracyclic scaffold 209. 
A one-pot spirocyclisation/intramolecular aza-Baylis-Hillman reaction was then carried 
out in 70% overall yield to demonstrate the efficiency with which these important 
tetracyclic scaffolds can be built (Scheme 3.11).86  
 
Scheme 3.11 – Synthesis of tetracyclic frameworks present in strychnos alkaloids86 
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3.2. Project Outline  
The aim of this part of the project was to develop new methodology to synthesise 
spirocyclic indolenine scaffolds in an efficient manner using DIA methodology 
developed in the Taylor group. As outlined in Chapter 1 (see Section 1.1.3), DIA 
methodology has previously been shown to be a quick and efficient way to build up the 
complexity in heterocyclic structures.20,21 An example of this is shown in Scheme 3.12 
where acid 210 and imine 37 are reacted in the presence of T3P and DIPEA to form the 
N-acyliminium ion intermediate. Lewis acid-promoted cyclisation afforded the fused 
polycyclic product 211 in 90% yield.  
 
Scheme 3.12 – Synthesis of polycyclic heterocycles using DIA methodology20 
It was envisaged that the appropriate acid starting materials and imine components 
could be combined under the standard DIA conditions of T3P and DIPEA to provide 
more complex 3D spirocyclic compounds. Our plan was that an indole acetic acid 
starting material 212 would be reacted with imine 37 in the presence of T3P and DIPEA 
in a DIA reaction to generate an N-acyliminium ion intermediate 213 (Scheme 3.13). 
The known nucleophilic reactivity of indoles would then be exploited to generate a 
spirocyclic scaffold in the 3-position of the indole to give an indolenine structure 214 
(Scheme 3.13).  
 
Scheme 3.13 – Synthesis of a spirocyclic indolenine using DIA methodology 
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The reaction conditions would then be optimised to determine the highest 
diastereoselectivity and yield possible. If successful, the project would then be extended 
to demonstrate the use of DIA methodology in the synthesis of various spirocyclic 
compounds by exploring the substrate scope of the indole acid and imine components. 
Substitution around the indole aromatic ring and in the 2-position would be explored, as 
well as varying the size of the spirocyclic ring formed. The imine substrate scope would 
be investigated to include other aromatic imine substrates with substitution around the 
aromatic ring and acyclic imine variants would also be explored (Figure 3.4).  
 
Figure 3.4 - Potential points for diversity around spirocyclic indolenine scaffold 
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3.3. Results and Discussion 
3.3.1. Background and Initial Result 
Previous work within the Taylor group on DIA methodology had focused on the acid-
promoted cyclisation of various carbon nucleophiles onto N-acyliminium ions formed in 
situ.20 The addition of a Lewis acid was found to be necessary for most carbon 
nucleophiles to react, presumably to increase the electrophilicity of the intermediate N-
acyliminium ion.20 For example, reaction of aromatic imine 37 with indole acid 215, and 
addition of BF3OEt2 after formation of the N-acyliminium ion, gave product 216 in 
80% yield (Scheme 3.14).20  
 
Scheme 3.14 – Synthesis of pentacycle 216 using DIA methodology 
Mechanistically, this pentacyclic product 216 may have formed via initial N-acylation 
and direct cyclisation through the C2-position of the indole as shown in Scheme 3.15 
(217→218→216). However, it is possible that the same product 216 could have formed 
via initial cyclisation through the C3-position of the indole to form a spirocyclic 
intermediate and a subsequent 1,2-migration reaction (217→219→218→216, Scheme 
3.15); similar reactions are well precedented under acidic conditions.107 Therefore, it 
was hypothesised that, in the above reaction (Scheme 3.14), product 216 could have 
been formed via a spirocyclic intermediate followed by a 1,2-migration promoted by the 
addition of BF3OEt2. An investigation of this hypothesis was planned; it was believed 
that, due to the electron-rich nature of an indole, the spirocyclisation step might occur 
without the need for a Lewis acid and the reaction would end at the spirocyclic product.  
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Scheme 3.15 – Proposed mechanism for the formation of indole 216 
Initial reaction investigations were carried out using an indole acid with a methyl group 
in the 2-position. This would increase the likelihood of a stable spirocyclic product 
being isolated and reduce the possibility of a 1,2-migration. The initial reaction used a 
commericially available indole acetic acid 212 and imine 37 in typical DIA conditions 
of T3P and DIPEA in CHCl3 at rt for 16 h (Scheme 3.16).* Pleasingly, in our hands, the 
reaction proceeded very efficiently and the desired spirocyclic product was obtained as a 
6:1 diastereomeric mixture of syn-214:anti-214 determined by analysis of the 1H NMR 
spectrum of the unpurified reaction mixture. The diastereoisomers were separable by 
column chromatography to give clean anti-214 and syn-214 in 7% yield and 34% 
respectively and 54% yield of mixed diastereoisomers, resulting in an overall yield of 
95%. An X-ray crystal structure of the major diastereoisomer was obtained (Figure 
3.5),† and surprisingly revealed that the 2-position of the indolenine and the hydrogen 
(from the imine) were syn to each other. This was interesting as it might have been 
expected, from a steric hindrance perspective, that the most favoured diastereoisomer 
would be anti-214. 
 
                                                
* The initial proof of concept was performed by Dr Graeme Coulthard in the Taylor 
group, but was repeated for the purpose of this project. 
† X-ray obtained by Dr Graeme Coulthard. 
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Scheme 3.16 –DIA spirocyclisation of indole acid 212 and imine 37 
 
 
 
 
 
Figure 3.5 – X-ray crystal structure of syn-214 (CCDC: 1436464) 
The likely mechanistic pathway is summarised below; following formation of the N-
acyliminium ion 213, the electron-rich nucleophilic indole would cyclise through the 3-
position resulting in the spirocyclic intermediate 220. Deprotonation by the base would 
give the spirocyclic product 214 (Scheme 3.17).  
 
Scheme 3.17 – Proposed mechanism for the formation of spirocyclic indolenines 
Assuming the reaction is irreversible, the diastereoselectivity of the reaction is 
determined by the facial selectivity of the nucleophilic addition into the N-acyliminium 
ion. The formation of syn-214 as the major product could be attributed to a π-π 
stabilising interaction between the aromatic ring of the indole and imine, as depicted in 
221 in Figure 3.6. Formation of the anti-214 product would therefore be due to the N-
N
N
H
OH
O
N
T3P (50% in THF) 
DIPEA, CHCl3
rt, 16 h
N
H
O
6:1 dr
95%
212 37 syn-214
N
N
H
O
anti-214
N
N
O
H
HB
N
H
O
N
213 220
N
N
O
H
214
N
N
H
O
syn-214
 66 
acyliminium ion 222 intermediate where there is a potentially destabilising clash 
between the methyl group and aromatic ring of the imine (Figure 3.6). 
 
Figure 3.6 – Stereochemical model for the new spirocyclisation reaction 
 
3.3.2. Optimisation of the Synthesis of Spirocyclic Compounds via 
N-Acyliminium Ions 
Following the promising initial result observed for the 2-substituted spirocyclic product, 
an optimisation process was carried out using aromatic imine 37 and 2-methyl indole 
acetic acid 212, using the established DIA conditions used previously (Table 3.1). The 
ratio of diastereoisomers was determined by analysis of the 1H NMR spectra of the 
crude product mixtures. Entry 1 shows the initial promising result for the DIA 
spirocyclisation reaction. Various solvents were then screened and it was seen that the 
best diastereomeric ratio of 9:1 of syn-214:anti-214 was observed when THF was used 
(Entry 2), also providing the product in good yield. Reactions carried out in 2-Me-THF, 
TBME and Et2O showed very poor solubility (Entries 6, 7, 8 and 9) and generally lower 
diastereomeric ratios and yields. Scale-up of the reaction in THF (Entry 10) showed a 
reproducible diastereomeric ratio and excellent yield. A good yield could be obtained 
after only 1 h in THF at rt (Entry 11). Lowering the temperature to 0 °C did not affect 
the diastereomeric ratio but the yield was lower (Entry 12). Increasing the reaction 
temperature to 30 °C (Entry 13) appeared to have little effect, but increasing to 40 °C 
initially showed an interesting switch in diastereoselectivity (Entry 14). Similarly, a 
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switch in diastereoselectivity was seen at 60 °C (Entry 16) but analysis of the 1H NMR 
spectrum of the unpurified reaction mixture showed an unclean reaction mixture that 
was more difficult to purify. However, it turned out that these results at a higher 
temperature were not reproducible as the repeated reactions (Entries 15 and 17) showed 
only a slight decrease in diastereoselectivity compared to the results at rt. As described 
later, it was found that introduction of acidic conditions can have a great effect on the 
diastereomeric ratio observed so it was considered that these initial observations may be 
due to acidic contamination. Ultimately, it was determined that the optimum conditions 
to use for further investigations were THF at rt for 16 h. 
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Entry Solvent Temp (°C) 
Time 
(h) 
Scale (mmol 
imine) 
Ratio of  
syn-214:anti-214 
Yield 
(%) 
1 CHCl3 20 16 1.60 6:1 95 
2 THF 20 16 0.38 9:1 82 
3 Toluene 20 16 0.38 7:1 79 
4 CH2Cl2 20 16 0.38 7.5:1 91 
5 CH3CN 20 16 0.38 5.5:1 61 
6 2-MeTHF 20 16 0.38 7.8:1 74 
7 TBME 20 16 0.38 1:1.1 51a 
8 TBME 20 16 0.38 1.5:1 42a 
9 Et2O 20 16 0.38 1:1.4 40a 
10 THF 20 16 1.52 10.8:1 92 
11 THF 20 1 0.38 10:1 86 
12 THF 0 3 0.38 10.3:1 44 
13 THF 30 16 0.38 9.7:1 88 
14 THF 40 16 0.38 1:1.5b 83 
15 THF 40 16 0.38 8.5:1 91 
16 THF 60 16 0.38 1:1.1b 49a 
17 THF 60 16 0.38 7:1 82 
a. Estimated yield of desired product; 1H NMR spectra shows contamination by minor 
impuritities.  
b. Observed ratios likely due to acidic contamination of the reaction mixture. 
Table 3.1 – Solvent and temperature screen for the DIA spirocyclisation reaction 
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3.3.3. Broadening the Substrate Scope of the Spirocyclisation 
Reaction 
A strategy for investigation into the substrate scope for the reaction was then envisaged. 
As discussed in the project outline (Figure 3.4), the indole acid substrate would be 
varied by substitution around the aromatic ring and in the 2-position. Additionally, the 
scope of the imine would be explored, as well as the size of the spirocyclic ring formed.  
3.3.3.1 Fischer Indole Synthesis of 2-Methyl Substituted Indoles  
The first point of diversity to be explored was substitution around the indole ring, 
keeping the 2-position substituent consistent as a methyl group. The required indole 
acids were unavailable commercially but could be synthesised using Fischer indole 
methodology. The Fischer indole reaction between arylhydrazones and ketones or 
aldehydes, in the presence of an acid catalyst, can be used to synthesise indole 
products.121 One of the main features of the Fischer indole synthesis is the possible 
formation of two 2,3-disubstituted regioisomers when unsymmetrical ketones are used 
(Scheme 3.18). 
 
Scheme 3.18 – Formation of regioisomers in the Fischer indole reaction 
 The regioselectivity is generally dependent on the acidity of the medium, substitution of 
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position, with the acid functionality on the 3-position of the indole. Therefore, it was 
important that the chosen synthesis afforded the correct regioisomer. A literature 
procedure for the synthesis of a 5-fluoro indole ester 225 discussed the effect on the 
regioselectivity of using different ketone substrates.  Liedtke et al. observed that when 
phenylhydrazine 223 was reacted under acidic conditions with substrate 224 (where R2 
= H or CH3), the alkyl acid functionality was solely directed to the 3-position of the 
indole product 225.123 If substrate 226 was used under the same conditions (with an 
ethoxycarbonyl tail end), the alkyl acid was typically directed to the 2-position of the 
indole product 227 (Scheme 3.18). It was noted that elongation of the alkyl chain 
inbetween the two functional groups in substrate 224 was tolerated and did not affect 
regioselectivity, which would be useful for this project in varying the size of the 
spirocyclic ring formed. However, if the alkyl chain was extended in substrate 226 or 
the alkyl chain on the tail end was extended then different C2/C3 regioisomeric mixtures 
were obtained.  
 
Due to this literature background, the synthesis of the 5-fluoro-substituted indole 231 
was initially investigated and the results are shown in Table 3.2. The fluoro-
phenylhydrazine hydrochloride salt 228 was used in the reaction as the free base form of 
these hydrazine-type starting materials are not very stable,122 and the HCl salt is 
commercially available.  Initially, synthesis of indole ester 231 was attempted by 
refluxing hydrazine 228 and ketone 229 in MeOH/H2SO4.123 Purification by column 
chromatography provided a 3% yield of the pure substituted indole 231 (Entry 1) due to 
coelution of the rest with the remaining hydrazine intermediate. The Fischer indole 
reaction between fluorophenylhydrazine 228 and methyl 4-oxopentanoate 229 was 
significantly improved by microwave irradiation (MW) at 90 °C and the product was 
isolated in 87% yield (Entry 2).123 Remaining methyl ester 229 was observed in the 1H 
NMR spectrum of the unpurified reaction mixture; attempts to eliminate this by using an 
excess of the hydrazine 228 were unsuccessful so careful purification by column 
chromatography was required. Alternative reaction conditions were attempted in order 
to carry out this indole synthesis on a larger scale. Use of HCl in EtOH under reflux 
conditions provided the product 232 in 21% yield (Entry 3).124  
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Entry Conditions  R group Yield (%) 
1 MeOH/H2SO4, reflux, 16 h Me 3 
2 MeOH/H2SO4, MW, 10 min, 120 °C Me 87 
3 2 M HCl/EtOH, reflux, 4.5 h Et 21 
Table 3.2 – Fischer Indole synthesis of 5-fluoro indole acetic ester 231 and 232 
Following the successful synthesis of a 5-fluoro substituted indole ester 231, the 
synthesis of other substituted indole substrates was focussed on. It was found that one 
set of Fischer indole conditions was not suitable for all the indole substrates, so a 
selection of conditions was used. This is due to the various substitution positions and 
groups that can affect the efficiency of the [3,3]-sigmatropic rearrangement reaction due 
to steric and electronic effects.122 The conditions shown in Table 3.2 were attempted on 
other substrates, as well as refluxing in EtOH/H2SO4,125 or initial formation of the 
hydrazone intermediate with acetic acid.126,127 The best conditions for the synthesis of 
each indole ester substrate are shown in Table 3.3 and Table 3.4. The conditions in 
Table 3.4 use the γ- or δ-keto-acid starting material, which undergoes an in situ 
esterification to form the ester product.  
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Hydrazine starting 
material 
Reaction 
Conditions 
Product Yield (%) 
 
R2 = Me 
MeOH/H2SO4, MW, 
90 °C, 20 min 
 
 
87 
 
R2 = Et 
2M HCl/EtOH, 
reflux, 4-20 h 
 
 
57 
Table 3.3 – Summary of Fischer Indole syntheses of indole ester substrates  
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Hydrazine starting 
material 
Reaction 
Conditions 
Product Yield (%) 
 
n = 2 
2M HCl/EtOH, 
reflux, 4.5 h 
 
 
59 
 
 
 
 
 
n = 1 
EtOH/H2SO4, 
reflux, 16-24 h 
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Table 3.4 – Summary of Fischer Indole syntheses of indole ester substrates  
Azaindoles are very common structures in biologically active compounds and are 
important in medicinal chemistry so an azaindole substrate example was highly desired 
as part of our methodology.85,128 Many classical indole syntheses have been used to 
synthesise azaindoles, such as the Reissert synthesis,129,130 the Bartoli synthesis,131 and 
the Larock synthesis132 amongst others, with the various methods more suited to certain 
substitution patterns around the indole ring. The most well-known Fischer indole 
synthesis has rarely been applied to azaindole chemistry due to the unfavourable 
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electron withdrawing properties of the nitrogen which can affect the [3,3]-sigmatropic 
rearrangement step of the cyclisation.128 Utilising the fact that Fischer indole 
cyclisations are more efficient when involving arylhydrazines with electron-donating 
groups,35 Suzenet et al. were able to develop a synthesis of 4- and 6-azaindoles via the 
Fischer indole reaction.128,133 Inclusion of a methoxy group in the para-position to the 
hydrazine function was shown to be essential for successful indole formation.128 The 
postulated mechanism for the reaction included cleavage of the N-N bond in 
intermediate 243 assisted by the mesomeric effect of the methoxy group (Scheme 3.19). 
It should also be noted that the absence of symmetry in the hydrazine starting material 
could lead to the formation of two possible isomers but the suggested mechanism makes 
formation of the other regioisomer less likely.128 
 
Scheme 3.19 – Fischer Indole mechanism for the synthesis of azaindoles 
Synthesis of indole 248 was initially attempted using the literature conditions,128 
although the desired product 248 was not in the precedented substrate scope. First, the 
hydrazine 247 was synthesised from the amine 246 using the literature procedure.128 
Reaction of hydrazine 247 with levulinic acid in 4 wt% H2SO4(aq) at 100 °C for 4 h 
resulted in an unclean reaction mixture which had no obvious product peaks by 1H 
NMR spectroscopy. Reaction in 2 M HCl/EtOH at reflux, previously used successfully 
for other substrates, also resulted in a messy crude reaction mixture that was not 
purified. Pleasingly, indole 248 was successfully synthesised using the established 
microwave conditions and was isolated in 77% yield (Scheme 3.20).  
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Scheme 3.20 – Synthesis of azaindole ester via Fischer indole methodology 
Hydrolysis of the indole ester substrates was then carried out to provide the required 
acid substrates. This could be achieved using the same conditions for all substrates and 
the results are shown in Table 3.5. 
 
 
 
 
 
 
 
 
 
 
Table 3.5 - Hydrolysis conditions of indole esters to give indole acids 
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3.3.3.2 Reaction of 2-Methyl Indole Substrates in DIA Spirocyclisation and 
Assignment of Stereochemistry  
The reaction of 5-fluoro substituted indole 249 and imine 37 was first attempted under 
the optimised conditions determined earlier (Table 3.1). The desired spirocyclic product 
256 was formed in a 6:1 ratio of syn-256:anti-256 diastereoisomers by 1H NMR 
spectroscopy. The diastereomeric ratio obtained is lower than the 10:1 dr for the 
unsubstituted indole in THF at rt (see Table 3.1, Entry 10). The two diastereoisomers 
were separated by column chromatography and isolated with a combined yield of 81%.  
 
Scheme 3.21 – DIA spirocyclisation reaction of 5-fluoro indole acid 256  
Following this promising result, the remaining indole acid substrates 250, 251, 252, 253, 
254 and 255 were reacted under the same conditions to give a range of spirocyclic 
products in good diastereoselectivity and 81-96% yield (Table 3.6). The major 
diastereoisomer formed in each reaction had syn relative stereochemistry. It each case, 
the diastereoselective ratio stated was determined by analysis of the unpurified reaction 
mixture using 1H NMR spectroscopy. The isolated masses of the products can suggest 
an alternative ratio of syn:anti products, as seen in the Chapter 5.3.2. This could be due 
to equilibration of the diastereoisomers to the more thermodynamically stable product 
under the column conditions, which is an observed process under acidic conditions that 
will be discussed in section 3.3.8. Alternatively, the ratio of products could be affected 
during the selection of the column fractions, which is done to ensure the purity of the 
products. 
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Table 3.6 – Spirocyclisation with 2-methyl 3-indole acetic acid derivatives  
These results show that the spirocyclic reaction is not adversely affected by substitution 
on the indole scaffold of the product. Most of the diastereoisomers were separable or 
partially separable by column chromatography, and this allowed complete 
characterisation of both products. Throughout the process, diagnostic peaks were 
observed in the 1H NMR spectra of the products and allowed the stereochemistry of the 
products to be assigned with some confidence, without the need for an X-ray crystal 
structure of each major isomer. The X-ray crystal structure of spirocyclic indolenine 
syn-214 (Figure 3.7) was used to determine the stereochemistry of the related 
compounds shown in Table 3.6. The protons that gave diagnostic signals in the 1H NMR 
spectra are shown in Figure 3.7. The aromatic proton (shown in red) was identified 
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unequivocally using HMBC analysis to confirm which aromatic proton was giving the 
diagnostic signal. The methyl group (shown in green) appears as a singlet, which is 
deshielded possibly due to anisotropic effects resulting from the neighbouring imine. 
The NCH proton (shown in blue) also appears as a singlet and shows diastereomeric 
character. 
    
Figure 3.7 – X-ray crystal structure of spirocyclic indolenine 214 
The diastereomeric ratios of the products were assigned from the 1H NMR spectrum of 
the crude mixture using the signal corresponding to an aromatic proton shown in Figure 
3.8. The 1H NMR spectra of the major diastereoisomer syn-214 and the minor 
diastereoisomer anti-214 are shown in Figure 3.9 and Figure 3.10 respectively and the 
diagnostic signals from the aromatic and methyl signals can be observed. 
 
Figure 3.8 – 1H NMR spectrum for crude mixture of spiroindolenine product syn-
214 and anti-214 
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Figure 3.9 – 1H NMR spectrum for the major spiroindolenine product syn-214  
 
 
Figure 3.10 - 1H NMR spectrum for the minor spiroindolenine product anti-214 
The 1H NMR spectra of the other compounds in Table 3.6 showed signals for the 
corresponding peaks at very similar chemical shift values to the values observed for syn-
214 and anti-214. The 1H NMR spectra of the major syn diastereoisomers contain an 
aromatic proton signal between 6.54-6.32 ppm and/or a methyl signal between 2.65-2.54 
ppm. The corresponding signals in the minor anti diastereoisomers appear at 5.99-5.81 
ppm for the aromatic signal and 1.97-1.66 ppm for the methyl group. The signal for the 
NCH protons at the reaction centre also show some diastereomeric character, but the 
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ppm range for the major and minor diastereoisomer was much wider and less consistent 
so these were not used diagnostically to determine the stereochemistry (although these 
signals proved useful for determination of the diastereomeric ratio). The reason for the 
difference in ppm can be attributed to the anisotropic effects of the surrounding aromatic 
groups relative to the methyl group and aromatic proton. From the X-ray crystal 
structure of spiroindolenine 214 (Figure 3.7), it can be seen that the aromatic proton is 
very close in proximity to the indole aromatic ring, and the methyl group is mostly 
unaffected by the surrounding groups. The structure of syn-214 and anti-214 is depicted 
in Figure 3.11, highlighting the position of the diagnostic aromatic and methyl groups 
relative to the rest of the molecule.  
  
Figure 3.11 – Structure of syn-214 and anti-214 highlighting the position of the 
diagnostic aromatic and methyl protons 
From Figure 3.11, it can be seen that in syn-214 the methyl group is not in close 
proximity to other groups in the molecule so a chemical shift of 2.65-2.54 ppm is 
observed and is expected for a methyl group next to an imine functionality. However, in 
anti-214 the methyl group is situated above the aromatic ring of the imine component 
and will be affected by the anisotropic effects of this group. As a result, the signal for 
the methyl group in anti-214 is observed between 1.97-1.66 ppm due to the increased 
electron shielding from the delocalised ring of electrons in the aromatic π-system. The 
aromatic proton signal is observed between 5.99-5.81 ppm in anti-214, which is very 
shielded for an aromatic proton and can be attributed to the assumed proximity to the 
methyl group. In syn-214, the aromatic proton is a lot more deshielded than in anti-214 
by proximity to the electron-withdrawing nitrogen on the indole aromatic ring. These 
diagnostic signals proved to be a very useful tool in the characterisation of the two 
diastereoisomers. In addition, an X-ray crystal structure of the bromo-substituted 
spirocyclic product syn-259 was also obtained to confirm that the 1H NMR spectroscopy 
diagnostic signals were consistent for the same diastereoisomer (Figure 3.12). 
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Figure 3.12 – X-ray crystal structure of syn-259 (CCDC: 1436468) 
 
3.3.4. DIA Spirocyclisation with Variation in the 2-Position of the 
Indole 
Following the successful reaction of 3-indole acetic acid 212 and imine 37, variation of 
the group in the 2-position was investigated to determine the effect on 
diastereoselectivty and yield. Initially, an indole acid substrate containing a phenyl 
group in the 2-position was pursued. Lavilla et al. had previously developed an efficient 
C2 arylation of tryptophan carboxylic acids and had also demonstrated the 
transformation on indole carboxylic acids.134 The literature conditions were therefore 
repeated on 3-indole acetic acid 215 to give 2-phenyl indole acid 263 in 56% yield 
(Scheme 3.22). 
 
Scheme 3.22 – C-H arylation of 3-indole acetic acid 263 
2-Phenyl-substituted indole 263 was then reacted in the subsequent DIA spirocyclisation 
reaction with imine 37 under the optimised conditions (Scheme 3.23) to give the 
spirocyclic product 264 in a 71% combined yield and 8:1 dr (by integration of the NCH 
proton signals in the 1H NMR spectrum unpurified reaction mixtures). Analysis of the 
1H NMR spectrum of the crude mixture suggested that the diastereoselectivity of the 
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reaction was opposite to that observed with the 2-methyl substrates. This was based on 
the observation of an aromatic peak at 5.96 ppm for the major product and at 6.22 ppm 
for the minor product (see Figure 3.13); for the 2-methyl products the aromatic proton 
signal at the more downfield position is the major diastereoisomer. An X-ray crystal 
structure of the major diastereoisomer was thus obtained, confirming this switch in 
stereoselectivity (Figure 3.14).  
 
Scheme 3.23 – DIA spirocyclisation reaction of 2-phenyl indole acid 263  
 
Figure 3.13 – 1H NMR spectrum of the unpurified reaction mixture of 
spiroindolenine 264 
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Figure 3.14 – X-ray crystal structure of anti-264 (CCDC: 1436405) 
As discussed earlier (see Section 3.3.1), the facial selectivity of the nucleophilic attack 
of the indole onto the N-acyliminium ion establishes the diastereoselectivity of the 
reaction. The reactive conformation of the N-acylimiminium ion intermediate appears to 
be affected by the presence of either a methyl group or phenyl group in the 2-position. 
Figure 3.15 and Figure 3.16 show the 2 possible conformers of the 2-methyl N-
acyliminium ion 265 and 2-phenyl N-acyliminium ion 266 respectively and how these 
relate to the major and minor diastereomeric products of 214 and 264. As previously 
mentioned, it was thought that when there is a methyl group in the 2-position, the 
aromatic rings of the indole and imine can form a π-π stabilising interaction and upon 
formation of the spirocycle the major product syn-214 is obtained (Figure 3.15). 
However, if there is a phenyl group in the 2-position then an alternative stronger π-π 
stabilising interaction between the 2-phenyl group and the aromatic ring of the imine is 
possible, which leads to the formation of the major diastereoisomer anti-264. In 
comparison to this stronger interaction, the possible π-π interaction between the 
aromatic rings of the indole and imine components is now less stabilising than the 
interaction in N-acyliminium ion 265 and syn-264 is the minor product (Figure 3.16).  
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Figure 3.15 – Stereochemical model of the 2-methyl spirocyclisation reaction  
 
Figure 3.16 – Stereochemical model of the 2-phenyl spirocyclisation reaction  
Variation of the group in the 2-position was targeted next to determine the effects of 
different groups on the diastereoselectivity and yield of the subsequent DIA 
spirocyclisation reaction. It was initially believed that having no group in the 2-position 
of the indole acid substrate would result in formation of a fused indole product, rather 
than a spirocycle.107,135,136 However, upon subjecting 3-indole acetic acid 215 and imine 
37 to the optimised reaction conditions for the DIA spirocyclisation, analysis of the 1H 
NMR spectrum of the crude mixture revealed a good conversion to the spirocyclic 
product with an 11:1 dr of syn-267:anti-267. Upon column chromatography, the 
spirocyclic product was obtained in a combined yield of 81% (Scheme 3.24). An X-ray 
crystal structure of the major diastereoisomer, syn-267, was obtained to confirm the 
diastereoselectivity (Figure 3.17).  
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Scheme 3.24 – DIA spirocyclisation of 2-H indole acid 215 and imine 37 
 
Figure 3.17 – X-ray crystal structure of syn-267 (CCDC: 1506360) 
Following the successful synthesis of spiroindolenine 267, synthesis of a 6-membered 
spirocycle with no substitution in the 2-position was attempted. Acid 268 and imine 37 
were reacted under the optimised DIA conditions but the 1H NMR spectrum of the 
unpurified reaction mixture appeared very broad making it challenging to determine the 
outcome of the reaction (Scheme 3.25). It was noted that the 1H NMR spectrum lacked 
the distinctive signals between 4-5 ppm correlating to the NCH protons. However, mass 
spectrometry suggested that the product was present so purification by column 
chromatography was attempted, but the obtained fractions also did not show any clean 
product. It was thought that the lack of substitution on the 2-position of the resulting 
spiroindolenine 269 may lead to trimerisation in solution, as had previously been seen 
with analogous work within the Taylor group.113 It was found that these trimers could be 
characterised by addition of TFA to break down the trimer to the monomer TFA salt. 
However, treatment of the reaction mixture with TFA appeared to show the presence of 
the rearranged product 270, as seen in previous work in the Taylor group after addition 
of a Lewis acid (Scheme 3.25).20 The reaction was not pursued as it had been anticipated 
that some of the 2-H spirocyclic targets could be a challenge due to potential migration 
and the presence of trimers.  
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Scheme 3.25 – DIA spirocyclisation reaction of 3-indole propanoic acid 268  
The reaction of imine 37 and Boc-protected tryptophan 271 was also attempted under 
the optimised DIA conditions (Scheme 3.26). It should be noted that the inclusion of an 
additional chiral centre means that there are now four possible diastereomeric products, 
which could complicate the purification. Perhaps unsurprisingly, analysis of the 1H 
NMR spectrum of the unpurified reaction mixture showed a complex mixture of 
products by 1H NMR spectroscopy but mass spectrometry showed an [M + Na]+ peak 
for the product 272. Upon thorough purification by column chromatography, many 
products were isolated but none looked clean by 1H NMR spectroscopy. Suspecting the 
presence of trimers due to the lack of substitution on the 2-position, the most promising 
product sample was treated with TFA but this did not clarify the situation. It was 
suggested that Boc induced rotamers could have been present, further complicating the 
appearance of the 1H NMR spectra. Therefore, it was decided that this product was not 
suitable and a potential tryptophan related product may need to contain a substituent in 
the 2-position with an alternative protecting group.  
 
Scheme 3.26 – DIA spirocyclisation reaction of Boc-protected tryptophan 271 
Complementary work on the DIA reaction of related tryptophan acid substrates 
containing an aromatic group at the 2-position of the indole with imine 37 has been 
successful, particularly when performed at higher temperatures.* 
 
                                                
* Work carried out by MChem student, Jai Mistry. 
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3.3.5. Pyrrole-based Acid Substrates in the DIA Spirocyclisation 
Reaction  
Pyrrole acetic acids were then investigated as potential substrates in the DIA 
spirocyclisation reaction. It has been shown that the dearomatisation of pyrroles via the 
2-position is possible,137-139 and another member of the Taylor group was able to 
demonstrate this using the DIA spirocyclisation methodology by reacting pyrroles 273 
and 274 with indole 37 at 70 °C in CHCl3 for 1 h to give spirocyclic products 275 and 
276 in good yields (Scheme 3.27).* An elevated reaction temperature was necessary for 
the complete reaction of the pyrrole acid substrates. The phenyl substituted pyrrole 
spirocycle 276 was also crystalline so an X-ray crystal structure of the major 
diastereoisomer syn-276 was obtained to determine the stereochemistry as pictured 
(Figure 3.18). These pyrrole examples showed the same stereoselectivity to the majority 
of indole substrates, where the nitrogen of the pyrrole is syn to the hydrogen of the NCH 
group. 
 
Scheme 3.27 – DIA spirocyclisation of 2-pyrrole acetic acids 273 and 274* 
  
Figure 3.18 – X-ray crystal structure of syn-276 (CCDC: 1436465)* 
                                                
* Reaction carried out and X-ray crystal structure obtained by Dr. Graeme Coulthard in 
the Taylor group.  
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A more challenging pyrrole substrate 278 was then targeted for use in the DIA 
spirocyclisation reaction. Diester pyrrole 277 had been synthesised within the Taylor 
group using literature procedures.140 Selective hydrolysis gave pyrrole acid 278 in a 
21% yield (Scheme 3.28).  
 
Scheme 3.28 – Selective hydrolysis of diester 277 
The pyrrole acid 278 was reacted with imine 37 in the DIA spirocyclisation using the 
same conditions as for the 2H-pyrroles and the product 279 was obtained in a 41% yield 
(Scheme 3.29). *  Unfortunately, product 279 was not crystalline so the relative 
stereochemistry could not be assigned.   
 
Scheme 3.29 – DIA spirocyclisation of 3-pyrrole acetic acid 278  
This example was particularly pleasing, as the synthesis of 3H-pyrroles is a challenge 
due to their inherent instability.141 Indeed, it was noted that during the process of 
obtaining NMR spectroscopic data for characterisation of 279 in CDCl3, an aldehyde 
peak became present in the 1H NMR spectra. This was thought to be due to the acidic 
CDCl3 initiating a ring-opening process to give the N-acyliminium ion 280, which could 
be hydrolysed to give aldehyde 281 (Scheme 3.30).  
                                                
* Spiroindolenine 279 was obtained in 59% yield by Dr. Graeme Coulthard. 
N
H
OEt
O
EtO
O
N
H
OH
O
EtO
O
KOH, H2O/EtOH
70 °C, 30 min
21%
277 278
N
T3P (50% in THF) (1.5 eq), 
DIPEA (1.85 eq)
CHCl3, 70 °C, 1 h
NO
37
N
H
N
H
O
OH
278
EtO2C EtO2C
279
41%
4:1 dr
 89 
 
Scheme 3.30 – Possible ring-opening mechanism of 3H-pyrrole spirocycle 
 
3.3.6. Preparation and Reaction of Different Imine Scaffolds in 
Spirocycle Synthesis 
Having successfully broadened the substrate scope for the acid components in the 
spirocyclisation reaction, an investigation into the scope of the imine components was 
started. Use of the methoxy-substituted aromatic imine 283 was investigated first. 6,7-
Dimethoxy-3,4-dihydroisoquinoline 283 was synthesised in 93% yield from the amine 
282 using NBS oxidation (Scheme 3.31).52  
 
Scheme 3.31 – Synthesis of methoxy-substituted aromatic imine 283 
The DIA reaction of methoxy-substituted imine 283 and the unsubstituted indole acetic 
acid 212 successfully proceeded under the optimised conditions for spirocycle synthesis 
(Scheme 3.32). The product 284 was obtained as a 3:1 mixture of syn-284:anti-284 by 
1H NMR spectroscopy and the diastereoisomers were partially separable by column 
chromatography. A combined yield of 73% indicated that variation of the imine scaffold 
was tolerated in the spirocycle synthesis. The diagnostic signals observed in the 1H 
NMR spectra for the indolenine-methyl group confirmed that the major diastereoisomer 
was syn-284 (singlet at 2.62 ppm for syn-284 and 1.90 ppm for anti-284). 
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Scheme 3.32 – DIA spirocyclisation of methoxy-substituted aromatic imine 283  
Other aromatic imine substrates were then reacted under the same conditions and the 
results are shown in Table 3.7. Tetra-substitution around the aromatic ring was shown 
not to hinder the reaction as spirocyclic product 285 was obtained in a 79% yield by 
performing the reaction at 70 °C in CHCl3 for 1 h. Another member of the Taylor group 
was able to show that thiophene- and pyrrole-fused imines were also suitable substrates 
and obtained the spirocyclic products 286 and 287 in 81% and 75% respectively.*  
 
 
 
 
 
a) Reaction performed at 70 °C in CHCl3 for 1 h. 
Table 3.7 – DIA spirocyclisation reactions of various aromatic imines* 
A dibenzylated imine 290 had previously been used as a model substrate in the 
development of DIA methodology to access a range of heterocycles.21 It was hoped that 
this substrate would be tolerated in the DIA spirocyclisation reaction, despite the 
increased steric bulk of the dibenzyl groups. The imine 290 was synthesised by 
                                                
* Thiophene- and pyrrole-fused imine examples carried out by Dr. Graeme Coulthard in 
the Taylor group. 
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dialkylation of Boc-protected lactam 289 and subsequent reduction of the crude amide. 
The Boc group was then removed by addition of TFA which initiated in situ elimination 
of the hemiaminal to give the imine 289 in a 46% yield over 3 steps (Scheme 3.33).  
 
Scheme 3.33 – Synthesis of dibenzylated imine 290 
Imine 290 had previously been reacted in other DIA reactions in toluene at 90 °C for 18 
h,21 and under these conditions the DIA spirocyclisation reaction proceeded to give 
product 291 in an 89% yield and 3:1 dr of syn-291:anti-291. An X-ray crystal structure 
was obtained for the major product and it was seen that the usual diastereoselectivity for 
the reaction of 2-methyl substituted indoles was observed, with the NCH proton and 
methyl group syn to each other (Figure 3.19). 
 
Scheme 3.34 – DIA spirocyclisation of dibenzylated imine 290  
  
Figure 3.19 – X-ray crystal structure of syn-291 (CCDC: 1436396) 
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The next imine substrate of interest was an acyclic imine 293. Acyclic imines are 
usually avoided in N-acyliminium chemistry because of their tendency to hydrolyse.142 
Imine 293 was synthesised following a literature procedure for the condensation of 
paramethoxybenzaldehyde 292 and methylamine to give the product in 95% with no 
further purification needed (Scheme 3.35).143 
 
Scheme 3.35 – Synthesis of acylic imine 293 
Subjecting this imine 293 and indole 212 to a range of DIA reaction conditions, varying 
the temperature and reaction time, showed that the optimum reaction conditions were in 
THF at 70 °C for 1 h. Using these conditions, the spirocyclic product 294 was isolated 
in a 71% yield with a 4.5:1 mixture of syn-294:anti-294 diastereoisomers by 1H NMR 
spectroscopy (Scheme 3.36). An amide byproduct resulting from hydrolysis of the 
intermediate N-acyliminium ion was also observed (but not isolated cleanly), indicating 
the increased tendency for acyclic N-acyliminium ions to undergo hydrolysis but 
pleasingly this was not the major product under the conditions used.  
 
Scheme 3.36 – DIA spirocyclisation of acylic imine 293 and indole acetic acid 212 
An X-ray crystal structure of the major diastereoisomer was also obtained to confirm the 
stereochemistry. It was observed that the diastereoisomer was syn-294 but it can be seen 
from the X-ray structure that the untethered imine creates a distorted shape when 
compared to the cyclic imine examples (Figure 3.20). 
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Figure 3.20 – X-ray crystal structure of syn-294 (CCDC: 1436400) 
Imine 293 was also successfully used in the DIA reaction with 2-phenyl indole 263 to 
give the spirocyclic product 295 in a 76% yield and 1.8:1 dr, with unassigned 
stereochemistry (Scheme 3.37). Unfortunately, the diastereoisomers were not separable 
following column chromatography. 
 
Scheme 3.37 – DIA spirocyclisation of 2-phenyl indole acid 263 and imine 193 
Next, isoquinoline 296 was employed in place of the imine substrate to determine 
whether cyclisation could occur and form a spirocyclic product 297 on this more 
difficult substrate; the main challenge is overcoming the loss of aromaticity upon 
cyclisation. The DIA reaction was attempted in THF at room temperature for 16 h and 
70 °C for 1 h but both gave starting materials only. Conducting the reaction under more 
forceful conditions of toluene at 90 °C for 16 h also resulted in no product formation 
(Scheme 3.38).  
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Scheme 3.38 – Attempted DIA spirocyclisation reaction using isoquinoline  
 
3.3.7. Addition of Lewis Acid to the Spirocyclisation Reaction 
It was previously shown in the group that when a Lewis acid was added to the reaction 
of acid 215 and imine 37 under DIA conditions, a pentacyclic product 216 was formed 
(Scheme 3.39).20 It was believed that the mechanism of the DIA reaction to give product 
216 initially reacted through the 3-position of the indole, and then a 1,2-migration would 
give the planar product 216 (Scheme 3.15). Assuming this is correct, the spirocyclic 
product 267 should rearrange to the planar product 216 if subjected to a Lewis acid, as 
observed in other related reactions.107  
 
Scheme 3.39 – DIA reaction of 3-indole acetic acid 215 and imine 37  
Thus, the spirocycle syn-267 was taken up in THF, then BF3OEt2 was added and the 
reaction was stirred at rt for 1 h. On analysis of the unpurified reaction mixture by 1H 
NMR spectroscopy, it could be seen that the spirocyclic products syn-267, anti-267 and 
the fused product 216 were present 1:2.4:1.1 ratio of syn-267:anti-267:216. As the 
reaction had not gone to completion, it was repeated at 70 °C with a similar ratio of 
products observed. 
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Scheme 3.40 – Attempted 1,2-migration of spiroindolenine 267 
The migration reaction appears to be a lot more facile when the Lewis acid is added in 
the one-pot DIA reaction. However, observation of the pentacyclic product following 
addition of BF3OEt2 to syn-267 confirms that a 1,2-migration reaction is possible and 
suggests that this is how formation of the pentacyclic product proceeds. The fact that an 
epimerisation from syn-267 to anti-267 in the presence of the Lewis acid also occurs 
suggests that this could be an important factor in facilitating the 1,2-migration reaction 
to give product 216.  
 
3.3.8. Equilibrium Studies on Spirocyclic Indolenines 
Throughout the development of the DIA spirocyclisation epimerisation of the 
diastereostereoisomers was occasionally observed with some products, particularly in 
acidic conditions. As discussed earlier, subjecting syn-267 to BF3OEt2 resulted in some 
epimerisation to anti-267 and rearrangement to give 216. This epimerisation reaction 
had also been observed when samples were stored in CDCl3 during 1H NMR 
spectroscopy, most noticeably with spiroindolenines containing a para-methoxy 
substituent on the imine (284 and 285). Therefore, some equilibrium studies were 
undertaken to attempt to determine what might be causing this epimerisation. The 
stability of the spirocyclic indolenine anti-214 was initially investigated by stirring the 
compound in THF at rt and 60 °C for 72 h, but no change in diastereomeric ratio was 
observed. Anti-214 was then subjected to the DIA reaction conditions and no change 
was observed (Scheme 3.41).  
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Scheme 3.41 – Reaction of anti-214 in THF and in DIA conditions 
As epimerisation had been observed in CDCl3 for the para-methoxy substituted 
spirocycles 284 and 285, the same test was carried out on syn-214. A 0.02 mmol 
solution of spiroindolenine syn-214 in CDCl3 was analysed by 1H NMR spectroscopy 
over 10 days, but no change in diastereomeric ratio was observed. 
 
Scheme 3.42 – 1H NMR spectroscopic equilibrium study on syn-214 
In earlier reactions where the reaction conditions had contained an acid (see Scheme 
3.59) epimerisation of syn-214 had been observed. Therefore, syn-214 was subjected to 
a stoichiometric amount of HCl in THF for 24 h and analysis of the 1H NMR spectrum 
of the unpurified reaction mixture showed a 1.6:1 dr of anti-214:syn-214, and after 72 h 
the dr was observed to be the same (Scheme 3.43). 
 
Scheme 3.43 – Epimerisation of syn-214 in HCl 
Therefore, it was concluded that epimerisation of the unfunctionalised spirocycle 214 
was possible under strong acidic conditions but did not occur under the basic DIA 
reaction conditions. However, as mentioned earlier, spirocycles 284 and 285 containing 
a para-methoxy substituent on the imine component had been observed to readily 
undergo epimerisation if kept in CDCl3. To investigate this, a 0.02 mmol solution of 
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syn-285 in CDCl3 was analysed by 1H NMR spectroscopy at regular intervals over 10 
days to observe any change in diastereomeric ratio. After one day, there was no change 
in diastereomeric ratio but by seven days a ~6:1 dr of syn-285:anti-285 was observed 
(Scheme 3.44). 
 
Scheme 3.44 – Epimerisation of syn-285 in CDCl3  
The spirocycle syn-284 was also subjected to strongly acidic reaction conditions, and 
after stirring in THF with HCl for 24 h, a complete switch in stereochemistry to anti-284 
was observed by 1H NMR spectroscopy (Scheme 3.45).  
 
 
Scheme 3.45 – Epimerisation of syn-284 to anti-284 in HCl 
A potential reason for the propensity of the methoxy-substituted spirocycle syn-284 to 
undergo epimerisation could be that the mesomeric effect of the methoxy group 
provides an alternative epimerisation pathway (Scheme 3.46). Epimerisation of syn-214 
requires ring-opening via movement of electrons from the nitrogen lone pair, which are 
usually less available due to the amide. 
 
Scheme 3.46 – Proposed mechanism for the epimerisation of syn-284 
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Spirocyclic indolenines syn-284 and syn-285 were also subjected to the DIA conditions 
but no change in diastereomeric ratio was observed by 1H NMR spectroscopy (Scheme 
3.47), showing that under the basic DIA reaction conditions no epimerisation occurs. 
 
Scheme 3.47 – Reaction of syn-284 and syn-285 under DIA conditions 
The conclusion from these experiments is that the diastereomeric ratios observed in the 
DIA spirocyclisation reactions must be kinetic ratios, formed as a result of the 
stabilising π-π stacking interaction between the aromatic rings of the indole and imine 
components. Subjecting the spiroindolenine products to the DIA reaction conditions 
confirmed that no epimerisation under these basic conditions occurred. However, it was 
shown that under strong acidic conditions, the spirocyclic products could undergo 
epimerisation to a presumably thermodynamic mixture of diastereoisomers. Spirocycles 
containing a para-methoxy substituent on the imine, such as syn-284 were shown to 
epimerise more readily, thought to be due to the +M effect of the methoxy group that 
was believed to provide an alternative epimerisation pathway. The position of the 
equilibrium was also shown to be dependent on the acidic reaction conditions.  
 
3.3.9. Derivatisation of Spirocyclic Products 
The DIA spirocyclisation reactions provide access to a broad range of spirocyclic 
indolenine scaffolds, which contain a lot of functionality to allow for further 
transformations. This provides the opportunity to add further structural diversity or to 
tune the properties of the compounds. Initially, reduction of the imine functionality in 
spiroindolenine syn-214 was investigated to afford a spirocyclic indoline product 298. A 
few reduction conditions were attempted including reduction with sodium 
cyanoborohydride,144 and reduction with a Hantzsch ester.145 However, the best yield 
was achieved by refluxing in NaBH4 to give the spiroindoline 298 in 81% yield (Scheme 
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3.48).144 The same reduction conditions were used on the 2-H spirocyclic indolenine 267 
and the spiroindoline 299 was produced in 87% yield (Scheme 3.48). 
 
Scheme 3.48 – NaBH4 reduction of spiroindolenines 214 and 267 
The reduction of spiroindolenine 214 was completely diastereoselective and an X-ray 
crystal structure of the product 298 was obtained to confirm that the stereochemistry of 
the product is that shown in Scheme 3.48. The X-ray structure confirmed that the 
hydride source approached from the least sterically hindered face to give spirocycle 
indoline 298 (Figure 3.21). 
  
Figure 3.21 – X-ray crystal structure of spiroindoline 298 (CCDC: 1436401) 
Reduction of the amide functionality within spirocyclic indolines 298 and 299 was then 
explored. Initially, LiAlH4 reduction of spirocyclic indolenine 214 was carried out to 
determine whether the imine and amide functional groups could be reduced 
simultaneously. With an excess of LiAlH4 and stirring at reflux for 3.5 h, none of the 
desired product 300 was isolated but indole 301 was isolated in 42% yield (Scheme 
3.49).  
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Scheme 3.49 – Attempted LiAlH4 reduction of syn-214 
It was thought that this indole product could form by coordination of a Lewis acidic 
metal species (Al or Li) to the imine and ring opening to give the intermediate N-
acyliminium ion 302. Nucleophilic addition of the hydride onto N-acyliminium ion 302 
to give the amide and subsequent reduction of the amide would give the product 301 
(Scheme 3.50). It was considered that the reduction of the amide should not occur 
before reduction of the imine, due to the lower electrophilicity but this cannot be ruled 
out as an alternative mechanism.  
 
Scheme 3.50 – Proposed mechanism of LiAlH4 reaction with syn-214 
The undesired formation of product 301 demonstrated that the reduction of the imine 
has to be done first using NaBH4 (as shown in Scheme 3.48), followed by reduction of 
the amide. Therefore, reduction of the spiroindolines 298 and 299 was carried out with 
LiAlH4 to give the diamine spirocyclic products 300 and 303 in 75% and 67% 
respectively (Scheme 3.51). 
 
Scheme 3.51 – LiAlH4 reduction of spiroindolines 298 and 299 
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Following the successful addition of a hydride nucleophile into the imine in 
spiroindolenines syn-214 and syn-267, other nucleophiles were attempted. MeLi was 
initially chosen as a methyl nucleophile as it was thought that the opposite 
stereochemistry to spiroindoline 298 could be achieved by nucleophilic attack of MeLi 
onto the least sterically hindered face of spiroindolenine syn-267. Therefore, MeLi was 
reacted with spiroindolenine syn-267 following literature conditions,146 and following 
purification two products were isolated (Scheme 3.52). The desired product 304 was 
isolated in 28% yield and comparison of the 1H NMR spectrum for the product 304 and 
spiroindoline 298 confirmed the opposite diastereoisomer was formed as expected.  
 
Scheme 3.52 – Reaction of syn-267 with MeLi 
It was believed that the other isolated product 305 was a cyclopropane compound 
formed by the MeLi acting as a base, rather than a nucleophile, and forming the enolate 
306 (Scheme 3.54). This could then add into the imine to form the cyclopropane 306, 
which was observed as a single diastereoisomer. A believable model of this structure 
was also able to be made (where minimal ring strain was observed and all bonds looked 
feasible) and gave one possible diastereoisomer so it was thought that this was the 
product observed.  
 
Scheme 3.53 – Suggested reaction mechanism for the possible formation of 
cyclopropane 305 
All of the characterisation data matched up for cyclopropane 305 except for the mass 
spectrum which did not detect the [M + H]+ ion. Therefore, it was thought that the 
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product should be deliberately formed by reaction with a base and an X-ray crystal of 
the product obtained to confirm the product. Reaction of spiroindolenine syn-267 with 
LHMDS at −78 °C for 2 h resulted in isolation of the same product in 70% yield. 
Fortunately, the product was crystalline and observation of the X-ray crystal structure 
showed that, rather than a cyclopropane product 305, a dimer 307 had formed (Scheme 
3.54). The reaction was diastereoselective and the X-ray crystal structure showed the 
interesting shape of the product formed (Figure 3.22). It should be noted that the 1H and 
13C NMR for the suspected product 305 and the dimer 307 matched, confirming that the 
dimer was formed in the MeLi reaction. 
 
Scheme 3.54 – Synthesis of dimer 308 by enolate formation of spiroindolenine 267 
 
Figure 3.22 – Front and side view of X-ray crystal structure of 307 
(CCDC:1506359) 
The dimer product 307 would have formed via formation of the enolate and 
intermolecular addition into the imine, rather than the previously thought intramolecular 
reaction shown in Scheme 3.53. The reaction was repeated at 10 times the dilution to 
investigate whether the cyclopropane product 305 could be formed using a diluted 
reaction mixture to promote the intramolecular reaction between the enolate and imine. 
The reaction mixture was analysed by 1H NMR spectroscopy and this confirmed that the 
product had formed selectively, but mass spectrometry was used to confirm the presence 
of dimer 307 by the observation of a [M + Na]+ peak at 599.2438, which was the most 
intense peak in the spectrum. 
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A Grignard reagent was then used as an alternative methyl nucleophile and the reaction 
conditions used were based on those used by Vincent et al. to add allylMgBr to a 
spiroindolenine (Scheme 3.55).147 Stirring the reaction at rt resulted in decomposition 
and no product was isolated. Reaction at too low temperatures resulted in poor 
conversion of the starting material but, upon stirring at 0 °C for 6 h, the product 304 was 
isolated in 62% yield (Scheme 3.55). The reaction was diastereoselective from the 
methyl approaching the least sterically hindered face to give the product 304 with the 
opposite stereochemistry to spiroindoline 298 confirmed by 1H NMR spectroscopy. It 
was assumed that the syn stereochemistry from the spiroindolenine starting material 
remained in tact in this reaction as there was no acidic additive or reagent in the 
reaction. 
 
Scheme 3.55 – Grignard addition to spiroindolenine syn-267 
Smith et al. demonstrated the addition of pyrrole into a spiroindolenine by reaction in 
the presence of AcOH.148 It was considered that in the presence of AcOH, a 1,2-
migration may take place instead of the nucleophilic addition but pleasingly the 
nucleophilic addition occurred preferentially.107 Subjecting syn-267 to Smith’s 
conditions and purification by column chromatography gave product 308 as one 
diastereoisomer in 86% yield (Scheme 3.56). The 1H NMR spectrum of the unpurified 
reaction mixture suggested a >20:1 ratio of diastereoisomers. It was assumed that, like 
the methyl product 304, the major diastereoisomer was as a result of nucleophilic attack 
on the least sterically hindered face. However, it cannot be assumed that the syn 
relationship of the starting material remained unchanged during the reaction. As 
discussed in section 3.8.8, under strongly acidic conditions syn-267 can epimerise to 
anti-267 and if this epimerisation occurred before addition of the pyrrole nucleophile the 
stereochemistry cannot be confidently assigned.  
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Scheme 3.56 – Addition of pyrrole to the spiroindolenine syn-267 
The nucleophilic addition of pyrrole was also carried out on the 2-methyl substituted 
spiroindolenine 214. Surprisingly, analysis of the crude reaction mixture by 1H NMR 
showed two diastereoisomers in a 1:1.1 ratio, suggesting that the pyrrole was as likely to 
attack from both sides of the imine despite one side being much more sterically 
hindered. However, following column chromatography, none of the pyrrole-substituted 
spiroindoline 309 was observed. Instead, syn-214 and anti-214 were isolated suggesting 
the addition of pyrrole is reversible when there is a substituent on the 2-position of the 
spiroindolenine (Scheme 3.57). 
 
Scheme 3.57 – Attempted addition of pyrrole to spiroindolenine syn-214 
The product of the DIA spirocyclisation reaction, spiroindolenine syn-267, contains an 
imine functionality that could potentially be used as the imine component in a second 
DIA reaction. To determine whether this was possible the spiroindolenine syn-267 was 
reacted with salicylic acid 310 under standard DIA conditions.21 Disappointingly, none 
of the desired product 311 was observed, perhaps because of the increased steric 
hindrance of this imine. Instead, the spiroindolenine syn-267 had epimerised to a 2.2:1 
dr of syn-267:anti-267 (Scheme 3.58). Epimerisation of syn-267 under acidic conditions 
has previously been discussed in Section 3.3.8.  
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Scheme 3.58 – Attempted DIA reaction of salicylic acid 310 with syn-267 
The reaction was repeated using thiosalicylic acid 312 to see if this gave the desired 
product 313. It has been previously suggested that when the acid component of a DIA 
reaction contains a thiol, the mechanism may proceed via initial nucleophilic attack of 
the sulfur into the imine, then intramolecular N-acylation.23 Reaction of the 
spiroindolenine syn-267 and thiosalicylic acid 312 under the standard DIA conditions 
resulted in none of the desired product 313. The spiroindolenine had been epimerised to 
a 1.4:1 dr of anti-267:syn-267 (Scheme 3.59). 
 
Scheme 3.59 – Attempted DIA reaction of thiosalicylic acid 312 with syn-267 
The derivatisation reactions shown highlight some of the possible transformations that 
can be done on the spiroindolenine products 214 and 267 obtained from the DIA 
spirocyclisation methodology. In addition, it is expected that these transformations 
would be possible on the other spirocyclic products described, and it should be noted 
that the transformations are not limited to the examples shown and that other reactions 
should be possible on these diverse scaffolds.  
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3.3.10. 3D Shape Analysis of Spirocycles 
Recently, there has been a lot of interest in the exploration of rigid, 3D scaffolds that 
can access new and interesting areas of chemical space. Spirocycles are inherently 3D as 
a result of the tetrahedral carbon centre and are therefore attracting a lot of attention as 
they are currently poorly represented in drug and screening libraries.83,149,150 Following 
the successful use of DIA methodology in the synthesis of spirocyclic indolenines, 
principal moments of inertia (PMI) plots were used to assess the 3D character of the 
synthesised compounds. Principal moments of inertia plots were introduced by Sauer 
and Schwarz,151 and have been used in the O’Brien group to assess the 3D shape of a 
virtual lead-like library.152 PMI plots are created by computationally generating the 
lowest energy 3D conformer of the molecule using a molecular mechanics analysis in 
Pipeline Pilot. The three principal moments of inertia are calculated from the 3D 
structure and sorted from lowest to highest value, I1, I2 and I3. The PMI values are then 
normalised by dividing the two lowest values by the highest (I1/I3 and I2/I3) to give the 
normalised PMI ratios (NPR1 and NPR2), which can be plotted against each other to 
give a 2D triangular plot.153 The triangular plot shows how rod-like, disc-like or sphere-
like the compounds are depending on whether they are nearer the top-left, bottom or top 
right of the triangular plot respectively.  
 
The PMI plot of 1439 FDA approved small molecule drugs was generated to visualise 
the 3D character of current drug compounds (Figure 3.23).154 The blue triangle shown 
on the PMI plot indicates the under-populated area of chemical space where the 
molecules are more 3D/spherical, with the top right point of the plot representing a truly 
spherical compound (adamantane). The blue triangle contains compounds which have 
values of (NPR1 + NPR2) > 1.2 and is situated away from the rod-disk axis. The PMI 
analysis of the FDA approved small molecule drugs demonstrates that only 23% are 
found within this attractive area, and the majority of compounds are rod- and/or disc-
like. This demonstrates the fact that 3D scaffolds are poorly represented in current drug 
libraries with most drug-screening libraries showing a similar shape distribution.83,155  
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Figure 3.23 – PMI plot of FDA approved small molecule drugs154 
The PMI plot of the lowest energy conformations of the major diastereomeric 
spirocycles synthesised was then generated,* as these were the compounds selectively 
formed in the highest yields throughout the development of the methodology (Figure 
3.24). In contrast to the PMI plot for the FDA approved drug molecules (Figure 3.23), 
88% of the major diastereoisomers are now in the (NPR1+NPR2)>1.2 region. The 
synthesised compounds can be seen to be very spherical, with spirocycles syn-257, syn-
261, syn-295, syn-259, syn-291, syn-256 and anti-264 in particular populating the most 
spherical areas of the PMI plot and the structures of these compounds are shown in 
Figure 3.25. Small changes in the substituents or position of the substituents can be seen 
to make a large difference in how spherical the spirocycle is, e.g. 7-bromo syn-260 is 
less spherical than 5-bromo syn-259. 
 
                                                
* Method of analysis in Pipeline Pilot devised by Mary Wheldon (O’Brien group), Paul 
Bond and Rod Hubbard at the University of York (York Structural Biology Laboratory). 
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Figure 3.24 – PMI plot of lowest energy conformers of major spirocyclic products. 
(All compounds are syn-isomers, except for anti-264) 
 
 
Figure 3.25 – Structure of the most spherical spiroindolenines  
 
The PMI analysis of the spirocyclic scaffolds generated throughout the development of 
the DIA spirocyclisation methodology has shown that the isolated compounds are much 
more spherical in nature than the majority of current drug molecules. Some of the 
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spirocyclic products in particular have a very spherical shape and access areas of 
chemical space that are currently under-explored. Notably, the DIA spirocyclisation 
process takes simple, flat building blocks and quickly builds up molecular complexity 
and shape to give products that have highly desirable 3D scaffolds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 110 
3.4. Conclusions and Future Work 
DIA methodology was successfully applied in the synthesis of novel spirocyclic 
indolenine products. The method provides a new, metal-free dearomatisation reaction 
where simple 2D building blocks can be used to synthesise a broad range of 3D 
spirocyclic scaffolds in an efficient manner. The procedure uses mild conditions making 
it compatible with a wide range of functional groups, demonstrated by the broad 
substrate scope of the reaction. Interesting examples from the substrate scope are shown 
in Figure 3.26, including the azaspirocycle syn-261, the 2-H spirocycle syn-267 and the 
2-phenyl spirocycle anti-264. The observed diastereoselectivity favouring the syn-
products for the 2-methyl spiroindolenines was rationalised by the presence of a 
stabilising π-π interaction between the aromatic rings of the indole and imine 
components, but this stereoselectivity was found to switch when a phenyl group was 
introduced to the 2-position. A number of X-ray crystal structures were obtained 
throughout the project to confirm the observed diastereoselectivity of the reaction. In 
addition, diagnostic signals in the 1H NMR spectra of the products allowed confident 
assignment of the stereochemistry of related compounds, which proved to be a useful 
tool.  
 
Figure 3.26 – Structures of spiroindolenines synthesised using DIA methodology 
The spirocyclic indolenine products formed through the DIA spirocyclisation 
methodology were primed for further functionalisation or derivatisation. This was 
successfully demonstrated with reduction of the imine and amide functionalities, and 
addition of nucleophiles into the imine. An interesting dimer product 307 was 
selectively formed by generation of the enolate and intermolecular addition into the 
spirocyclic imine. 
 
The PMI analysis of the spirocyclic products indicated that the synthesised compounds 
were generally very spherical and occupy areas of chemical space that are currently 
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underexplored. Spirocyclic indolenines syn-257, syn-261, syn-295, syn-259, syn-291, 
syn-256 and anti-264 were all in a very spherical region of the PMI plot. Interestingly, 
small changes in the substituents were shown to dramatically change how spherical the 
products were. The structure of the spirocyclic indolenine products also allows further 
derivatisation (as demonstrated in the project) so that the properties of the products can 
be tuned further. The results of the 3D shape analysis highlight the efficiency of this 
methodology as a way of quickly building complex 3D scaffolds from simple 2D 
building blocks. The PMI analysis of the FDA approved small molecule drugs also 
emphasises the number of planar compounds that are currently used as drug compounds, 
so the development of methodology that can effectively produce 3D compounds would 
allow exploration of new and interesting chemical space.  
 
A natural progression for this project would be to investigate an enantioselective route 
towards the spirocyclic indolenine products. The stereoselectivity of the reaction is 
determined by the facial selectivity of the nucleophilic attack onto the N-acyliminium 
ion intermediate. It was thought that enantioselectivity could be induced at this point by 
the introduction of a chiral phosphoric acid or a thiourea organocatalyst. Jacobsen et al. 
employed a thiourea organocatalyst in an enantioselective Pictet-Spengler reaction for 
the synthesis of a range of tetrahydrocarbazoles.156 However, initial attempts within the 
Taylor group to employ such catalysts in the DIA reaction have proven unsuccessful and 
resulted in no enantiomeric enrichment of the spirocyclic products. Therefore, 
development of an asymmetric variant of the DIA spirocyclisation process could take a 
significant amount of work.  
 
Initial attempts to use the DIA spirocyclisation methodology in the synthesis of 
aspidospermidine will be discussed in the next chapter. Future work for this project 
could focus on showcasing the methodology in the synthesis of other natural products 
containing a spirocyclic scaffold, to demonstrate the versatility of the methodology.  
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4. Attempted Synthesis of Aspidospermidine using Direct 
Imine Acylation Methodology 
4.1. Introduction to Aspidospermidine 
4.1.1. Classification and Biological Activity of the Aspidosperma 
Family 
The aspidosperma family of indole alkaloids is a large subclass of natural products that 
are biosynthetically derived from tryptamine and a monoterpene unit.157,158 They are 
classified based on the original terpene component and compounds that have a 
quaternary carbon centre as a feature of the terpene are part of the aspidosperma family, 
some examples of which are shown in Figure 4.1.157,159 
 
Figure 4.1 – Members of the aspidosperma family157 
Aspidospermidine 169, the parent compound of the aspidosperma family, has attracted a 
lot of attention from groups who wish to showcase new synthetic methodologies.87 The 
scaffold is a desirable target to demonstrate the ability to build up spirocyclic centres, 
and aspidospermidine has also been shown to possess some adrenergic receptor 
activity.88 Tabersonine 316 is an important member of the aspidosperma family due to 
its role in the biosynthesis and chemical synthesis of other important aspidosperma 
alkaloids. It is the precursor for the biologically active alkaloid vindoline 317 and 
biosynthetic and chemical pathways have been demonstrated for this transformation 
(Scheme 4.1).160,161 The potent anti-cancer drugs Vinblastine 318 and Vincristine 319, 
two biologically active vinca alkaloids, are derived from the dimerisation of vindoline 
317 and catharanine (a member of the iboga family of alkaloids) and are used in the 
treatment of leukaemia, Hodgkin’s lymphoma and other cancers (Scheme 4.1).160 The 
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biological importance of these compounds highlights the necessity for new synthetic 
strategies towards these spirocyclic scaffolds. 
 
Scheme 4.1 – Generation of Vinblastine and Vincristine  
 
4.1.2. Previous Syntheses of Aspidospermidine 
Groups wishing to demonstrate new methodology often choose aspidospermidine 169 as 
the synthetic target as it is a simple spirocyclic member of the aspidosperma family. 
Often, methodology aimed towards aspidospermidine can be applied to other examples 
through small modifications of the spirocyclic scaffold. One of the most common 
methods for the synthesis of aspidospermidine 169 involves the late stage construction 
of the indole moiety, first demonstrated by Stork and Dolfini.162 Pictet-Spengler and 
Bischler-Napieralski based approaches are also popular methods due to their general 
applicability to other related alkaloids.163  
 
The late-stage dearomatisation reaction of an indole to generate the final spirocyclic ring 
in the aspidospermidine scaffold is a common strategy.87,164-166 Heathcock et al. 
demonstrated a facile method for the late-stage formation of the spirocyclic ring.87 The 
haloacetamide functionality was chosen for the displacement reaction as it reduced the 
need to use protecting groups and the reactivity could be increased through the use of an 
iodo- rather than bromo- or chloro-acetamide. After halogen exchange on the 
chloroacetamide 320, the iodoacetamide was treated with silver trifluoroacetate to give 
the spirocyclic indolenine 321 in 46% yield. This yield was dramatically improved to 
86% through the use of silver triflate, as this modification prevents the formation of a 
trifluoroacetate-related side-product (Scheme 4.2).87 Reduction of the spirocyclic 
indolenine gave (±)-aspidospermidine 169 in an overall yield of 5.9% over 13 steps.87 
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Scheme 4.2 – Synthesis of aspidospermidine 169 via a late-stage dearomatisation87 
This effective strategy has also been used in an efficient synthesis of (±)-
aspidospermidine 169 from the commercially available carbazole 322 (Scheme 4.3).166 
The substituted carbazole 323 was synthesised in 64% yield over four steps and then 
LiAlH4 reduction of the ketone gave an intermediate alcohol. Addition of HCl to quench 
the reaction initiated a dehydration reaction to form an α,β-unsaturated iminium ion 
which was trapped intramolecularly by the amide to give the cyclised product 324 in 
94% yield.166 After a three-step sequence to the mesylated alcohol 325, (±)-
aspidospermidine 169 was generated in a one-pot alkylation/reduction reaction which 
gave the target compound in 20% overall yield over 10 steps (Scheme 4.3).166 
 
Scheme 4.3 - Synthesis of aspidospermidine 169 via a late stage aromatisation166  
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Fuji et al. demonstrated the first enantioselective synthesis of (−)-aspidospermidine 169 
in 1987, based on the Pictet-Spengler approach.163,167 The chiral lactone 326 contained 
the necessary C9 unit with the appropriate stereochemistry to form the monoterpene part 
of the target compound.163 Indole 328 was obtained in a 1:1 ratio of diastereoisomers 
and 84% yield from a Pictet-Spengler reaction of acid 327 and tryptamine, and 
subsequent base hydrolysis (Scheme 4.4). Separation of the diastereoisomers gave only 
3S-328, which cyclised upon treatment with TfOH to give the desired product 329 in 
60% yield. Reduction of the spiroindolenine 329 and amide functionality provided (−)-
aspidospermidine 169 (Scheme 4.4).167 This transformation of alcohol 328 to 
spiroindolenine 329 was also demonstrated by Prasad et al. in a complementary 
synthesis of (−)-aspidospermidine 169 and other aspidosperma alkaloids from a 
common starting material.168 
 
Scheme 4.4 – Synthesis of (−)-aspidospermidine 169 via a Pictet-Spengler 
reaction167 
Movassaghi and Medley used a novel, stereoselective double cyclisation cascade in a 
concise synthesis of (−)-N-methylaspidospermidine.169 Upon treatment with the mildly 
basic additive 3-cyanopyridine in acetonitrile, chiral lactam 330 underwent nucleophilic 
spirocyclisation onto the activated electrophilic carbonyl (Scheme 4.5). This resulted in 
the formation of 2-chlorospiroindoleninium intermediate 331, which reacted further at 
its C2 position via attack of the tethered vinyl group with loss of HCl to give 332. It was 
suggested that the second cyclisation occurs without the use of an activated alkene due 
to the presence of the chlorine on the 2-position and the resulting enhanced 
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electrophilicity.169 The use of Tf2O ensures the interruption of the Bischler-Napieralski 
reaction,94 and subsequent reduction by sodium cyanoborohydride produced the indoline 
333. Hydrogenation of the alkene gave (−)-N-methylaspidospermidine 334 (Scheme 
4.5).169 
 
Scheme 4.5 – Synthesis of (−)-N-methylaspidospermidine 334 via an interrupted 
Bischler-Napieralski reaction169 
Marino et al. employed a ketene lactonisation reaction, developed within their group,170 
to provide a novel approach to the enantiospecific synthesis of aspidosperma 
alkaloids.171 The key reaction allows the chirality of the sulfoxide to be transferred 
through a novel [3,3]-sigmatropic rearrangement of a chiral vinyl sulfoxide 335 with a 
ketene (Scheme 4.6). The lactone 336 was then converted into cyclic enone 337 in three 
steps, which upon treatment with NaH forms the tricyclic core scaffold 338 through a 
tandem conjugate addition/intramolecular alkylation reaction (Scheme 4.6). The 
sequence was completed by Boc cleavage and subsequent conjugate addition, followed 
by Wolff-Kishner and LiAlH4 reductions to provide (+)-aspidospermidine 169 (Scheme 
4.6).171 This unique approach to the synthesis of the aspidosperma alkaloids allows 
access to both enantiomeric series, and derivatisation of the intermediates can provide 
access to other aspidosperma alkaloids.170  
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Scheme 4.6 – Synthesis of (+)-aspidospermidine via a late stage indole formation171 
Rawal et al. described a highly regio- and stereocontrolled approach to the 
aspidosperma alkaloids via a [4+2] cycloaddition reaction.172 This approach was then 
applied in the asymmetric synthesis of (+)-aspidospermidine and other related alkaloid 
natural products (Scheme 4.7). The strategy involved the enantioselective Diels-Alder 
reaction between 2-ethylacrolein 339 with 1-amino-3-siloxydiene 340 catalysed by a 
chiral Cr(III)-salen complex 341. The cycloadduct 342 was obtained in an 84% yield 
with a 95% ee. A subsequent Wittig reaction and Grubbs ring-closing metathesis 
afforded the fused bicycle 343 which was arylated using the iodonium fluoride salt to 
give the enantiomerically enriched product 344 in 62% over three steps. Late-stage 
construction of the indole moiety via a TiCl3 mediated reduction of the nitro group and 
subsequent condensation provided the indole 345. Following this, removal of the 
carbamate and introduction of an alcohol group provided the necessary functionality to 
allow a displacement reaction to give the spirocyclic ring junction and the synthesis of 
(+)-aspidospermidine 169 was completed (Scheme 4.7).172 
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Scheme 4.7 – Synthesis of (−)-aspidospermidine 169 via a Diels-Alder reaction172 
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4.2. Project Outline 
The biological importance of the spirocyclic scaffolds contained in the aspidosperma 
alkaloid core structures makes the development of new syntheses towards these 
structures desirable. It was envisaged that the DIA spirocyclisation methodology 
developed in this project could be applicable in the synthesis of these indole alkaloids. 
(±)-Aspidospermidine 169 was chosen as the target compound to explore the 
methodology as it has the simplest spirocyclic scaffold. The DIA spirocylisation 
reaction would provide efficient access to the spirocyclic core, and a concise synthesis 
of (±)-aspidospermidine should be possible (Scheme 4.8). Reaction of an indole 346 and 
imine 347 under the DIA spirocyclisation conditions would give a spirocyclic 
indolenine 348 and further steps would give access to (±)-aspidospermidine 169 
(Scheme 4.8). This DIA approach also has the potential for further derivatisation, which 
could provide access to other aspidosperma alkaloids.  
  
Scheme 4.8 – Overall strategy towards the synthesis of (±)-aspidospermidine 169 
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4.3. Results and Discussion 
4.3.1. Proposed Routes Towards (±)-Aspidospermidine 
The aim of the project was to use the developed DIA spirocyclisation methodology in 
the synthesis of (±)-aspidospermidine 169. The spirocyclic centre could be synthesised 
from the DIA reaction of an appropriate indole acid substrate (349 or 354) and imine 
substrate (350 or 351) (Scheme 4.9). Upon formation of the spirocyclic centre, the 6-
membered ring would need to be synthesised to form the polycyclic scaffold 353 and a 
global reduction would then afford aspidospermidine 169 in an efficient manner.  
 
Scheme 4.9 – Proposed route to (±)- aspidospermidine using DIA spirocyclisation 
A number of methods can be imagined for the cyclisation to give the final 6-membered 
ring in the synthesis. Mukai et al. had previously demonstrated the use of an 
intermolecular cross metathesis reaction between two key components in the synthesis 
of another aspidosperma family alkaloid member, goniomitine.173 We envisaged that if 
we also started with a 2-vinyl substituted indole acetic acid 349 and a vinyl substituted 
imine 350 or 351, we could initially set the spirocyclic centre of the scaffold using DIA 
methodology and then carry out an intramolecular ring-closing metathesis to form the 
polycyclic product 353 (Scheme 4.9). Global reduction of this product would provide 
aspidospermidine 169. Alternatively, a 2-iodo indole acid 354 could be used in a DIA 
spirocyclisation reaction with the vinyl-substituted imine 350 or 351 and a subsequent 
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intramolecular Heck reaction could be could be performed to form the 6-membered ring 
(Scheme 4.9). In unpublished results* within the Taylor group, it was found that 2-iodo 
indole 354 could be reacted with imine 37 under DIA conditions to give spirocyclic 
product 356 in a 4:1 dr and 75% yield (Scheme 4.10). Therefore, it was reasoned that 
the proposed DIA reaction between iodo indole acid 354 and vinyl imine 351 should 
proceed.  
 
Scheme 4.10 – DIA reaction of iodosubstituted indole 354 and imine 37* 
An alternative use of the iodo indole acid 354 would be in a Sonogashira reaction with 
imine 357 or 358 (Scheme 4.11).  This approach has been utilised in the synthesis of 
(±)-quebrachamine 314, where the indole and piperidine components were joined by a 
Sonogashira reaction and lactamisation to afford the desired natural product.174 In our 
proposed route, following the Sonogashira reaction, reduction of the alkyne 359 would 
give product 360. A DIA reaction would provide the N-acyliminium intermediate 361, 
which should undergo a transannular spirocyclisation reaction to give the 
spiroindolenine 362. Reduction of the amide and imine would give aspidospermidine 
169 (Scheme 4.11). 
 
                                                
* Work carried out by Dr. Graeme Coulthard in the Taylor group. 
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Scheme 4.11 – Proposed route to aspidospermidine via a Sonogashira approach 
Work was then focused on the synthesis of the necessary indole acid and imine 
components for testing the three proposed routes to aspidospermidine 169 (Figure 4.2). 
The 2-vinyl substituted indole acid 349 was required for use in the route containing a 
ring-closing metathesis step (Scheme 4.9). The 2-iodo indole acid 354 would be used in 
the route containing an intramolecular Heck reaction (Scheme 4.9), and also the route 
containing a Sonogashira reaction (Scheme 4.11). It was considered that in the planned 
DIA reactions, the number of possible diastereoisomers that could be formed would be 
reduced to 2 possible isomers if imine 350 was used (Scheme 4.9). However, it was 
found that there was limited literature precedent for six membered imines such as these 
and a disubstituted vinyl imine initially appeared more challenging to synthesise, so 
imine 351 was selected for synthesis. An analogous alkyne substituted imine 358 would 
also be required for the synthesis involving a Sonogashira reaction (Figure 4.2). 
 
Figure 4.2 – Structure of target indole and imine compounds 
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4.3.2. Synthesis of Indole Acid Components 
Synthesis of the 2-vinyl substituted indole acid 349 began with the commercially 
available 3-indole acetic acid 215, which was esterified to give indole 363 in 97% yield.  
An iodo group was introduced in the 2-position via an iodination procedure to give the 
2-iodinated indole 364 in 77% yield.174 A subsequent Suzuki reaction with vinyl boronic 
acid pinacol ester 365 installed the vinyl group at the 2-position to give product 366 in 
67% yield.113 Hydrolysis of this ester 366 proved more challenging than expected; 
difficulties in the purification and isolation of the product meant that the acid 349 could 
not be isolated. It was thought that polymerisation of this acid 349 was the main issue, 
as a plastic-like residue was often produced (Scheme 4.12).  
 
Scheme 4.12 – Attempted synthesis of vinyl substituted indole 349 
It was thought that the synthesis of a methyl-substituted vinyl group in the 2-position 
could inhibit any polymerisation reactions and make isolation of the product easier and 
need not affect the planned ring-closing metathesis, as this group would be removed in 
the reaction. The synthesis of indole acid 371 began with esterification of the 
commericially available 3-indole acetic acid 215 to give the methyl ester 367. A 
subsequent iodination reaction gave iodo indole 368 in 81% yield. The desired ester 370 
was efficiently synthesised via a Suzuki reaction with iodinated methyl ester 368 and 1-
propenyl boronic acid pinacol ester 369. Pleasingly, a subsequent hydrolysis gave acid 
371 in 95% yield as a stable solid product (Scheme 4.13).  
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Scheme 4.13 – Synthesis of a substituted alkene indole acid 371 
Iodo acid 254 was synthesised from the iodinated indole ester 368 (Scheme 4.14). It was 
found that ester 368 is unstable upon standing in air and it decomposed after ~72 h. 
Hydrolysis of ester 368 was achieved using 2 M NaOH in MeOH,175 to give acid 254 in 
88% yield, but careful acidification was required in the work-up. If the solution was 
taken to pH 1 formation of a brown oil was observed, which was believed to be the 
oxindole product from characteristic 1H NMR spectroscopic signals. However, careful 
acidification to pH 4-5 resulted in formation of a white precipitate, which upon isolation 
was confirmed to be the desired product 354. This acid was found to be very unstable 
and would decompose to the suspected oxindole product after ~24 h. Therefore, it is 
important that iodo acid 354 is synthesised fresh, just before use in the subsequent DIA 
reactions. 
 
Scheme 4.14 – Synthesis of 2-iodo substituted indole acid 354 
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4.3.3. Work Towards Synthesis of the Imine Component 
A route for the synthesis of vinyl-substituted imine 351 was investigated next. In a 
previous approach, the Taylor group synthesised allyl ethyl lactam 372. The allyl group 
was then cleaved and converted into alcohol 373 via ozonolysis of the alkene and 
subsequent reduction. *  With this alcohol available in the group, two elimination 
reactions to give vinyl lactam 374 were explored. Mesylation of alcohol 373, followed 
by heating the reaction mixture at 50 °C overnight was unsuccessful; analysis of the 1H 
NMR spectrum of the unpurified reaction mixture clearly showed only starting material 
(Scheme 4.15). An alternative dehydration reaction was also attempted on the alcohol 
373 using Grieco’s conditions,173,176 but only alcohol 373 and tributylphosphine were 
observed in the 1H NMR spectrum of the unpurified reaction mixture (Scheme 4.15). 
Therefore, an alternative route towards the vinyl substituted imine 351 was considered. 
 
Scheme 4.15 – Attempted elimination reactions of alcohol 373* 
Next, we investigated whether it was possible to access the substituted alkene compound 
375 via an isomerisation reaction. RhCl3 hydrate and Wilkinson’s catalyst (Scheme 
4.16) were both attempted but the Boc-deprotected starting material 376 was observed 
in both cases.177,178  
 
Scheme 4.16 – Attempted isomerisation of allyl 372 
                                                
* Synthesis of 372 and 373 carried out by Dr. Graeme Coultard and Dr. William 
Unsworth in the Taylor group. 
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It was considered that the isomerisation reaction may proceed if the Boc group was 
removed, which was carried out with TFA in CH2Cl2 to give lactam 376 in 96% yield 
(Scheme 4.17). RhCl3 hydrate177 and Wilkinson’s catalyst178 were used again on the 
Boc-deprotected compound 376 but analysis of the 1H NMR spectrum of the unpurified 
reaction mixture contained mainly starting material by 1H NMR spectroscopy. Some 
potential product-like peaks were present at ~5.5 ppm which could be due to the internal 
alkene signals. The reactions were not purified as they were performed on a small scale 
and contained mainly starting material (Scheme 4.17). 
 
Scheme 4.17 – Boc-deprotection of lactam 372 and attempted isomerisation 
Nishida et al. had shown that the reaction of Grubbs’ 2nd generation catalyst in the 
presence of vinyloxytrimethylsilane results in an isomerisation reaction of terminal 
alkenes to the corresponding internal alkene.179 The group used varying equivalents of 
the vinyloxytrimethylsilane and showed that 10 equivalents were occasionally necessary 
for a quantitative reaction, but also showed that 1 equivalent was sufficient in some 
cases. In our case, 5 equivalents were used (Scheme 4.17) but analysis of the of the 1H 
NMR spectrum of the unpurified reaction mixture showed mainly starting material with 
some very small potential product signals at ~5.5 ppm.  
 
These results suggest that isomerisation is possible on the unprotected lactam 376, and 
future work could involve reaction of the lactam 376 with RhCl3 hydrate for a longer 
reaction time to determine if the reaction would proceed further. However, as more 
promising routes were being developed simultaneously, this strategy was not 
investigated any further in this project.  
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In the proposed routes, two imines 351 and 358 were targeted as substrates so a 
common intermediate for their synthesis was desired (Figure 4.2). Imine 351 contains an 
alkene and imine 358 contains an alkyne, so an aldehyde intermediate would be useful 
as this can be transformed into each of these functional groups in one step. Initially, 
efforts were focussed on the best way to introduce an ethyl group, beginning with 
enolate formation of lactam 288 with n-BuLi followed by alkylation with ethyl iodide 
(Scheme 4.18). However, analysis of the 1H NMR spectrum of the unpurified reaction 
mixture indicated a complex mixture of products and upon attempted purification by 
column chromatography none of the desired product 378 was obtained.  
 
Scheme 4.18 – Attempted alkylation of lactam 288 
The alkylation reaction was then attempted on the unprotected lactam 379 by formation 
of the dianion, followed by alkylation and subsequent protection of the amide.180 
Pleasingly, under the conditions shown in Scheme 4.19, the ethyl-substituted lactam 378 
was isolated in 74% yield. It was found that the reaction yield decreased to 13% yield if 
the ethyl iodide was stirred for 2 h rather than 20 min. 
 
Scheme 4.19 – Ethyl alkylation of unprotected lactam 288 
Investigations to determine the best way to generate the aldehyde group were then 
explored. Installation of an alcohol group was initially attempted by formation of the 
enolate with LDA (formed in situ) followed by addition of formaldehyde as reported in 
the literature (Scheme 4.20).181 However, analysis of the 1H NMR spectrum of the 
unpurified reaction mixture showed a complex mixture of products that upon 
purification by column chromatography gave none of the desired product 380. The 
reaction was attempted using paraformaldehyde as the electrophile, but the reaction was 
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unsuccessful and analysis of the unpurified reaction mixture by mass spectrometry 
showed no signal for the [M + H]+ ion.  
 
Scheme 4.20 – Attempted addition of an alcohol group to lactam 288 
Ethyl formate was selected as an alternative electrophile, as it would allow the aldehyde 
to be installed directly. The lactam 288 was reacted with LDA to form the enolate and 
ethyl formate was added to the reaction mixture and stirred overnight (Scheme 4.21).182 
Purification by column chromatography gave 382 in 13% yield, which would most 
likely be formed by reaction of an ethoxide with the lactam 288 and ring-opening 
(Scheme 4.12). This suggested that alkylation with ethyl formate must have occurred in 
order to release the ethoxide, but none of the desired aldehyde 381 could be isolated. A 
mixture of other products were also observed but could not be identified, suggesting that 
this reaction is not selective for one product. 
 
Scheme 4.21 – Attempted direct installation of an aldehyde  
The ring-opening of 288 by ethoxide is made possible by the attached electron-
withdrawing Boc group. Therefore, addition of the electrophile to the unprotected amide 
enolate was attempted. The commercially available lactam 379 was reacted with two 
equivalents of n-BuLi to generate the dianion, followed by addition of ethyl formate and 
then Boc2O (Scheme 4.22). Unfortunately, ester 382 was observed in the crude reaction 
mixture by 1H NMR spectroscopy and this was confirmed by mass spectrometry.  
N
O
Boc N
O
Boc
HO
1. LDA, THF, −78 - 0 °C, 30 min
380288
2. CH2O (37% in H2O), rt, 5 h
0%
288
381
N
O
Boc 1. LDA, −78 - 0 °C, 30 min N
O
Boc
O
0%
N
H
Boc
O OEt
13%
382
2. ethyl formate (3 eq), 
    −78 °C - rt, 5 h
via
N
O
Boc
EtO
288
 129 
 
Scheme 4.22 – Attempted installation of an aldehyde to unprotected lactam 379 
This result suggested that the remaining ethoxide needed to be quenched before 
protection of the amide to remove it from the reaction mixture and reduce reaction with 
the amide. Thus, lactam 379 was reacted with 2 equivalents of n-BuLi and then ethyl 
formate was added. Following this, the reaction was quenched with saturated NH4Cl(aq). 
Analysis of the crude reaction mixture by 1H NMR spectroscopy indicated that none of 
product 383 was present (Scheme 4.23).  
 
Scheme 4.23 – Attempted addition of aldehyde onto unprotected lactam 379 
It was thought that the problems of introducing the alcohol or aldehyde into the α-
position of the lactam ring were due to the mono-substitution at the α-position. Alcohol 
380 could be susceptible to elimination reactions and aldehyde 381 could undergo 
tautomerisation, which would result in either the formation of incorrect products or 
difficulty in introducing a second group in this position. Therefore, the introduction of 
the aldehyde group was attempted after the ethyl group had been installed (Scheme 
4.24). Following similar conditions (LHMDS) for reaction with ethyl formate, none of 
the desired product 384 was isolated after purification by column chromatography. 
Instead, a ring-opened product 385 was isolated in 39% yield, which would be made via 
formation of the desired product 384 followed by attack of the ethoxide into the amide 
carbonyl and ring-opening onto the α-carbon to form a stabilised anion that is quenched 
in the aqueous work-up. Another product 386 was also isolated in 11% yield, formed by 
attack of the ethoxide onto the starting material and ring-opening onto the nitrogen  
(Scheme 4.24). 
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Scheme 4.24 – Reaction of ethyl-substituted lactam 378 with ethyl formate 
The formation of product 385 shows that ethyl formate can install the aldehyde 
functional group (Scheme 4.24). To decrease the chance of ring-opening, a reaction with 
unprotected lactam 387 was undertaken. The Boc group was removed from the ethyl 
substituted lactam 378 by stirring in TFA:CH2Cl2 to give the lactam 387 in 93% yield 
(Scheme 4.25).183 Formation of the enolate and addition of ethyl formate at −78 °C gave 
no product 388 (Scheme 4.25). The reaction was repeated at 50 °C but analysis of the 1H 
NMR spectrum of the unpurified reaction mixture indicated no product formation.  
 
Scheme 4.25 – Attempted addition of aldehyde onto unprotected lactam 387 
After these unsuccessful attempts to directly install the aldehyde using ethyl formate, an 
alternative route via an ester was attempted. Cossy et al. had shown that Boc-protected 
lactam 288 could be reacted with LHMDS to form the enolate, followed by addition of 
methylchloroformate. These conditions were repeated to obtain 389 in 88% yield.184  
 
Scheme 4.26 – Synthesis of ester-substituted lactam 389 
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The same conditions were attempted on the ethyl-substituted lactam 378 and following 
purification by column chromatography, two products were isolated (Scheme 4.27). The 
desired product 390 was obtained in a 17% yield, but the major product of the reaction 
was the oxygen-acylated product 391 that was isolated in 56% yield. The reaction was 
repeated using Mander’s reagent (methyl cyanoformate) and pleasingly the ester-
substituted product 390 was isolated in a 59% yield (Scheme 4.27). 
 
Scheme 4.27 – Synthesis of ester substituted lactam 390  
With the ester and ethyl groups successfully installed on the lactam ring, the conversion 
of the ester into an aldehyde became the next priority. Initially, it was thought that the 
ester could be reduced to an alcohol and subsequent oxidation would provide the 
aldehyde. Loreto had shown that an ester on an analogous lactam compound could be 
efficiently reduced using calcium tetrahydridoborate, prepared in situ by stirring NaBH4 
and CaCl2 together.185 Lactam 390 was subjected to these conditions but none of the 
desired reduced product 392 was observed (Scheme 4.28). Instead, the amide had been 
reduced to give the hemiaminal 393 in quantitative yield (1:1.4 dr), which required no 
purification following work-up. 
 
Scheme 4.28 – Attempted reduction of ester 390 
Presumably, the Boc group was promoting reduction of the amide rather than the ester. 
Therefore, it was hoped that if the Boc group was removed, the desired reduction of the 
ester would occur, as the CaBH4 should not be reactive enough to reduce the amide. 
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Removal of the Boc group proceeded efficiently to give lactam 394 in 96% yield, but 
subsequent reduction with the previously employed CaBH4 conditions resulted in no 
reaction and starting material was observed (Scheme 4.29).  
 
Scheme 4.29 – Attempted reduction of the ester group on unprotected lactam 394 
It was realised that it should be possible to convert hemiaminal 393 into imine 396 by 
reaction with TFA via removal of the Boc group and elimination. The reduction of 
lactam 390 to hemiaminal 393 was also attempted using NaBH4, rather than CaBH4, and 
hemiaminal was isolated in 89% yield (Scheme 4.30). The unpurified reaction mixture 
was sufficiently clean to be taken onto the subsequent reaction. Reaction of hemiaminal 
393 in TFA:CH2Cl2 provided the imine 396 in 87% crude yield (Scheme 4.30). The 
product was sufficiently clean without additional purification but was seen to 
decompose over time. In a repeat reaction, purification by column chromatography gave 
imine 396 in a 47% yield. It was concluded that it is better to use these imines promptly 
after isolation without chromatography. It was planned that this imine could also be 
trialled in the DIA spirocyclisation step with indoles 354 and 371 to synthesise a 
different spirocyclic intermediate. 
 
Scheme 4.30 – Synthesis of ester-substituted cyclic imine 396 
Alternative conditions were then investigated for the reduction of the ester-substituted 
lactam 390. DIBAL reduction of the ester was attempted to determine if it could be 
directly reduced to the aldehyde (Scheme 4.31). Lactam 390 was reacted with DIBAL at 
−78 °C for 2 h in CH2Cl2 and the 1H NMR spectrum of the unpurified reaction mixture 
indicated product-like signals in the aldehyde region. Attempted purification by column 
chromatography was unable to completely separate the products of the reaction but 
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assisted in confirming that hemiaminal 393 was the main product of the reaction. The 
suggested aldehyde products 384 and 397 are possible structures that could explain the 
presence of aldehyde peaks in the 1H NMR spectrum, but the open chain form of these 
structures could also be present providing an alternative explanation for the observed 
aldehyde signals. The reaction was repeated in toluene and a similar result was 
observed. Considering the capricious nature of DIBAL as a reducing reagent, these 
conditions were not explored further. 
 
Scheme 4.31 – Attempted DIBAL reduction of ester 390 
Other reduction conditions were carried out on the unprotected amide 394 to reduce the 
likelihood of the amide being reduced to the hemiaminal (Table 4.1). Reduction with 
LiBH4 initially resulted in a 50% yield of alcohol 395 but this result was not 
reproducible and only 28% yield was achieved on a larger scale (Entry 1). Reduction 
with the bulkier base LiAlH(OtBu)3 required 4 equivalents of the base and heating to 60 
°C to give a 45% yield of the alcohol 395 (Entries 2 and 3).186 Kim et al. had shown that 
an analogous ester compound could be reduced under Luche conditions.187,188 Ester 394 
was initially heated with NaBH4 and CeCl3 but analysis of the crude reaction mixture by 
1H NMR spectroscopy and TLC showed formation of the product and other byproducts 
(Entry 4). Stirring the reaction at rt for 2.5 days resulted in much cleaner conversion but 
analysis of the crude reaction mixture showed a 1:2.2 ratio of ester 394 and alcohol 395 
(Entry 5).187 
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Entry Conditions Alcohol 395 Ester 394 
1 LiBH4, 0 °C-rt, 2 h 50% - 0.19 mmol 
28% - 3.76 mmol 
- 
2 LiAlH(OtBu)3 (2 eq), THF, 0 °C-rt - -a 
3 LiAlH(OtBu)3 (2 eq), THF, 60 °C, 20 h, 
then LiAlH(OtBu)3 (2 eq), 60 °C, 3 days 
45% - 
4 NaBH4/CeCl3, EtOH, reflux, 3 h -a - 
5 NaBH4/CeCl3, EtOH, rt, 2.5 days 2.2b 1a 
a) Analysis of the 1H NMR spectrum of the unpurified reaction mixture showed the 
product present. b) Ratio of products from 1H NMR spectrum of crude reaction mixture.  
Table 4.1 – Reduction of ester 394 to alcohol 395 
LiAlH4 was then explored at low temperature to avoid amide reduction. Initially, 3 
equivalents of LiAlH4 were added to ester 394 in THF at −78 °C and stirred for 1 h. 
Surprisingly, the 1H NMR spectrum of the crude reaction mixture indicated that 
aldehyde 388 was the major product rather than the expected alcohol 395. This reaction 
gave a 1:2.7:4.7 ratio of alcohol 395, ester 394 and aldehyde 388 respectively (Table 
4.2, Entry 1). The diagnostic peaks for the aldehyde 388, ester 394 and alcohol 395 were 
a doublet at 9.62 ppm for the aldehyde proton, a singlet at 3.71 ppm for the methyl 
group of the ester and two doublets at 3.51 ppm for the diastereomeric CH2 protons 
adjacent to the OH respectively. Formation of the aldehyde was thought to be due to a 
chelation effect between the oxygen on the amide and the oxygen of the aldehyde 
forming a stable tetrahedral intermediate that would be quenched upon work-up. Further 
experiments were conducted to determine if the ratio of starting material to product 
could be improved (Table 4.2). A solvent swap to Et2O resulted in a better conversion of 
the starting material to the aldehyde (Entry 5). It was observed that increasing the 
reaction temperature to 0 °C resulted in significantly more alcohol 395 than aldehyde 
HN
O
O OMe
Conditions HN
O
OH
395394
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388 (Entries 3 and 7). It was found that reaction at −40 °C in Et2O gave a 10:1:9 ratio of 
alcohol 395 to ester 394 to aldehyde 388 (Entry 8).  
 
 
 
Entry 
 
Conditions 
Ratio of productsa 
Alcohol 
395 
Ester 
394 
Aldehyde 
388 
1 LiAlH4 (3 eq), THF, -78 °C, 1 h 1 2.7 4.7  
2 LiAlH4 (3 eq), THF, -78 °C, 2 h 1 2.1 3.6  
3 LiAlH4 (3 eq), THF, 0 °C, 1 h 3.2 1 1.8 
4 LiAlH4 (6 eq), THF, -78 °C, 1 h 1 2.5 3.7 
5 LiAlH4 (3 eq), Et2O, -78 °C, 1 h 1 1.2 4.1 
6 LiAlH4 (3 eq), Et2O, - 78 °C, 3 h 1 2.9 4.4 
7 LiAlH4 (3 eq), Et2O, 0 °C, 1 h 20 1 1.8 
8 LiAlH4 (3 eq), Et2O, - 40 °C, 1 h 10 1 9 
a) Ratio determined by 1H NMR spectroscopy of the unpurified reaction mixture. 
Table 4.2 – LiAlH4 reduction of ester 394  
 
It was initially thought that the best conditions to take forward were LiAlH4 (3 eq) in 
Et2O at −78 °C for 1 h (Entry 5), in order to get the most aldehyde 388 out of the 
reaction, and recycle the recovered starting material. These conditions were therefore 
repeated on a larger scale (4.54 mmol) and the crude mixture was purified by column 
chromatography to provide the aldehyde 388, alcohol 395 and recovered ester 394 in 
49%, 32% and 11% respectively (Scheme 4.32).  
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Scheme 4.32 – LiAlH4 reduction of ester 394 
Whilst isolating 49% of the aldehyde 388 was a useful result, a significant amount of 
alcohol 395 was also isolated possibly from the exotherm of the larger scale reaction 
increasing the reaction temperature and increasing the double reduction reaction. As a 
comparison with the reaction in Et2O, the reaction was carried out in THF on a larger 
scale and 35% of aldehyde 388 was isolated (Scheme 4.33). However, the starting 
material was recovered in an 18% yield showing that this reaction was less efficient than 
in Et2O. Poor recovery of the unpurified material was also a problem, indicating that a 
more efficient work-up procedure was required. 
  
Scheme 4.33 – LiAlH4 reduction of ester 394 
It was then considered that better conditions to select would be reaction with LiAlH4 (3 
eq) in Et2O at −40 °C for 1 h as this maximised conversion of the starting material to 
either aldehyde 388 or alcohol 395 but ensures that aldehyde 388 would be the main 
product. It was shown that the alcohol 395 could be directly oxidised to the aldehyde 
388 in 60% yield using DMP (Scheme 4.34).189  
 
Scheme 4.34 – Synthesis of aldehyde 388 via oxidation of alcohol 395 
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With this in mind, it was thought that the ester 394 could first be reduced to a mixture of 
aldehyde 388 and alcohol 395, then separated by column chromatography and the 
alcohol 395 subsequently oxidised to give aldehyde 388. Alternatively, following 
reduction of the ester 395, the crude reaction mixture could be subjected to DMP 
oxidation conditions to convert the alcohol 395 into aldehyde 388 in a two-step process. 
Attempting to access the aldehyde 388 in this two-step process gave the product in a 
24% yield, which was no improvement on partial reduction of the starting material using 
the conditions shown in Scheme 4.32 where the aldehyde was directly obtained in 49% 
yield.  
 
Scheme 4.35 – Synthesis of the aldehyde 388 via reduction of the ester 394 and 
oxidation of the crude mixture 
It should be noted that the inconsistency observed in the yields of the LiAlH4 reduction 
reactions is likely to be due to the difficulties associated with the work-up, as the crude 
reaction mixtures were seen to be very clean by 1H NMR spectroscopy. Use of 
Rochelle’s salt to try and break down the metal-chelated products was attempted but 
recovery of the reaction material following aqueous work-up was variable. The 1H NMR 
spectrum for the unpurified reaction mixture of the DMP oxidation also showed good 
conversion to the desired product, suggesting that this two-step process could be 
efficient if the work-up procedures were further optimised.  
 
Reduction of the Boc-protected lactam 390 was also attempted using the bulkier base, 
LiAlH(tBuO)3, to determine if the added steric bulk would prevent reduction of the 
amide to the hemiaminal and give aldehyde 384 through the chelating effect observed 
with LiAlH4. However, reaction of Boc-protected lactam 390 with LiAlH(tBuO)3 in 
THF at −78 °C for 1 h resulted in the formation of hemiaminal 393 in a 1:4 dr (Scheme 
4.36), although the products were not isolated and so yields are not given. This 
confirmed the need for deprotection of the amide before reduction of the ester.  
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Scheme 4.36 – Attempted reduction of the Boc-protected lactam 390 
To progress the synthesis of the imine, conversion of the aldehyde to the alkene was 
achieved using Wittig conditions.190 The ylide was initially formed in situ by adding n-
BuLi to the phosphonium bromide salt, and the aldehyde was subsequently added. Upon 
column chromatography, the triphenylphosphine oxide byproduct 398 was inseparable 
from the alkene 397 so a yield was calculated from the ratios of the signals in the 1H 
NMR spectrum and the masses of the known components. On a small scale, a 32% yield 
of alkene 397 was calculated (Table 4.3, Entry 1). Unfortunately, upon scaling up the 
reaction the yield of the alkene continued to decrease and the ethyl-substituted lactam 
387 was isolated in 89% yield, which was likely formed as a result of a retro-Claisen 
condensation (Table 4.3).  
 
Entry Scale Yield 397 (%)a Yield 387 (%)a 
1 0.56 mmol 32 - 
2 2.96 mmol 22 - 
3 4.57 mmol 13 89 
a) Yield based on ratio of signals of alkene 397 and triphenylphosphine oxide 398 in 1H 
NMR spectrum of the isolated product. 
Table 4.3 – Synthesis of alkene 397 via a Wittig reaction 
It was therefore decided to reintroduce the Boc group onto the amide as it was required 
in the imine formation step. Protection of the amide with a Boc group could be done 
with the triphenylphosphine oxide impurity present, and introduction of the protecting 
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group allowed separation by column chromatography giving the clean product 374. 
Initially, the reaction conditions shown in Scheme 4.37 were carried out for 4 h and the 
product 374 was isolated in a 35% yield. A 47% yield of recovered starting material 397 
was also isolated along with inseparable triphenylphosphine oxide. The reaction was 
difficult to monitor by TLC as the starting material and triphenylphosphine have the 
same RF values so only product formation can be observed. Therefore the unreacted 
starting material was resubjected to the protection conditions and stirred overnight to 
give the product 374 in 89% yield (Scheme 4.37).191  
 
Scheme 4.37 – Boc protection of lactam 397 
The same procedure as used previously (Scheme 4.30) was then used to convert Boc-
protected amide 374 into imine 351. Amide 374 was reduced to the hemiaminal with 
NaBH4 and the unpurified reaction mixture was reacted with TFA in CH2Cl2 to 
deprotect the nitrogen and promote the elimination to the imine so that imine 351 was 
isolated in 80% yield over 2 steps (Scheme 4.38). The unpurified imine was sufficiently 
clean for use in the subsequent reaction, but was seen to decompose reasonably quickly. 
Upon attempted purification by column chromatography, the product could not be 
isolated and the product was suspected unstable on the silica and was also volatile.  
 
Scheme 4.38 – Synthesis of vinyl substituted imine 399 
The culmination of these studies towards the synthesis of imine 351 is shown in Scheme 
4.39. This is currently the most advanced route towards this substrate and provides 
imine 351 in an overall yield of 4.7% in 7 steps. The starting lactam is commercially 
available and inexpensive. Alternatively, if a DIA reaction could be successfully 
performed using ester imine 396, this will significantly reduce the number of steps 
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needed to access the imine substrate. However, this would require more functional 
group transformations to be performed on the spirocyclic compound, which could 
potentially be difficult due to the increased steric bulk.  
 
Scheme 4.39 – Synthesis of vinyl-substituted imine 351  
 
4.3.4. Investigations into the DIA Spirocyclisation Step in the 
Synthesis of Aspidospermidine 
Having successfully synthesised iodo indole acid 354, vinyl indole acid 371 and imines 
351 and 396, preliminary DIA spirocyclisation reactions were attempted. Initially, iodo 
indole acid 354 was reacted with imine 351 under the optimised DIA conditions (THF at 
rt) but the reaction did not go to completion. Reaction of the iodo indole 354 and imine 
351 at 70 °C in CHCl3 for 20 h (Scheme 4.40) was more promising. Analysis of the 1H 
NMR spectrum of the unpurified reaction mixture indicated the presence of aldehyde 
401 (singlet at 9.26 ppm), produced by hydrolysis of the N-acyliminium ion in the work-
up, but some promising product-like peaks were also observed in the alkene region (e.g. 
multiplets at 5.64-5.56, 5.32-5.25 and 5.04-5.00 ppm). It was considered that the 
reaction could appear unclean due to the formation of four possible diastereoisomers. 
Purification by column chromatography was attempted but due to the small scale of the 
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reaction (0.10 mmol), analysis of the fractions was challenging. However, the [M + Na]+ 
ion for the product 400 was observed in the mass spectrum suggesting successful 
formation of the product 400. 
 
Scheme 4.40 – DIA spirocyclisation reaction of indole 354 and imine 351 
Synthesis of the ester imine 396 had proven much simpler and with more of this imine 
in hand the DIA spirocyclisation reactions were performed using this substrate. The iodo 
indole acid 354 was reacted with the ester-substituted imine 396 at 70 °C in CHCl3 for 
20 h (Scheme 4.41), which resulted in a cleaner 1H NMR spectrum of the unpurified 
reaction mixture when compared to the reaction with vinyl-substituted imine 351. 
Separation of the suspected diastereoisomers proved challenging by column 
chromatography and resulted in three different fractions that appeared to contain a 
mixture of diastereoisomers by 1H NMR spectroscopy, but lack of material (~6 mg for 
the combined column fractions) made obtaining a routine 13C NMR spectrum and 2D 
data difficult. Mass spectrometry analysis suggested the presence of the product 402 in 
each fraction, although a yield cannot be stated. The ester group in spirocyclic product 
402 could in principle be converted into an alkene for a subsequent intramolecular Heck 
reaction.  
 
Scheme 4.41 – DIA spirocyclisation reaction of indole 354 and imine 397 
DIA spirocylisation of the ester imine 396 was also attempted with the methyl-
substituted vinyl indole acid 354 in CHCl3 in 70 °C for 20 h (Scheme 4.42). Analysis of 
the 1H NMR spectrum of the unpurified reaction mixture suggested the product may 
have formed but also showed the presence of some aldehyde 404 (singlet at 9.67 ppm) 
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suggesting the need for more forceful reaction conditions to combat the added steric 
bulk of the ester and substituted alkene. Purification by column chromatography was 
attempted to determine if separation of the suspected diastereoisomers was possible. 
Unfortunately, separation of the individual diastereoisomers by column chromatography 
was challenging and the products could not be fully characterised, despite obtaining 
slightly more material for each fraction (~14 mg). Mass spectrometry analysis suggested 
the presence of the product 403 in each fraction, but a yield is not given. Conversion of 
the ester group into an alkene in the spirocyclic product 403 could provide the dialkene 
for a ring-closing metathesis reaction.  
 
Scheme 4.42 – DIA spirocyclisation reaction of indole 371 and imine 396 
Overall, the preliminary investigations into the key DIA spirocyclisation reactions were 
very promising. The reactions could only be conducted on a small scale (~0.10 mmol) 
due to the difficulty in synthesising the required imine substrates, but analysis of the 
reactions by mass spectrometry and 1H NMR spectroscopy indicated the formation of 
products. It is anticipated that performing these reactions on a larger scale would result 
in successful formation of the desired spirocyclic products and allow separation of the 
diastereoisomers.  
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4.4. Conclusions and Future Work  
Work towards the synthesis of (±)-aspidospermidine using DIA methodology was 
undertaken and two proposed routes were targeted, including an intramolecular Heck 
reaction and a ring-closing metathesis reaction. The synthesis of the required iodo indole 
acid 354 was successfully carried out to give the product in a 67% yield over three steps 
(Scheme 4.14). Isolation of the vinyl-substituted indole acid 349 was not possible, but 
this problem was solved by substitution of the vinyl group to prevent any 
polymerisation. As a result, the methyl-substituted vinyl indole acid 371 could be 
produced in 53% yield in 4 steps (Scheme 4.13). 
 
Synthesis of the vinyl-substituted imine substrate 351 proved a lot more challenging, 
and future work should focus on optimisation of this route. An alternative ester imine 
396 was also synthesised (Scheme 4.30), which could also be used in the DIA 
spirocyclisation reaction. Conversion of the ester to the alkene would be necessary to set 
up a ring-closing metathesis reaction for formation of the 6-membered ring (Scheme 
4.43). The benefit of this would be a more efficient synthesis of the required imine.  
 
Scheme 4.43 – Proposed use of imine 396 in the synthesis of aspidospermidine 
Despite the challenging synthesis, sufficient amounts of the imines 351 and 396 were 
obtained to allow preliminary investigations into the key DIA spirocyclisation step. 
Figure 4.3 shows the structures of the spirocyclic scaffolds that were synthesised using 
DIA methodology. The test reactions were performed on a relatively small scale (~0.1 
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mmol), but analysis of the reaction by mass spectrometry and 1H NMR spectroscopy 
suggested the successful formation of products. Optimisation of the DIA reactions is 
required, but the preliminary results are promising and suggest that this methodology 
could be successfully utilised in the synthesis of (±)-aspidospermidine 169. Product 400 
could be used in a subsequent intramolecular Heck reaction to generate the 6-membered 
ring in the natural product scaffold. Following conversion of the ester to the alkene, 
product 402 and 403 could be used in an intramolecular Heck or ring-closing metathesis 
respectively to produce the 6-membered ring.  
 
Figure 4.3 – Structures of the spirocycles made using DIA methodology 
The DIA reactions also indicated that the ester-substituted imine 397 was a more 
suitable substrate than vinyl-substituted imine 351. It was thought that this could be due 
to the suspected unstable and volatile nature of imine 351. As with the vinyl-substituted 
indole acids 349 and 371, the stability of the imine might be improved by substitution of 
a methyl group onto the vinyl to give imine 405 (Figure 4.4). As attempted in this 
project, the substituted vinyl functionality could be accessed by isomerisation of the 
easily installed allyl group. Further work on the isomerisation conditions could provide 
a feasible route to this compound.  
 
Figure 4.4 – Alternative imines for use in the DIA spirocyclisation reaction 
A potential issue with the DIA spirocyclisation reaction was the generation of four 
possible diastereoisomers. Whilst this was not unexpected, the preliminary 
investigations of the DIA spirocyclisations suggested a lack of selectivity. A divinyl 
imine 350 (where R = H2C=CH2) would eliminate the possibility of four 
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diastereoisomers and could therefore improve the efficiency of the DIA spirocyclisation 
(Figure 4.4).  
 
In summary, this project has successfully proven that the DIA spirocyclisation 
methodology can be applied to the synthesis of (±)-aspidospermidine 169. Whilst the 
synthesis was not completed, the preliminary investigations into the key DIA reaction 
were promising and the desired spirocyclic scaffolds were formed. It is believed that 
with optimisation of the spirocyclisation step, and development of the subsequent 
reactions, the synthesis of (±)-aspidospermidine 169 could be completed.  
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5. Experimental 
5.1. General Information 
Except where stated, all reagents were purchased from commercial sources and used 
without further purification. Except where stated, all experimental procedures were 
carried out under an atmosphere of argon. Reactions carried out at room temperature (rt) 
includes temperatures between 20-25 °C. Anhydrous CH2Cl2 and toluene were obtained 
from an Innovative Inc. PureSolv® solvent purification system. Anhydrous THF was 
obtained by distillation over sodium benzophenone ketyl immediately before use. 
Chloroform was used as supplied without additional drying. Petrol refers to the fraction 
of petroleum ether boiling in the range of 40-60 °C and was purchased in Winchester 
quantities. Brine refers to a saturated solution. Water is distilled water. 1H NMR and 13C 
NMR spectra were recorded on a JEOL ECX400 or JEOL ECS400 spectrometer, 
operating at 400 MHz and 100 MHz, respectively. All spectral data were acquired at 
295 K. Chemical shifts (δ) are quoted in parts per million (ppm). The residual solvent 
peaks, δH 7.26 and δC 77.0 for CDCl3 and δH 2.50 and δC 39.5 for DMSO-d6 were used 
as a reference. Coupling constants (J) are reported in Hertz (Hz) to the nearest 0.5 Hz. 
The multiplicity abbreviations used are: s singlet, d doublet, t triplet, q quartet, m 
multiplet. Signal assignment was achieved by analysis of DEPT, COSY, NOESY, 
HMBC and HSQC experiments where required. Infrared (IR) spectra were recorded on 
a PerkinElmer UATR two spectrometer as a thin film. Mass-spectra (low and high-
resolution) were obtained by the University of York Mass Spectrometry Servive, using 
electrospray ionisation (ESI) on a Bruker Daltonics, Micro-TOF spectrometer. The 
melting points were determined using Gallenkamp apparatus and are uncorrected. Thin 
layer chromatography was carried out on Merck silica gel 60F254 pre-coated aluminium 
foil sheets and were visualised using UV light (254 nm) and stained with either basic 
aqueous potassium permanganate or ethanolic p-anisaldehyde as appropriate. Flash 
column chromatography was carried out using slurry packed silica gel (SiO2), 35-75 µm 
particle size, 60 Å pore size, under a light positive pressure, eluting with the specified 
solvent system. Petrol refers to petroleum ether 40–60 °C. Microwave experiments were 
carried out using sealed vessels in a CEM Discover microwave reactor with variable 
power output (0-200 W). Pressure was recorded by the cavity lid, which resisted the 
deformation of the vial cap as pressure increased.  
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PMI shape analysis154 
Computational analysis was carried out in collaboration with Mary Wheldon (O’Brien 
group), Paul Bond and Rod Hubbard (York Structural Biology Laboratory).  
The following describes how a PMI plot was generated in the software package, 
Pipeline Pilot. A SMILES (simplified molecular input line entry specification) file 
containing the SMILES strings for all compounds was generated using ChemDraw 12.0, 
compiled in NotePad ++ and saved as a *.SMI file. This was input into the online 
Pipeline Pilot 8.5.0.200, 2011 protocol (described below). The generated conformations 
were used to generate the three Principal Moments of Inertia (I1, I2 and I3), which were 
then normalised by dividing the two lower values by the largest (I1/I3 and I2/I3) using 
Pipeline Pilot built-in components to generate NPR1 and NPR2.  
Principal moments of inertia (PMI) about the principal axes of a molecule were 
calculated according to the following rules:  
1. The moments of inertia are computed for a series of straight lines through the 
centre of mass.   
2. Distances are established along each line proportional to the reciprocal of the 
square root of I on either side of the centre of mass. The locus of these distances 
forms an ellipsoidal surface. The principal moments are associated with the 
principal axes of the ellipsoid.   
3.    If all three moments are equal, the molecule is considered to be a symmetrical 
top. If no moments are equal, the molecule is considered to be an unsymmetrical 
top.   
A file containing information for all conformations was generated and the *.csv file was 
saved in Excel 2013. The values for NPR1 and NPR2 for the lowest energy conformer 
were extracted from the generated data and a PMI plot was generated, whereby NPR1 
was the x-axis and NPR2 was the y-axis.  
Pipeline Pilot setup of workflow154 
The following describes the settings for the protocol used in Pipeline Pilot. Prior to 
conformer generation a wash step was performed, which involved ionising the molecule 
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at pH 7.4, converting to the canonical tautomer and adding hydrogens. 3-dimensional 
coordinates were then generated using the built-in Conformation Generator component 
from the Discovery Studio Component Collection. Two copies of the molecule were 
generated, the original and mirror image. Conformers were generated using the BEST 
method in Catalyst using the rel option, run directly on the server and not through the 
built-in Conformation Generator component with a chosen maximum relative energy 
threshold of 20 kcal mol-1, maximum of 255 conformers for each compound. 
Conformations were read and mirrored if the wrong enantiomer was generated. 
Duplicates were filtered with a chosen RMSD (root mean square deviation) threshold of 
0.1. Minimisation was performed using the CHARMm (chemistry at Harvard 
macromolecular mechanics) forcefield with Momany-Rone partial charge estimation 
and a Generalised Born implicit solvent model. Duplicates were filtered again with a 
RMSD threshold of 0.1. 
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5.2. General Procedures 
General Procedure A: Preparation of Jones reagent 
Conc. H2SO4 (2.5 mL, 46.90 mmol, 1.88 eq) was added dropwise to a stirred solution of 
CrO3 (2.5 g, 25.0 mmol, 1 eq) in water (7.5 mL, 416 mmol, 16.6 eq) at 0 °C. The 
resulting orange solution was stirred at 0 °C for 10 min to give a 2.5 M aqueous solution 
of Jones reagent.  
 
General Procedure B: Jones oxidation of primary alcohol to carboxylic acid  
The Jones reagent (prepared following general procedure A, 1.4 eq, 10.6 mL, 2.5 M) 
was added to a stirred solution of primary alcohol (1 eq, 1.88 mL, 18.85 mmol) in 
acetone (120 mL) at 0 °C until the reaction mixture remained orange in colour. The 
mixture was stirred at 0 °C for 40 min and then IPA (~50 mL) was added until the 
reaction mixture remained blue/green. Water was added until the solid was solubilised 
and the organic solvent was evaporated under reduced pressure. The remaining aqueous 
mixture was diluted with water (20 mL), Et2O (50 mL) and 1 M NaOH(aq) (50 mL). The 
two layers were separated and the aqueous phase was acidified with 3 M HCl(aq) and 
extracted with Et2O (3 x 100 mL). The combined organics were washed with water (50 
mL) and brine (50 mL), dried (MgSO4), filtered and evaporated under reduced pressure 
to give the product.  
 
General Procedure C: Activation of zinc powder and generation of allylzinc 
bromide 
Zinc powder (1.2 eq, 170 mg, 2.6 mmol) was stirred in a solution of 1 M HCl(aq) for 1 
min before the solvent was removed by pipette suction, leaving the zinc powder behind. 
The zinc was triturated with water (2 mL), EtOH (2 mL) and Et2O (2 mL) and dried 
under reduced pressure to provide the activated zinc. Allyl bromide (1 eq, 207 µL, 2.4 
mmol) was added to a stirred suspension of the activated zinc in dry THF (1 mL) at rt 
under Ar. The reaction mixture was stirred for 5 min to give the allylzinc bromide 134.  
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General Procedure D: Nucleophilic addition of an allylmetal bromide into a N-
acyliminium ion 
Trans-cinnamoyl chloride (1.2 eq, 303 mg, 1.82 mmol) was added to a stirred solution 
of 3,4-dihydroisoquinoline 37 (1 eq, 200 mg, 1.52 mmol) in solvent (6 mL) and stirred 
at rt-65 °C for 1 h under Ar. The resulting solution was cooled to −78 °C and the 
allylmetal bromide (1.2 eq, 1.82 mmol) was added. The reaction was stirred at −78 °C 
or rt for 1.5-3 h under Ar. Sat. NH4Cl(aq) (10 mL) was added and the reaction was 
extracted into Et2O (20 mL). The two layers were separated and the aqueous layer was 
extracted with Et2O (2 x 20 mL). The combined organics were dried (MgSO4) and 
filtered, and the solvent removed under reduced pressure to give the crude product.  
 
General Procedure E: Addition of an allylmetal bromide into an imine and 
subsequent trapping with an acid chloride 
Allylmetal bromide (1.1 eq, 0.84 mmol) was slowly added to a stirred solution of imine 
(1 eq, 0.76 mmol) in THF (3 mL) at −78 °C under Ar. The reaction mixture was allowed 
to warm to rt and stirred for 2.5 h. After this time, the reaction was cooled to −78 °C and 
a solution of trans-cinnamoyl chloride (1.2 eq, 152 mg, 0.91 mmol) in THF (1 mL) was 
added. The reaction was allowed to warm to rt and the resulting solution was stirred for 
2 h. Sat. NH4Cl(aq) (5 mL) was added and the reaction was extracted into Et2O (10 mL). 
The two layers were separated and the aqueous layer was extracted with Et2O (2 x 10 
mL). The combined organics were dried (MgSO4) and filtered, and the solvent removed 
under reduced pressure to give the crude product. 
 
General Procedure F: Synthesis of bispidones via a double Mannich reaction 
A solution of N-protected piperidone (1 eq, 7.50 g, 37.64 mmol), acetic acid (1 eq, 2.16 
mL, 37.64 mmol) and benzylamine (1 eq, 4.12 mL, 37.64 mmol) in MeOH (45 mL) was 
added dropwise over 20 min to a stirred suspension of paraformaldehyde (2.2 eq, 2.49 g, 
82.81 mmol) in MeOH (75 mL) heated at reflux under Ar. The resulting mixture was 
stirred and heated at reflux for 1 h. Then paraformaldehyde (2.2 eq, 2.49 g, 82.81 mmol) 
was added in one portion. The resulting mixture was stirred and heated at reflux for 4 h. 
The mixture was allowed to cool to rt and the solvent was evaporated under reduced 
pressure. The residue was dissolved in Et2O (150 mL) and washed with 1 M KOH(aq) 
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(150 mL). The aqueous layer was extracted with Et2O (5 x 150 mL) and the combined 
organics were dried (MgSO4), filtered and evaporated under reduced pressure to give the 
crude product. 
 
General Procedure G: Reduction of bispidones 
p-Toluenesulfonyl hydrazide (1.2 eq, 6.43 g, 34.54 mmol) was added in one portion to a 
stirred solution of N-protected bispidone  (1 eq, 9.51 g, 28.78 mmol) in EtOH (250 mL) 
at rt under Ar. The resulting solution was stirred and heated at reflux for 3.5 h (TLC 
analysis indicated disappearance of bispidone). The reaction was allowed to cool to rt 
and the solvent was evaporated under reduced pressure. The residue was dissolved in 
THF:H2O (4:1, 180 mL) and cooled to 0 °C. NaBH4 (9.15 g, 241.75 mmol) was added 
portionwise over 20 min (CARE – vigorous effervescence). The resulting mixture was 
stirred at rt for 18 h. The mixture was then stirred and heated at reflux for a specified 
time. The solution was allowed to cool to rt and water (150 mL) was added. The layers 
were separated and the aqueous layer was extracted with Et2O (4 x 100 mL). The 
combined organics were dried (MgSO4), filtered and evaporated under reduced pressure 
to give the crude product. 
 
General Procedure H: Hydrogenation of benzyl protecting group 
20% (w/w) Pd(OH)2/C (10 mol %, 1.26 g, 1.80 mmol) was added to a stirred solution of 
N-benzyl bispidine (1 eq, 5.70 g, 18.01 mmol) in EtOH (170 mL) at rt under Ar. The 
flask was evacuated and back-filled with Ar three times and finally evacuated and back-
filled with H2. Then, the mixture was stirred at rt for 18 h, replacing the H2 balloon as 
required. The solids were removed by filtration through a pad of Celite® and the solvent 
was evaporated under reduced pressure to give the product. 
 
General Procedure I: Synthesis of imines using NBS 
N-Bromosuccinimide (1.1 eq, 15.64 g, 87.87 mmol) was added portionwise to a stirred 
solution of tetrahydroisoquinoline (1 eq, 10 mL, 79.89 mmol) in CH2Cl2 (150 mL) at rt 
under Ar. The resulting mixture was stirred at rt for 3 h. NaOH(aq) (30% w/v, 50 mL) 
was added and the reaction mixture was stirred vigorously at rt for 16 h. The two layers 
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were separated and the organic layer was washed with water (150 mL). The aqueous 
layer was extracted with CH2Cl2 (3 x 100 mL). The combined organics were dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
 
General Procedure J: Synthesis of spirocycles by direct imine acylation 
DIPEA (1.85 eq, 245 µL, 1.41 mmol) and T3P (1.5 eq, 725 mg of a 50% w/v solution in 
THF, 1.14 mmol) were added to a stirred solution of imine (1 eq, 0.762 mmol) and acid 
(1.2 eq, 0.909 mmol) in solvent (4 mL) at a specified temperature. The resulting solution 
was stirred in a sealed vessel for a specified time. The solution was diluted with CH2Cl2 
(10 mL) and poured into sat. NaHCO3(aq) (10 mL). The two layers were separated and 
the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined organics were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product.  
 
General Procedure K: NaBH4 reduction of spirocyclic indolenine 
NaBH4 (4 eq, 1.32 mmol) was added portionwise (CARE: effervescence) to a stirred 
solution of imine (1 eq, 0.33 mmol) in MeOH (5 mL) at 0 °C under Ar. The reaction 
mixture was heated to reflux and stirred for 3.5 h and then allowed to cool to rt. The 
solvent was evaporated under reduced pressure and the resulting residue taken up in 
H2O (10 mL) and CH2Cl2 (10 mL). The two layers were separated and the aqueous layer 
was extracted with CH2Cl2 (3 x 10 mL). The combined organics were dried (MgSO4), 
filtered and evaporated under reduced pressure to give the crude product.  
 
General Procedure L: LiAlH4 reduction of spirocyclic indoline 
LiAlH4 (4 eq, 2.00 mmol) was added to a stirred solution of amide (1 eq, 0.50 mmol) in 
dry THF (15 mL) at 0 °C under Ar. The resulting suspension was heated to reflux and 
stirred for 2.5 h, then the reaction was allowed to cool to rt. The reaction was diluted 
with EtOAc (5 mL) and H2O was carefully added until effervescence ceased. NaSO4 
was added and the resulting suspension stirred for 30 min, then the mixture was filtered 
and the solvent evaporated under reduced pressure to give the crude product. 
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5.3. Reaction Procedures and Compound 
Characterisation 
5.3.1. Chapter 2  
3,4-Dihydroisoquinoline 37 
 
37 
Using general procedure I, N-bromosuccinimide (15.64 g, 87.87 mmol) and 
tetrahydroisoquinoline (10 mL, 79.89 mmol) in CH2Cl2 (150 mL) at rt under Ar, then 
NaOH(aq) (30% w/v, 50 mL) gave the crude product. Purification by flash column 
chromatography on silica with petrol-EtOAc (5:1) and then EtOAc as eluent gave 3,4-
dihydroisoquinoline 37 (8.97 g, 86%) as an orange oil, RF (1:1 petrol-EtOAc) 0.10; 1H 
NMR (400 MHz, CDCl3) δ 8.35 (s, 1H, CHN), 7.40-7.13 (m, 4H, Ar), 3.81-3.75 (m, 2H, 
CH2), 2.79-2.61 (m, 2H, CH2); 13C NMR (100.6 MHz, CDCl3) δ 160.2 (C=N), 136.1 
(ipso-Ar), 130.9 (Ar), 128.3 (ipso-Ar), 127.3 (Ar), 127.0 (Ar), 126.9 (Ar), 47.2 (CH2N), 
24.9 (CH2). HRMS (ESI) m/z calcd for C9H9N (M + H)+ 132.0808, found 132.0812 
(−3.8 ppm error). Spectroscopic data consistent with those reported in the literature.192  
Lab Book Reference: SC2/6 
 
3-Methylbut-3-enoic acid 40 
 
40 
Using general procedure B, Jones reagent (10.6 mL of a 2.5 M solution, 26.39 mmol) 
and 3-methyl-3-buten-1-ol (1.88 mL, 18.85 mmol) in acetone (120 mL) at 0 °C gave the 
acid 40 (1.14 g, 61%) as a yellow oil, 1H NMR (400 MHz, CDCl3) δ 4.97-4.95 (m, 1H, 
C=CHAHB), 4.90-4.89 (m, 1H, C=CHAHB), 3.09 (d, J = 1.0 Hz, 2H, CH2), 1.84 (t, J = 
N
HO
O
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1.0 Hz, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 177.7 (C=O), 137.9 (C=CH2), 115.4 
(C=CH2), 43.1 (CH2), 22.4 (CH3); Spectroscopic data consistent with those reported in 
the literature.193 
Lab Book Reference: SC1/2 
 
2-Methyl-6,7-dihydro-1H-pyrido[2,1-a]isoquinolin-4(11bH)-one 41 
 
41 
DIPEA (0.53 mL, 3.05 mmol) and T3P (1.46 g of a 50% w/v solution in THF, 2.29 
mmol) were added to a stirred solution of 3,4-dihydroisoquinoline 37 (200 mg, 1.52 
mmol) and 3-methyl-3-butenoic acid 40 (183 mg, 1.83 mmol) in CH2Cl2 (15 mL) under 
Ar at rt. The resulting solution was stirred and heated at reflux for 1.5 h. The solution 
was cooled to 0 °C and TFA (0.58 mL, 7.63 mmol) was added under Ar. The solution 
was stirred and heated at 45 °C for 18 h. The solution was cooled to rt, diluted with 
CH2Cl2 (20 mL) and poured into sat. NaHCO3(aq) (20 mL). The two layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 30 mL). The combined 
organics were dried (MgSO4), filtered and evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with petrol-
EtOAc (3:1) as eluent gave dihydropyridone 41 (150 mg, 46%) as a yellow oil, RF 
(EtOAc) 0.20; IR (ATR) 2934, 1669 (C=O), 1624 (C=C), 1417, 1150, 761 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.26-7.15 (m, 4H, Ar), 5.86 (dd, J = 2.5, 1.5 Hz, 1H, 
CHC(O)), 4.80-4.71 (m, 2H, CHN, CHAHBN), 2.97-2.76 (m, 3H, CHAHBN, CH2), 2.58 
(dd, J = 17.0, 5.0 Hz, 1H, CHAHBCMe=CH), 2.41-2.31 (m, 1H, CHAHBCMe=CH), 1.97 
(dd, J = 1.0, 1.0 Hz, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 165.4 (C=O), 150.2 
(C(CH3)3), 135.9 (ipso-Ar), 134.9 (ipso-Ar), 129.0 (Ar), 126.7 (Ar), 126.6 (Ar), 125.6 
(Ar), 120.7 (CHC(O)), 54.3 (CHN), 38.6 (C=CCH2), 37.7 (NCH2), 29.5 (CH2), 22.7 
(CH3); HRMS (ESI) m/z calcd for C14H15NO (M + H)+ 214.1226, found 214.1218 (+4.0 
ppm error). Spectroscopic data consistent with those reported in the literature.20 
N O
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Lab Book Reference: SC1/3 
 
(E)-4-Bromobut-2-enoic acid 77 
 
77 
(E)-Methyl 4-bromobut-2-enoate 76 (0.35 mL, 3.0 mmol) was added to a stirred 
solution of bis(tributyltin) oxide (3.06 mL, 6.0 mmol) in toluene (30 mL) under Ar at rt. 
The resulting mixture was stirred and heated at reflux for 18 h. The mixture was allowed 
to cool to rt and the solvent was evaporated under reduced pressure. The residue was 
dissolved in EtOAc (30 mL) and extracted with sat. NaHCO3(aq) (3 x 25 mL). The 
combined aqueous layers were acidified to pH 4-5 with 5 M HCl(aq) and extracted with 
EtOAc (3 x 25 mL). The combined organics were washed with brine (40 mL), dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
Residual tin impurities were removed by partitioning the crude product in EtOAc (20 
mL) and water (20 mL). The mixture was basified with sat. NaHCO3(aq) (20 mL) and the 
aqueous layer was washed with EtOAc (3 x 20 mL). The aqueous layer was acidified to 
pH 4-5 with 5 M HCl(aq) and extracted into EtOAc (3 x 20 mL). The combined organics 
were dried (MgSO4) and the solvent evaporated reduced pressure to give the allylic acid 
46 (283 mg, 57%) as an orange solid, mp 66-67  °C (lit,53 72-73 °C); 1H NMR (400 
MHz, CDCl3) δ 7.12 (dt, J = 15.0, 7.5 Hz, 1H, CH=CHC(O)), 6.05 (dt, J = 15.0, 1.5 Hz, 
1H, CH=CHC(O)), 4.03 (dd, J = 7.5, 1.5 Hz, 2H, CH2); 13C NMR (100.6 MHz, CDCl3) 
δ 171.0 (C=O), 144.4 (CH=CHC(O)), 123.7 (CH=CHC(O)), 28.7 (CH2). Spectroscopic 
data consistent with those reported in the literature.53  
Lab Book Reference: SC1/13 
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(E)-4-(Phenylsulfonyl)but-2-enoic acid 79  
 
79 
n-Butyllithium (3.44 mL of a 1.6 M solution in hexanes, 5.5 mmol) was added dropwise 
to a stirred solution of allylsulfonylbenzene 78 (0.76 mL, 5.0 mmol) in THF (10 mL) at 
−78 °C under Ar. The resulting solution was stirred at −78 °C for 1 h. Dry CO2 
(obtained by passing CO2 gas through conc. H2SO4) was bubbled into the reaction flask 
and the reaction mixture was allowed to warm to rt. After 3 h, 2 M HCl(aq) (10 mL) was 
added. The mixture was basified with 2 M NaOH(aq) (until pH > 14) and the impurities 
were extracted with Et2O (50 mL). The aqueous layer was acidified with 2 M HCl(aq) (10 
mL) and extracted with Et2O (3 x 50 mL). The combined organics were dried (MgSO4), 
filtered and evaporated under reduced pressure to give the crude product. Trituration of 
the crude product by stirring in Et2O (5 mL) gave a solid which was collected by 
filtration to give the 4-phenylsulfonylcrotonic acid 79 (136 mg, 12%) as a white solid, 
mp 141-142 °C (lit.,54 145 °C) 1H NMR (400 MHz, CDCl3) δ 7.90-7.87 (m, 2H, Ph), 
7.72-7.68 (m, 1H, Ph), 7.62-7.57 (m, 2H, Ph), 6.89 (dt, J = 15.5, 8.0 Hz, 1H, 
C(O)CH=CH), 5.86 (dt, J = 15.5, 1.5 Hz, 1H, C(O)CH=CH), 3.97 (dd, J = 8.0, 1.5 Hz, 
2H, CH2); 13C NMR (100.6 MHz, CDCl3) δ 168.9 (C=O), 138.0 (ipso-Ph), 135.6 
(C(O)CH=CH), 134.3 (Ph), 129.4 (Ph), 128.5 (C(O)CH=CH), 128.3 (Ph), 59.1 (CH2); 
HRMS (ESI) m/z calcd for C10H10O4S (M + Na)+ 249.0192, found 249.0202 (−4.4 ppm 
error). Spectroscopic data consistent with those reported in the literature.54  
Lab Book Reference: SC1/8 
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5-(2-(Phenylsulfonyl)ethylidene)-4b,5,8,9,15,16-hexahydropyrimido[2,1-a:4,3-
a']diisoquinolin-6(13bH)-one 82 
 
82 
DIPEA (52 µL, 0.30 mmol) and T3P (146 mg of a 50% w/v solution in THF, 0.25 
mmol) were added to a stirred solution of 3,4-dihydroisoquinoline 37 (20 mg, 0.15 
mmol) and (E)-4-(phenylsulfonyl)but-2-enoic acid 73 (40 mg, 0.18 mmol) in toluene (2 
mL) at rt under Ar. The resulting solution was stirred in a sealed vessel at rt for 3 h. The 
solution was diluted with CH2Cl2 (5 mL) and poured into sat. NaHCO3(aq) (10 mL). The 
two layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). 
The combined organics were washed with water (10 mL) and brine (10 mL), dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with petrol-EtOAc (3:2) as eluent 
gave a single diastereoisomer of 82 with undefined relative stereochemistry (11 mg, 
31%) as a brown oil, RF (3:2 petrol-EtOAc) 0.2; IR (ATR) 2928, 1696 (C=O), 1655 
(C=C), 1604, 1426, 1305, 1142, 729 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.65-7.63 (m, 
2H, Ar), 7.56-7.52 (m, 1H, Ar), 7.50-7.47 (m, 1H, Ar), 7.44-7.40 (m, 2H, Ar), 7.30-7.14 
(m, 6H, Ar), 7.00 (d, J = 7.0 Hz, 1H, Ar), 5.92 (s, 1H, NCHN), 5.49 (ddd, J = 8.5, 6.0, 
2.0, 1H, C(O)C=CH), 5.02 (ddd, J = 15.5, 8.5, 1.0 Hz, 1H, CHAHBSO2Ph), 4.95 (br s, 
1H, NCHC=C), 4.80-4.76 (m, 1H, NCH), 4.57 (ddd, J = 15.5, 6.0, 2.0 Hz, 1H, 
CHAHBSO2Ph), 2.95-2.81 (m, 3H, 3 x NCH), 2.75-2.70 (m, 1H, CH), 2.50 (dd, J = 16.5, 
4.0 Hz, 1H, CH), 2.41 (dd, J = 12.0, 7.0 Hz, 1H, CH), 2.29 (ddd, J = 12.0, 12.0, 4.0 Hz, 
1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 162.6 (C=O), 138.7 (ipso-Ar), 136.3 (ipso-
Ar), 136.2 (ipso-Ar), 134.4 (ipso-Ar), 133.3 (Ar), 133.0 (ipso-Ar), 132.4 (C(O)C=C), 
129.8 (Ar), 129.3 (C=CH), 129.1 (Ar), 128.9 (Ar), 128.8 (Ar), 128.2 (Ar), 127.9 (Ar), 
127.8 (Ar), 127.0 (Ar), 126.9 (Ar), 125.4 (Ar), 74.8 (NCHN), 62.6 (NCHC=C), 56.3 
(CH2SO2Ph), 37.9 (NCH2), 36.3 (NCH2), 28.6 (CH2), 28.4 (CH2); HRMS (ESI) m/z 
calcd for C28H26N2O3S (M + H)+ 471.1737, found 471.1727 (+0.9 ppm error). The 1H 
and 13C NMR spectra were assigned using the 2D COSY and HSQC spectra.  
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Lab Book Reference: SC1/14 
 
(E)-4-Iodo-3-methylbut-3-en-1-ol 96 
 
 
96 
Trimethylaluminium (2 M in hexanes, 15.5 mL, 31.0 mmol) was added dropwise to a 
stirred solution of zirconocene dichloride (643 mg, 2.2 mmol) in CH2Cl2 (40 mL) at −20 
°C under Ar. The reaction mixture was stirred for 10 min and then water (288 µL, 16.0 
mmol) was added dropwise (caution: exothermic reaction). The reaction mixture was 
stirred for a further 15 min, and then 3-butyn-1-ol 95 (756 µL, 10 mmol) (pretreated 
with trimethyl aluminium (2 M in hexanes, 2 mL, 4.0 mmol) in CH2Cl2 (10 mL) at 0 °C) 
was added slowly. The reaction mixture was allowed to warm to rt and stirred for 3 h. 
The reaction mixture was then cooled to – 20 °C and a solution of I2 (3.05 g, 12.0 
mmol) in Et2O (25 mL) was added dropwise. The reaction mixture was allowed to warm 
to rt and stirred for 2 h. The reaction was cooled to 0 °C and quenched by careful 
addition of water (40 mL). The resulting biphasic mixture was filtered through a pad of 
Celite® and the layers were separated. The organic layer was washed with Na2S2O3(aq) 
(30 mL) and brine (30 mL), dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica using hexane-Et2O (8:2) as eluent gave the iodo substituted alkene 96 (1.57 g, 
74%) as a yellow liquid, RF (8:2 hexane-Et2O) 0.2; 1H NMR (400 MHz, CDCl3) δ 6.02 
(tq, J = 1.0, 1.0 Hz, 1H, C(CH3)=CHI), 3.72 (t, J = 6.5 Hz, 2H, CH2OH), 2.48 (td, J = 
6.5, 1.0 Hz, 2H, CH2C=C), 1.88 (d, J = 1.0 Hz, 3H, CH3); 13C NMR (100.6 MHz, 
CDCl3) δ 144.5 (C(CH3)=CHI), 76.9 (C=CHI), 60.1 (CH2), 42.4 (CH2), 23.8 (CH3). 
Spectroscopic data consistent with those reported in the literature.56 
Lab Book Reference: SC2/48 
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(E)-4-Iodo-3-methylbut-3-enoic acid 90 
 
90 
Using general procedure B, Jones reagent (synthesised using general procedure A, 3.7 
mL of a 2.5 M aqueous solution, 9.25 mmol) and (E)-4-iodo-3-methylbut-3-en-1-ol 96 
(1.37 g, 6.47 mmol) in acetone (20 mL) gave the acid product 90 (736 mg, 50%) as an 
orange solid, mp 55-58 °C; 1H NMR (400 MHz, CDCl3) δ 11.37 (s, 1H, OH), 6.20 (d, J 
= 0.5 Hz, 1H, C=CHI), 3.24 (s, 2H, CH2), 1.94 (d, J = 0.5 Hz, 3H, CH3); 13C NMR 
(100.6 MHz, CDCl3) δ 176.6 (C=O), 139.5 (C=CI), 80.4, (C=CI), 43.7 (CH2), 23.9 
(CH3). Spectroscopic data consistent with those reported in the literature.194 
Lab Book Reference: SC2/57 
 
1-Iodo-2-methyl-6,7-dihydro-1H-pyrido[2,1-a]isoquinolin-4(11bH)-one 97 
 
97 
DIPEA (238 µL, 1.37 mmol) and T3P (706 mg of a 50% w/v solution in THF, 1.11 
mmol) were added to a stirred solution of 3,4-dihydroisoquinoline 37 (97 mg, 0.74 
mmol) (E)-4-iodo-3-methylbut-3-enoic acid 90 (200 mg, 0.88 mmol) in CH2Cl2 (3 mL) 
at rt under Ar. The resulting solution was stirred in a sealed vessel at rt for 1.5 h. TFA 
(113 µL, 1.48 mmol) was added and the reaction mixture was stirred and heated at 45 
°C for 16 h. After being allowed to cool to rt, the solution was diluted with CH2Cl2 (10 
mL) and poured into sat. NaHCO3(aq) (10 mL). The two layers were separated and the 
aqueous layer was extracted with CH2Cl2 (2 x 10 mL). The combined organics were 
washed with water (10 mL) and brine (10 mL), dried (MgSO4), filtered and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with hexane-EtOAc (19:1 then 9:1) as eluent gave a single 
diastereoisomer of 97 with undefined relative stereochemistry (28 mg, 11%) as a yellow 
HO
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oil, RF (9:1 petrol-EtOAc) 0.3; IR (ATR) 3064, 2924, 1747, 1682 (C=O), 1639, 1152, 
1014, 654, 631 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.29-7.23 (m, 2H, Ar), 7.19-7.15 
(m, 2H, Ar), 6.42-6.41 (m, 1H, CHC(O)), 4.46 (br s, 1H, NCHCHI), 3.99 (ddd, J = 12.5, 
6.0, 4.0 Hz, 1H, NCHAHB), 3.77 (dd, J = 2.0, 1.0 Hz, 1H, CHI), 3.19-3.03 (m, 2H, 
NCHAHB, CHCHD), 2.80-2.74 (m, 1H, CHCHD), 2.05 (d, J = 1.0 Hz, 3H, CH3); 13C 
NMR (100.6 MHz, CDCl3) δ 164.0 (C=O), 141.0 (C(CH3)), 134.6 (ipso-Ar), 133.9 
(ipso-Ar), 129.6 (Ar), 127.6 (Ar), 127.1 (Ar), 125.9 (Ar), 80.3 (CHC(O)), 66.1 (ICH), 
53.5 (NCH), 37.7 (NCH2), 28.2 (CH2), 22.1 (CH3); HRMS (ESI) m/z calcd for 
C14H14INO (M + H)+ 340.0193, found 340.0195 (−0.9 ppm error).  
Lab Book Reference: SC2/60 
 
(But-3-yn-1-yloxy)(tert-butyl)dimethylsilane 99 
 
99 
tert-Butyldimethylsilyl chloride (5.43 g, 36.0 mmol) and imidazole (3.68 g, 54 mmol) 
were added to a stirred solution of 3-butyn-1-ol 95 (2.27 mL, 30 mmol) in CH2Cl2 (100 
mL) at rt under Ar. The reaction mixture was stirred for 1 h. Then, the reaction mixture 
was diluted with CH2Cl2 (20 mL) and washed with 1 M HCl(aq) (100 mL) and brine (50 
mL), dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica using EtOAc as eluent 
gave the protected alkynol 99 (5.14 g, 93%) as a pale yellow liquid, RF (EtOAc) 0.8; 1H 
NMR (400 MHz, CDCl3) δ 3.73 (t, J = 7.0 Hz, 2H, OCH2), 2.39 (td, J = 7.0, 2.5 Hz, 2H, 
CH2C CH), 1.95 (t, J = 2.5 Hz, C CH), 0.89 (s, 9H, Si(CH3)2C(CH3)3), 0.06 (s, 6H, 
Si(CH3)2C(CH3)3); 13C NMR (100.6 MHz, CDCl3) δ 81.5 (C CH), 69.3 (C CH), 61.7 
(OCH2), 25.9 (Si(CH3)2C(CH3)3), 22.8 (CH2C CH), 18.3 (Si(CH3)2C(CH3)3), −5.3 
(Si(CH3)2C(CH3)3). Spectroscopic data consistent with those reported in the literature.195 
Lab Book Reference: SC2/49 
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(E)-tert-Butyl((4-iodobut-3-en-1-yl)oxy)dimethylsilane 100 
 
100 
ZrCp2Cl2 (1.58 g, 5.4 mmol) was added to THF (20 mL) in a flame-dried flask and 
stirred at rt under Ar. The flask was shielded from light with an aluminium foil wrap. 
LiEt3BH (1 M in THF, 5.4 mL, 5.4 mmol) was added dropwise and the reaction was 
stirred for 1 h. (But-3-yn-1-yloxy)(tert-butyl)dimethylsilane 99 (500 mg, 2.7 mmol) was 
added to the reaction mixture and stirred for 10 min. I2 (1.52 g, 6.00 mmol) was added 
and the resulting solution stirred at rt for 20 min. The resulting solution was poured into 
sat. NaHCO3(aq) (50 mL) and extracted with Et2O (30 mL). The two layers were 
separated and the aqueous layer was extracted with Et2O (2 x 20 mL). The combined 
organics were washed with Na2S2O3(aq) (50 mL) and brine (50 mL). The organic layer 
was dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica using hexane-EtOAc 
(19:1) as eluent gave iodo-substituted alkene 100 (354 mg, 36%) as a pale yellow oil, RF 
(9:1 hexane:EtOAc) 0.90; 1H NMR (400 MHz, CDCl3) δ 6.54 (dt, J = 14.5, 7.5 Hz, 1H, 
CH=CHI), 6.08 (dt, J = 14.5, 1.5 Hz, 1H, CH=CHI), 3.65 (t, J = 6.5 Hz, 2H, OCH2), 
2.26 (dtd, J = 7.5, 6.5, 1.5 Hz, 2H, CH2C=C), 0.89 (s, 9H, Si(CH3)2C(CH3)3), 0.05 (s, 
6H, Si(CH3)2C(CH3)3). Spectroscopic data consistent with those reported in the 
literature.196 
Lab Book Reference: SC2/52 
 
(E)-4-Iodobut-3-en-1-ol 101 
 
101 
ZrCp2Cl2 (2.92 g, 10 mmol) was added to THF (30 mL) in a flame-dried flask and 
stirred at rt under Ar. The flask was shielded from light with an aluminium foil wrap. 
LiEt3BH (1 M in THF, 10 mL, 10 mmol) was added dropwise and the reaction as stirred 
for 75 min.  A solution of 3-butyn-1-ol 95 (378 µL, 5 mmol) in THF (pretreated with 
LiEt3BH (5.00 mL, 5.00 mmol) at rt under Ar) was added to the reaction mixture and 
TBDMSO I
HO I
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stirred for 10 min. I2 (1.52 g, 6 mmol) was added and the resulting solution stirred at rt 
for 2 h. The solution was poured into sat. NaHCO3(aq) (50 mL) and extracted with Et2O 
(30 mL). The two layers were separated and the organic layer was washed with 
Na2S2O3(aq) (50 mL) and brine (50 mL). The organic layer was dried (MgSO4), filtered 
and evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica using hexane-EtOAc (3:1) as eluent gave iodo-
substituted alkene 101 (354 mg, 36%) as a pale yellow oil.  
Lab Book Reference: SC2/55 
 
TBAF (1 M in THF, 1.26 mL, 1.26 mmol) was added to a stirred solution of (E)-tert-
butyl((4-iodobut-3-en-1-yl)oxy)dimethylsilane 100 (263 mg, 0.84 mmol) in THF (20 
mL) at rt under Ar. The resulting solution was stirred for 1 h. Sat. NH4Cl(aq) (20 mL) 
was added and the mixture was extracted into Et2O (20 mL). The two layers were 
separated and the aqueous layer was extracted with Et2O (2 x 20 mL). The combined 
organics were washed with brine (20 mL), dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica using hexane-EtOAc (3:1) as eluent gave iodo-substituted 
alkene 101 (137 mg, 83%) as a colourless oil, RF (3:1 hexane-EtOAc) 0.15; 1H NMR 
(400 MHz, CDCl3) δ 6.54 (dt, J = 14.5, 7.5 Hz, 1H, CH=CHI), 6.17 (dt, J = 14.5, 1.5 
Hz, 1H, CH=CHI), 3.69 (t, J = 6.0 Hz, 2H, HOCH2), 2.33 (dtd, J = 7.5, 6.0, 1.5 Hz, 2H, 
CH2C=C), 1.44 (s, 1H, OH); 13C NMR (100.6 MHz, CDCl3) δ 142.6 (C=CI), 77.3 
(C=CI), 61.0 (CH2OH), 39.2 (CH2C=C). Spectroscopic data consistent with those 
reported in the literature.196 
Lab Book Reference: SC2/56 
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(E)-4-Iodobut-3-enoic acid 91 
 
91 
Using general procedure B, Jones reagent (synthesised using general procedure A, 0.3 
mL of a 2.5 M aqueous solution, 0.75 mmol) and (E)-4-iodobut-3-en-1-ol 101 (106 mg, 
0.54 mmol) in acetone gave acid 91 (97 mg, 79%) as an orange solid, mp 56-58 °C 
(lit.194 56-58 °C); 1H NMR (400 MHz, CDCl3) δ 6.62 (dt, J = 14.5, 7.5 Hz, 1H, 
CH=CHI), 6.31 (dd, J = 14.5, 1.5 Hz, 1H, CH=CHI), 3.14 (dd, J = 7.5, 1.5 Hz, 2H, 
CH2); 13C NMR (100.6 MHz, CDCl3) δ 176.0 (C=O), 136.3 (C=CI), 79.7, (C=CI), 40.4 
(CH2. Spectroscopic data consistent with those reported in the literature.194 
Lab Book Reference: SC2/59 
 
(E)-5-(2-Iodovinyl)-4b,5,8,9,15,16-hexahydropyrimido[2,1-a:4,3-a']diisoquinolin-
6(13bH)-one 104 
 
104 
DIPEA (127 µL, 0.72 mmol) and T3P (380 mg of a 50% w/v solution in THF, 0.59 
mmol) were added to a stirred solution of 3,4-dihydroisoquinoline 37 (51 mg, 0.39 
mmol) and (E)-4-iodobut-3-enoic acid 91 (100 mg, 0.47 mmol) in CH2Cl2 (2 mL) at rt 
under Ar. The resulting solution was stirred in a sealed vessel at rt for 1 h. TFA (60 µL, 
0.79 mmol) was added and the reaction was stirred and heated at 45 °C for 16 h. After 
being allowed to cool to rt, the solution was diluted with CH2Cl2 (10 mL) and poured 
into sat. NaHCO3(aq) (10 mL). The two layers were separated and the aqueous layer was 
extracted with CH2Cl2 (2 x 10 mL). The combined organics were washed with water (10 
mL) and brine (10 mL), dried (MgSO4), filtered and evaporated under reduced pressure 
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to give the crude product. Purification by flash column chromatography on silica with 
petrol-EtOAc (3:2) as eluent gave a single diastereoisomer of 104 with undefined 
relative stereochemistry (14.5 mg, 16%) as a yellow oil, RF (9:1 petrol-EtOAc) 0.3; IR 
(ATR) 3061, 2924, 1687, 1639, 1604, 1425, 1149, 945, 657 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.51-7.49 (m, 1H, Ar), 7.28-7.27 (m, 2H, Ar), 7.20-7.16 (m, 3H, Ar), 7.13-
7.11 (m, 1H, Ar), 7.05-7.03 (m, 1H, Ar), 6.60 (dd, J = 14.5, 9.5 Hz, 1H, CH=CHI), 6.15 
(d, J = 14.5 Hz, 1H, CH=CHI), 5.88 (s, 1H, NCHN), 4.72 (ddd, J = 13.0, 4.0, 4.0 Hz, 
1H, NCH), 4.38 (d, J = 9.5 Hz, 1H, NCHCHC=C), 3.38 (dd, J = 9.5, 9.5 Hz, 1H, 
NCHCHC=C), 3.16-3.09 (m, 1H, NCH), 2.96-2.88 (m, 2H, 2 x NCH), 2.80-2.63 (m, 
3H, 3 x CH), 2.56-2.51 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 167.1 (C=O), 
141.4 (CH=CHI), 136.7 (ipso-Ar), 135.9 (ipso-Ar), 133.4 (ipso-Ar), 132.5 (ipso-Ar), 
129.3 (Ar), 128.5 (Ar), 127.8 (Ar), 127.7 (Ar), 127.5 (Ar), 127.3 (Ar), 127.1 (Ar), 125.3 
(Ar), 81.6 (CH=CHI), 74.2 (NCHN), 61.2 (NCHCHC=C), 53.2 (NCHCHC=C), 38.7 
(NCH2), 36.3 (NCH2), 28.7 (CH2), 28.6 (CH2); HRMS (ESI) m/z calcd for C22H21IN2O 
(M + H)+ 457.0771, found 457.0779 (−1.7 ppm error). The 1H and 13C NMR spectra 
were assigned using the 2D COSY and HSQC spectra. 
Lab Book Reference: SC2/61 
 
2-(Trimethylsilyl)but-3-enoic acid 106 
 
106 
TMEDA (distilled over CaH2, 389 µL, 2.60 mmol) was added to a solution of 
allyltrimethylsilane 105 (317 µL, 2.00 mmol) in THF (14 mL) in a flame-dried flask at 
rt under Ar. The resulting solution was cooled to −30 °C and s-BuLi (2.0 mL of a 1.3 M 
solution in hexane, 2.6 mmol) was added. The resulting yellow solution was stirred at 
−30 °C for 1 h. After cooling to −78 °C, trimethylaluminium (1.1 mL of a 2 M solution 
in hexanes, 2.2 mmol) was added and the mixture was stirred at −78 °C for 20 min. Dry 
CO2 (obtained by passing CO2 gas through CaCl2 and into the reaction) was bubbled 
into the reaction mixture and stirred for 10 min. The resulting colourless solution was 
HO
O
SiMe3
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quenched by slow addition of H2O (10 mL). After being allowed to warm to rt, the 
reaction mixture was extracted with Et2O (20 mL). The two layers were separated and 
the aqueous layer was acidified using 3 M HCl(aq) (10 mL) and extracted with Et2O (2 x 
20 mL). The combined organics were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude product which contained an 80:20 mixture (by 1H 
NMR spectroscopy) of α:γ substituted acid products. Purification by column 
chromatography using CH2Cl2 as eluent gave the α-substituted acid 106 (86 mg, 27%) 
as a white solid, RF (CH2Cl2) 0.1; 1H NMR (400 MHz, CDCl3) δ 5.99 (ddd, J = 17.0, 
10.0, 10.0 Hz, 1H, CH=CHAHB), 4.98 (dd, J = 10.0, 1.0 Hz, 1H, CH=CHAHB), 4.91 (dd, 
J = 17.0, 1.0 Hz, 1H, CH=CHAHB), 2.94 (d, J = 10.0 Hz, CHC(O)), 0.13 (s, 9H, SiMe3); 
13C NMR (100.6 MHz, CDCl3) δ 179.4 (C=O), 132.5 (CH=CH2), 113.8 (CH=CH2), 45.3 
(CHC(O)), −3.0 (SiMe3). Diagnostic signals for the γ-substituted acid: 1H NMR (400 
MHz, CDCl3) δ 6.08 (dt, J = 18.5, 6.5 Hz, 1H, =CH), 5.82 (dt, J = 18.5, 1.5 Hz, 1H, 
=CH), 3.17 (dd, J = 6.5, 1.5 Hz, 1H, CH2C(O)), 0.06 (s, 9H, SiMe3) Spectroscopic data 
consistent with those reported in the literature.63 
Lab Book Reference: SC2/41 
 
(4bS*,5R*)-5-Vinyl-4b,5,8,9,15,16-hexahydropyrimido[2,1-a:4,3-a']diisoquinolin-
6(13bH)-one 110 
 
110 
DIPEA (71 µL, 0.41 mmol) and T3P (209 mg of a 50% w/v solution in THF, 0.33 
mmol) were added to a stirred solution of 3,4-dihydroisoquinoline 37 (29 mg, 0.22 
mmol) and 2-(trimethylsilyl)but-3-enoic acid 106 (42 mg, 0.27 mmol) in CH2Cl2 (2 mL) 
at rt under Ar. The resulting solution was stirred in a sealed vessel at rt for 2 h. 
BF3OEt2 (54 µL, 0.44 mmol) was added and the reaction mixture was stirred at rt for 
16 h. The solution was diluted with CH2Cl2 (10 mL) and poured into sat. NaHCO3(aq) 
N
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(10 mL). The two layers were separated and the aqueous layer was extracted with 
CH2Cl2 (2 x 10 mL). The combined organics were washed with water (10 mL) and brine 
(10 mL), dried (MgSO4), filtered and evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with petrol-
EtOAc (3:2) as eluent gave a single diastereoisomer of 110 with undefined relative 
stereochemistry (9 mg, 25%) as a yellow oil, RF (2:1 hexane-EtOAc) 0.2; IR (ATR) 
2923, 2853, 1642 (C=O), 1555, 1426, 1040, 920, 701, 661 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.53-7.51 (m, 1H, Ar), 7.29-7.27 (m, 2H, Ar), 7.20-7.10 (m, 5H, Ar), 5.96 
(ddd, J = 17.0, 10.0, 9.5 Hz, 1H, CH=CHAHB), 5.89 (s, 1H, NCHN), 5.40 (dd, J = 10.0, 
1.0 Hz, 1H, CH=CHAHB), 5.18 (ddd, J = 17.0, 1.0, 1.0 Hz, 1H, CH=CHAHB), 4.71 (ddd, 
J = 13.0, 4.0, 4.0 Hz, 1H, NCH), 4.41 (d, J = 9.5 Hz, 1H, NCHCHC=C), 3.37 (dd, J = 
9.5, 9.5 Hz, 1H, NCHCHC=C), 3.19-3.12 (m, 1H, NCH), 2.96-2.88 (m, 2H, 2 x NCH), 
2.80-2.64 (m, 3H, 3 x CH), 2.56-2.51 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 
168.8 (C=O), 136.9 (ipso-Ar), 136.6 (ipso-Ar), 134.9 (Ar), 133.4 (ipso-Ar), 132.8 (ipso-
Ar), 129.2 (Ar), 128.4 (Ar), 127.8 (Ar), 127.7 (Ar), 127.6 (Ar), 127.1 (CH=CH2), 127.0 
(Ar), 125.1 (Ar), 120.9 (CH=CH2), 74.1 (NCHN), 61.7 (NCHCHC=C), 51.2 
(NCHCHC=C), 38.6 (NCH2), 36.4 (NCH2), 29.7 (CH2), 28.7 (CH2); HRMS (ESI) m/z 
calcd for C22H21N2O (M + Na)+ 353.1624, found 353.1607 (+4.8 ppm error). The 1H 
and 13C NMR spectra were assigned using the 2D COSY and HSQC spectra. 
Lab Book Reference: SC2/46 
 
2-(Dimethyl(phenyl)silyl)but-3-enoic acid 113 
 
      113 
Chloro(dimethyl)phenylsilane (2.00 g, 11.75 mmol) was added to a solution of allylzinc 
bromide (synthesised using general procedure C, 2.35 M in THF, 10 mL, 23.51 mmol) 
and the resulting suspension was stirred at rt for 1.5 h. The reaction was cooled to 0 °C 
and sat. NH4Cl(aq) (50 mL) was carefully added and the reaction mixture was extracted 
into Et2O (50 mL). The two layers were separated and the aqueous layer was extracted 
HO
O
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into Et2O (2 x 50 mL). The combined organics were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude allyl silane product; (1H NMR (400 
MHz, CDCl3) 7.56-7.51 (m, 2H, Ar), 7.38-7.35 (m, 3H, Ar), 5.79 (ddt, J = 17.0, 10.0, 
8.0 Hz, 1H, CH=CH2), 4.88 (ddt, J = 11.5, 2.0, 1.0 Hz, 1H, CH=CHAHB), 4.85-4.84 (m, 
1H, CH=CHAHB), 1.77 (ddd, J = 8.0, 1.0, 1.0 Hz, 2H, CH2), 0.29 (s, 6H, 2 x CH3)). 
TMEDA (distilled over CaH2, 1.77 mL, 11.82 mmol) and s-BuLi (9.24 mL of a 1.28 M 
solution in hexane, 11.82 mmol) were added to a solution of allyl(dimethyl)phenylsilane 
(1.39 g, 7.88 mmol) in THF (23 mL) in a flame-dried flask at −78 °C under Ar. The 
resulting solution was stirred at for 1 h and then trimethylaluminium (5.12 mL of a 2 M 
solution in hexanes, 10.24 mmol) was added and the mixture was stirred at −78 °C for 
20 min. Dry CO2 (obtained by passing CO2 gas through CaCl2 and into the reaction) was 
bubbled into the reaction mixture and stirred for 10 min, then stirred at 0 °C for 10 min, 
The resulting colourless solution was quenched by slow addition of sat. NH4Cl(aq) (20 
mL). After being allowed to warm to rt, the reaction mixture was extracted with Et2O 
(500 mL). The two layers were separated and the aqueous layer was acidified using 3 M 
HCl(aq) (30 mL) and extracted with Et2O (2 x 50 mL). The combined organics were 
dried (MgSO4) and evaporated under reduced pressure to give the crude product. 
Purification by column chromatography using hexane-EtOAc (8:2) as eluent gave the 
acid 113 (820 mg, 31%) as a colourless oil, RF (hexane-EtOAc 8:2) 0.3; 1H NMR (400 
MHz, CDCl3) 7.51-7.50 (m, 2H, Ar), 7.42-7.32 (m, 3H, Ar), 5.93 (dt, J = 17.0, 10.0 Hz, 
1H, CH=CH2), 4.94 (ddd, J = 10.0, 1.5, 0.5 Hz, 1H, CH=CHcisHtrans), 4.79 (ddd, J = 
17.0, 1.5, 0.5 Hz, 1H, CHcisHtrans), 3.12 (d, J = 10.0 Hz, 1H, CH), 0.432 (s, 3H, CH3), 
0.429 (s, 3H, CH3); HRMS (ESI) m/z calcd for C12H16O2Si (M + Na)+ 243.0812, found 
243.0815 (+1.4 ppm error). Spectroscopic data consistent with those reported in the 
literature.63  
Lab Book Reference: SC6/25 
 
 168 
(4bS*,5S*)-6-Oxo-4b,5,6,8,9,13b,15,16-octahydropyrimido[2,1-a:4,3-
a']diisoquinoline-5-carbonitrile 117 
 
117 
DIPEA (139 µL, 0.80 mmol) and T3P (362 mg of a 50% w/v solution in THF, 0.57 
mmol) were added to a stirred solution of 3,4-dihydroisoquinoline 37 (100 mg, 0.76 
mmol) and cyanoacetic acid 116 (39 mg, 0.46 mmol) in CH2Cl2 (4 mL) at rt under Ar. 
The resulting solution was stirred in a sealed vessel at rt for 7 h. The solution was 
diluted with CH2Cl2 (10 mL) and poured into sat. NaHCO3(aq) (10 mL). The two layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The 
combined organics were washed with water (10 mL) and brine (10 mL), dried (MgSO4), 
filtered and evaporated under reduced pressure to give the crude product which 
contained a 5:1 mixture of diastereoisomers by 1H NMR spectroscopy. Purification by 
flash column chromatography on silica with hexane-EtOAc (2:1) as eluent gave the 
major diastereoisomer of 117 (96 mg, 77%) as a cream solid, RF (2:1 hexane-EtOAc) 
0.20; mp 181-184 °C; IR (ATR) 3026, 2892, 2247 (C N), 1654 (C=O), 1427, 1285, 
909, 726 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.55-7.51 (m, 1H, Ar), 7.50-7.46 (m, 1H, 
Ar), 7.31-7.23 (m, 4H, Ar), 7.21-7.14 (m, 2H, Ar), 5.94 (s, 1H, NCHN), 4.86-4.82 (m, 
1H, NCH), 4.80 (d, J = 10.5 Hz, 1H, C(O)CHCN), 3.84 (d, J = 10.5 Hz, 1H, 
NCHCHCN), 3.09 (ddd, J = 12.5, 12.5, 3.5 Hz, 1H, NCH), 2.99-2.88 (m, 2H, 2 x NCH), 
2.79 (ddd, J = 16.0, 3.0, 3.0 Hz, 1H, CH), 2.69-2.64 (m, 1H, CH), 2.60-2.56 (m, 2H, 2 x 
CH);13C NMR (100.6 MHz, CDCl3) δ 160.6 (C=O), 136.2 (ipso-Ar), 134.1 (ipso-Ar), 
133.1 (ipso-Ar), 131.3 (ipso-Ar), 129.4 (Ar), 128.8 (Ar), 128.2 (Ar), 128.1 (Ar) 127.3 
(Ar), 127.2 (Ar), 127.2 (Ar), 126.4 (Ar), 117.6 (C N), 74.7 (NCHN), 59.6 
(C(O)CHCN), 38.8 (NCH2), 28.3 (CHCHCN), 35.9 (NCH2), 28.3 (CH2), 28.3 (CH2); 
HRMS (ESI) m/z calcd for C21H19N3O (M + Na)+ 352.1420, found 352.1416 (+1.0 ppm 
error) and the minor diastereoisomer of 117, 80% clean by 1H NMR spectroscopy, (18 
mg, 11%) as a cream solid, RF (2:1 hexane-EtOAc) 0.10; 1H NMR (400 MHz, CDCl3) 
N
N
O
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for 117: δ 7.54 (d, J = 8.0 Hz, 1H, Ar), 7.38 (d, J = 8.0 Hz, 1H, Ar), 7.32-7.28 (m, 2H, 
Ar), 7.24-7.15 (m, 4H, Ar), 5.44 (s, 1H, NCHN), 4.85-4.80 (m, 1H, NCH), 4.34 (d, J = 
11.0 Hz, 1H, C(O)CHCN), 3.83 (d, J = 11.0 Hz, 1H, NCHCHCN), 3.53-3.46 (m, 1H, 
NCH), 3.43-3.14 (m, 4H, 2 x NCH, 2 x CH), 2.97 (dd, J = 16.0, 3.5 Hz, 1H, CH), 2.77 
(dd, J = 16.5, 4.5 Hz, 1H, CH); 13C NMR (100.6 MHz, CDCl3) for 117: δ 159.8 (C=O), 
135.7 (ipso-Ar), 135.0 (ipso-Ar), 133.1 (ipso-Ar), 132.6 (ipso-Ar), 129.5 (Ar), 129.3 
(Ar), 128.7 (Ar), 128.4 (Ar) 128.3 (Ar), 126.9 (Ar), 126.2 (Ar), 124.9 (Ar), 116.7 (C
N), 78.7 (NCHN), 53.9 (C(O)CHCN), 45.6 (NCH2), 42.2 (NCH2), 37.7 (CHCHCN), 
29.2 (CH2), 27.5 (CH2); HRMS (ESI) m/z calcd for C21H19N3O (M + Na)+ 352.1420, 
found 352.1407 (+3.2 ppm error). The 1H and 13C NMR spectra were assigned using the 
2D COSY and HSQC spectra. 
Lab Book Reference: SC3/4 
 
(E)-1-(1-Allyl-3,4-dihydroisoquinolin-2(1H)-yl)-3-phenylprop-2-en-1-one 119 
 
119 
DIPEA (0.53 mL, 3.05 mmol) and T3P (1.45 g of a 50% solution in THF, 2.28 mmol) 
were added to a stirred solution of 3,4-dihydroisoquinoline 37 (200 mg, 1.52 mmol) and 
trans-cinnamic acid 118 (271 mg, 1.83 mmol) in CH2Cl2 (15 mL) under Ar at rt. The 
resulting solution was stirred and heated at 45 °C for 2.5 h. The solution was cooled to 
−30 °C and allyl trimethylsilane 105 (1.21 mL, 7.3 mmol) followed by BF3OEt2 (0.56 
mL, 4.56 mmol) were added. The mixture was allowed to warm to rt and stirred for 2 h. 
The mixture was diluted with CH2Cl2 (10 mL) and poured into sat. NaHCO3(aq) (20 mL). 
The two layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 10 
mL). The combined organics were washed with water (20 mL) and brine (20 mL), dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with petrol-EtOAc (1:1) as eluent 
gave substituted diene 119 (240 mg, 52%) as a yellow oil, RF (1:1 petrol-EtOAc) 0.6 
and 0.3, mixture of rotamers; IR (ATR) 2934, 1643 (C=O), 1597 (C=C), 1428, 1193, 
N O
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908, 727 cm-1; 1H NMR (400 MHz, CDCl3) 55:45 mixture of rotamers δ; 7.72 (d, J = 
15.5 Hz, 0.55H, CH=CHPh), 7.71 (d, J = 15.5 Hz, 0.45H, CH=CHPh), 7.46-7.52 (m, 
2H, Ar), 7.41-7.33 (m, 3H, Ar), 7.22-7.12 (m, 4H, Ar), 6.99 (d, J = 15.5 Hz, 0.45H, 
CH=CHPh), 6.97 (d, J = 15.5 Hz, 0.55H, CH=CHPh), 5.95-5.82 (m, 1.45H, CH=CH2, 
NCH), 5.22-5.03 (m, 2.55H, C=CH2, NCH), 4.74 (ddd, J = 13.0, 5.5, 2.5 Hz, 0.45H, 
CH), 4.06 (ddd, J = 13.5, 5.0, 5.0 Hz, 0.55H, CH), 3.71 (ddd, J = 13.5, 10.0, 5.0 Hz, 
0.55H, CH), 3.26 (ddd, J = 13.0, 11.5, 5.5 Hz, 0.45H, CH), 3.07-2.61 (m, 4H, 2 x CH, 
CH2); 13C NMR (100.6 MHz, CDCl3) rotamers δ 166.0 and 165.8 (C=O), 142.8 and 
142.6 (CH=CHPh), 136.9 and 136.2 (ipso-Ar), 135.3 and 135.2 (ipso-Ar), 134.8 and 
133.9 (CH=CH2), 134.5 and 133.3 (ipso-Ar), 130.3, 129.5, 129.1, 128.8, 128.7, 128.5, 
128.1, 127.7, 127.4, 127.0, 126.8, 126.6, 126.3 and 126.1 (9 x Ar), 118.7 and 117.2 
(CH=CH2), 118.0 and 117.4 (CH=CHPh), 56.6 and 52.6 (NCH), 41.6 and 41.1 (CH2), 
40.4 and 36.1 (CH2), 29.3 and 28.1 (CH2CH=CH2); HRMS (ESI) m/z calcd for 
C21H21NO (M + H)+ 304.1696, found 304.1684 (+3.3 ppm error). 
Lab Book Reference: SC1/15 
 
(Table 2.3, Entry 2) 
Using general procedure D, trans-cinnamoyl chloride 136 (167 mg, 1.01 mmol) and 3,4-
dihydroisoquinoline 37 (110 mg, 0.84 mmol) in THF at 65 °C, then allylmagnesium 
bromide 137 (1 M in Et2O, 0.92 mL, 0.92 mmol) at −78 °C for 1.5 h gave the crude 
product. Purification by flash column chromatography on silica using hexane-EtOAc 
(8:1 then 4:1 then 1:1) as eluent gave the diene 119 (43 mg, 17%) as a yellow oil. 
Lab Book Reference: SC2/64 
 
(Table 2.3, Entry 3) 
Using general procedure D, trans-cinnamoyl chloride 136 (152 mg, 0.91 mmol) and 3,4-
dihydroisoquinoline 37 (100 mg, 0.76 mmol) in CH2Cl2 at rt, then allylmagnesium 
bromide 137 (1 M in Et2O, 0.91 mL, 0.91 mmol) at −78 °C for 1.5 h gave the crude 
product. Purification by flash column chromatography on silica using hexane-EtOAc 
(8:1 then 4:1 then 1:1) as eluent gave the diene 119 (55 mg, 24%) as a yellow oil. 
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Lab Book Reference: SC2/65 
 
(Table 2.3, Entry 4) 
Using general procedure D, trans-cinnamoyl chloride 136 (152 mg, 0.91 mmol) and 3,4-
dihydroisoquinoline 37 (100 mg, 0.76 mmol) in THF at 65 °C, then allylzinc bromide 
134 (synthesised using general procedure C, 0.91 M in THF, 1 mL, 0.91 mmol) at −78 
°C for 2 h gave the crude product. Purification by flash column chromatography on 
silica using hexane-EtOAc (3:1 then 1:1) as eluent gave the diene 119 (136 mg, 59%) as 
a yellow oil.  
Lab Book Reference: SC2/62 
 
(Table 2.3, Entry 5) 
Using general procedure D, trans-cinnamoyl chloride 136 (400 mg, 2.4 mmol) and 3,4-
dihydroisoquinoline 37 (262 mg, 2.0 mmol) in THF at 65 °C, then allylzinc bromide 
134 (synthesised using general procedure C, 2.4 M in THF, 1 mL, 2.4 mmol) at −78 °C 
for 3 h gave the crude product. Purification by flash column chromatography on silica 
using hexane-EtOAc (4:1 then 2:1 then 1:1) as eluent gave the diene 119 (430 mg, 70%) 
as a yellow oil. 
Lab Book Reference: SC2/66 
 
(Table 2.3, Entry 6) 
Using general procedure D, trans-cinnamoyl chloride 136 (400 mg, 2.4 mmol) and 3,4-
dihydroisoquinoline 37 (262 mg, 2.0 mmol) in CH2Cl2 at rt, then allylzinc bromide 134 
(synthesised using general procedure C, 2.4 M in THF, 1 mL, 2.4 mmol) at −78 °C for 3 
h gave the crude product. Purification by flash column chromatography on silica using 
hexane-EtOAc (4:1 then 2:1 then 1:1) as eluent gave the diene 119 (220 mg, 37%) as a 
yellow oil. 
Lab Book Reference: SC2/67 
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(Table 2.3, Entry 7) 
Using general procedure D, trans-cinnamoyl chloride 136 (303 mg, 1.82 mmol) and 3,4-
dihydroisoquinoline 37 (200 mg, 1.52 mmol) in THF at 65 °C, then allylzinc bromide 
134 (synthesised using general procedure C, 1.82 M in THF, 1 mL, 1.82 mmol) added at 
−78 °C then allowed to warm to rt for 2 h gave the crude product. Purification by flash 
column chromatography on silica using hexane-EtOAc (4:1 then 2:1 then 1:1) as eluent 
gave the diene 119 (351 mg, 76%) as a yellow oil. 
Lab Book Reference: SC2/68 
 
(Table 2.4, Entry 1) 
Using general procedure E, 3,4-dihydroisoquinoline 37 (100 mg, 0.76 mmol) and 
allylmagnesium bromide 137 (1 M in Et2O, 0.84 mL, 0.84 mmol), then trans-cinnamoyl 
chloride 136 (152 mg, 0.91 mmol) in THF (1 mL) gave the crude product. Purification 
by flash column chromatography on silica using hexane-EtOAc (4:1 then 2:1 then 1:1) 
as eluent gave the diene 119 (100 mg, 43%) as a yellow oil. 
Lab Book Reference: SC2/69 
 
(Table 2.4, Entry 2) 
Using general procedure E, 3,4-dihydroisoquinoline 37 (100 mg, 0.76 mmol) and 
allylzinc bromide 134 (synthesised using general procedure C, 0.84 M in THF, 1 mL, 
0.84 mmol), then trans-cinnamoyl chloride 136 (152 mg, 0.91 mmol) in THF (1 mL) 
gave the crude product. Purification by flash column chromatography on silica using 
hexane-EtOAc (4:1 then 2:1 then 1:1) as eluent gave the diene 119 (150 mg, 65%) as a 
yellow oil. 
Lab Book Reference: SC2/70 
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6,7-Dihydro-1H-pyrido[2,1-a]isoquinolin-4(11bH)-one 108 
 
108 
Grubbs’ 2nd generation catalyst (19 mg, 0.022 mmol) was added in one portion to a 
stirred solution of diene 119 (82 mg, 0.27 mmol) in toluene (3 mL) at rt under Ar. The 
resulting solution was stirred at rt for 20 h and then the solvent was evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with petrol-EtOAc (1:1) as eluent gave dihydropyridone 108 
(38 mg, 72%) as a yellow oil, RF (1:1 petrol-EtOAc) 0.2; IR (ATR) 2945, 1659 (C=O), 
1606 (C=C), 1419, 1143, 723 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.27-7.14 (m, 4H, 
Ar), 6.68 (ddd, J = 10.0, 6.5, 2.0 Hz, 1H, CH=CHC(O)), 6.08 (dd, J = 10.0, 3.0 Hz, 1H, 
CH=CHC(O)), 4.83-4.73 (m, 2H, CHN, NCHACHB), 3.01-2.72 (m, 4H, NCHAHB, CH2, 
CHCHDC=C), 2.34 (dddd, J = 17.0, 14.5, 3.0, 2.0 Hz, 1H, CHCHDC=C); 13C NMR 
(100.6 MHz, CDCl3) δ 164.6 (C=O), 139.0 (CH=CHC(O)), 135.7 (ipso-Ar), 134.7 
(ipso-Ar), 128.9 (Ar), 126.7 (Ar), 126.6 (Ar), 125.6 (Ar), 125.3 (CH=CHC(O)), 54.4 
(CHN), 37.8 (NCH2), 33.3 (C=CCH2), 29.4 (NCH2CH2); HRMS (ESI) m/z calcd for 
C13H13NO (M + H)+ 200.1070, found 200.1076 (−2.1 ppm error). 
Lab Book Reference: SC1/20 
 
(1R*,5S*)-tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate 48 
 
48 
Using general procedure F, tert-butyl 4-oxopiperidine-1-carboxylate (7.50 g, 37.64 
mmol), acetic acid (2.16 mL, 37.64 mmol), benzylamine (4.12 mL, 37.64 mmol) and 
paraformaldehyde (2 x (2.49 g, 82.81 mmol)) in MeOH (45 and 75 mL) at reflux under 
Ar gave the crude product. Purification by flash column chromatography on silica with 
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petrol-EtOAc (3:1) as eluent gave N-Boc bispidone 48 (9.51 g, 76%) as a yellow oil, RF 
(3:1 petrol-EtOAc) 0.2; 1H NMR (400 MHz, CDCl3) 50:50 mixture of rotamers δ 7.36-
7.24 (m, 5H, Ar), 4.58 (d, J = 13.5 Hz, 1H, C(O)NCH), 4.42 (d, J = 13.5 Hz, 1H, 
C(O)NCH), 3.54 (d, J = 13.0 Hz, 1H, CHAHBAr), 3.48 (d, J = 13.0 Hz, 1H, CHAHBAr), 
3.36 (dd, J = 13.5, 2.0 Hz, 1H, C(O)NCH), 3.28 (dd, J = 13.5, 2.0 Hz, 1H, C(O)NCH), 
3.20 (d, J = 11.5 Hz, 1H, NCH), 3.16 (d, J = 11.5 Hz, 1H, NCH), 2.72 (dd, J = 11.0, 3.5 
Hz, 1H, NCH), 2.66 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 2.44 (br s, 1H, CH), 2.40 (br s, 
1H, CH), 1.54 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3) rotamers δ 213.4 (C=O, 
ketone), 154.6 (C=O, Boc), 137.3 (ipso-Ar), 128.6 (Ar), 128.2 (Ar), 127.1 (Ar), 79.9 
(C(CH3)3), 61.7 (CH2Ar), 58.9 (NCH2), 58.6 (NCH2), 50.3 (C(O)NCH2), 49.6 
(C(O)NCH2), 47.4 (2 x CH), 28.5 (C(CH3)3). Spectroscopic data consistent with those 
reported in the literature.46 
Lab Book Reference: SC3/79 
 
 (1R*,5S*)-tert-Butyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate 49 
 
49 
Using general procedure G, p-toluenesulfonyl hydrazide (6.43 g, 34.54 mmol), N-Boc 
bispidone 48 (9.51 g, 28.78 mmol) in EtOH (250 mL) at rt under Ar, then NaBH4 (9.15 
g, 241.75 mmol) at rt for 18 h and reflux for 4 h gave the crude product. Purification by 
flash column chromatography on silica with petrol-EtOAc (4:1) as eluent gave N-Boc 
bispidine 49 (5.71 g, 62%) as a pale yellow oil, RF (4:1 petrol-EtOAc) 0.2; 1H NMR 
(400 MHz, CDCl3) 50:50 mixture of rotamers δ 7.34-7.19 (m, 5H, Ar), 4.16 (br d, J = 
13.0 Hz, 1H, C(O)NCH), 4.00 (br d, J = 13.0 Hz, 1H, C(O)NCH), 3.44 (d, J = 13.5 Hz, 
1H, CHAHBAr), 3.30 (d, J = 13.5 Hz, 1H, CHAHBAr), 3.11-3.01 (m, 2H, C(O)NCH), 
2.98 (br d, J = 11.0 Hz, 1H, NCH), 2.88 (br d, J = 11.0 Hz, 1H, NCH), 2.22 (br d, J = 
11.0 Hz, 1H, NCH), 2.16 (br d, J = 11.0 Hz, 1H, NCH), 1.87 (br s, 1H, CH), 1.78 (br s, 
1H, CH), 1.67-1.44 (m, 2H, CH2), 1.52 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, 
CDCl3) rotamers δ 155.0 (C=O), 138.9 (ipso-Ar), 128.5 (Ar), 128.0 (Ar), 126.5 (Ar), 
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78.6 (C(CH3)3), 63.4 (CH2Ar), 58.9 (NCH2), 58.6 (NCH2), 48.3 (C(O)NCH2), 47.5 
(C(O)NCH2), 31.1 (CH2), 28.9 (2 x CH), 28.6 (C(CH3)3). Spectroscopic data consistent 
with those reported in the literature.46 
Lab Book Reference: SC3/84 
 
(1R*,5S*)-tert-Butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate 63 
 
63 
Using general procedure H, 20% (w/w) Pd(OH)2/C (1.26 g, 1.80 mmol) and bispidine 
49 (5.70 g, 18.01 mmol) in EtOH (170 mL) at rt under Ar for 18 h gave amine 63 (3.97 
g, 98%) as a yellow oil, IR (ATR) 3385 (N-H), 2919, 1681 (C=O), 1420, 1391, 1363, 
1238, 1169, 1126, 732 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.10 (d, J = 13.0 Hz, 2H, 
NCH), 3.21 (d, J = 13.5 Hz, 2H, NCH), 3.08 (dd, J = 13.0, 3.0 Hz, 4H, NCH), 1.93-1.89 
(m, 1H, CHAHB), 1.81-1.75 (m, 3H, CHAHB, 2 x CH), 1.48 (s, 9H, C(CH3)3); 13C NMR 
(100.6 MHz, CDCl3) δ 155.6 (C=O), 80.2 (C(CH3)3), 50.4 (NCH2), 48.8 (NCH2), 30.6 
(CH2), 28.4 (C(CH3)3), 27.4 (CH); HRMS (ESI) m/z calcd for C12H22N2O2 (M + H)+ 
227.1754, found 2227.1751 (+1.5 ppm error). 
Lab Book Reference: SC4/5 
 
(1R*,5R*)-tert-Butyl 3,7-diazabicyclo[3.3.1]non-7-ene-3-carboxylate 64 
 
64 
Using general procedure I, N-bromosuccinimide (77 mg, 0.43 mmol) and amine 63 (89 
mg, 0.39 mmol) in CH2Cl2 (10 mL) at rt for 2 h, then 30% NaOH(aq) (3 mL) for 2 h gave 
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the crude product. Purification by column chromatography on silica with MeOH-CH2Cl2 
(1:19) as eluent gave imine 64 (65 mg, 75%) as an orange oil, RF (9:1 CH2Cl2-MeOH) 
0.30; IR (ATR) 2930, 1681 (C=O), 1580 (C=N), 1423, 1365, 1264, 1239, 1167, 1136, 
731 cm−1; 1H NMR (400 MHz, CDCl3) 50:50 mixture of rotamers δ 7.84 (br s, 1H, 
CH=N), 4.23 (br d, J = 13.0 Hz, 0.5H, C(O)NCH), 4.17 (br d, J = 13.0 Hz, 0.5H, 
C(O)NCH), 4.08 (br d, J = 13.0 Hz, 0.5H, C(O)NCH), 4.01 (br d, J = 13.0 Hz, 0.5H, 
C(O)NCH), 3.83-3.67 (m, 2H, CH=NCH2), 2.96 (br d, J = 13.0 Hz, 0.5H, C(O)NCH), 
2.87 (br d, J = 12.5 Hz, 0.5H, C(O)NCH), 2.84 (br d, J = 12.5 Hz, 0.5H, C(O)NCH), 
2.76 (br d, J = 13.0 Hz, 0.5H, C(O)NCH), 2.42 (br s, 0.5H, CH), 2.32 (br s, 0.5H, CH), 
1.94 (br s, 0.5H, CH), 1.90-1.84 (m, 1.5H, CHAHB, CH), 1.69-1.66 (m, 1H, CHAHB), 
1.41 (s, 9H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3) rotamers δ 163.5 and 163.11 
(CH=N), 154.9 (C=O), 79.7 (C(CH3)3), 55.3 and 55.2 (CH=NCH2), 50.7 and 49.6 
(C(O)NCH2), 45.4 and 44.5 (C(O)NCH2), 33.1 and 32.9 (N=CHCH), 28.7 (CH), 28.3 
(C(CH3)3), 26.1 (CH2); HRMS (ESI) m/z calcd for C12H20N2O2 (M + H)+ 225.1598, 
found 225.1601 (−1.3 ppm error). 
Lab Book Reference: SC1/29 
 
(1R*,5S*)-Ethyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate 123 
 
123 
Using general procedure F, ethyl 4-oxopiperidine-1-carboxylate 122 (3.7 mL, 24.53 
mmol), acetic acid (1.41 mL, 24.53 mmol), benzylamine (2.95 mL, 26.98 mmol) and 
paraformaldehyde (2 x (1.93 g, 53.97 mmol)) in MeOH (35 mL and 55 mL) gave the 
crude product. Purification by flash column chromatography on silica with petrol-
EtOAc (3:1) as eluent gave N-ethyl carbamate bispidone 123 (4.80 g, 64%) as a yellow 
oil, RF (3:1 petrol-EtOAc) 0.20; IR (ATR) 2893, 2760, 1706 (C=O, ketone), 1671 (C=O, 
carbamate), 1412, 1208, 1099 cm−1; 1H NMR (400 MHz, CDCl3) 50:50 mixture of 
rotamers δ 7.30-7.19 (m, 5H, Ar), 4.67 (ddd, J = 13.5, 2.0, 2.0 Hz, 1H, C(O)NCH), 4.44 
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(ddd, J = 13.5, 2.0, 2.0 Hz, 1H, C(O)NCH), 4.28-4.13 (m, 2H, OCH2CH3), 3.52 (d, J = 
13.0 Hz, CHAHBAr), 3.32-3.23 (m, 4H, CHAHBAr, C(O)NCH, 2 x NCH), 3.14 (ddd, J = 
11.0, 2.0, 2.0 Hz, 1H, C(O)NCH), 2.64 (dd, J = 11.0, 2.0 Hz, 1H, NCH), 2.56 (dd, J = 
11.0, 2.0 Hz, 1H, NCH), 2.40 (br m, 1H, CH), 2.32 (br m, 1H, CH), 1.28-1.20 (m, 3H, 
OCH2CH3); 13C NMR (100.6 MHz, CDCl3) rotamers δ 213.0 (C=O, ketone), 155.5 
(C=O, carbamate), 137.4 (ipso-Ar), 128.8 (Ar), 128.1 (Ar), 127.1 (Ar), 61.9 (CH2Ar), 
61.5 (OCH2CH3), 59.4 (NCH2), 58.6 (NCH2), 50.1 (C(O)NCH2), 49.9 (C(O)NCH2), 
47.8 (CH), 47.5 (CH), 14.6 (OCH2CH3); HRMS (ESI) m/z calcd for C17H22N2O3 (M + H 
+ MeOH)+ 335.1965, found 335.1959. 
Lab Book Reference: SC2/25 
 
(1R*,5S*)-Ethyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate 120 
 
120 
Using general procedure G, p-toluenesulfonyl hydrazide (4.49 g, 24.09 mmol) and N-
ethyl carbamate bispidone 123 (6.07 g, 20.07 mmol) in EtOH (150 mL) at rt under Ar, 
then NaBH4 (6.38 g, 168.59 mmol) at rt for 18 h, then reflux for 8 h gave the crude 
product. Purification by flash column chromatography on silica with petrol-EtOAc (4:1) 
as eluent gave N-ethyl carbamate bispidine 120 (3.78 g, 65%) as a pale yellow oil, RF 
(6:1 Petrol-EtOAc) 0.20; IR (ATR) 2871, 1668 (C=O), 1412, 1216, 1110 cm−1; 1H 
NMR (400 MHz, CDCl3) 50:50 mixture of rotamers δ 7.29-7.19 (m, 5H, Ar), 4.28 (br d, 
J = 13.0 Hz, 1H, C(O)NCH), 4.24-4.15 (m, 2H, OCH2CH3), 4.06 (br d, J = 13.0 Hz, 1H, 
C(O)NCH), 3.49 (d, J = 13.0 Hz, 1H, CHAHBAr), 3.17 (d, J = 13.0 Hz, 1H, CHAHBAr), 
3.11-3.03 (m, 3H, 2 x C(O)NCH, NCH), 2.87 (br d, J = 11.0 Hz, 1H, NCH), 2.28 (ddd, 
J = 11.0, 2.0, 2.0 Hz, 1H, NCH), 2.12 (ddd, J = 11.0, 2.0, 2.0 Hz, 1H, NCH), 1.87 (br s, 
1H, CH), 1.77 (br s, 1H, CH), 1.72-1.57 (m, 2H, CH2), 1.28 (t, J = 7.0 Hz, OCH2CH3); 
13C NMR (100.6 MHz, CDCl3) rotamers δ 155.7 (C=O), 138.9 (ipso-Ar), 128.7 (Ar), 
127.9 (Ar), 126.6 (Ar), 63.7 (CH2Ar), 60.8 (OCH2CH3), 59.2 (NCH2), 58.1 (NCH2), 
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48.1 (2 x C(O)NCH2), 31.5 (CH2), 29.1 (CH), 28.9 (CH), 14.8 (OCH2CH3); HRMS 
(ESI) m/z calcd for C17H24N2O2 (M + H)+ 289.1911, found 289.1897 (+4.0 ppm error). 
Lab Book Reference: SC1/58 
 
(1R*,5S*)-Ethyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate 124 
 
124 
Using general procedure H, 20% (w/w) Pd(OH)2/C (721 mg, 1.03 mmol) and bispidine 
120 (2.96 g, 10.26 mmol) in EtOH (80 mL) at rt under H2 for 18 h gave amine 124 (2.04 
g, 100%) as a pale brown oil, RF (9:1 CH2Cl2-MeOH) 0.10; IR (ATR) 3470 (NH), 2912, 
1690 (C=O), 1430, 1234, 1128, 779 cm−1; 1H NMR (400 MHz, CDCl3) δ 4.23-3.97 (m, 
2H, NCH), 4.10 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.11-3.05 (m, 4H, NCH), 2.94 (ddd, J = 
13.5, 2.5, 2.5 Hz, 2H, NCH), 1.88-1.71 (m, 2H, CH2), 1.66 (br s, 2H, CH), 1.22 (t, J = 
7.0 Hz, 3H, OCH2CH3); 13C NMR (100.6 MHz, CDCl3) δ 156.1 (C=O), 61.2 
(OCH2CH3), 51.2 (NCH2), 48.8 (NCH2), 31.1 (CH2), 27.8 (CH), 14.6 (OCH2CH3); 
HRMS (ESI) m/z calcd for C10H18N2O2 (M + H)+ 199.1441, found 199.1432 (+4.5 ppm 
error). 
Lab Book Reference: SC2/31 
 
(1R*,5R*)-Ethyl 3,7-diazabicyclo[3.3.1]non-7-ene-3-carboxylate 121 
 
121 
Using general procedure I, N-bromosuccinimide (2.30 g, 11.76 mmol) and amine 120 
(2.33 g, 12.94 mmol) in CH2Cl2 (60 mL) at rt for 4 h, then 30% NaOH(aq) (30 mL) for 
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18 h gave the crude product. Purification by column chromatography on silica with 
MeOH-CH2Cl2 (1:19) as eluent gave imine 121 (1.07 g, 46%) as an orange oil, RF (1:19 
MeOH-CH2Cl2) 0.20; IR (ATR) 2927, 1683 (C=O), 1582 (C=N), 1432, 1263, 1230, 
1129, 730 cm−1; 1H NMR (400 MHz, CDCl3) 50:50 mixture of rotamers for 121, δ 7.84 
(br s, 1H, CH=N), 4.26-4.01 (m, 2H, C(O)NCH), 4.05 (q, J = 7.0 Hz, 2H, OCH2CH3), 
3.81-3.67 (m, 2H, CH=NCH2), 2.99 (br d, J = 13.0 Hz, 0.5H, C(O)NCH), 2.90 (br d, J 
= 13.0 Hz, 1H, C(O)NCH), 2.82 (br d, J = 13.0 Hz, 0.5H, C(O)NCH), 2.43 (br s, 0.5H, 
CH), 2.39 (br s, 0.5H, CH), 1.96 (br s, 0.5H, CH), 1.92 (br s, 0.5H, CH), 1.89-1.84 (m, 
1H, CHAHB), 1.70-1.67 (m, 1H, CHAHB), 1.21 (t, J = 7.0 Hz, 3H, OCH2CH3); 13C NMR 
(100.6 MHz, CDCl3) rotamers for 121 δ 163.4 and 163.1 (CH=N), 155.7 (C=O), 61.3 
(OCH2CH3), 55.2 and 55.1 (CH=NCH2), 50.2 and 50.1 (C(O)NCH2), 44.9 (C(O)NCH2), 
32.8 and 32.7 (N=CHCH), 28.4 (CH), 25.9 (CH2), 14.5 (OCH2CH3); 1H NMR spectrum 
of the product indicates ~17% of the trimer as shown by broad signals at δ 4.26-4.02, 
3.10-2.77 and 1.28-1.17 ppm. HRMS (ESI) m/z calcd for C10H16N2O2 (M + H)+ 
197.1285, found 197.1284 (+0.4 ppm error). 
Lab Book Reference: SC1/76 
 
(1R*,5R*)-tert-Butyl 13-methyl-8-oxo-4,5,6,8,13,13a-hexahydro-1H-1,5-
methano[1,5]diazocino[2,1-b]quinazoline-3(2H)-carboxylate 127 
  
127 
DIPEA (90 µL, 0.52 mmol) and T3P (267 mg of a 50% solution in THF, 0.42 mmol) 
were added to a stirred solution of imine 64 (63 mg, 0.28 mmol) and N-
methylanthranilic acid 38 (52 mg, 0.34 mmol) in toluene (2 mL) at rt. The resulting 
solution was stirred and heated at 90 °C in a sealed vessel for 20 h. The solution was 
alloed to cool to rt. Then the solution was diluted with CH2Cl2 (10 mL) and poured into 
sat. NaHCO3(aq) (10 mL). The two layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 10 mL). The combined organics were dried (MgSO4), 
filtered and evaporated under reduced pressure to give the crude product. Purification by 
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flash column chromatography on silica with petrol-EtOAc (7:3) as eluent gave a gave a 
single diastereoisomer of 127 with undefined relative stereochemistry (28 mg, 28%) as a 
dark yellow oil, RF (1:1 petrol-EtOAc) 0.20; IR (ATR) 2974, 1688 (C=O), 1651 (C=O), 
1421, 1235, 1167, 1135, 762 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.93 (br d, J = 7.5 Hz, 
1H, Ar), 7.35 (ddd, J = 8.5, 7.5, 1.5 Hz, 1H, Ar), 6.80 (br dd, J = 7.5, 7.5 Hz, 1H, Ar), 
6.58 (br d, J = 8.5 Hz, 1H, Ar), 4.91 (dd, J = 14.0, 10.5 Hz, 1H, NCH), 4.63 (d, J = 3.0 
Hz, 1H, NCHNCH3), 4.19-4.16 (m, 1H, NCH), 4.04-4.02 (m, 1H, NCH), 3.93-3.89 (m, 
1H, NCH), 2.91 (s, 3H, NCH3), 2.90-2.74 (m, 2H, NCH, CHAHB), 2.58 (dd, J = 14.0, 
3.0 Hz, 1H, NCH), 2.23 (br s, 2H, 2 x CH), 1.64-1.61 (m, 1H, CHAHB), 1.48 (s, 9H, 
C(CH3)3); 13C NMR (100.6 MHz, CDCl3) δ 163.4 (Ar(C=O)N), 156.7 (C=O, Boc), 
146.6 (ipso-Ar), 133.8 (Ar), 128.9 (Ar), 118.1 (Ar), 115.4 (ipso-Ar), 112.1 (Ar), 80.2 
(C(CH3)3), 75.5 (NCHN), 47.9 (NCH2), 43.5 (NCH2), 35.2 (CH), 34.5 (CH), 29.7  
(CH2), 28.4 (CH3), 26.6 (C(CH3)); HRMS (ESI) m/z calcd for C20H27N3O3 (M + Na)+ 
380.1945, found 380.1937 (+2.3 ppm error).  
Lab Book Reference: SC1/35 
 
(1R*,5R*)-Ethyl 13-methyl-8-oxo-4,5,6,8,13,13a-hexahydro-1H-1,5-
methano[1,5]diazocino[2,1-b]quinazoline-3(2H)-carboxylate 128 
  
128 
DIPEA (116 µL, 0.67 mmol) and T3P (343 mg of a 50% solution in THF, 0.54 mmol) 
were added to a stirred solution of imine 121 (71 mg, 0.36 mmol) and N-
methylanthranilic acid 38 (65 mg, 0.43 mmol) in toluene (3 mL) under Ar at rt. The 
resulting solution was stirred and heated at 90 °C in a sealed vessel for 20 h. The 
solution was allowed to cool to rt. Then, the solution was diluted with CH2Cl2 (10 mL) 
and poured into sat. NaHCO3(aq) (10 mL). The two layers were separated and the 
aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined organics were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
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product. Purification by flash column chromatography on silica with petrol-EtOAc (2:1) 
as eluent gave a gave a single diastereoisomer of 128 with undefined relative 
stereochemistry (77 mg, 65%) as a pale yellow oil, RF (EtOAc) 0.40; IR (ATR) 2923, 
1690 (C=O), 1646 (C=O), 1605 (C=C), 1430, 1226, 1131, 754 cm−1; 1H NMR (400 
MHz, CDCl3) δ 7.92 (dd, J = 7.5, 1.5 Hz, 1H, Ar), 7.34 (ddd, J = 8.5, 7.5, 1.5 Hz, 1H, 
Ar), 6.82-6.78 (m, 1H, Ar), 6.57 (dd, J = 8.5, 0.5 Hz, 1H, Ar), 4.92 (dd, J = 14.0, 10.5 
Hz, 1H, NCH), 4.63 (d, J = 3.0 Hz, 1H, NCHNCH3), 4.17 (q, J = 7.0 Hz, 2H, 
OCH2CH3), 4.20-3.94 (m, 2H, NCH), 2.90 (s, 3H, CH3), 2.92-2.81 (m, 2H, 2 x NCH), 
2.58 (dd, J = 14.0, 2.5 Hz, 1H, NCH), 2.27-2.21(m, 2H, 2 x CH), 1.65-1.61 (m, 1H, 
OCHAHB), 1.44 (ddd, J = 13.5, 2.0, 2.0 Hz, 1H, CHAHB), 1.28 (t, J = 7.0 Hz, CH2CH3); 
13C NMR (100.6 MHz, CDCl3) δ 163.3 (Ar(C=O)N), 156.8 (C=O, carbamate), 146.6 
(ipso-Ar), 133.7 (Ar), 128.8 (Ar), 118.0 (Ar), 115.2 (ipso-Ar), 112.0 (Ar), 75.5 
(NCHN), 61.7 (OCH2CH3), 48.8 (NCH2), 48.4 (NCH2), 43.4 (NCH2), 35.0 (CH), 34.5 
(CH), 27.8 (CH2), 26.4 (CH3), 14.6 (OCH2CH3); HRMS (ESI) m/z calcd for C18H23N3O3 
(M + H)+ 330.1812, found 330.1804 (+2.1 ppm error). Product 128 is a single 
diastereoisomer of unknown stereochemistry.  
Lab Book Reference: SC1/48 
 
(1R*,5R*,6R*)-tert-Butyl 6-allyl-7-cinnamoyl-3,7-diazabicyclo[3.3.1]nonane-3-
carboxylate 129 
 
129 
Using general procedure D, trans-cinnamoyl chloride 136 (83 mg, 0.50 mmol) and 
imine 64 (100 mg, 0.45 mmol) in THF at 65 °C for 2.5 h, then allylzinc bromide 134 
(synthesised using general procedure C, 0.54 M in THF, 1 mL, 0.54 mmol) added at −78 
°C then allowed to warm to rt for 16 h gave the crude product. Purification by flash 
column chromatography on silica using hexane-EtOAc (2:1) as eluent gave the diene 
129 (31 mg, 17%) as a colourless oil, RF (2:1 hexane-EtOAc) 0.20; IR (ATR) 2975, 
2855, 1682, 1644, 1600, 1424, 1364, 1239, 1169, 1135, 995, 761, 730 cm−1; 1H NMR 
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(400 MHz, CDCl3) 50:50 mixture of rotamers δ 7.51-7.42 (m, 3H, CH=CHPh, Ph), 
7.37-7.30 (m, 3H, Ph), 6.93-6.84 (m, 1H, CH=CHPh), 5.88-5.76 (m, 0.5H, CH=CH2), 
5.74-5.64 (m, 0.5H, CH=CH2), 5.13-5.03 (m, 2H, CH=CH2), 4.93-4.72 (m, 0.5H, 
NCHCH2), 4.63-4.60 (m, 0.5H, NCH), 4.48-4.35 (m, 0.5H, NCH), 4.27-4.05 (m, 2.5H, 
NCHCH2, 2 x NCH), 3.49-3.40 (m, 0.5H, NCH), 3.14-2.94 (m, 2.5H, NCH), 2.48-2.28 
(m, 2H, CH2C=C), 2.10-2.07 (m, 1H, CHAHB), 1.87-1.84 (m, 2H, 2 x CH), 1.67-1.62 
(m, 1H, CHAHB), 1.38 (s, 4.5H, C(CH3)3), 1.36 (s, 4.5H, C(CH3)3);13C NMR (100.6 
MHz, CDCl3) rotamers δ 167.1 and 166.1 (C=O), 154.7 and 154.6 (C=O, carbamate), 
141.5 and 141.2 (Ar), 135.7 (ipso-Ar), 135.1, 134.0, 129.1, 129.0, 128.7, 128.6, 128.5, 
(CH2=CH, Ar), 127.7, 127.6, 119.1 and 119.0 (CH=CHPh, CH=CHPh), 118.3 and 117.1 
(CH2=CH), 79.7 (C(CH3)3),  57.7 and 53.5 (NCH), 50.0, 49.2, 48.9, 47.9, 46.9 and 43.4 
(NCH2), 37.2 and 35.1 (CH2C=C), 29.8, 29.6 and 29.2 (CH), 28.3, 28.2 and 28.1 
(C(CH3)3), 27.9 and 27.8 (CH), 26.2 and 26.0 (CH2 bridge); HRMS (ESI) m/z calcd for 
C24H32N2O3 (M + H)+ 397.2486, found 397.2491 (−1.5 ppm error). 
Lab Book Reference: SC3/55 
 
(1R*,5R*,6R*)-Ethyl 6-allyl-7-cinnamoyl-3,7-diazabicyclo[3.3.1]nonane-3-
carboxylate 131 
 
131 
DIPEA (0.68 mL, 3.90 mmol) and T3P (2.02 g of a 50% solution in THF, 3.17 mmol) 
were added to a stirred solution of imine 121 (415 mg, 2.11 mmol) and trans-cinnamic 
acid (375 mg, 2.53 mmol) in CH2Cl2 (20 mL) under Ar at rt. The resulting solution was 
stirred and heated at 45 °C for 2.5 h. The solution was cooled to −30 °C and allyl 
trimethylsilane (1.68 mL, 10.55 mmol) followed by BF3OEt2 (0.78 mL, 6.33 mmol) 
were added. The mixture was allowed to warm to rt and stirred for 2.5 h. Then, the 
solution was diluted with CH2Cl2 (20 mL) and poured into sat. NaHCO3(aq) (20 mL). 
The two layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 10 
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mL). The combined organics were washed with water (20 mL) and brine (20 mL), dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with MeOH-CH2Cl2 (1:19) as 
eluent gave substituted diene 131 (489 mg, 63%) as a pale yellow oil, RF (1:19 MeOH-
CH2Cl) 0.50; IR (ATR) 2932, 1687 (C=O), 1643 (C=O), 1599 (C=C), 1429, 1231, 1135, 
995, 760 cm−1; 1H NMR (400 MHz, CDCl3) 50:50 mixture of rotamers δ 7.67-7.41 (m, 
3H, CH=CHPh, Ph), 7.38-7.28 (m, 3H, Ph), 6.93-6.84 (m, 1H, CH=CHPh), 5.88-5.76 
(m, 0.5H, CH=CH2), 5.76-5.64 (m, 0.5H, CH=CH2), 5.14-4.94 (m, 2H, CH=CH2), 4.86-
4.78 (m, 0.5H, NCHCH2), 4.67-4.64 (m, 0.5H, NCH), 4.43-4.30 (m, 1H, NCH), 4.29-
3.81 (m, 4.5H, OCH2CH3, NCHCH2, 2 x NCH), 3.51-3.41 (m, 0.5H, NCH), 3.17-2.97 
(m, 2.5H, NCH), 2.47-2.29 (m, 2H, CH2C=C), 2.13-2.07 (m, 1H, CHAHB), 1.94-1.79 
(m, 2H, 2 x CH), 1.71-1.65 (m, 1H, CHAHB), 1.23-1.17 (m, 2H, OCH2CH3), 1.02-0.98 
(m, 1H, OCH2CH3); 13C NMR (100.6 MHz, CDCl3) rotamers δ 167.1, 166.2, 165.9 and 
165.4 (C=O), 155.9 and 155.8 (C=O, carbamate), 142.1, 141.9, 141.4 and 141.0 
(CHPh), 135.6 and 135.4 (ipso-Ar), 135.0, 134.5, 133.9 and 133.8 (CH2=CH), 129.3, 
129.1, 129.0, 128.7, 128.6, 128.5, 127.7, 127.6 and 128.5 (Ar), 119.1, 118.8, 118.5 and 
118.4 (CH=CHPh), 118.3, 117.7, 117.5 and 117.1 (CH2=CH), 61.4 and 61.2 
(OCH2CH3), 57.8, 57.4, 53.2 and 53.0 (NCH), 49.7, 49.6, 48.9, 48.6 (NCH2), 46.8 and 
46.7 (NCH2), 43.0 and 42.6 (NCH2), 37.1, 36.8, 35.2 and 35.1 (CH2C=C), 30.1 and 29.9 
(CH), 27.9, 27.8 and 27.7 (CH), 26.3 and 26.1 (CH2 bridge), 14.5 and 14.3 (OCH2CH3); 
HRMS (ESI) m/z calcd for C22H28N2O3 (M + H)+ 369.2173, found 369.2169 (+0.6 ppm 
error). 
Lab Book Reference: SC1/62 
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(1R*,5R*,11aR*)-Ethyl 8-oxo-4,5,6,8,11,11a-hexahydro-1H-1,5-methanopyrido[1,2-
a][1,5]diazocine-3(2H)-carboxylate 132 
  
132 
Grubbs’ 2nd generation catalyst (22 mg, 0.026 mmol) was added in one portion to a 
stirred solution of diene 131 (114 mg, 0.31 mmol) in toluene (6 mL) at rt under Ar. The 
resulting solution was stirred at rt for 20 h and then the solvent was evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with EtOAc as eluent gave a single diastereoisomer (by 1H 
NMR spectroscopy) of dihydropyridone 132 (76 mg, 93%) as a pale brown oil, RF 
(EtOAc) 0.10; IR (ATR) 2867, 1691 (C=O), 1659 (C=O), 1610 (C=C), 1427, 1233, 
1146, 818 cm−1; 1H NMR (400 MHz, CDCl3) δ 6.48 (ddd, J = 9.5, 6.0, 2.5 Hz, 1H, 
CH=CHC(O)), 5.89 (dd, J = 9.5, 2.0 Hz, 1H, CH=CHC(O)), 4.37 (dd, J = 14.5, 10.5 Hz, 
1H, NCH), 4.09 (q, J = 7.0 Hz, 2H, OCH2CH3), 4.11-4.00 (m, 1H, NCH), 3.94 (br d, J = 
11.5 Hz, 1H, NCH), 3.54 (br d, J = 10.0 Hz, 1H, NCHCH2), 2.86-2.76 (m, 3H, NCH), 
2.37-2.21 (m, 3H, CH=CHCH2, CH), 1.89-1.83 (m, 1H, CHAHB), 1.76 (s, 1H, CH), 1.49 
(ddd, J = 13.0, 2.5, 2.5 Hz, 1H, CHAHB), 1.21 (t, J = 7.0 Hz, OCH2CH3); 13C NMR 
(100.6 MHz, CDCl3) δ 166.2 (C=O, dihydropyridone), 156.4 (C=O, carbamate), 138.3 
(CH=CHC(O)), 125.5 (CH=CHC(O)), 61.5 (OCH2CH3), 55.8 (NCH), 49.7 (NCH2), 
48.8 (NCH2), 43.6 (NCH2), 34.2 (CH), 32.6 (CH2CH=CH), 25.5 (CH), 24.5 (CH2), 14.6 
(OCH2CH3); HRMS (ESI) m/z calcd for C14H20N2O3 (M + H)+ 265.1547, found 
265.1540 (+2.5 ppm error). 
Lab Book Reference: SC1/59 
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(1R*,5R*,11aR*)-Ethyl 8-oxooctahydro-1H-1,5-methanopyrido[1,2-
a][1,5]diazocine-3(2H)-carboxylate 167 
  
167 
10% (w/w) Pd/C (42 mg, 0.04 mmol) was added to a stirred solution of dihydropyridone 
132 (54 mg, 0.20 mmol) in a 3:1 mixture of 1,4-dioxane:cyclohexene (8 mL) at rt under 
N2. The resulting suspension was stirred and heated at 100 °C for 20 h.  The reaction 
was allowed to cool to rt. The solids were removed by filtration through a pad of Celite® 
and the solvent was evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with EtOAc as eluent resulted in 
no product isolation. Flushing the column with MeOH gave tetrahydropyridone 167 (53 
mg, 96%) as a yellow oil, IR (ATR) 2931, 2864, 1689 (C=O), 1632 (C=O), 1431, 1230, 
1137, 767 cm−1; 1H NMR (400 MHz, CDCl3) δ 4.84 (dd, J = 14.0, 11.0 Hz, 1H, NCH), 
4.13 (q, J = 7.0 Hz, 2H, OCH2CH3), 4.08-3.87 (m, 2H, 2 x NCH), 3.26-3.23 (m, 1H, 
NCH), 2.88-2.74 (m, 2H, 2 x NCH), 2.46-2.30 (m, 3H, NCH, 2 x CH), 2.20-2.17 (m, 
1H, CH), 2.01-1.96 (m, 1H, CH), 1.82-1.53 (m, 5H, 2 x CH, CHAHB, 2 x CH), 1.38 (br 
d, J = 13.0 Hz, 1H, CHAHB), 1.25 (t, J = 7.0 Hz, 3H, OCH2CH3); 13C NMR (100.6 MHz, 
CDCl3) δ 170.4 (C=O, dihydropyridone), 156.8 (C=O, carbamate), 61.5 (OCH2CH3), 
57.4 (NCH), 49.1 (NCH2), 48.2 (NCH2), 42.3 (NCH2), 35.5 (CH), 32.6 (CH2), 26.1 
(CH), 25.3 (CH2 bridge), 19.7 (CH2), 14.7 (OCH2CH3); HRMS (ESI) m/z calcd for 
C14H22N2O3 (M + H)+ 267.1703, found 267.1701 (+0.6 ppm error). 
Lab Book Reference: SC1/66 
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(1S*,5R*,11aR*)-3-methyldecahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocine 
168 
 
168 
A solution of tetrahydropyridone 167 (47 mg, 0.18 mmol), in THF (2 mL) was added to 
a stirred suspension of lithium aluminium hydride (41 mg, 1.08 mmol), in THF (3 mL) 
at 0 °C. The resulting mixture was stirred and heated at reflux for 2.5 h. The reaction 
mixture was allowed to cool to rt before being cooled to 0 °C. H2O (0.1 mL), 20% 
NaOH(aq) (0.1 mL) and H2O (0.1 mL) were carefully added. The solids were removed by 
filtration through a pad of Celite® and washed with Et2O (10 mL). The filtrate was 
extracted with Et2O (3 x 10 mL) and the combined organic extracts were dried (MgSO4) 
and evaporated under reduced pressure to give the crude tricyclic amine product 168 (23 
mg, 66%). Diagnostic peaks: 13C NMR (100.6 MHz, CDCl3) δ 63.7 (CHN), 46.6 
(NMe). Spectroscopic data consistent with those reported in the literature.69 
Lab Book Reference: SC1/69 
 
6-Ethoxy-2,3,4,5-tetrahydropyridine 145 
 
145 
Triethyloxonium tetrafluoroborate 155 (2.28 g, 12 mmol) was added to a stirred solution 
of piperidin-2-one 154 (396 mg, 4 mmol) in CH2Cl2 (10 mL) at rt under Ar. 4 Å 
molecular sieves (2.2 g) and K2CO3 (2.21 g, 16 mmol) were added and the reaction 
mixture was stirred for 1.5 h. The reaction mixture was diluted with CH2Cl2 (20 mL) 
and the solids were removed by filtration through a pad of Celite®. The filtrate was 
washed with sat. NaHCO3(aq) (50 mL), dried (MgSO4), filtered and evaporated under 
reduced pressure (care: product is volatile) to give imidate 145 (414 mg, 82%) as a 
colourless liquid, 1H NMR (400 MHz, CDCl3) δ 4.02 (q, J = 7.0 Hz, 2H, OCH2CH3), 
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3.48-3.45 (m, 2H, NCH2), 2.17-2.13 (m, 2H, N=CCH2), 1.75-1.69 (m, 2H, CH2), 1.59-
1.53 (m, 2H, CH2), 1.25 (t, J = 7.0 Hz, 3H, OCH2CH3). Spectroscopic data consistent 
with those reported in the literature.197 
Lab Book Reference: SC2/34 
 
2H-Pyran-2,6(3H)-dione 141 
 
141 
trans-Glutaconic acid 156 (1 g, 7.69 mmol) was taken up in acetic anhydride (2.91 mL, 
30.75 mmol) and stirred and heated at reflux for 25 min. The reaction mixture was 
allowed to cool to rt and the solvent was evaporated under reduced pressure to give the 
crude product 141 as a brown oily residue. Attempted purification by flash column 
chromatography using (1:9 MeOH-EtOAc) as eluent resulted in decomposition and no 
product isolated. The 1H NMR spectrum of the crude reaction mixture contained a 75:25 
mixture of 141 and acetic anhydride. 1H NMR (400 MHz, CDCl3) for 141 δ 6.96 (dt, J = 
10.0, 3.5 Hz, 1H, CH=), 6.26 (dt, J = 10.0, 2.0 Hz, 1H, CH=), 3.54 (dd, J = 3.5, 2.0 Hz, 
2H, CH2); Diagnostic signal for acetic anhydride: 1H NMR (400 MHz, CDCl3) δ 2.18 (s, 
6H, 2 x CH3). Spectroscopic data consistent with those reported in the literature.80 
Lab Book Reference: SC2/29 
 
(Z)-3-(Piperidin-2-ylidene)-2H-pyran-2,6(3H)-dione 157 
 
157 
trans-Glutaconic acid 156 (186 mg, 1.43 mmol) was taken up in acetic anhydride (1.54 
mL, 5.72 mmol) and stirred and heated at reflux for 25 min. The reaction mixture was 
O
O
O
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allowed to cool to rt and the solvent was evaporated under reduced pressure to give the 
crude product 141 as a brown oily residue. The residue was taken up in toluene (40 mL) 
and imidate 145 (200 mg, 1.57 mmol) was added to the stirred solution at rt under Ar. 
The reaction mixture was stirred and heated to reflux for 24 h. The reaction was allowed 
to cool to rt and the solvent was evaporated under reduced pressure. The residue was 
taken up in CH2Cl2 (50 mL) and washed with sat. NaHCO3(aq). The aqueous layer was 
extracted with CH2Cl2 (2 x 30 mL) and the combined organics were dried (MgSO4), 
filtered and the solvent evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica using EtOAc-petrol (1:1) as 
eluent gave the product 157 (104 mg, 38%) as a yellow solid, mp 170-172 °C; RF 
(EtOAc) 0.20; IR (ATR) 3431, 3067, 2962, 2877, 1717 (C=O), 1684 (C=O), 1645, 
1613, 1582, 1467, 1444, 1409, 1362, 1326, 1283, 955, 796 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 11.44 (br s, 1H, NH), 7.41 (d, J = 9.5 Hz, 1H, HC=CH), 5.53 (d, J = 9.5 Hz, 
1H, HC=CH), 3.57-3.55 (m, 2H, NCH2), 2.77-2.76 (m, 2H, CH2), 1.92-1.86 (m, 4H, 
CH2); 13C NMR (100.6 MHz, CDCl3) δ 167.9 (C=O), 165.5 (C=O), 162.7 (C), 143.1 
(HC=), 100.9 (HC=), 91.7 (C), 42.4 (NCH2), 25.3 (CH2), 20.8 (CH2), 18.3 (CH2); 
HRMS (ESI) m/z calcd for C10H11NO3 (M + H)+ 194.0812, found 194.0812 (−0.3 ppm 
error). 
Lab Book Reference: SC2/38 
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5.3.2. Chapter 3 
Methyl 2-(5-fluoro-2-methyl-1H-indol-3-yl)acetate 231 
 
231 
A mixture of methyl 4-oxopentanoate (136 µL, 1.10 mmol) and 4-
fluorophenylhydrazine hydrochloride 228 (163 mg, 1.00 mmol) in MeOH (3 mL) and 
conc. H2SO4 (120 µL) was stirred under microwave irradiation at 120 °C for 10 min. 
After being allowed to cool to room temperature, H2O (10 mL) was added and the 
reaction was extracted with CH2Cl2 (3 × 10 mL). The combined organics were dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography on silica using CH2Cl2 as eluent gave the substituted indole 
231 (194 mg, 87%) as a pale yellow oil, RF (CH2Cl2) 0.30; 1H NMR (400 MHz, DMSO-
d6) δ 10.99 (s, 1H, NH), 7.22 (dd, J = 9.0, 4.5 Hz, 1H, Ar), 7.11 (dd, J = 10.0, 2.5 Hz, 
1H, Ar), 6.82 (ddd, J = 9.0, 9.0, 2.5, 1H, Ar), 3.66 (s, 2H, CH2C(O)), 3.58 (s, 3H, 
OCH3), 2.32 (s, 3H, CH3); 13C NMR (100.6 MHz, DMSO-d6) δ 171.9 (C=O), 156.8 (d, 
J = 230.5 Hz, ipso-Ar), 135.6 (C=CCH3), 131.6 (ipso-Ar), 128.6 (d, J = 10.0 Hz, ipso-
Ar), 111.2 (d, J = 10.0 Hz, Ar), 107.9 (d, J = 25.5 Hz, Ar), 103.7 (d, J = 4.5 Hz, 
C=CCH3), 102.4 (d, J = 23.5 Hz, Ar), 51.5 (OCH3), 29.8 (CH2C(O)), 11.4 (CH3); 19F 
NMR (376 MHz, DMSO-d6) δ −125.50 (ddd, J = 10.0, 10.0, 4.5); HRMS (ESI) m/z 
calcd for C12H12FNO2 (M + H)+ 222.0925, found 222.0932 (−3.3 ppm error). 
Spectroscopic data consistent with those reported in the literature.123 
Lab Book Reference: SC3/42 
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2-(5-Fluoro-2-methyl-1H-indol-3-yl)acetic acid 249 
 
249 
1 M NaOH(aq) (10 mL) was added to a stirred solution of methyl 2-(5-fluoro-2-methyl-
1H-indol-3-yl)acetate 231 (448 mg, 2.03 mmol) in 1:1 THF/MeOH (40 mL).  The 
resulting solution was stirred at room temperature for 16 h. The reaction mixture was 
concentrated under reduced pressure and the resulting solid residue dissolved in water (5 
mL). Conc. HCl was added dropwise until a solid precipitate was observed. The solid 
was isolated by vacuum filtration, washed with water (5 mL) and hexane (5 mL) and air 
dried to give the indole acetic acid 249 (369 mg, 87%) as a pale orange solid, mp 164–
166 °C [lit.198 179–182 °C (from MeCN)]; IR (ATR) 3411 (NH), 2908 (OH), 2736, 
2631, 1715 (C=O), 1587, 1481, 1241, 920, 840, 605 cm−1; 1H NMR (400 MHz, DMSO-
d6) δ 12.11 (s, 1H, OH), 10.94 (s, 1H, NH), 7.22 (dd, J = 9.0, 4.5 Hz, 1H, Ar), 7.12 (dd, 
J = 10.0, 2.5 Hz, 1H, Ar), 6.81 (ddd, J = 9.0, 9.0, 2.5, 1H, Ar), 3.54 (s, 2H, CH2C(O)), 
2.31 (s, 3H, CH3); 13C NMR (100.6 MHz, DMSO-d6) δ 173.1 (C=O), 156.8 (d, J = 
230.5 Hz, ipso-Ar), 135.3 (C=CCH3), 131.6 (ipso-Ar), 128.7 (d, J = 10.0 Hz, ipso-Ar), 
111.1 (d, J = 10.0 Hz, Ar), 107.8 (d, J = 26.0 Hz, Ar), 104.4 (d, J = 4.5 Hz, C=CCH3), 
102.5 (d, J = 23.0 Hz, Ar), 29.8 (CH2C(O)), 11.4 (CH3); 19F NMR (376 MHz, DMSO-
d6) δ −125.70 (ddd, J = 10.0, 10.0, 4.5 Hz); HRMS (ESI) m/z calcd for C11H10FNO2 (M 
+ H)+ 208.0768, found 208.0771 (−1.4 ppm error). 
Lab Book Reference: SC3/24 
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Ethyl 2-(5-methoxy-2-methyl-1H-indol-3-yl)acetate 234 
 
234 
A mixture of methyl 4-oxopentanoate (354 µL, 2.86 mmol) and 4-
methoxyphenylhydrazine hydrochloride 233 (500 mg, 2.86 mmol) in 2 M HCl/EtOH 
(20 mL) was stirred at 100 °C for 4 h. After cooling to room temperature the solvent 
was concentrated until a solid precipitate was observed. The precipitate was removed by 
filtration and the filtrate concentrated under reduced pressure. The residue was dissolved 
in CH2Cl2 (50 mL) and washed with H2O (50 mL). The aqueous layer was extracted 
with CH2Cl2 (4 × 50 mL). The combined organics were dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by flash column chromatography on 
silica with hexane-acetone (9:1 then 8:2) as eluent gave indole ethyl ester 234 (404 mg, 
57%) as a brown oil, RF (8:2 hexane-acetone) 0.10; IR (ATR) 3397 (NH), 2982, 1724 
(C=O), 1627, 1592, 1485, 1216, 1174, 1031, 799 cm−1; 1H NMR (400 MHz, CDCl3) δ 
7.74 (s, 1H, NH), 7.15 (d, J = 8.5 Hz, 1H, Ar), 7.00 (d, J = 2.5 Hz, 1H, Ar), 6.77 (dd, J 
= 8.5, 2.5 Hz, 1H, Ar), 4.13 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.86 (s, 3H, OCH3), 3.64 (s, 
2H, CH2C(O)), 2.40 (s, 3H, CH3), 1.24 (t, J = 7.0 Hz, 3H, OCH2CH3); 13C NMR (100.6 
MHz, CDCl3) δ 172.0 (C=O), 154.1 (ipso-Ar), 133.4 (C=CCH3), 130.1 (ipso-Ar), 129.0 
(ipso-Ar), 111.0 (Ar), 110.9 (Ar), 104.6 (C=CCH3), 100.5 (Ar), 60.6 (OCH2CH3), 55.9 
(OCH3),  30.6 (CH2C(O)), 14.3 (OCH2CH3), 11.8 (CH3);  HRMS (ESI) m/z calcd for 
C14H17NO3 (M + H)+ 248.1281, found 248.1274 (+3.0 ppm error). Spectroscopic data 
consistent with those reported in the literature.199  
Lab Book Reference: SC3/35 
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2-(5-Methoxy-2-methyl-1H-indol-3-yl)acetic acid 250 
 
250 
1 M NaOH (10 mL) was added to a stirred solution of ethyl 2-(5-methoxy-2-methyl-1H-
indol-3-yl)acetate 234 (395 mg, 1.60 mmol) in 1:1 THF/MeOH (40 mL). The reaction 
mixture was concentrated under reduced pressure and the resulting solid residue 
dissolved in water (5 mL). The solution was acidified (~pH 1) using conc. HCl resulting 
in the formation of an oily residue. CH2Cl2 (30 mL) and 1 M HCl (40 mL) were added 
and the two layers were separated. The aqueous layer was extracted with CH2Cl2 (2 × 30 
mL) and the combined organics were dried (MgSO4), filtered and concentrated under 
reduced pressure to give the indole acetic acid 250 (331 mg, 95%) as a green/brown 
solid, mp 141–143 °C (lit.200 162 °C (from EtOH)); IR (ATR) 3353 (NH), 3104 (OH), 
2903, 1723 (C=O), 1589, 1485, 1309, 1209, 1167, 1016, 804, 647 cm−1; 1H NMR (400 
MHz, DMSO-d6) δ 12.03 (s, 1H, OH), 10.65 (s, 1H, NH), 7.12 (d, J = 8.5 Hz, 1H, Ar), 
6.88 (d, J = 2.5 Hz, 1H, Ar), 6.62 (dd, J = 8.5, 2.5, 1H, Ar), 3.72 (s, 3H, OCH3) 3.52 (s, 
2H, CH2C(O)), 2.29 (s, 3H, CH3); 13C NMR (100.6 MHz, DMSO-d6) δ 173.3 (C=O), 
153.0 (ipso-Ar), 133.7 (C=CCH3), 130.1 (ipso-Ar), 128.7 (ipso-Ar), 110.9 (Ar), 109.5 
(Ar), 103.8 (C=CCH3), 100.1 (Ar), 55.3 (OCH3), 29.9 (CH2C(O)), 11.4 (CH3); HRMS 
(ESI) m/z calcd for C12H13NO3 (M + H)+ 220.0968, found 220.0967 (+0.6 ppm error). 
Spectroscopic data consistent with those reported in the literature.200  
Lab Book Reference: SC3/36 
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Ethyl 3-(2-methyl-1H-indol-3-yl)propanoate 236 
 
236 
A mixture of 5-oxohexanoic acid (0.83 mL, 6.92 mmol) and phenylhydrazine 
hydrochloride 235 (1.0 g, 6.92 mmol) in a 2 M HCl/EtOH solution (6 mL) was stirred at 
100 °C for 4.5 h. The reaction mixture was allowed to cool to rt and the solvent was 
evaporated under reduced pressure. The resulting mixture was diluted with water (200 
mL) and extracted into EtOAc (100 mL). The two layers were separated and the 
aqueous extracted with EtOAc (2 x 100 mL). The combined organics were dried 
(MgSO4), filtered and the solvent evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica using CH2Cl2 as eluent 
gave the indole ester 236 (948 mg, 59%) as an orange oil, RF (CH2Cl2) 0.30; IR (ATR) 
3398 (NH), 2980, 2919, 1712 (C=O), 1622, 1362, 1443, 1371, 1299, 1159, 1049, 859 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.76 (br s, 1H, NH), 7.51 (d, J = 7.0 Hz, 1H, Ar), 
7.27-7.25 (m, 1H, Ar), 7.14-7.06 (m, 2H, Ar), 4.12 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.04 
(t, J = 7.5 Hz, 2H, CH2), 2.62 (t, J = 7.5 Hz, 2H, CH2), 2.39 (s, 3H, CH3), 1.23 (t, J = 7.0 
Hz, 3H, OCH2CH3); 13C NMR (100.6 MHz, CDCl3) δ 173.5 (C=O), 135.1 (ipso-Ar), 
131.3 (C=CCH3), 128.1 (ipso-Ar), 120.8 (Ar), 119.0 (Ar), 117.7 (Ar), 110.2 (Ar), 109.9 
(C=CCH3), 60.3 (OCH2CH3), 35.1 (CH2), 19.6 (CH2), 14.1 (OCH2CH3), 11.3 (CH3); 
HRMS (ESI) m/z calcd for C14H17NO2 (M + H)+ 232.1332, found 232.1334 (−0.7 ppm 
error). Spectroscopic data consistent with those reported in the literature.201  
Lab Book Reference: SC3/64 
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3-(2-Methyl-1H-indol-3-yl)propanoic acid 251 
 
251 
1 M NaOH(aq) (20 mL) was added to a stirred solution of the dimethyl-indole ester 236 
(888 mg, 3.84 mmol) in 1:1 MeOH-THF (80 mL) at rt. The resulting solution was 
stirred at rt for 8 h and then the solvent was evaporated under reduced pressure. The 
resulting residue was taken up in a minimum amount of water (5 mL) and the resulting 
solution was taken to pH 1 with conc. HCl(aq) resulting in an oily residue. Water (40 mL) 
was added and the resulting mixture was extracted into CH2Cl2 (50 mL) and the two 
layers separated. The aqueous was extracted into CH2Cl2 (2 x 50 mL) and the combined 
organics dried (MgSO4), filtered and the solvent evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica using 
hexane-EtOAc-AcOH (60:39.5:0.5) as eluent gave the indole acid 251 (476 mg, 61%) as 
a yellow solid, mp 121–123 °C (lit.202 132–134 °C); IR (ATR) 3384 (NH), 2929, 2634, 
1692 (C=O), 1464, 1406, 1308, 1294, 1211, 920 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
12.02 (s, 1H, OH), 10.68 (s, 1H, NH), 7.39 (d, J = 7.5 Hz, 1H, Ar), 7.22-7.20 (m, 1H, 
Ar), 6.97 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.91 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 
2.87 (t, J = 7.5 Hz, 2H, CH2), 2.45 (t, J = 7.5, 2H, CH2), 2.31 (s, 3H, CH3); 13 C NMR 
(100.6 MHz, DMSO-d6) δ 174.2 (C=O), 135.2 (ipso-Ar), 131.7 (C=CCH3), 127.9 (ipso-
Ar), 119.9 (Ar), 118.1 (Ar), 117.3 (Ar), 110.4 (Ar), 108.9 (ipso-Ar), 35.1 (CH2), 19.4 
(CH2), 11.2 (CH3); HRMS (ESI) m/z calcd for C12H13NO2 (M + H)+ 204.1019, found 
204.1014 (+2.5 ppm error).  
Lab Book Reference: SC3/68 
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Ethyl 2-(5-bromo-2-methyl-1H-indol-3-yl)acetate 238 
 
238 
A mixture of 4-oxopentanoic acid (0.46 mL, 4.47 mmol) and 4-bromophenylhydrazine 
hydrochloride 237 (1.00 g, 4.47 mmol) in a solution of EtOH (6 mL) and conc. H2SO4 
(aq) (0.45 mL) was stirred at reflux for 16 h. The reaction mixture was allowed to cool to 
room temperature, then water (20 mL) and EtOAc (20 mL) was added. The two layers 
were separated and the aqueous layer was extracted with EtOAc (1 × 10 mL). The 
combined organic phases were washed with 10% HCl (10 mL) and then sat. NaHCO3 
(10 mL), dried (MgSO4), filtered and concentrated under reduced pressure. Purification 
by flash column chromatography on silica using CH2Cl2 as eluent gave the indole ester 
238 (834 mg, 63%) as an orange solid, mp 59–61 °C [lit.203 65–68 °C]; RF (CH2Cl2) 
0.30; IR (ATR) 3355 (NH), 2981, 2901, 1716 (C=O), 1578, 1469, 1434, 1368, 1304, 
1260, 1162, 1030, 793 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H, NH), 7.64 (d, J 
= 2.0 Hz, 1H, Ar), 7.17 (dd, J = 8.5, 2.0 Hz, 1H, Ar), 7.07 (d, J = 8.5 Hz, 1H, Ar), 4.15 
(q, J = 7.0 Hz, 2H, OCH2CH3), 3.62 (s, 2H, CH2C(O)), 2.35 (s, 3H, CH3), 1.26 (t, J = 
7.0 Hz, 3H, OCH2CH3); 13C NMR (100.6 MHz, CDCl3) δ 171.8 (C=O), 134.1 
(C=CCH3), 133.7 (ipso-Ar), 130.2 (ipso-Ar), 123.9 (Ar), 120.7 (Ar), 112.7 (ipso-Ar), 
111.6 (Ar), 104.3 (C=CCH3), 60.8 (OCH2CH3), 30.2 (CH2C(O)), 14.2 (OCH2CH3), 11.7 
(CH3); HRMS (ESI) m/z calcd for C13H1479BrNO2 (M + H)+ 296.0281, found 296.0279 
(+0.7 ppm error). Spectroscopic data consistent with those reported in the literature.204 
Lab Book Reference: SC3/65 
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2-(5-Bromo-2-methyl-1H-indol-3-yl)acetic acid 253 
 
253 
1 M NaOH(aq) (10 mL) was added to a stirred solution of bromo-substituted indole ester 
238 (622 mg, 2.10 mmol) in 1:1 THF/MeOH (42 mL).  The resulting solution was 
stirred at room temperature for 8 h. The reaction mixture was concentrated under 
reduced pressure and the residue dissolved in water (5 mL). The solution was made 
acidic (~pH 1) with conc. HCl resulting in the formation of a gummy precipitate. The 
resulting mixture was extracted into EtOAc (30 mL) and the two layers separated. The 
aqueous layer was extracted into EtOAc (2 x 20 mL) and the combined organics dried 
(MgSO4), filtered and the solvent evaporated under reduced pressure to give the indole 
acid 253 (513 mg, 91%) as a brown solid, mp 159–161 °C [lit.,198 189–191 °C]; 1H 
NMR (400 MHz, DMSO-d6) δ 12.12 (br s, 1H, OH), 11.08 (s, 1H, NH), 7.54 (d, J = 2.0 
Hz, 1H, Ar), 7.21 (d, J = 8.5 Hz, 1H, Ar), 7.09 (dd, J = 8.5, 2.0 Hz, 1H, Ar), 3.56 (s, 2H, 
CH2C(O)), 2.32 (s, 3H, CH3); 13C NMR (100.6 MHz, DMSO-d6) δ 173.0 (C=O), 135.0 
(C=CCH3), 133.7 (ipso-Ar), 130.2 (ipso-Ar), 122.4 (Ar), 120.0 (Ar), 112.4 (Ar), 111.0 
(ipso-Ar), 103.9 (C=CCH3), 29.7 (CH2C(O)), 11.3 (CH3); HRMS (ESI) m/z calcd for 
C11H1079BrNO2 (M + H)+ 267.9968, found 267.9982 (+0.7 ppm error). Spectroscopic 
data consistent with those reported in the literature.205 
Lab Book Reference: SC3/70 
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Ethyl 2-(7-bromo-2-methyl-1H-indol-3-yl)acetate 240 
 
240 
A mixture of 4-oxopentanoic acid (0.46 mL, 4.47 mmol) and 2-bromophenylhydrazine 
hydrochloride 239 (1.0 g, 4.47 mmol) in a solution of EtOH (6 mL) and conc. H2SO4 (aq) 
(0.45 mL) was stirred at reflux for 16 h. The reaction mixture was allowed to cool to rt 
and water (20 mL) was added. The resulting mixture was extracted into EtOAc (20 mL), 
the two layers separated and the aqueous extracted with EtOAc (10 mL). The combined 
organics were washed with 10% HCl(aq) (10 mL) and sat. NaHCO3 (aq) (10 mL), then 
dried (MgSO4), filtered and the solvent evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica using CH2Cl2 as 
eluent gave the indole ester 240 (550 mg, 42%) as an orange solid, mp 64–66 °C; RF 
(CH2Cl2) 0.45; IR (ATR) 3350 (NH), 2980, 2912, 1718 (C=O), 1623, 1583, 1491, 1446, 
1368, 1304, 1296, 1151, 1030, 772 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H, 
NH), 7.47 (d, J = 8.0 Hz, 1H, Ar), 7.27-7.25 (m, 1H, Ar), 6.98 (dd, J = 8.0, 8.0 Hz, 1H, 
Ar), 4.13 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.66 (s, 2H, CH2C(O)), 2.44 (s, 3H, CH3), 1.24 
(t, J = 7.0 Hz, 3H, OCH2CH3); 13C NMR (100.6 MHz, CDCl3) δ 171.7 (C=O), 133.7 
(C=CMe), 133.5 (ipso-Ar), 129.6 (ipso-Ar), 123.5 (Ar), 120.7 (Ar), 117.4 (Ar), 106.0 
(C=CMe), 103.9 (ipso-Ar), 60.8 (OCH2CH3), 30.6 (CH2C(O)), 14.2 (OCH2CH3), 11.8 
(CH3); HRMS (ESI) m/z calcd for C13H1479BrNO2 (M + H)+ 296.0281, found 296.0275 
(+1.8 ppm error). Spectroscopic data consistent with those reported in the literature.125 
Lab Book Reference: SC3/67 
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2-(7-Bromo-2-methyl-1H-indol-3-yl)acetic acid 252 
 
252 
1 M NaOH(aq) (8 mL) was added to a stirred solution of the bromo-substituted indole 
ester 240 (459 mg, 1.55 mmol) in 1:1 MeOH-THF (30 mL) at rt. The resulting solution 
was stirred at rt for 8 h and then the solvent was evaporated under reduced pressure to 
give the crude product. The residue was taken up in a minimum amount of water (5 mL) 
and the resulting solution was taken to pH 1 with conc. HCl(aq) resulting in an oily 
mixture. The resulting mixture was extracted into CH2Cl2 (50 mL) and the two layers 
separated. The aqueous was extracted into CH2Cl2 (2 x 50 mL) and the combined 
organics dried (MgSO4), filtered and the solvent evaporated under reduced pressure to 
give the indole acid 252 (360 mg, 86%) as a brown solid, mp 128–131 °C (lit.206 160–
161 °C);  IR (ATR) 3380 (NH), 2902, 2634, 1690 (C=O), 1625, 1590, 1558, 1456, 
1401, 1225, 1191, 768 cm−1; 1H NMR (400 MHz, DMSO-d6) δ 12.13 (br s, 1H, OH), 
11.02 (s, 1H, NH), 7.39 (d, J = 8.0 Hz, 1H, Ar), 7.21-7.19 (m, 1H, Ar), 6.89 (dd, J = 8.0, 
8.0 Hz, 1H, Ar), 3.57 (s, 2H, CH2C(O)), 2.35 (s, 3H, CH3); 13C NMR (100.6 MHz, 
DMSO-d6) δ 173.0 (C=O), 135.0 (C=CCH3), 133.4 (ipso-Ar), 130.0 (ipso-Ar), 122.6 
(Ar), 119.8 (Ar), 117.1 (Ar), 105.5 (C=CCH3), 103.3 (ipso-Ar), 29.9 (CH2C(O)), 11.24 
(CH3); HRMS (ESI) m/z calcd for C11H1079BrNO2 (M + H)+ 267.9968, found 267.9974 
(−2.4 ppm error). 
Lab Book Reference: SC3/69 
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Ethyl 2-(2,4,6-trimethyl-1H-indol-3-yl)acetate 242 
 
242 
A mixture of 4-oxopentanoic acid (0.59 mL, 5.79 mmol) and 3,5-
dimethylphenylhydrazine hydrochloride 241 (1.00 g, 5.79 mmol) in 2 M H2SO4/EtOH 
(40 mL) was stirred at 100 °C for 20 h. The reaction mixture was allowed to cool to rt 
and the solvent was evaporated under reduced pressure. The resulting residue was 
diluted with water (20 mL) and extracted into EtOAc (50 mL). The two layers were 
separated and the aqueous extracted with EtOAc (2 x 50 mL). The combined organics 
were washed with sat. NaHCO3 (aq) (10 mL), then dried (MgSO4), filtered and the 
solvent evaporated under reduced pressure to give the crude product. Purification by 
flash column chromatography on silica using CH2Cl2 as eluent gave the indole ester 242 
(1.035 g, 72%) as a pale yellow solid, mp 84–86 °C (lit.207 101–102 °C); RF (CH2Cl2) 
0.35; IR (ATR) 3353 (NH), 2978, 2909, 1710 (C=O), 1624, 1467, 1442, 1330, 1302, 
1233, 1157, 1027, 828 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.75 (s, 1H, NH), 6.85 (d, J 
= 1.0 Hz, 1H, Ar), 6.67 (s, 1H, Ar), 4.14 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.81 (s, 2H, 
CH2C(O)), 2.64 (s, 3H, CH3), 2.39 (s, 3H, CH3), 2.33 (s, 3H, CH3), 1.25 (t, J = 7.0 Hz, 
3H, OCH2CH3; 13C NMR (100.6 MHz, CDCl3) δ 172.7 (C=O), 135.7 (ipso-Ar), 132.0 
(C=CCH3), 130.7 (ipso-Ar), 129.1 (ipso-Ar), 124.6 (ipso-Ar), 123.1 (Ar), 108.3 (Ar), 
104.7 (C=CCH3), 60.6 (OCH2CH3), 31.7 (CH2C(O)), 21.3 (CH3), 19.8 (CH3), 14.2 
(OCH2CH3), 11.6 (CH3); HRMS (ESI) m/z calcd for C15H19NO2 (M + H)+ 246.1489, 
found 246.1494 (−2.1 ppm error). 
Lab Book Reference: SC4/24 
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2-(2,4,6-Trimethyl-1H-indol-3-yl)acetic acid 254 
 
254 
1 M NaOH(aq) (20 mL) was added to a stirred solution of the dimethyl-indole ester 242 
(930 mg, 3.79 mmol) in 1:1 MeOH-THF (80 mL) at rt. The resulting solution was 
stirred at rt for 20 h and then the solvent was evaporated under reduced pressure to give 
the crude product. The residue was taken up in a minimum volume of water (5 mL) and 
conc. HCl(aq) was added dropwise until a solid precipitate was observed. The solid was 
isolated by vacuum filtration, washed with water (5 mL) and hexane (5 mL) and air 
dried to give the indole acetic acid 254 (651 mg, 79%) as a pale red solid, mp 190–192 
°C (lit.207 203.5–204.5 °C); IR (ATR) 3398 (NH), 2918, 1706 (C=O), 1622, 1561, 1467, 
1436, 1400, 1215, 843 cm−1; 1H NMR (400 MHz, DMSO-d6) δ 10.62 (s, 1H, NH), 6.85 
(s, 1H, Ar), 6.47 (s, 1H, Ar), 3.65 (s, 2H, CH2C(O)), 2.49 (s, 3H, CH3), 2.29 (s, 3H, 
CH3), 2.26 (s, 3H, CH3); 13 C NMR (100.6 MHz, CDCl3) δ 174.1 (C=O), 135.6 (ipso-
Ar), 132.2 (C=CCH3), 128.7 (ipso-Ar), 128.0 (ipso-Ar), 124.6 (ipso-Ar), 121.9 (Ar), 
108.4 (Ar), 104.2 (C=CCH3), 31.2 (CH2C(O)), 21.2 (CH3), 19.5 (CH3), 11.2 (CH3); 
HRMS (ESI) m/z calcd for C13H15NO2 (M + H)+ 218.1176, found 218.1175 (+0.4 ppm 
error). 
Lab Book Reference: SC4/29 
 
5-Hydrazinyl-2-methoxypyridine 247 
 
247 
A solution of sodium nitrite 246 (278 mg, 4.03 mmol) in water (3 mL) was added 
dropwise to a solution of 5-amino-2-methoxypyridine (500 mg, 4.03 mmol) in 6 M 
HCl(aq) at 0 °C and the resulting solution was stirred for 30 min. A solution of 
N
H
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O
N
N
H
NH2
MeO
 201 
SnCl2H2O (2.28 g, 10.12 mmol) in 6 M HCl(aq) was added slowly to the reaction 
mixture at 0 °C. The mixture was stirred for 2.5 h at 0 °C, then KOH(aq) (40 % w/v) was 
added until the mixture reached pH 14. The reaction mixture was extracted into EtOAc 
(3 x 30 mL) and the combined organics were dried (MgSO4), filtered and the solvent 
evaporated under reduced pressure to give the hydrazine 247 (532 mg, 95%) as a red 
solid (product stable for ~2 days if kept below 5°C but better to use straight away), mp 
59-60 °C (lit. 64 °C); 1H NMR (400 MHz, CDCl3) δ 7.76 (dd, J = 3.0, 0.5 Hz, 1H, Ar), 
7.20 (dd, J = 9.0, 3.0 Hz, 1H, Ar), 6.66 ( dd, J = 9.0, 0.5 Hz, 1H, Ar), 4.93 (br s, 1H, 
NH), 3.87 (s, 3H, OCH3), 3.61 (br s, 2H, NH2); 13C NMR (100.6 MHz, CDCl3) δ 158.8 
(ipso-Ar), 141.8 (ipso-Ar), 130.4 (Ar), 125.8 (Ar), 110.8 (Ar), 53.4 (OCH3). 
Spectroscopic data consistent with those reported in the literature.128 
Lab Book Reference: SC4/17 
 
Methyl 2-(5-methoxy-2-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)acetate 248 
 
248 
A mixture of methyl 4-oxopentanoate (136 µL, 1.08 mmol) and 5-hydrazinyl-2-
methoxypyridine 247 in MeOH (3 mL) and conc. H2SO4(aq) (120 µL)  was placed in a 
suitable microwave vessel. The vessel was sealed and the mixture was stirred under 
microwave irradiation at 120 °C for 10 min. After being allowed to cool to rt, the 
mixture was diluted with EtOAc (20 mL) and washed with 10% aq. HCl (20 mL). The 
two layers were separated and the aqueous layer was taken to pH 7 with sat. 
NaHCO3(aq). The aqueous layer was extracted into EtOAc (3 x 20 mL) and the combined 
organics were dried (MgSO4), filtered and the solvent evaporated under reduced 
pressure to give the indole ester 248 (181 mg, 77%) as a brown oil, IR (ATR) 3344 
(NH), 2949, 1722 (C=O), 1619, 1579, 1475, 1436, 1288, 1241, 1166, 1100, 1023, 803 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H, NH), 7.32 (d, J = 8.5 Hz, 1H, Ar), 6.42 
(d, J = 8.5 Hz, 1H, Ar), 3.94 (s, 3H, OCH3), 3.77 (s, 2H, CH2C(O)), 3.69 (s, 3H, OCH3), 
N
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2.31 (s, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 173.1 (C=O), 159.6 (ipso-Ar), 
142.4 (ipso-Ar), 135.9 (C=CCH3), 123.6 (ipso-Ar), 120.8 (Ar), 104.6 (C=CCH3), 103.4 
(Ar), 53.3 (OCH3), 51.9 (OCH3), 28.4 (CH2C(O)), 12.2 (CH3); HRMS (ESI) m/z calcd 
for C12H14N2O3 (M + H)+ 235.1077, found 235.1083 (−2.6 ppm error). 
Lab Book Reference: SC4/25 
 
2-(5-Methoxy-2-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)acetic acid 255 
 
255 
1 M NaOH(aq) (4 mL) was added to a stirred solution of the azaindole ester 248 (183 mg, 
0.781 mmol) in 1:1 MeOH-THF (15 mL) at rt. The resulting solution was stirred at rt for 
16 h and then the solvent was evaporated under reduced pressure. The resulting residue 
was taken up in a minimum amount of water (5 mL) and the resulting solution was 
taken to pH 7 with 5 M HCl(aq). The mixture was extracted into EtOAc (3 x 20 mL), the 
combined organics dried (MgSO4), filtered and the solvent evaporated under reduced 
pressure to give azaindole acid 255 (140 mg, 81%) as a yellow solid, 191–193 °C; IR 
(ATR) 3192 (NH), 2968, 1697 (C=O), 1623, 1581, 1447, 1405, 1315, 1250, 1107, 1017, 
818, 592 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 12.08 (s, 1H, OH), 10.91 (s, 1H, NH), 
7.53 (d, J = 8.5 Hz, 1H, Ar), 6.42 (d, J = 8.5 Hz, 1H, Ar), 3.83 (s, 3H, OCH3), 3.58 (s, 
2H, CH2C(O)), 2.32 (s, 3H, CH3); 13C NMR (100.6 MHz, DMSO-d6) δ 173.1 (C=O), 
158.6 (ipso-Ar), 142.3 (ipso-Ar), 136.3 (C=CCH3), 123.3 (ipso-Ar), 121.0 (Ar), 104.3 
(C=CCH3), 102.7 (Ar), 52.4 (OCH3), 28.3 (CH2C(O)), 12.0 (CH3); HRMS (ESI) m/z 
calcd for C11H12N2O3 (M + H)+ 221.0921, found 221.0922 (−0.6 ppm error). 
Lab Book Reference: SC4/22 
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2-(2-Phenyl-1H-indol-3-yl)acetic acid 263 
 
263 
Pd(OAc)2 (10.8 mg, 0.048 mmol), iodobenzene (164 µL, 1.44 mL), AgBF4 (374 mg, 
1.92 mmol) and TFA (74 µL, 0.96 mmol) were added to a solution of 3-indole acetic 
acid 215 (168 mg, 0.96 mmol) in DMF (4.8 mL) at rt in a suitable microwave vessel. 
The vessel was sealed and the reaction mixture was stirred under microwave irradiation 
at 90 °C for 20 min. The reaction was allowed to cool and filtered through a pad of 
Celite®. The filtrate was evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography with hexane-EtOAc (3:1 then 2:1) as 
eluent gave the indole acetic acid 263 (136 mg, 56%) as a pale brown solid, mp 163-165 
°C (lit. 174-175 °C) RF (3:1 hexane:EtOAc) 0.10; 1H NMR (400 MHz, CDCl3) δ 8.16 
(br s, 1H, NH), 7.67 (d, J = 8.0 Hz, 1H, Ar), 7.65-7.62 (m, 2H, Ar), 7.51-7.47 (m, 2H, 
Ar), 7.43-7.39 (m, 2H, Ar), 7.26-7.22 (m, 1H, Ar), 7.18 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, 
Ar), 3.88 (s, 2H, CH2C(O)); 13C NMR (100.6 MHz, CDCl3) δ 177.6 (C=O), 136.4 (ipso-
Ar), 135.7 (ipso-Ar), 132.2 (ipso-Ar), 129.0 (Ar), 128.8 (ipso-Ar), 128.2 (Ar), 122.7 
(Ar), 120.2 (Ar), 119.2 (Ar), 110.9 (Ar), 104.9 (ipso-Ar), 30.7 (CH2); HRMS (ESI) m/z 
calcd for C16H13NO2 (M + H)+ 252.1019, found 252.1015 (1.5 ppm error). 
Spectroscopic data consistent with those reported in the literature.134 
Lab Book Reference: SC4/44 
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2-(5-(Ethoxycarbonyl)-2,4-dimethyl-1H-pyrrol-3-yl)acetic acid 278 
 
278 
KOH (664 mg, 11.84 mmol) was added to a stirred solution of pyrrole diester 277 (1.00 
g, 3.95 mmol) in water (8 mL) and EtOH (4 mL) and heated to 70 °C. The reaction was 
stirred for 30 min then allowed to cool to rt. The reaction was acidified with 10 % 
HCl(aq) (20 mL) and the reaction was extracted with EtOAc (3 x 10 mL). The combined 
organics were dried (MgSO4), filtered and the solvent evaporated under reduced 
pressure to give the crude product. Purification by column chromatography on silica 
using hexane-EtOAc-AcOH (75:23:2) as eluent gave the acid 278 (192 mg, 21%) as a 
brown solid, mp 160–162 °C (lit.140 194–196 °C); RF  (75:23:2 hexane-EtOAc-AcOH) 
0.55; IR (ATR) 3304, 2985, 2917, 1706 (C=O), 1670 (C=O), 1444, 1274, 1218, 
1172, 1091, 770, 722, 699, 623 cm−1; 1H NMR (400 MHz, CDCl3) 9.06 (br s, 1H, NH), 
4.29 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.41 (s, 2H, CH2C(O)), 2.28 (s, 3H, CH3), 2.23 (s, 
3H, CH3), 1.34 (t, J = 7.0 Hz, 3H, OCH2CH3); 13C NMR (100 MHz, CDCl3) 177.2 
(C=O), 162.0 (C=O), 131.2 (ipso-Ar), 127.6 (ipso-Ar), 117.2 (ipso-Ar), 113.9 (ipso-
Ar), 59.9 (OCH2CH3), 29.8 (CH2C(O)), 14.5 (CH3), 11.5 (CH3), 10.6 (CH3); HRMS 
(ESI) m/z calcd for C11H15NO4 (M + Na)+ 248.0893, found 248.0899 (−2.3 ppm error). 
Spectroscopic data consistent with those reported in the literature.140  
Lab Book Reference: SC4/45 
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6,7-Dimethoxy-3,4-dihydroisoquinoline 283 
 
283 
N-Bromosuccinimide (840 mg, 4.72 mmol) was added portionwise to a stirred solution 
of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 282 (830 mg, 4.30 mmol) in CH2Cl2 
(20 mL) at 0 °C under Ar. The resulting solution was stirred at 0 °C for 1 h. NaOH(aq) 
(30% w/v, 9 mL) was added and the reaction was stirred at rt for 2 h. The two layers 
were separated and the organic layer was washed with water (50 mL), dried (MgSO4), 
filtered and evaporated under reduced pressure to give the crude product. Purification by 
flash column chromatography on silica using EtOAc-MeOH (98:2) as eluent gave the 
imine 283 (766 mg, 93%) as a pale yellow oil, RF (95:5 EtOAc-MeOH) 0.15; 1H NMR 
(400 MHz, CDCl3) δ 8.23 (s, 1H, HC=N), 6.81 (s, 1H, Ar), 6.67 (s, 1H, Ar), 3.91 (s, 3H, 
OCH3), 3.90 (s, 3H, OCH3), 3.75-3.70 (m, 2H, NCH2), 2.70-2.66 (m, 2H, CH2); 13C 
NMR (100.6 MHz, CDCl3) δ 159.6 (C=N), 151.1 (ipso-Ar), 147.8 (ipso-Ar), 129.8 
(ipso-Ar), 121.5 (ipso-Ar), 110.3 (Ar), 110.3 (Ar), 56.1 (OCH3), 56.0 (OCH3), 47.3 
(NCH2), 24.7 (CH2). Spectroscopic data consistent with those reported in the 
literature.208 
Lab Book Reference: SC3/50 
 
5,5-Dibenzyl-2,3,4,5-tetrahydropyridine 290 
 
290 
LHMDS (1 M in THF, 36.14 mL, 36.14 mmol) was added to a solution of N-Boc-
piperidin-2-one 288 (3.00 g, 15.06 mmol) in THF (64 mL) and stirred at −78 °C for 1 h 
under Ar. Benzyl bromide (4.30 mL, 36.14 mmol) was added and the reaction mixture 
was allowed to warm to rt and stirred for 2 h. Sat. NH4Cl(aq) (200 mL) was added and 
the reaction mixture was extracted with EtOAc (3 x 200 mL). The combined organics 
N
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were dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
benzyl-substituted lactam 289, which was used directly in the next step without further 
purification. The crude material was dissolved in THF (150 mL) and the resulting 
solution was cooled to −78 °C under Ar. Lithium triethylborohydride (1 M in THF, 
45.18 mL, 45.18 mmol) was added carefully over 5 min and the reaction mixture was 
stirred for 30 min at −78 °C. A premixed solution of ethanol (136 mL) and conc. HCl 
(14 mL) was carefully added and the reaction mixture was diluted with CH2Cl2 (500 
mL). The reaction mixture was washed with water (300 mL) and the organic layer was 
dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product, which was used directly in the next step without further purification. A 1:1 
mixture of CH2Cl2:TFA (32mL:32mL) that had been precooled to 0 °C was added to the 
crude product and the resulting mixture was stirred at 0 °C for 30 min. The reaction was 
allowed to warm to rt and the volatiles were removed under reduced pressure. The 
residue was taken up in CH2Cl2 (500 mL) and the resulting solution was washed with 
sat. NaHCO3 (300 mL). The organic layer was dried (MgSO4), filtered and the solvent 
evaporated under reduced pressure to give the crude product as a yellow oil. Purification 
by flash column chromatography on silica using hexane-EtOAc (1:1) as eluent gave 
imine 290 (1.84 g, 46%) as a white solid, mp 60-62 °C (lit.21 63-65 °C); RF (hexane-
EtOAc 1:1) 0.20; 1H NMR (400 MHz, CDCl3) δ 7.76 (s, 1H, N=CH), 7.31-7.22 (m, 6H, 
Ar), 7.17-7.15 (m, 4H, Ar), 3.21 (ddd, J = 5.5, 5.5, 2.5 Hz, 2H, NCH2), 2.89 (d, J = 13.5 
Hz, 2H, CHAHBPh), 2.67 (d, J = 13.5 Hz, 2H, CHAHBPh), 1.60-1.57 (m, 2H, CH2), 1.32-
1.26 (m, 2H, CH2); 13C NMR (100.6 MHz, CDCl3) δ 169.0 (N=CH), 137.1 (Ar), 130.4 
(Ar), 128.1 (Ar), 126.5 (Ar), 48.8 (NCH2), 45.0 (CH2Ph), 42.4 (C), 27.1 (CH2), 18.7 
(CH2); HRMS (ESI) m/z calcd for C19H21N (M + H)+ 264.1747, found 264.1742 (+1.9 
ppm error). Spectroscopic data consistent with those reported in the literature.21 
Lab Book Reference: SC5/19 
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(E)-N-(4-Methoxybenzylidene)methanamine 293 
 
293 
Methylamine (2 M in MeOH, 16.5 mL, 33.0 mmol) was added to a stirred solution of 
paramethoxybenzaldehyde 292 (3.64 mL, 30.0 mmol) in EtOH (15 mL) at 40 °C. The 
resulting solution was removed from the heat and stored in the fridge for 2.5 h. The 
solvent was evaporated under reduced pressure and the residue was taken up in CH2Cl2 
(20 mL). The reaction mixture was washed with H2O (10 mL) and the organics were 
dried (MgSO4), filtered and evaporated under reduced pressure to give the imine 293 
(4.47 g, 100%) as a yellow oil, 1H NMR (400 MHz, CDCl3) δ 8.21-8.20 (m, 1H, HCN), 
7.66-7.63 (m, 2H, Ar), 6.93-6.90 (m, 2H, Ar), 3.834-3.829 (m, 3H, OCH3), 3.48-3.47 
(m, 3H, NCH3); 13C NMR (100.6 MHz, CDCl3) δ 161.8 (CH=N), 161.4 (ipso-Ar), 129.3 
(Ar), 129.2 (ipso-Ar), 113.9 (Ar), 55.3 (OCH3), 48.1 (NCH3); HRMS (ESI) m/z calcd 
for C9H12NO (M + H)+ 150.0913, found 150.0909 (2.9 ppm error). Spectroscopic data 
consistent with those reported in the literature.209 
Lab Book Reference: SC4/51 
 
 (1'R*,10b'R*)-2-Methyl-5',6'-dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-
a]isoquinolin]-3'(10b'H)-one syn-214 and (1'R*,10b'S*)-2-methyl-5',6'-dihydro-
2'H-spiro[indole-3,1'-pyrrolo[2,1-a]isoquinolin]-3'(10b'H)-one anti-214 
    
syn-214   anti-214 
Using general procedure J, DIPEA (245 µL, 1.41 mmol), T3P (725 mg of a 50% w/v 
solution in THF, 1.14 mmol), imine 37 (100 mg, 0.76 mmol) and 2-methyl-3-indole 
acetic acid 212 (172 mg, 0.91 mmol) in THF (4 mL) for 16 h at rt gave the crude 
product which contained a 11:1 mixture of spirocycles syn-214 and anti-214 based on 
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analysis by 1H NMR spectroscopy: δ 6.32 (d, 11H, Ar) and 5.93 (d, 1H, Ar). 
Purification by flash column chromatography with EtOAc as eluent sequentially 
furnished anti-214 (18 mg, 8%), a 1:3.3 mixture of anti-214:syn-214 (27 mg, 12%) 
and syn-214 (166 mg, 72%). Total combined yield of syn-214 and anti-214: 211 mg, 
92%. The isolated yields suggest a 7.7:1 ratio of syn-214:anti-214. Syn-214 was 
recrystallised from EtOAc and an X-ray crystal structure obtained. CCDC 1436464 
contains the supplementary crystallographic data.  
 
Syn-214: Yellow solid, mp 177-179 °C; RF (EtOAc) 0.15; IR (ATR) 3070, 2921, 1690 
(C=O), 1577, 1458, 1429, 1414, 1305, 909, 726 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.40 (d, J = 7.5 Hz, 1H, Ar), 7.11 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.99-6.91 (m, 3H, 
Ar), 6.86 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.78 (dd, J = 7.5, 7.5 Hz, 1H, Ar), 6.32 (d, 
J = 7.5 Hz, 1H, Ar), 5.27 (s, 1H, NCH), 4.58-4.53 (m, 1H, NCHAHB), 3.10 (d, J = 16.0 
Hz, 1H, CHCHDC(O)), 3.09-2.97 (m, 2H, NCHAHB, CHEHF), 2.82-2.77 (m, 1H, 
CHEHF), 2.60 (s, 3H, CH3), 2.44 (d, J = 16.0 Hz, 1H, CHCHDC(O)); 13C NMR (100.6 
MHz, CDCl3) δ 180.4 (C=N), 170.4 (C=O), 153.7 (ipso-Ar), 140.3 (ipso-Ar), 133.3 
(ipso-Ar), 132.0 (ipso-Ar), 129.0 (Ar), 128.4 (Ar), 127.1 (Ar), 126.6 (Ar), 125.5 (Ar), 
123.5 (Ar), 120.9 (Ar), 120.1 (Ar), 63.3 (C), 60.4 (NCH), 39.9 (CH2C(O)), 37.3 
(NCH2), 28.9 (CH2), 16.4 (CH3); HRMS (ESI) m/z calcd for C20H18N2O (M + H)+ 
303.1492, found 303.1496 (−1.4 ppm error).  
 
Anti-214: Yellow oil, RF (EtOAc) 0.25; IR (ATR) 3070, 2920, 2855, 1690 (C=O), 1578, 
1458, 1424, 1305, 925, 758, 731 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 7.5 
Hz, 1H, Ar), 7.53 (d, J = 7.5 Hz, 1H, Ar), 7.46 (ddd, J = 7.5, 7.5, 1.0 Hz, Ar), 7.36 (ddd, 
J = 7.5, 7.5, 1.0 Hz, Ar), 7.12-7.09 (m, 2H, Ar), 6.91-6.85 (m, 1H, Ar), 5.93 (d, J = 7.5 
Hz, 1H, Ar), 5.36 (s, 1H, NCH), 4.58-4.53 (m, 1H, NCHAHB), 3.16-3.02 (m, 3H, 
NCHAHB, CHEHF, CHCHDC(O)), 2.89-2.85 (m, 1H, CHEHF), 2.58 (d, J = 17.0 Hz, 1H, 
CHCHDC(O)), 1.85 (s, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 182.4 (C=N), 170.0 
(C=O), 154.8 (ipso-Ar), 140.2 (ipso-Ar), 133.0 (ipso-Ar), 132.0 (ipso-Ar), 129.3 (Ar), 
129.1 (Ar), 127.7 (Ar), 127.3 (Ar), 126.3 (Ar), 123.7 (Ar), 121.6 (Ar), 120.6 (Ar), 61.7 
(C), 61.6 (NCH), 40.1 (CH2C(O)), 37.1 (NCH2), 28.5 (CH2), 17.2 (CH3); HRMS (ESI) 
m/z calcd for C20H18N2O (M + H)+ 303.1492, found 303.1497 (−1.8 ppm error). 
 209 
Lab Book Reference: SC4/82 
 
(1'R*,10b'R*)-5-Fluoro-2-methyl-5',6'-dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-
a]isoquinolin]-3'(10b'H)-one syn-256 and (1'R*,10b'S*)-5-fluoro-2-methyl-5',6'-
dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-a]isoquinolin]-3'(10b'H)-one anti-256 
    
syn-256    anti-256 
Using general procedure J, DIPEA (245 µL, 1.41 mmol), T3P (725 mg of a 50% w/v 
solution in THF, 1.14 mmol), imine 37 (100 mg, 0.76 mmol) and 2-(5-fluoro-2-methyl-
1H-indol-3-yl)acetic acid 249 (188 mg, 0.91 mmol) in THF (4 mL) for 16 h at rt gave 
the crude product which contained 6:1 mixture of syn-256:anti-256 based on analysis 
by 1H NMR spectroscopy: δ 6.32 (d, 6H, Ar) and 5.96 (d, 1H, Ar). Purification by 
flash column chromatography with EtOAc as eluent sequentially furnished anti-256 
(21 mg, 9%) and syn-256 (177 mg, 72%). Total combined yield of syn-256 and anti-
256: 198 mg, 81%. The isolated yields suggest a 8.4:1 ratio of syn-256:anti-256. 
 
Syn-256: Yellow solid, mp 193-196 °C; RF (EtOAc) 0.15; IR (ATR) 2924, 1694 (C=O), 
1598, 1462, 1415, 1178, 920, 727 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.33 (dd, J = 8.5, 
4.5 Hz, 1H, Ar), 7.02-6.95 (m, 2H, Ar), 6.83-6.78 (m, 2H, Ar), 6.68 (dd, J = 8.0, 2.5 Hz, 
1H, Ar), 6.32 (d, J = 8.0 Hz, 1H, Ar), 5.26 (s, 1H, NCH), 4.56-4.52 (m, 1H, NCHAHB), 
3.12-2.96 (m, 3H, CHCHDC(O)), NCHAHB, CHEHF), 2.84-2.79 (m, 1H, CHEHF), 2.58 (s, 
3H, CH3), 2.43 (d, J = 16.5 Hz, 1H, CHCHDC(O)); 13C NMR (100.6 MHz, CDCl3) δ 
180.3 (C=N), 170.1 (C=O), 160.8 (d, J = 245.5 Hz, CF), 149.8 (d, J = 2.0 Hz, ipso-Ar), 
142.1 (d, J = 9.0 Hz, ipso-Ar), 133.3 (ipso-Ar), 131.6 (ipso-Ar), 129.3 (Ar), 127.3 (Ar), 
126.8 (Ar), 123.4 (Ar), 120.8 (d, J = 9.0 Hz, Ar), 115.1 (d, J = 23.5 Hz, Ar), 108.9 (d, J 
= 25.5 Hz, Ar), 63.8 (d, J = 2.0 Hz, C), 60.3 (NCH), 39.8 (CH2C(O)), 37.3 (NCH2), 28.9 
(CH2), 16.4 (CH3); 19F NMR (376 MHz, CDCl3) δ −115.90 (ddd, J = 8.5, 8.5, 4.5 Hz); 
HRMS (ESI) m/z calcd for C20H17FN2O (M + H)+ 321.1398, found 321.1384 (+4.3 ppm 
error).  
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Anti-256: Yellow oil, RF (EtOAc) 0.25; IR (ATR) 2925, 1696 (C=O), 1601, 1466, 1421, 
1306, 1156, 732 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.53 (dd, J = 8.5, 4.5 Hz, 1H, Ar), 
7.25 (dd, J = 7.5, 2.5 Hz, 1H, Ar), 7.17-7.12 (m, 3H, Ar), 6.93-6.89 (m, 1H, Ar), 5.96 
(d, J = 8.0 Hz, 1H, Ar), 5.32 (s, 1H, NCH), 4.58-4.53 (m, 1H, NCHAHB), 3.16-3.02 (m, 
3H, NCHAHB, CHEHF, CHCHDC(O)), 2.90-2.85 (m, 1H, CHEHF), 2.60 (d, J = 17.0 Hz, 
1H,  CHCHDC(O)), 1.84 (s, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 182.3 (C=N), 
169.7 (C=O), 161.6 (d, J = 245.5 Hz, CF), 150.7 (d, J = 2.0 Hz, ipso-Ar), 142.2 (d, J = 
8.5 Hz, ipso-Ar), 133.1 (ipso-Ar), 131.8 (ipso-Ar), 129.4 (Ar), 127.9 (Ar), 127.4 (Ar), 
123.6 (Ar), 121.5 (d, J = 8.5 Hz, Ar), 115.8 (d, J = 23.5 Hz, Ar), 109.5 (d, J = 25.0 Hz, 
Ar), 62.1 (d, J = 2.0 Hz, C), 61.6 (NCH), 40.1 (CH2C(O)), 37.2 (NCH2), 28.5 (CH2), 
17.2 (CH3); 19F NMR (376 MHz, CDCl3) δ −115.00 (ddd, J = 8.5, 8.5, 4.5 Hz); HRMS 
(ESI) m/z calcd for C20H17FN2O (M + H)+ 321.1398, found 321.1383 (+4.5 ppm error). 
Lab Book Reference: SC3/28 
 
(1'R*,10b'R*)-5-Methoxy-2-methyl-5',6'-dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-
a]isoquinolin]-3'(10b'H)-one syn-257 and (1'R*,10b'S*)-5-methoxy-2-methyl-5',6'-
dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-a]isoquinolin]-3'(10b'H)-one anti-257 
   
syn-257    anti-257 
Using general procedure J, DIPEA (245 µL, 1.41 mmol), T3P (725 mg of a 50% w/v 
solution in THF, 1.14 mmol), imine 37 (100 mg, 0.76 mmol) and 2-(5-methoxy-2-
methyl-1H-indol-3-yl)acetic acid 250 (199 mg, 0.91 mmol) in THF (4 mL) for 16 h at rt 
gave the crude product which mixture contained 6:1 mixture of syn-257:anti-257 
based on analysis by 1H NMR spectroscopy: δ 6.33 (d, 6H, Ar) and 5.99 (d, 1H, Ar). 
Purification by flash column chromatography with EtOAc as eluent sequentially 
furnished anti-257 (38 mg, 15%), a 1:3 mixture of anti-257:syn-257 (18 mg, 7%) and 
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syn-257 (160 mg, 63%). Total combined yield of syn-257 and anti-257: 216 mg, 85%. 
The isolated yields suggest a 4.1:1 ratio of syn-257:anti-257. 
 
Syn-257: Pale orange solid, mp 121-124 °C; RF (EtOAc) 0.15; IR (ATR) 2934, 2836, 
1689, 1610, 1579, 1470, 1431, 1305, 1178, 907, 724 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.28 (d, J = 8.5 Hz, 1H, Ar), 6.99-6.92 (m, 2H, Ar), 6.82-6.78 (m, 1H, Ar), 6.62 (dd, J 
= 8.5, 2.5 Hz, 1H, Ar), 6.52 (d, J = 2.5 Hz, 1H, Ar), 6.33 (d, J = 8.0 Hz, 1H, Ar), 5.25 
(s, 1H, NCH), 4.56-4.51 (m, 1H, NCHAHB), 3.57 (s, 3H, OCH3), 3.11-2.95 (m, 3H, 
CHCHDC(O), NCHAHB, CHEHF), 2.83-2.78 (m, 1H, CHEHF), 2.55 (s, 3H, CH3), 2.43 (d, 
J = 16.5 Hz, 1H, CHCHDC(O)); 13C NMR (100.6 MHz, CDCl3) δ 178.0 (C=N), 170.4 
(C=O), 157.8 (ipso-Ar), 147.5 (ipso-Ar), 141.8 (ipso-Ar), 133.2 (ipso-Ar), 132.0 (ipso-
Ar), 129.0 (Ar), 127.1 (Ar), 126.7 (Ar), 123.6 (Ar), 120.3 (Ar), 113.2 (Ar), 107.5 (Ar), 
63.3 (C), 60.7 (NCH), 55.5 (OCH3), 40.0 (CH2C(O)), 37.3 (NCH2), 29.0 (CH2), 16.2 
(CH3); HRMS (ESI) m/z calcd for C21H20N2O2 (M + H)+ 333.1598, found 333.1595 
(+0.8 ppm error).  
 
Anti-257: Pale orange solid, mp 168-171°C; RF (EtOAc) 0.25; IR (ATR) 2923, 2836, 
1690 (C=O), 1596, 1576, 1473, 1431, 1305, 1026, 909, 727 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.48 (d, J 8.5 Hz, 1H, Ar), 7.12-7.10 (m, 2H, Ar), 7.08 (d, J = 2.5 Hz, 1H, Ar), 
6.95 (dd, J = 8.5, 2.5 Hz, 1H, Ar), 6.92-6.88 (m, 1H, Ar), 5.99 (d, J = 8.0 Hz, 1H, Ar), 
5.30 (s, 1H, NCH), 4.56-4.52 (m, 1H, NCHAHB), 3.88 (s, 3H, OCH3), 3.15-3.02 (m, 3H, 
CHCHDC(O), NCHAHB, CHEHF), 2.92-2.84 (m, 1H, CHEHF), 2.59 (d, J = 17.0 Hz, 1H, 
CHCHDC(O)), 1.81 (s, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 180.2 (C=N), 170.0 
(C=O), 158.7 (ipso-Ar), 148.3 (ipso-Ar), 141.8 (ipso-Ar), 133.0 (ipso-Ar), 132.1 (ipso-
Ar), 129.2 (Ar), 127.7 (Ar), 127.3 (Ar), 123.8 (Ar), 121.0 (Ar), 113.4 (Ar), 108.4 (Ar), 
61.9 (C), 61.7 (NCH), 55.8 (OCH3), 40.5 (CH2C(O)), 37.1 (NCH2), 28.5 (CH2), 17.1 
(CH3); HRMS (ESI) m/z calcd for C21H20N2O2 (M + H)+ 333.1598, found 333.1594 
(+0.3 ppm error).  
Lab Book Reference SC3/56 
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(1'R*,10b'R*)-2,4,6-Trimethyl-5',6'-dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-
a]isoquinolin]-3'(10b'H)-one syn-258 and (1'R*,10b'S*)-2,4,6-trimethyl-5',6'-
dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-a]isoquinolin]-3'(10b'H)-one anti-258 
   
        syn-258     anti-258 
Using general procedure J, DIPEA (245 µL, 1.41 mmol), T3P (725 mg of a 50% w/v 
solution in THF, 1.14 mmol), imine 37 (100 mg, 0.76 mmol) and acid 254 (197 mg, 
0.91 mmol) in THF (4 mL) for 16 h at rt gave the crude product which contained 9:1 
mixture of syn-258:anti-258 based on analysis by 1H NMR spectroscopy: δ 5.21 (s, 
9H, NCH) and 5.61 (s, 1H, NCH). Purification by flash column chromatography with 
EtOAc as eluent sequentially furnished a mixture of anti-258 with minor 
contaminants (24 mg, 10%) and syn-258 (198 mg, 78%). The isolated yields suggest 
a 8.2:1 ratio of syn-258:anti-258. 
 
Syn-258: Pale orange solid, mp 128-130 °C; RF (EtOAc) 0.10; IR (ATR) 3055, 2923, 
1688 (C=O), 1626, 1593, 1459, 1433, 1305, 1264, 851, 729 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.16 (s, 1H, Ar), 7.02-6.97 (m, 2H, Ar), 6.75-6.71 (m, 1H, Ar), 6.50 (s, 1H, 
Ar), 6.04 (d, J = 8.0 Hz, 1H, Ar), 5.21 (s, 1H, NCH), 4.59-4.54 (m, 1H, NCHAHB), 3.23-
3.08 (m, 2H, NCHAHB, CHEHF), 2.99 (d, J = 17.5 Hz, 1H, CHCHDC(O)), 2.83-2.78 (m, 
1H, CHEHF), 2.65 (d, J = 17.5 Hz, 1H, CHCHDC(O)), 2.52 (s, 3H, CH3), 2.24 (s, 3H, 
CH3), 1.83 (s, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 182.5 (C=N), 170.6 (C=O), 
154.9 (ipso-Ar), 138.3 (ipso-Ar), 136.1 (ipso-Ar), 133.2 (ipso-Ar), 132.8 (ipso-Ar), 
132.7 (ipso-Ar), 128.9 (Ar), 128.8 (Ar), 127.1 (Ar), 126.2 (Ar), 125.0 (Ar), 118.7 (Ar), 
61.3 (C), 59.7 (NCH), 37.9 (CH2C(O), NCH2), 27.6 (CH2), 21.1 (CH3), 19.2 (CH3), 16.0 
(CH3); HRMS (ESI) m/z calcd for C22H22N2O (M + H)+ 331.1805, found 331.1800 
(+1.4 ppm error). 
 
Anti-258: Orange oil, RF (EtOAc) 0.20; IR (ATR) 2923, 1688 (C=O), 1579, 1459, 
1423, 1376, 1359, 1331, 1304, 1200, 923, 732 cm-1; 1H NMR (400 MHz, CDCl3) δ 
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7.22 (s, 1H, Ar), 7.12-7.11 (m, 2H, Ar), 6.95-6.90 (m, 2H, Ar), 6.06 (d, J = 7.5 Hz, 1H, 
Ar), 5.61 (s, 1H, NCH), 4.59-4.55 (m, 1H, NCHAHB), 3.34 (dd, J = 17.5, 1.0 Hz, 1H, 
CHCHDC(O)), 3.17-2.99 (m, 2H, NCHAHB, CHEHF), 2.86 (dd, J = 16.0, 3.0 Hz, 1H, 
CHEHF), 2.51 (s, 3H, CH3), 2.47 (d, J = 17.5 Hz, 1H, CHCHDC(O)), 2.42 (s, 3H, CH3), 
1.79 (s, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 182.3 (C=N), 170.6 (C=O), 155.4 
(ipso-Ar), 139.3 (ipso-Ar), 133.9 (ipso-Ar), 133.0 (ipso-Ar), 132.6 (ipso-Ar), 132.1 
(ipso-Ar), 129.24 (Ar), 129.19 (Ar), 127.5 (Ar), 127.4 (Ar), 124.0 (Ar), 119.3 (Ar), 61.5 
(C), 58.1 (NCH), 37.2 (NCH2), 36.7 (CH2C(O)), 28.4 (CH2), 21.4 (CH3), 18.4 (CH3), 
17.1 (CH3); HRMS (ESI) m/z calcd for C22H22N2O (M + H)+ 331.1805, found 331.1803 
(+0.6 ppm error). 
Lab Book Reference SC4/39 
 
(1'R*,10b'R*)-5-Bromo-2-methyl-5',6'-dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-
a]isoquinolin]-3'(10b'H)-one syn-259 and (1'R*,10b'S*)-5-bromo-2-methyl-5',6'-
dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-a]isoquinolin]-3'(10b'H)-one anti-259 
    
syn-259    anti-259 
Using general procedure J, DIPEA (245 µL, 1.41 mmol), T3P (725 mg of a 50% w/v 
solution in THF, 1.14 mmol), imine 37 (100 mg, 0.76 mmol) and acid 253 (243 mg, 
0.91 mmol) in THF (4 mL) for 16 h at rt gave the crude product which contained 12:1 
mixture of syn-259:anti-259 based on analysis by 1H NMR spectroscopy: δ 6.33 (d, 
12H, Ar) and 5.96 (d, 1H, Ar). Purification by flash column chromatography with 
EtOAc as eluent sequentially furnished anti-259 (28 mg, 9%) and syn-259 (250 mg, 
87%). Total combined yield of syn-259 and anti-259: 278 mg, 96%. Syn-259 was 
recrystallised from EtOAc and an X-ray crystal structure obtained. CCDC 1436468 
contains the supplementary crystallographic data. 
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Syn-259: Orange solid, mp 164-167 °C; RF (EtOAc) 0.15; IR (ATR) 2918, 2852, 1695, 
1648, 1604, 1572, 1449, 1423, 1410, 1302, 1246, 1193, 803, 760, 739 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.28-7.24 (m, 2H, Ar), 7.13-7.12 (m, 1H, Ar), 7.05-6.98 (m, 2H, 
Ar), 6.83 (dd, J = 7.5, 7.5 Hz, 1H, Ar), 6.33 (d, J = 8.0 Hz, 1H, Ar), 5.27 (s, 1H, NCH), 
4.59-4.54 (m, 1H, NCHAHB), 3.13-2.97 (m, 3H, CHCHDC(O), NCHAHB, CHEHF), 2.86-
2.81 (m, 1H, CHEHF), 2.60 (s, 3H, CH3), 2.45 (d, J = 16.5 Hz, 1H, CHCHDC(O)); 13C 
NMR (100.6 MHz, CDCl3) δ 180.8 (C=N), 170.0 (C=O), 152.7 (ipso-Ar), 142.3 (ipso-
Ar), 133.3 (ipso-Ar), 131.5 (Ar), 131.4 (ipso-Ar), 129.3 (Ar), 127.5 (Ar), 126.8 (Ar), 
124.3 (Ar), 123.3 (Ar), 121.4 (Ar), 119.2 (ipso-Ar), 63.9 (C), 60.4 (NCH), 39.7 
(CH2C(O)), 37.3 (NCH2), 28.9 (CH2), 16.5 (CH3); HRMS (ESI) m/z calcd for 
C20H17BrN2O (M + H)+ 381.0597, found 381.0597 (−0.1 ppm error). 
 
Anti-259: Orange oil, RF (EtOAc) 0.25; IR (ATR) 2926, 2867, 1696 (C=O), 1604, 1578, 
1455, 1423, 1305, 1186, 735 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 2.0 Hz, 
1H, Ar), 7.58 (dd, J = 8.0, 2.0 Hz, 1H, Ar), 7.45 (d, J = 8.0 Hz, 1H, Ar), 7.14-7.11 (m, 
2H, Ar), 6.93-6.89 (m, 1H, Ar), 5.96 (d, J = 8.0 Hz, 1H, Ar), 5.34 (s, 1H, NCH), 4.57-
4.52 (m, 1H, NCHAHB), 3.15-3.02 (m, 3H, CHCHDC(O), NCHAHB, CHEHF), 2.89-2.85 
(m, 1H, CHEHF), 2.58 (d, J = 17.0 Hz, 1H, CHCHDC(O)), 1.83 (s, 3H, CH3); 13C NMR 
(100.6 MHz, CDCl3) δ 183.0 (C=N), 169.6 (C=O), 153.8 (ipso-Ar), 142.4 (ipso-Ar), 
133.1 (ipso-Ar), 132.7 (Ar), 131.7 (ipso-Ar), 129.4 (Ar), 127.9 (Ar), 127.4 (Ar), 125.1 
(Ar), 123.6 (Ar), 122.0 (Ar), 119.8 (ipso-Ar), 62.0 (C), 61.4 (NCH), 40.0 (CH2C(O)), 
37.1 (NCH2), 28.4 (CH2), 17.2 (CH3); HRMS (ESI) m/z calcd for C20H17BrN2O (M + 
H)+ 381.0597 found 381.0598 (−0.1 ppm error). 
Lab Book Reference SC3/73 
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(1'R*,10b'R*)-7-Bromo-2-methyl-5',6'-dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-
a]isoquinolin]-3'(10b'H)-one syn-260 and (1'R*,10b'S*)-7-bromo-2-methyl-5',6'-
dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-a]isoquinolin]-3'(10b'H)-one anti-260 
     
        syn-260              anti-260 
Using general procedure J, DIPEA (245 µL, 1.41 mmol), T3P (725 mg of a 50% w/v 
solution in THF, 1.14 mmol), imine 37 (100 mg, 0.76 mmol) and acid 252 (243 mg, 
0.91 mmol) in THF (4 mL) for 16 h at rt gave the crude product which contained 13:1 
mixture of syn-260:anti-260 based on analysis by 1H NMR spectroscopy: δ 6.33 (d, 
12H, Ar) and 5.96 (d, 1H, Ar). Purification by flash column chromatography with 
EtOAc as eluent sequentially furnished anti-260 (24 mg, 8%), a 1:2.3 mixture of 
anti-260:syn-260 (11 mg, 4%) and syn-260 (227 mg, 78%). Total combined yield of 
syn-260 and anti-260: 262 mg, 90%. The isolated yields suggest a 8.6:1 ratio of syn-
260:anti-260. 
 
Syn-260: Orange solid, mp 190-192 °C; RF (4:1 EtOAc-hexane) 0.15; IR (ATR) 2940, 
2858, 1692, 1571, 1456, 1431, 1417, 1302, 1195, 803, 760 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.26 (d, J = 8.0 Hz, 1H, Ar), 6.99-6.93 (m, 2H, Ar), 6.90 (d, J = 7.5 Hz, 1H, 
Ar), 6.82 (dd, J = 7.5, 7.5 Hz, 1H, Ar), 6.73 (dd, J = 7.5, 7.5 Hz, 1H, Ar), 6.32 (d, J = 
8.0 Hz, 1H, Ar), 5.28 (s, 1H, NCH), 4.55-4.51 (m, 1H, NCHAHB), 3.11-2.95 (m, 3H, 
CHCHDC(O), NCHAHB, CHEHF), 2.82-2.78 (m, 1H, CHEHF), 2.65 (s, 3H, CH3), 2.41 (d, 
J = 16.5 Hz, 1H, CHCHDC(O)); 13C NMR (100.6 MHz, CDCl3) δ 182.1 (C=N), 169.9 
(C=O), 151.9 (ipso-Ar), 142.0 (ipso-Ar), 133.2 (ipso-Ar), 131.8 (Ar), 131.6 (ipso-Ar), 
129.1 (Ar), 127.3 (Ar), 126.9 (Ar), 126.8 (Ar), 123.4 (Ar), 119.9 (Ar), 113.9 (ipso-Ar), 
64.9 (C), 60.3 (NCH), 39.9 (CH2C(O)), 37.3 (NCH2), 28.8 (CH2), 16.7 (CH3); HRMS 
(ESI) m/z calcd for C20H1779BrN2O (M + H)+ 381.0597, found 381.0597 (0.0 ppm error). 
Anti-260: Orange oil, RF (4:1 EtOAc-hexane) 0.25; IR (ATR) 2933, 2861, 1690 (C=O), 
1575, 1458, 1421, 1306, 1181, 783, 736 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J 
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= 8.0 Hz, 1H, Ar), 7.47 (d, J = 7.5 Hz, 1H, Ar), 7.26-7.22 (m, 1H, Ar), 7.15-7.10 (m, 
2H, Ar), 6.94-6.90 (m, 1H, Ar), 5.95 (d, J = 8.0 Hz, 1H, Ar), 5.35 (s, 1H, NCH), 4.57-
4.52 (m, 1H, NCHAHB), 3.15-3.01 (m, 3H, CHCHDC(O), NCHAHB, CHEHF), 2.89-2.84 
(m, 1H, CHEHF), 2.58 (d, J = 17.0 Hz, 1H, CHCHDC(O)), 1.89 (s, 3H, CH3); 13C NMR 
(100.6 MHz, CDCl3) δ 184.0 (C=N), 169.6 (C=O), 153.1 (ipso-Ar), 142.0 (ipso-Ar), 
133.0 (ipso-Ar), 132.6 (Ar), 131.7 (ipso-Ar), 129.4 (Ar), 127.9 (Ar), 127.7 (Ar), 127.6 
(Ar), 123.5 (Ar), 120.6 (Ar), 114.5 (ipso-Ar), 63.4 (C), 61.5 (NCH), 40.2 (CH2C(O)), 
37.2 (NCH2), 28.5 (CH2), 17.5 (CH3); HRMS (ESI) m/z calcd for C20H1779BrN2O (M + 
Na)+ 403.0416 found 403.0400 (+4.1 ppm error). 
Lab Book Reference SC3/72 
 
(1S*,10bR*)-5'-Methoxy-2'-methyl-5,6-dihydro-2H-spiro[pyrrolo[2,1-
a]isoquinoline-1,3'-pyrrolo[3,2-b]pyridin]-3(10bH)-one syn-261 and (1S*,10bS*)-5'-
methoxy-2'-methyl-5,6-dihydro-2H-spiro[pyrrolo[2,1-a]isoquinoline-1,3'-
pyrrolo[3,2-b]pyridin]-3(10bH)-one anti-261 
   
syn-261    anti-261 
Using general procedure J, DIPEA (245 µL, 1.41 mmol), T3P (725 mg of a 50% w/v 
solution in THF, 1.14 mmol), imine 37 (100 mg, 0.76 mmol) and acid 255 (200 mg, 
0.91 mmol) in THF (4 mL) for 16 h at rt gave the crude product which contained a 
>20:1 mixture of syn-261:anti-261 based on analysis by 1H NMR spectroscopy: δ 
6.36 (d, Ar). Purification by flash column chromatography with EtOAc as eluent 
furnished syn-261 (226 mg, 89%). The isolated yields suggest a >20:1 ratio of syn-
261:anti-261. 
 
Syn-261: Yellow solid, mp 139-141 °C; RF (EtOAc) 0.10; IR (ATR) 2939, 1687 (C=O), 
1594, 1472, 1407, 1307, 1222, 1145, 1022, 909, 829, 645 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.50 (d, J = 8.0 Hz, 1H, Ar), 6.96-6.92 (m, 2H, Ar), 6.82-6.78 (m, 1H, Ar), 
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6.39 (d, J = 8.5 Hz, 1H, Ar), 6.36 (d, J = 8.0 Hz, 1H, Ar) 5.30 (s, 1H, NCH), 4.58-4.54 
(m, 1H, NCHAHB), 3.70 (s, 3H, OCH3), 3.20-3.11 (m, 1H, NCHAHB), 3.06-2.99 (m, 2H, 
CHEHF, CHCHDC(O)), 2.74-2.69 (m, 1H, CHEHF), 2.59 (s, 3H, CH3), 2.46 (d, J = 16.0 
Hz, 1H, CHCHDC(O)); 13C NMR (100.6 MHz, CDCl3) δ 178.2 (C=N), 170.3 (C=O), 
162.2 (ipso-Ar), 159.2 (ipso-Ar), 140.9 (ipso-Ar), 134.6 (ipso-Ar), 131.7 (ipso-Ar), 
129.4 (Ar), 128.8 (Ar), 127.1 (Ar), 126.5 (Ar), 123.3 (Ar), 109.5 (Ar), 62.1 (C), 60.0 
(NCH), 53.5 (OCH3), 38.0 (CH2C(O)), 37.6 (NCH2), 29.1 (CH2), 16.8 (CH3); HRMS 
(ESI) m/z calcd for C20H19N3O2 (M + H)+ 334.1550, found 334.1550 (+0.1 ppm error). 
Lab Book Reference SC4/32 
 
(1'R*,11b'R*)-2-Methyl-2',3',6',7'-tetrahydrospiro[indole-3,1'-pyrido[2,1-
a]isoquinolin]-4'(11b'H)-one syn-262 and (1'R*,11b'S*)-2-methyl-2',3',6',7'-
tetrahydrospiro[indole-3,1'-pyrido[2,1-a]isoquinolin]-4'(11b'H)-one anti-262 
    
syn-262   anti-262 
Using general procedure J, DIPEA (245 µL, 1.41 mmol), T3P (725 mg of a 50% w/v 
solution in THF, 1.14 mmol), imine 37 (100 mg, 0.76 mmol) and acid 251 (184 mg, 
0.91 mmol) in THF (4 mL) for 16 h at rt gave the crude product which contained 4:1 
mixture of syn-262:anti-262 based on analysis by 1H NMR spectroscopy: δ 6.54 (d, 
4H, Ar) and 5.81 (d, 1H, Ar). Purification by flash column chromatography with 
EtOAc-MeOH (98:2) as eluent sequentially furnished a 4.8:1 mixture of syn-
262:anti-262 (96 mg, 40%) and syn-262 (77 mg, 32%). Total combined yield of syn-
262 and anti-262: 173 mg, 72%. The isolated yields suggest a 9.5:1 ratio of syn-
262:anti-262.  
 
Syn-262: Yellow solid, mp 156-158 °C; RF (98:2 EtOAc-MeOH) 0.20; IR (ATR) 2928, 
2867, 1640 (C=O), 1577, 1455, 1432, 1410, 1247, 1047, 731 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.35 (d, J = 7.5 Hz, 1H, Ar), 7.14 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 7.09 (d, J 
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= 7.5 Hz, 1H, Ar), 6.94 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 6.90-6.86 (m, 2H, Ar), 6.82-6.78 
(m, 1H, Ar), 6.54 (d, J = 8.0 Hz, 1H, Ar), 5.32 (s, 1H, NCH), 5.06-5.01 (m, 1H, 
NCHAHB), 2.94-2.74 (m, 4H, CHEHF, NCHAHB, CHCHDC(O)), 2.64-2.60 (m, 1H, 
CHCHDC(O)), 2.62 (s, 3H, CH3), 2.44 (ddd, J = 13.5, 9.5, 8.0 Hz, 1H, CHEHFCH2C(O)), 
1.46 (dd, J = 13.5, 5.0, 5.0 Hz, 1H, CHEHFCH2C(O)); 13C NMR (100.6 MHz, CDCl3) δ 
183.0 (C=N), 169.3 (C=O), 154.2 (ipso-Ar), 139.1 (ipso-Ar), 135.7 (ipso-Ar), 132.4 
(ipso-Ar), 128.7 (Ar), 128.3 (Ar), 126.9 (Ar), 126.0 (Ar), 125.0 (Ar), 123.6 (Ar), 123.0 
(Ar), 120.3 (Ar), 61.8 (C), 60.4 (NCH), 39.7 (NCH2), 29.2 (CH2C(O), CH2), 28.0 
(CH2CH2C(O)), 17.1 (CH3); HRMS (ESI) m/z calcd for C21H20N2O (M + H)+ 317.1648 
found 317.1646 (+1.1 ppm error).  
 
Diagnostic peaks for anti-262: 1H NMR (400 MHz, CDCl3) δ 5.81 (d, J = 8.0 Hz, 1H, 
Ar), 5.40 (s, 1H, NCH), 1.97 (s, 1H, CH3) HRMS (ESI) m/z calcd for C21H20N2O (M + 
H)+ 317.1648, found 317.1645 (+0.8 ppm error).  
Lab Book Reference SC3/78 
 
(1'R*,10b'S*)-2-Phenyl-5',6'-dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-
a]isoquinolin]-3'(10b'H)-one anti-264 and (1'R*,10b'R*)-2-phenyl-5',6'-dihydro-
2'H-spiro[indole-3,1'-pyrrolo[2,1-a]isoquinolin]-3'(10b'H)-one syn-264 
    
 anti-264    syn-264 
Using general procedure J, DIPEA (132 µL, 0.76 mmol), T3P (394 mg of a 50% w/v 
solution in THF, 0.62 mmol), imine 37 (53 mg, 0.41 mmol) and acid 263 (125 mg, 0.50 
mmol) in THF (2 mL) for 16 h at rt gave the crude product which contained 8:1 
mixture of anti-264:syn-264 based on analysis by 1H NMR spectroscopy: δ 5.40 (s, 
8H, NCH) and 5.77 (s, 1H, NCH). Purification by flash column chromatography with 
EtOAc-hexane (1:1) as eluent sequentially furnished a 1:1.1 mixture of syn-264:anti-
264 (57 mg, 38%) and anti-264 (49 mg, 33%). Total combined yield of syn-264 and 
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anti-264: 106 mg, 71%. The isolated yields suggest a 2.9:1 ratio of syn-264:anti-264. 
Anti-264 was recrystallised from EtOAc and an X-ray crystal structure was obtained. 
CCDC 1436405 contains the supplementary crystallographic data. 
 
Anti-264: Cream solid, mp 201-203 °C; RF (EtOAc) 0.20; IR (ATR) 3062, 2931, 1689 
(C=O), 1522, 1494, 1458, 1420, 1307, 910, 754, 694 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.74 (d, J = 7.5 Hz, 1H, Ar), 7.59 (d, J = 7.0 Hz, 1H, Ar), 7.51 (ddd, J = 7.5, 7.5, 1.0 
Hz, 1H, Ar), 7.45-7.41 (m, 1H, Ar), 7.31-7.27 (m, 1H, Ar), 7.16 (dd, J = 8.0, 8.0 Hz, 
1H, Ar), 7.09-7.06 (m, 2H, Ar), 6.99 (dd, J = 7.5, 7.5 Hz, 1H, Ar), 6.87 (dd, J = 7.5, 7.5 
Hz, 1H, Ar), 6.71 (d, J = 7.5 Hz, 1H, Ar), 5.98 (d, J = 8.0 Hz, 1H, Ar), 5.40 (s, 1H, 
NCH), 4.36-4.31 (m, 1H, NCHAHB), 3.30 (dd, J = 17.5, 1.0 Hz, 1H, CHCHDC(O)), 3.21 
(d, J = 17.5 Hz, 1H, CHCHDC(O)), 2.91 (ddd, J = 13.0, 13.0 Hz, 3.0 Hz, 1H, NCHAHB), 
2.36 (dd, J = 16.0, 3.0 Hz, 1H, CHEHF), 1.80 (ddd, J = 16.5, 13.0, 6.0 Hz, 1H, CHEHF); 
13C NMR (100.6 MHz, CDCl3) δ 181.0 (C=N), 170.7 (C=O), 154.4 (ipso-Ar), 141.5 
(ipso-Ar), 134.7 (ipso-Ar), 134.1 (ipso-Ar), 131.6 (ipso-Ar), 130.1 (Ar), 129.3 (Ar), 
128.5 (Ar), 127.9 (Ar), 127.5 (Ar), 127.4 (Ar), 127.0 (Ar), 126.7 (Ar), 123.6 (Ar), 121.6 
(Ar), 121.4 (Ar), 62.8 (C), 62.7 (NCH), 40.9 (CH2C(O)), 37.0 (NCH2), 27.6 (CH2); 
HRMS (ESI) m/z calcd for C25H20N2O (M + H)+ 365.1648, found 365.1646 (+0.6 ppm 
error).  
 
Diagnostic signals for syn-264: 1H NMR (400 MHz, CDCl3) δ 6.23 (d, J = 8.0 Hz, 1H, 
Ar), 5.77 (s, 1H, NCH), 4.68-4.64 (m, 1H, NCH). 
Lab Book Reference: SC4/48 
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(1'R*,10b'R*)-5',6'-Dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-a]isoquinolin]-
3'(10b'H)-one syn-267 and (1'R*,10b'S*)-5',6'-dihydro-2'H-spiro[indole-3,1'-
pyrrolo[2,1-a]isoquinolin]-3'(10b'H)-one anti-267 
    
        syn-267     anti-267 
Using general procedure J, DIPEA (489 µL, 2.81 mmol), T3P (1.45 g of a 50% w/v 
solution in THF, 2.28 mmol), imine 37 (200 mg, 1.52 mmol) and 3-indole acetic acid 
(318 mg, 1.82 mmol) in THF (8 mL) for 16 h at rt gave the crude product which 
contained 11:1 mixture of syn-267:anti-267 based on analysis by 1H NMR 
spectroscopy: δ 6.44 (d, 11H, Ar) and 5.92 (d, 1H, Ar). Purification by flash column 
chromatography with EtOAc as eluent sequentially furnished a mixture of anti-267 
and a minor contaminant (18 mg, 8%) and syn-267 (160 mg, 73%). Total combined 
yield of syn-267 and anti-267: 178 mg, 81%. The isolated yields suggest a 8.9:1 ratio 
of syn-267:anti-267. Syn-267 was recrystallised from EtOAc and an X-ray crystal 
structure was obtained. CCDC 1506360 contains the supplementary crystallographic 
data. 
 
Syn-267: Pale yellow solid, mp 155-158 °C; RF (EtOAc) 0.20; IR (ATR) 3026, 2925, 
1687 (C=O), 1608, 1458, 1431, 1415, 1306, 923, 768, 730 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.42 (s, 1H, N=CH), 7.52 (d, J = 8.0 Hz, 1H, Ar), 7.18 (ddd, J = 7.5, 7.5, 1.5 
Hz, 1H, Ar), 7.01-6.92 (m, 4H, Ar), 6.81-6.77 (m, 1H, Ar), 6.44 (d, J = 8.0 Hz, 1H, Ar), 
5.50 (s, 1H, NCH), 4.58-4.54 (m, 1H, NCHAHB), 3.32 (dd, J = 16.5, 1.5 Hz, 1H, 
CHCHDC(O)), 3.14-2.99 (m, 2H, NCHAHB, CHEHF), 2.84-2.79 (m, 1H, CHEHF), 2.43 
(d, J = 16.5 Hz, 1H, CHCHDC(O)); 13C NMR (100.6 MHz, CDCl3) δ 173.2 (C=N), 170.0 
(C=O), 154.6 (ipso-Ar), 139.3 (ipso-Ar), 133.3 (ipso-Ar), 131.8 (ipso-Ar), 129.1 (Ar), 
128.6 (Ar), 127.2 (Ar), 126.7 (Ar), 126.6 (Ar), 123.7 (Ar), 121.4 (Ar), 121.2 (Ar), 63.3 
(C), 58.7 (NCH), 37.9 (CH2C(O)), 37.4 (NCH2), 29.1 (CH2);  HRMS (ESI) m/z calcd for 
C19H16N2O (M + H)+ 289.1335, found 289.1333 (+0.9 ppm error).  
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Anti-267: Yellow oil, RF (EtOAc) 0.35; 1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H, 
N=CH), 7.68 (d, J = 7.5 Hz, 1H, Ar), 7.61 (d, J = 7.0 Hz, 1H, Ar), 7.52-7.43 (m, 2H, 
Ar), 7.12-7.10 (m, 2H, Ar), 6.85-6.81 (m, 1H, Ar), 5.92 (d, J = 7.5 Hz, 1H, Ar), 5.33 (s, 
1H, NCH), 4.60-4.53 (m, 1H, NCHAHB), 3.13-2.99 (m, 3H, NCHAHB, CHEHF, 
CHCHDC(O)), 2.89-2.81 (m, 1H, CHEHF), 2.61 (d, J = 17.0 Hz, 1H, CHCHDC(O)); 
HRMS (ESI) m/z calcd for C19H16N2O (M + H)+ 289.1335, found 289.1340 (−1.5 ppm 
error).  
Lab Book Reference SC5/77 
 
(1'R*,10b'R*)-Ethyl 2,4-dimethyl-3'-oxo-3',5',6',10b'-tetrahydro-2'H-spiro[pyrrole-
3,1'-pyrrolo[2,1-a]isoquinoline]-5-carboxylate and (1'R*,10b'S*)-ethyl 2,4-
dimethyl-3'-oxo-3',5',6',10b'-tetrahydro-2'H-spiro[pyrrole-3,1'-pyrrolo[2,1-
a]isoquinoline]-5-carboxylate 279 
   
279  
Using general procedure J, DIPEA (141 µL, 0.81 mmol), T3P (419 mg of a 50% w/v 
solution in THF, 0.66 mmol), imine 37 (47 mg, 0.44 mmol) and acid 278 (120 mg, 0.53 
mmol) in THF (3 mL) for 1 h at 70 °C gave the crude product which contained a 3.8:1 
mixture of diastereoisomers 279-A and 279-B based on analysis by 1H NMR 
spectroscopy: δ 5.15 (s, 3.8H, NCH) and 5.05 (s, 1H, NCH). Purification by flash 
column chromatography with EtOAc-MeOH (100:0 then 95:5) as eluent furnished 
279-A (55 mg, 37%) and 279-B (7 mg, 4%). Total yield of 279-A and 279-B: 62 mg, 
41%. The isolated yields suggest a 7.9:1 ratio of 279-A and 279-B. 
 
279-A: Yellow oil, Rf  (9.5:0.5 EtOAc/MeOH) 0.20; IR (ATR) 3301, 2980, 2930, 
1655, 1435, 1270, 1213, 1174, 1092, 910, 728 cm−1; 1H NMR (400 MHz, CDCl3) δ 
7.18–7.10 (m, 2H, Ar), 7.07-7.03 (m, 1H, Ar), 6.42 (d, J = 7.5 Hz, 1H, Ar), 5.15 (s, 1H, 
NCH), 4.50–4.45 (m, 1H, NCHAHB), 4.36–4.25 (m, 2H, OCH2), 3.12–2.98 (m, 2H, 
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NCHAHB, CHEHF), 2.93 (d, J = 16.5 Hz, 1H, CHCHDC(O)), 2.86-2.82 (m, 1H, CHEHF), 
2.49 (s, 3H, CH3), 2.35 (dd, J = 16.5, 2.0 Hz, 1H, CHCHDC(O)), 1.79 (s, 3H, CH3), 1.33 
(t, J = 7.0 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3) δ 180.1 (C=N), 169.5 (C=O), 
163.1 (C=O), 151.3 (ipso-Ar), 140.1 (ipso-Ar), 133.1 (ipso-Ar), 131.5 (ipso-Ar), 
129.2 (Ar), 127.8 (Ar), 127.4 (Ar), 123.8 (Ar), 67.4 (C), 60.8 (OCH2), 59.2 (NCH), 
37.6 (C(O)CH2), 37.4 (NCH2), 28.3 (CH2), 16.2 (CH3), 14.3 (CH3), 11.1 (CH3); 
HRMS (ESI) m/z calcd for C20H22N2O3 [M + H]+ 339.1703, found 339.1688 (+4.4 ppm 
error). 
 
279-B: Yellow oil, RF  (9.5:0.5 EtOAc/MeOH) 0.30; IR (ATR) 3304, 2927, 1660, 
1633, 1436, 1269, 1208, 1174, 1088, 1025, 919, 773, 729 cm−1; 1H NMR (400 MHz, 
CDCl3) δ 7.19–7.12 (m, 2H, Ar), 7.10–7.06 (m, 1H, Ar), 6.47 (d, J = 7.5 Hz, 1H, Ar), 
5.05 (s, 1H, NCH), 4.51–4.36 (m, 3H, OCH2, NCHAHB), 3.14–2.99 (m, 2H, NCHAHB, 
CHEHF), 2.91–2.79 (m, 1H, CHEHF), 2.86 (d, J = 16.5 Hz, 1H, CHCHDC(O)), 2.47 (s, 
3H, CH3), 2.29 (d, J = 16.5 Hz, 1H, CHCHDC(O)), 1.78 (s, 3H, CH3), 1.42 (t, J = 7.0 Hz, 
3H, CH3); 13C NMR (100 MHz, CDCl3) δ 182.3 (C=N), 169.5 (C=O), 163.2 (C=O), 
147.7 (ipso-Ar), 141.0 (ipso-Ar), 133.1 (ipso-Ar), 132.0 (ipso-Ar), 129.4 (Ar), 127.9 
(Ar), 127.8 (Ar), 123.4 (Ar), 67.7 (C), 61.1 (OCH2), 57.9 (NCH), 37.3 (C(O)CH2), 
36.9 (NCH2), 28.3 (CH2), 17.2 (CH3), 14.3 (CH3), 11.2 (CH3); HRMS (ESI) m/z 
calcd for C20H22N2O3 [M + H]+ 339.1703, found 339.1698 (+1.5 ppm error).  
Lab Book Reference: SC4/46 
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(1'R*,10b'R*)-8',9'-Dimethoxy-2-methyl-5',6'-dihydro-2'H-spiro[indole-3,1'-
pyrrolo[2,1-a]isoquinolin]-3'(10b'H)-one syn-284 and (1'R*,10b'S*)-8',9'-
dimethoxy-2-methyl-5',6'-dihydro-2'H-spiro[indole-3,1'-pyrrolo[2,1-a]isoquinolin]-
3'(10b'H)-one anti-284 
     
syn-284    anti-284 
Using general procedure J, DIPEA (245 µL, 1.41 mmol), T3P (725 mg of a 50% w/v 
solution in THF, 1.14 mmol), 6,7-dimethoxy-3,4-dihydroisoquinoline 283 (145 mg, 0.76 
mmol) and 2-(2-methyl-1H-indol-3-yl)acetic acid 212 (172 mg, 0.91 mmol) in THF (4 
mL) for 16 h at rt gave the crude product which contained 3:1 mixture of syn-284:anti-
284 based on analysis by 1H NMR spectroscopy: δ 6.43 (s, 3H, Ar) and 6.54 (s, 1H, 
Ar). Purification by flash column chromatography with EtOAc-MeOH (98:2) as 
eluent sequentially furnished anti-284 (44 mg, 16%), a 1:3 mixture of anti-284:syn-
284 (15 mg,  5%) and syn-284 (143 mg, 52%). Total combined yield of syn-284 and 
anti-284: 202 mg, 73%. The isolated yields suggest a 3.2:1 ratio of syn-284:anti-284. 
 
Syn-284: Yellow solid, mp 163-165 °C; RF (EtOAc) 0.15; IR (ATR) 2933, 2835, 1693, 
1518, 1457, 1256, 1124, 770, 730 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 7.5 
Hz, 1H, Ar), 7.17-7.13 (m, 1H, Ar), 6.94-6.87 (m, 2H, Ar), 6.43 (s, 1H, Ar), 5.72 (s, 1H, 
Ar), 5.21 (s, 1H, NCH), 4.53 (dd, J = 13.5, 5.0 Hz, 1H, NCHAHB), 3.73 (s, 3H, OCH3), 
3.48 (s, 3H, OCH3), 3.12-3.08 (m, 2H, CHCHDC(O), NCHAHB), 2.95 (ddd, J = 13.5, 
13.5, 5.0 Hz, 1H, CHEHF), 2.74-2.69 (m, 1H, CHEHF), 2.62 (s, 3H, CH3), 2.47 (d, J = 
16.5 Hz, 1H, CHCHDC(O)); 13C NMR (100.6 MHz, CDCl3) δ 181.0 (C=N), 170.4 
(C=O), 153.8 (ipso-Ar), 147.7 (ipso-Ar), 147.6 (ipso-Ar), 140.5 (ipso-Ar), 128.6 (Ar), 
125.8 (Ar), 125.5 (ipso-Ar), 124.0 (ipso-Ar), 121.4 (Ar), 120.1 (Ar), 111.1 (Ar), 105.9 
(Ar), 63.1 (C), 60.2 (NCH), 55.6 (OCH3 x 2), 39.8 (CH2C(O)), 37.5 (NCH2), 28.3 
(CH2), 16.4 (CH3); HRMS (ESI) m/z calcd for C22H22N2O3 (M + H)+ 363.1703, found 
363.1694 (+2.5 ppm error).  
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Anti-284: Yellow oil, RF (EtOAc) 0.25; IR (ATR) 2932, 2853, 1692 (C=O), 1518, 1457, 
1433, 1256, 1027, 800 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.58-7.53 (m, 2H, Ar), 7.43 
(ddd, J = 7.5, 7.5, 1.5 Hz, 1H, Ar), 7.37 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.54 (s, 1H, 
Ar), 5.34 (s, 1H, Ar), 5.27 (s, 1H, NCH), 4.56-4.51 (m, 1H, NCHAHB), 3.80 (s, 3H, 
OCH3), 3.24 (s, 3H, OCH3), 3.13-2.91 (m, 3H, CHCHDC(O), NCHAHB, CHEHF), 2.79-
2.74 (m, 1H, CHEHF), 2.59 (d, J = 17.0 Hz, 1H, CHCHDC(O)), 1.90 (s, 3H, CH3); 13C 
NMR (100.6 MHz, CDCl3) δ 182.9 (C=N), 170.1 (C=O), 155.0 (ipso-Ar), 148.3 (ipso-
Ar), 147.3 (ipso-Ar), 140.0 (ipso-Ar), 129.2 (Ar), 126.3 (Ar), 124.9 (ipso-Ar), 123.5 
(ipso-Ar), 121.8 (Ar), 120.4 (Ar), 111.3 (Ar), 105.7 (Ar), 61.9 (C), 61.8 (NCH), 55.8 
(OCH3), 55.0 (OCH3), 39.7 (CH2C(O)), 37.1 (NCH2), 27.9 (CH2), 17.4 (CH3); HRMS 
(ESI) m/z calcd for C22H22N2O3 (M + H)+ 363.1703, found 363.1688 (+4.3 ppm error). 
Lab Book Reference SC3/57 
 
(1'R*,10b'S*)-7',10'-Dibromo-8',9'-dimethoxy-2-methyl-5',6'-dihydro-2'H-
spiro[indole-3,1'-pyrrolo[2,1-a]isoquinolin]-3'(10b'H)-one syn-285 and 
(1'R*,10b'R*)-7',10'-dibromo-8',9'-dimethoxy-2-methyl-5',6'-dihydro-2'H-
spiro[indole-3,1'-pyrrolo[2,1-a]isoquinolin]-3'(10b'H)-one anti-285 
   
syn-285    anti-285 
Using general procedure J, DIPEA (193 µL, 1.11 mmol), T3P (572 mg of a 50% w/v 
solution in THF, 0.90 mmol), 5,8-dibromo-6,7-dimethoxy-3,4-dihydroisoquinoline (210 
mg, 0.60 mmol) and 2-methyl-3-indole acetic acid 212 (136 mg, 0.72 mmol) in THF 
(3.2 mL) for 1 h at 70 °C gave the crude product which contained 9:1 mixture of syn-
285:anti-285 based on analysis by 1H NMR spectroscopy: δ 5.47 (s, 9H, NCH) and 
5.63 (s, 1H, NCH). Purification by flash column chromatography with EtOAc as 
eluent sequentially furnished anti-285 (27 mg, 8%) and syn-285 (222 mg, 71%). 
Total combined yield of syn-285 and anti-285: 249 mg, 79%. The isolated yields 
suggest a 8.2:1 ratio of syn-214:anti-214. 
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Syn-285: Yellow solid, mp 156-158 °C; RF (EtOAc) 0.10; IR (ATR) 2936, 1693 (C=O), 
1579, 1526, 1456, 1401, 1295, 1114, 1023, 756 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.38 (d, J = 7.5 Hz, 1H, Ar), 7.11 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.77 (dd, J = 7.5, 
7.5 Hz, 1H, Ar), 6.36 (d, J = 7.5, 7.5 Hz, 1H, Ar), 5.47 (s, 1H, NCH), 4.61-4.51 (m, 1H, 
NCHAHB), 3.73 (s, 3H, OCH3), 3.41 (s, 3H, OCH3), 3.01-2.84 (m, 4H, CHCHDC(O), 
NCHAHB, CHEHF), 2.60 (s, 3H, CH3), 2.36 (d, J = 17.5 Hz, 1H, CHCHDC(O)); 13C NMR 
(100.6 MHz, CDCl3) δ 183.2 (C=N), 170.9 (C=O), 154.4 (ipso-Ar), 149.9 (ipso-Ar), 
149.5 (ipso-Ar), 140.3 (ipso-Ar), 133.6 (ipso-Ar), 131.1 (ipso-Ar), 128.1 (Ar), 124.9 
(Ar), 121.3 (Ar), 120.2 (Ar), 119.9 (ipso-Ar), 117.8 (ipso-Ar), 61.9 (C), 61.8 (NCH), 
60.7 (OCH3), 60.6 (OCH3), 40.0 (CH2C(O)), 37.7 (NCH2), 30.9 (CH2), 16.5 (CH3); 
HRMS (ESI) m/z calcd for C22H2079Br2N2O3 (M + H)+ 518.9913, found 518.9937 (−4.6 
ppm error). 
 
Anti-285: Yellow solid, mp 149-151 °C; RF (EtOAc) 0.35; IR (ATR) 2927, 2854, 1698 
(C=O), 1576, 1459, 1408, 1293, 1025, 979, 772 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.53-7.51 (m, 1H, Ar), 7.46 (d, J = 7.5 Hz, 1H, Ar), 7.35 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, 
Ar), 7.29 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 5.63 (s, 1H, NCH), 4.65-4.57 (m, 1H, 
NCHAHB), 3.87 (s, 3H, OCH3), 3.71 (s, 3H, OCH3), 3.05-2.97 (m, 2H, CHCHDC(O), 
CHEHF), 2.92-2.84 (m, 2H, NCHAHB, CHEHF), 2.59 (d, J = 18.0 Hz, 1H, CHCHDC(O)), 
1.66 (s, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 180.5 (C=N), 170.7 (C=O), 154.3 
(ipso-Ar), 150.4 (ipso-Ar), 150.1 (ipso-Ar), 144.4 (ipso-Ar), 134.0 (ipso-Ar), 131.3 
(ipso-Ar), 128.6 (Ar), 126.2 (Ar), 121.5 (Ar), 120.4 (Ar), 120.2 (ipso-Ar), 117.1 (ipso-
Ar), 63.4 (NCH), 61.8 (C), 60.9 (OCH3), 60.7 (OCH3), 40.8 (CH2C(O)), 37.4 (NCH2), 
31.0 (CH2), 16.7 (CH3); HRMS (ESI) m/z calcd for C22H2079Br2N2O3 (M + H)+ 
518.9913, found 518.9928 (−2.7 ppm error).  
Lab Book Reference SC4/34 
 
 226 
(1'R*,8a'R*)-8',8'-Dibenzyl-2-methyl-6',7',8',8a'-tetrahydro-2'H-spiro[indole-3,1'-
indolizin]-3'(5'H)-one syn-291 and (1'R*,8a'S*)-8',8'-dibenzyl-2-methyl-6',7',8',8a'-
tetrahydro-2'H-spiro[indole-3,1'-indolizin]-3'(5'H)-one anti-291 
    
syn-291    anti-291 
Using general procedure J, DIPEA (74 µL, 0.43 mmol), T3P (219 mg of a 50% w/v 
solution in THF, 0.35 mmol), imine 290 (60 mg, 0.23 mmol) and 2-methyl-3-indole 
acetic acid 212 (53 mg, 0.28 mmol) in toluene (1 mL) for 18 h at 90 °C gave the crude 
product which contained 3:1 mixture of syn-291:anti-291 based on analysis by 1H 
NMR spectroscopy: δ 6.33-6.31 (m, 6H, Ar) and 6.40 (d, 2H, Ar). Purification by flash 
column chromatography with EtOAc-Et2O (10:90 then 20:80 then 50:50) as eluent 
sequentially furnished anti-291 (26 mg, 26%) and syn-291 (63 mg, 63%). Total 
combined yield of syn-291 and anti-291: 89 mg, 89%. Syn-291 was recrystallised from 
EtOAc to obtain an X-ray crystal structure. CCDC 1436396 contains the supplementary 
crystallographic data. The isolated yields suggest a 2.4:1 ratio of syn-291:anti-291. 
 
Syn-291: Brown solid, mp 225-227 °C; RF (EtOAc) 0.35; IR (ATR) 3028, 2938, 1683, 
1589, 1454, 1422, 1283, 908, 728 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.07 (d, J = 7.5 
Hz, 1H, Ar), 7.71 (d, J = 7.5 Hz, 1H, Ar), 7.48 (dd, J = 7.5, 7.5 Hz, 1H, Ar), 7.40 (dd, J 
= 7.5, 7.5 Hz, 1H, Ar), 7.36-7.28 (m, 3H, Ar), 7.24-7.22 (m, 2H, Ar), 7.09-7.07 (m, 3H, 
Ar), 6.33-6.31 (m, 2H, Ar), 4.41 (dd, J = 13.0, 5.5 Hz, 1H, NCHAHB), 3.47 (d, J = 13.5 
Hz, 1H, CHCHD), 3.35-3.32 (m, 2H, NCHAHB, CHCHD), 3.13 (d, J = 17.5 Hz, 1H, 
CHEHFCO), 2.54 (ddd, J = 13.0, 13.0, 3.5 Hz, 1H, NCH), 2.45 (d, J = 13.5 Hz, 1H, 
CHGHH), 2.33 (d, J = 17.5 Hz, 1H, CHEHFCO), 2.19 (s, 3H, CH3), 2.20-2.10 (m, 1H, 
CH), 2.09 (d, J = 13.5 Hz, 1H, CHGHH), 1.56-1.50 (m, 2H, 2 x CH), 1.24-1.17 (m, 1H, 
CH); 13C NMR (100.6 MHz, CDCl3) δ 185.1 (C=N), 170.6 (C=O), 156.1 (ipso-Ar), 
137.6 (ipso-Ar), 136.6 (ipso-Ar), 135.9 (ipso-Ar), 130.84 (Ar), 130.75 (Ar), 129.5 (Ar), 
128.3 (Ar), 127.8 (Ar), 126.7 (Ar), 126.7 (Ar), 126.2 (Ar), 125.9 (Ar), 125.4 (Ar), 121.2 
(Ar), 64.8 (NCH), 60.0 (C), 43.3 (C), 40.4 (NCH2), 40.0 (CH2Ar), 38.7 (CH2C(O)), 34.8 
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(CH2Ar), 31.1 (CH2), 20.2 (CH2), 16.0 (CH3); HRMS (ESI) m/z calcd for C30H30N2O (M 
+ H)+ 435.2431, found 435.2447 (−3.8 ppm error).  
 
Anti-291: Yellow oil, RF (EtOAc) 0.50; IR (ATR) 3029, 2932, 1686 (C=O), 1601, 1556, 
1454, 1441, 1265, 732, 701 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 7.5 Hz, 1H, 
Ar), 7.43 (dd, J = 7.5, 7.5 Hz, 1H, Ar), 7.35-7.20 (m, 7H, Ar), 7.02- 6.98 (m, 1H, Ar), 
6.90 (dd, J = 7.5, 7.5 Hz, 2H, Ar), 6.40 (d, J = 7.5 Hz, 2H, Ar), 4.39 (dd, J = 13.0, 5.0 
Hz, 1H, NCHAHB), 3.77 (s, 1H, NCH), 3.30 (d, J = 13.5 Hz, 1H, CHCHD), 3.00 (d, J = 
13.5 Hz, 1H, CHCHD), 2.93-2.88 (m, 4H, CHEHFCO, CH3), 2.64 (ddd, J = 13.0, 13.0, 
3.5 Hz, 1H, NCHAHB), 2.49 (d, J = 14.0 Hz, 1H, CHGHH), 2.46 (d, J = 14.0 Hz, 1H, 
CHGHH), 2.39 (d, J = 16.5 Hz, 1H, CHEHFCO), 2.19-2.04 (m, 1H, CH), 1.59-1.52 (m, 
2H, 2 x CH), 1.09-1.01 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 180.1 (C=N), 
171.3 (C=O), 152.4 (ipso-Ar), 145.3 (ipso-Ar), 136.8 (ipso-Ar), 135.8 (ipso-Ar), 131.0 
(Ar), 130.8 (Ar), 128.9 (Ar), 128.3 (Ar), 127.6 (Ar), 126.82 (Ar), 126.79 (Ar), 126.2 
(Ar), 120.7 (Ar), 120.4 (Ar), 71.4 (NCH), 61.2 (C), 42.5 (C), 40.9 (CH2Ar), 40.8 
(NCH2), 39.7 (CH2C(O)), 35.7 (CH2Ar), 31.0 (CH2), 21.9 (CH3), 20.0 (CH2); HRMS 
(ESI) m/z calcd for C30H30N2O (M + H)+ 435.2431, found 435.2445 (−3.3 ppm error).  
Lab Book Reference: SC4/88 
 
(2'R*,3R*)-2'-(4-Methoxyphenyl)-1',2-dimethylspiro[indole-3,3'-pyrrolidin]-5'-one 
syn-294 and (2'S*,3R*)-2'-(4-methoxyphenyl)-1',2-dimethylspiro[indole-3,3'-
pyrrolidin]-5'-one anti-294  
   
syn-294    anti-294 
Using general procedure J, DIPEA (245 µL, 1.41 mmol), T3P (725 mg of a 50% w/v 
solution in THF, 1.14 mmol), imine 293 (113 mg, 0.76 mmol) and acid 212 (172 mg, 
0.91 mmol) in THF (4 mL) for 1 h at 70 °C gave the crude product which contained 4:1 
mixture of syn-294:anti-294 based on analysis by 1H NMR spectroscopy: δ 4.40 (s, 
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4H, NCH) and 4.66 (s, 1H, NCH). Purification by flash column chromatography with 
EtOAc as eluent sequentially furnished anti-294 (32 mg, 13%) and syn-294 (141 mg, 
58%). Total combined yield of syn-294 and anti-294: 173 mg, 71%. Syn-294 was 
recrystallised from EtOAc to obtain an X-ray crystal structure. CCDC 1436400 contains 
the supplementary crystallographic data. The isolated yields suggest a 4.4:1 ratio of 
syn-294:anti-294. 
 
Syn-294: Orange solid, mp 166-168 °C; RF (EtOAc) 0.20; IR (ATR) 2910, 1682 (C=O), 
1608, 1583, 1511, 1455, 1248, 1171, 1023, 843, 774 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.42 (d, J = 7.5 Hz, 1H, Ar), 7.18 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.82-6.74 (m, 
5H, Ar), 6.03 (d, J = 7.5 Hz, 1H, Ar), 4.40 (s, 1H, NCH), 3.78 (s, 3H, OCH3), 2.97-2.92 
(m, 4H, NCH3, CHAHBC(O)), 2.44 (d, J = 17.0 Hz, 1H, CHAHBC(O)), 2.38 (s, 3H, CH3); 
13C NMR (100.6 MHz, CDCl3) δ 183.3 (C=N), 173.1 (C=O), 159.7 (ipso-Ar), 154.4 
(ipso-Ar), 137.1 (ipso-Ar), 128.4 (Ar), 128.1 (Ar), 127.7 (ipso-Ar), 125.1 (Ar), 123.8 
(Ar), 119.7 (Ar), 114.0 (Ar), 67.0 (NCH), 61.0 (C), 55.3 (OCH3), 36.8 (CH2C(O)), 29.0 
(NCH3), 16.1 (CH3); HRMS (ESI) m/z calcd for C20H20N2O2 (M + H)+ 321.1598, found 
321.1589 (+2.6 ppm error).  
 
Anti-294: Orange oil, RF (EtOAc) 0.40; IR (ATR) 2926, 1694 (C=O), 1612, 1573, 1513, 
1459, 1396, 1250, 1176, 1031, 732 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 7.5 
Hz, 1H, Ar), 7.42-7.36 (m, 2H, Ar), 7.29-7.25 (m, 1H, Ar), 6.89-6.84 (m, 4H, Ar), 4.66 
(s, 1H, NCH), 3.80 (s, 3H, OCH3), 2.99-2.95 (m, 4H, NCH3, CHAHBC(O)), 2.52 (d, J = 
16.5 Hz, 1H, CHAHBC(O)), 1.62 (s, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 181.4 
(C=N), 173.3 (C=O), 160.0 (ipso-Ar), 143.8 (ipso-Ar), 128.8 (Ar), 128.2 (ipso-Ar), 
127.4 (Ar), 127.1 (ipso-Ar), 126.3 (Ar), 120.4 (Ar), 120.2 (Ar), 114.5 (Ar), 70.4 (NCH), 
61.8 (C), 55.3 (OCH3), 36.8 (CH2C(O)), 29.2 (NCH3), 17.7 (CH3); HRMS (ESI) m/z 
calcd for C20H20N2O2 (M + H)+ 321.1598, found 321.1594 (+1.0 ppm error). 
Lab Book Reference: SC4/53 
 
 229 
(2'R*,3R*)-2'-(4-Methoxyphenyl)-1'-methyl-2-phenylspiro[indole-3,3'-pyrrolidin]-
5'-one syn-295 and (2'S*,3R*)-2'-(4-methoxyphenyl)-1'-methyl-2-
phenylspiro[indole-3,3'-pyrrolidin]-5'-one anti-295 
   
syn-295    anti-295 
Using general procedure J, DIPEA (116 µL, 0.67 mmol), T3P (286 mg of a 50% w/v 
solution in THF, 0.45 mmol), imine 293 (45 mg, 0.30 mmol) acid 263 (90 mg, 0.36 
mmol) in THF (1.5 mL) for 1 h at 70 °C gave the crude product which contained a 
1.8:1 mixture of syn-295:anti-295 based on analysis by 1H NMR spectroscopy: δ 
4.96 (s, 1.8H, NCH) and 4.92 (s, 1H, NCH). Purification by flash column 
chromatography with hexane-EtOAc (1:1) as eluent furnished an inseparable 1:1.2 
mixture of diastereoisomers. Total yield of syn-295 and anti-295: 73 mg, 76%. 
 
Anti-295 and syn-295: Pale brown solid, mp 169-171 °C; RF (1:1 hexane-EtOAc) 0.20; 
IR (ATR) 3060, 2932, 1693, 1612, 1586, 1513, 1458, 1304, 1249, 1176, 1032, 911, 731 
cm-1; 1H NMR (400 MHz, CDCl3) for a 1.2:1 mixture of diastereoisomers δ 7.99-7.97 
(m, 2.4H, Ar), 7.61 (m, 1H, Ar), 7.56-7.48 (m, 7.8H, Ar), 7.46-7.42 (m, 1.2H, Ar), 7.39-
7.34 (m, 2H, Ar), 7.27 (dd, J = 7.5, 7.5 Hz, 2H, Ar), 7.20-7.16 (m, 1.2H, Ar), 6.95-6.91 
(m, 1.2H, Ar), 6.71-6.64 (m, 5.8H, Ar), 6.44-6.40 (m, 2H, Ar), 6.35-6.32 (m, 2H, Ar), 
4.96 (s, 1H, NCH), 4.92 (s, 1.2H, NCH), 3.70 (s, 3.6H, OCH3), 3.64 (s, 3H, OCH3), 3.44 
(d, J = 18.0 Hz, 1H, CHAHBC(O)), 3.23 (d, J = 18.0 Hz, 1.2H, CHAHBC(O)), 3.06 (d, J = 
18.0 Hz, 1H, CHAHBC(O)), 3.05 (d, J = 18.0 Hz, 1.2H, CHAHBC(O)), 2.92 (s, 3H, CH3), 
2.84 (s, 3.6H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 179.6 (C=N), 179.0 (C=N), 174.4 
(C=O), 173.8 (C=O), 159.4 (ipso-Ar), 159.3 (ipso-Ar), 153.6 (ipso-Ar), 153.4 (ipso-Ar), 
140.6 (ipso-Ar), 134.6 (ipso-Ar), 132.4 (ipso-Ar), 131.1 (Ar), 130.3 (Ar), 129.0 (Ar), 
128.96 (Ar), 128.3 (Ar), 128.2 (Ar), 128.1 (Ar), 127.89 (Ar), 127.88 (Ar), 127.4 (Ar), 
127.3 (ipso-Ar), 126.9 (Ar), 125.7 (Ar), 125.4 (ipso-Ar), 123.5 (Ar), 121.1 (Ar), 120.8 
(Ar), 120.7 (Ar), 113.6 (Ar), 113.3 (Ar), 71.8 (NCH), 68.4 (NCH), 61.7 (C), 61.1 (C), 
55.2 (OCH3), 55.1 (OCH3), 39.4 (CH2C(O)), 39.3 (CH2C(O)), 29.7 (CH3), 29.5 (CH3); 
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HRMS (ESI) m/z calcd for C25H22N2O2 (M + H)+ 383.1754, found 383.1743 (+3.0 ppm 
error). 
Lab Book Reference: SC4/61 
 
(1'S*,2S*,10b'R*)-2-Methyl-5',6'-dihydro-2'H-spiro[indoline-3,1'-pyrrolo[2,1-
a]isoquinolin]-3'(10b'H)-one 298 
 
298 
Using general procedure K, NaBH4 (50 mg, 1.32 mmol) and imine syn-214 (100 mg, 
0.33 mmol) in MeOH (5 mL) at reflux for 3.5 h gave the crude product. Purification by 
flash column chromatography using EtOAc-hexane (9:1) as eluent gave spiroindoline 
298 (81 mg, 81%) as a cream solid, mp 229-231 °C; RF (EtOAc) 0.50; IR (ATR) IR 
(ATR) 3318 (NH), 3058, 2924, 1682 (C=O), 1606, 1578, 1459, 1305, 1143, 909, 727 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 7.5 Hz, 1H, Ar), 6.97-6.89 (m, 3H, Ar), 
6.83 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.80-6.78 (m, 1H, Ar), 6.46 (d, J = 8.0 Hz, 1H, 
Ar), 6.43 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 5.18 (s, 1H, NCH), 4.52-4.47 (m, 1H, 
NCHAHB), 4.05 (br s, 1H, NH), 4.01 (q, J = 7.0 Hz, 1H, CHCH3), 2.97-2.81 (m, 3H, 
NCHAHB, CHEHF, CHCHDC(O)), 2.73 (dd, J = 16.5, 1.0 Hz, 1H, CHCHDC(O)), 2.69-
2.65 (m, 1H, CHEHF), 1.64 (d, J = 7.0 Hz, CH3); 13C NMR (100.6 MHz, CDCl3) δ 170.8 
(C=O), 149.6 (ipso-Ar), 134.3 (ipso-Ar), 133.2 (ipso-Ar), 132.9 (ipso-Ar), 128.5 (Ar), 
128.2 (Ar), 126.7 (Ar), 126.4 (Ar), 125.7 (Ar), 122.4 (Ar), 119.2 (Ar), 109.4 (Ar), 62.2 
(NCH), 61.8 (CHCH3), 53.9 (C), 44.8 (CH2C(O)), 37.3 (NCH2), 29.3 (CH2), 15.7 (CH3); 
HRMS (ESI) m/z calcd for C20H20N2O (M + H)+ 305.1648, found 305.1645 (+1.1 ppm 
error). 298 was recrystallised from EtOAc to obtain an X-ray crystal structure. CCDC 
1436401 contains the supplementary crystallographic data. 
Lab Book Reference: SC5/48 
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(1'S*,2S*,10b'R*)-2-Methyl-3',5',6',10b'-tetrahydro-2'H-spiro[indoline-3,1'-
pyrrolo[2,1-a]isoquinoline] 300 
 
300 
Using general procedure L, LiAlH4 (76 mg, 2.00 mmol) and amide 298 (153 mg, 0.50 
mmol) in dry THF (15 mL) under Ar at reflux for 2.5 h gave the crude product. 
Purification by flash column chromatography EtOAc as eluent gave spiroindoline 300 
(110 mg, 75%) as a white solid, mp 141-143 °C; RF (EtOAc) 0.45; IR (ATR) 3356 
(NH), 2981, 2897, 2804, 1604, 1467, 1330, 935, 762, 556 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.48 (d, J = 7.5 Hz, 1H, Ar), 7.02 (dd, J = 7.5, 1.0 Hz, 1H, Ar), 6.96-6.91 (m, 
2H, Ar), 6.89-6.81 (m, 2H, Ar), 6.54 (d, J = 7.5 Hz, 1H, Ar), 6.49 (ddd, J = 7.5, 7.5, 1.0 
Hz, 1H, Ar), 4.02 (q, J = 7.0 Hz, 1H, CHCH3), 3.64 (s, 1H, NCH), 3.30-3.22 (m, 2H, 
NCH), 3.14-3.06 (m, 1H, CH), 2.67 (dd, J = 16.0, 4.0 Hz, 1H, CH), 2.60-2.46 (m, 3H, 2 
x NCH, CH), 1.98-1.92 (m, 1H, CH), 1.50 (d, J = 7.0 Hz, 3H, CHCH3); 13C NMR 
(100.6 MHz, CDCl3) δ 150.0 (ipso-Ar), 136.3 (ipso-Ar), 136.1 (ipso-Ar), 135.3 (ipso-
Ar), 128.1 (Ar), 127.2 (Ar), 127.1 (Ar), 125.5 (Ar), 125.2 (Ar), 125.0 (Ar), 118.1 (Ar), 
108.8 (Ar), 69.4 (NCH), 63.9 (CHCH3), 56.7 (C), 52.2 (NCH2), 49.9 (NCH2), 41.6 
(CH2), 29.2 (CH2), 16.1 (CH3); HRMS (ESI) m/z calcd for C20H22N2 (M + H)+ 
291.1856, found 291.1860 (−1.6 ppm error).  
Lab Book Reference: SC5/37 
 
2-(2-(2-Methyl-1H-indol-3-yl)ethyl)-1,2,3,4-tetrahydroisoquinoline 301 
 
301 
Using general procedure L, LiAlH4 (27 mg, 0.70 mmol) and syn-214 (20 mg, 0.07 
mmol) in dry THF (3 mL) under Ar at reflux for 3.5 h gave the crude product. 
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Purification by flash column chromatography using hexane-EtOAc (1:1) as eluent gave 
indole 301 (9 mg, 42%) as a yellow oil, RF (hexane-EtOAc 1:1) 0.10; 1H NMR (400 
MHz, CDCl3) δ 7.80 (br s, 1H, Ar), 7.55-7.53 (m, 1H, Ar), 7.29-7.26 (m, 2H, Ar), 7.16-
7.05 (m, 5H, Ar), 3.82 (s, 2H, CH2N), 3.06-2.98 (m, 4H, 2 x CH2), 2.93-2.90 (m, 2H, 
CH2), 2.81-2.77 (m, 2H, CH2), 2.41 (s, 3H, CH3); HRMS (ESI) m/z calcd for C19H18N2O 
(M + H)+ 291.1856, found 291.1848 (+1.9 ppm error). 
Lab Book Reference: SC5/4 
 
(1'S*,10b'R*)-5',6'-Dihydro-2'H-spiro[indoline-3,1'-pyrrolo[2,1-a]isoquinolin]-
3'(10b'H)-one 299 
 
299 
Using general procedure K, NaBH4 (52 mg, 1.39 mmol) and imine syn-267 (100 mg, 
0.35 mmol) in MeOH (5 mL) at reflux for 3.5 h gave the crude product. Purification by 
flash column chromatography using EtOAc as eluent gave spiroindoline 299 (87 mg, 
87%) as a cream solid, mp 211-213 °C; RF (EtOAc) 0.30; IR (ATR) 3330 (NH), 2924, 
2855, 1675 (C=O), 1606, 1487, 1459, 1415, 1306, 909, 729 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.33-7.31 (m, 1H, Ar), 7.01-6.93 (m, 3H, Ar), 6.85 (ddd, J = 7.5, 7.5, 1.0 Hz, 
1H, Ar), 6.77-6.75 (m, 1H, Ar), 6.47 (d, J = 8.0 Hz, 1H, Ar), 6.44-6.40 (m, 1H, Ar), 
5.04 (s, 1H, NCH), 4.51-4.47 (m, 1H, NCHAHB), 4.09 (d, J = 10.0 Hz, 1H, NHCHAHB), 
3.35 (d, J = 10.0 Hz, 1H, NHCHAHB), 2.98-2.84 (m, 4H, NCHAHB, CH, CHAHBC(O)), 
2.71-2.67 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 171.3 (C=O), 150.6 (ipso-Ar), 
134.1 (ipso-Ar), 132.9 (ipso-Ar), 131.5 (ipso-Ar), 128.7 (Ar), 128.4 (Ar), 126.7 (Ar), 
126.0 (Ar), 125.6 (Ar), 122.4 (Ar), 118.8 (Ar), 109.5 (Ar), 68.2 (NCH), 57.6 (NHCH2), 
52.4 (C), 46.2 (CH2C(O)), 35.1 (NCH2), 29.2 (CH2); HRMS (ESI) m/z calcd for 
C19H18N2O (M + H)+ 291.1492, found 291.1486 (+1.9 ppm error).  
Lab Book Reference: SC5/49 
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(1'S*,10b'R*)-3',5',6',10b'-Tetrahydro-2'H-spiro[indoline-3,1'-pyrrolo[2,1-
a]isoquinoline] 303 
 
303 
Using general procedure L, LiAlH4 (78 mg, 2.04 mmol) and amide 299 (148 mg, 0.51 
mmol) in dry THF (15 mL) under Ar at reflux for 2.5 h gave the crude product. 
Purification by flash column chromatography EtOAc as eluent gave spiroindoline 303 
(94 mg, 67%) as a yellow oil, RF (EtOAc) 0.10; IR (ATR) 3291 (NH), 2923, 2790, 1638, 
1604, 1577, 1484, 1264, 1026, 731, 701 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.04 (d, J 
= 8.0 Hz, 1H, Ar), 7.00-6.97 (m, 2H, Ar), 6.90 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.83 
(dd, J = 7.5, 7.5 Hz, 1H, Ar), 6.79-6.77 (m, 1H, Ar), 6.60 (d, J = 8.0 Hz, 1H, Ar), 6.47 
(ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 4.01 (d, J = 9.5 Hz, 1H, NHCHAHB), 3.71 (d, J = 9.5 
Hz, 1H, NHCHAHB), 3.54 (s, 1H, NCH), 3.31-3.12 (m, 3H, 2 x NCH, CH), 2.79-2.75 
(m, 1H, CH), 2.65-2.56 (m, 2H, NCH), 2.29 (ddd, J = 13.0, 9.5, 8.0 Hz, 1H, CH), 2.17 
(ddd, J = 13.0, 8.0, 2.5 Hz, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 150.9 (ipso-Ar), 
135.7 (ipso-Ar), 135.4 (ipso-Ar), 135.0 (ipso-Ar), 128.4 (Ar), 127.2 (Ar), 126.0 (Ar), 
125.7 (Ar), 125.2 (Ar), 125.0 (Ar), 118.8 (Ar), 109.1 (Ar), 73.1 (NCH), 60.7 (NHCH2), 
55.0 (C), 52.7 (NCH2), 49.4 (NCH2), 42.7 (CH2), 29.4 (CH2); HRMS (ESI) m/z calcd for 
C19H20N2 (M + H)+ 277.1699, found 277.1700 (−0.2 ppm error).  
Lab Book Reference: SC5/38 
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(1'S*,2R*,10b'R*)-2-Methyl-5',6'-dihydro-2'H-spiro[indoline-3,1'-pyrrolo[2,1-
a]isoquinolin]-3'(10b'H)-one 304 
 
304 
MeMgBr (3M in Et2O, 0.59 mL, 1.77 mmol) was added to a stirred solution of 
spiroindolenine syn-267 (170 mg, 0.59 mmol) in dry THF (7 mL) at 0 °C under Ar. The 
resulting solution was stirred at 0 °C for 6 h, then quenched with NH4Cl (10 mL) and 
diluted with CH2Cl2 (10 mL). The two layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 10 mL). The combined organics were dried (MgSO4), 
filtered and evaporated under reduced pressure to give the crude product. Purification by 
flash column chromatography using EtOAc-hexane (9:1) as eluent gave the 
spiroindoline 304 (112 mg, 62%) as an orange solid, mp 141-143 °C; RF (EtOAc) 0.45; 
IR (ATR) 3319 (NH), 3051, 2926, 1676 (C=O), 1606, 1459, 1415, 1305, 1264, 730, 701 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.38-7.36 (m, 1H, Ar), 7.02-6.95 (m, 2H, Ar), 6.93-
6.91 (m, 1H, Ar), 6.83 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.76 (d, J = 7.5 Hz, 1H, Ar), 
6.43-6.39 (m, 2H, Ar), 4.94 (s, 1H, NCH), 4.49-4.45 (m, 1H, NCHAHB), 4.32 (q, J = 6.5 
Hz, 1H, CHCH3), 3.05 (dd, J = 16.0, 1.0 Hz, 1H, CHCHDC(O)), 2.96-2.82 (m, 2H, 
NCHAHB, CHEHF), 2.71-2.64 (m, 1H, CHEHF), 2.52 (d, J = 16.0 Hz, 1H, CHCHDC(O)), 
1.31 (d, J = 6.5 Hz, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 171.8 (C=O), 148.9 
(ipso-Ar), 134.6 (ipso-Ar), 132.8 (ipso-Ar), 130.7 (ipso-Ar), 128.5 (Ar), 128.3 (Ar), 
126.6 (Ar), 126.2 (Ar), 125.7 (Ar), 122.7 (Ar), 118.4 (Ar), 109.2 (Ar), 67.6 (NCH), 61.3 
(CHCH3), 56.7 (C), 40.4 (CH2C(O)), 37.0 (NCH2), 29.3 (CH2), 19.5 (CH3); HRMS 
(ESI) m/z calcd for C20H20N2O (M + H)+ 305.1648, found 305.1650 (−0.5 ppm error).  
Lab Book Reference: SC5/46 
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(8aR*,8bS*,13cS*,21aR*,21bS*,26cS*)-5,6,8b,9,18,19,21a,21b,22,26c-
Decahydrobenzo[7,8]indolizino[2,1-a]benzo[7,8]indolizino[2,1-d]indolo[3,2-
b]carbazole-8,21(8aH,13cH)-dione 307 
 
307 
LHMDS (1 M in THF, 0.57 mL, 0.57 mmol) was added to a solution of spiroindolenine 
syn-267 (110 mg, 0.38 mmol) in THF (5 mL) at −78 °C under Ar and the resulting 
mixture was stirred at 2.5 h. Sat. NH4Cl(aq) (10 mL) was added and the reaction was 
extracted into Et2O (3 x 10 mL). The combined organics were dried (MgSO4), filtered 
and evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica using hexane-EtOAc (1:1) as eluent gave the dimer 
307 as an orange solid, mp 163-165 °C, RF (1:1 Hex-EtOAc) 0.30; IR (ATR) 3346, 
3051, 2927, 1672 (C=O), 1606, 1459, 1433, 1402, 1305, 1264, 1040, 730 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.58-7.54 (m, 2H, Ar), 7.01-6.97 (m, 4H, Ar), 6.94-6.91 (m, 2H, 
Ar), 6.86-6.82 (m, 2H, Ar), 6.73 (d, J = 7.0 Hz, 2H, Ar), 6.55 (d, J = 8.0 Hz, 2H, Ar), 
6.41-6.38 (m, 2H, Ar), 5.28 (s, 2H, NH), 5.22 (s, 2H, NCH), 4.60-4.56 (m, 2H, NCH), 
4.29 (d, J = 11.5 Hz, 2H, CHCO), 3.04 (ddd, J = 12.5, 12.5, 3.5 Hz, 2H, NCH), 2.91-
2.83 (m, 2H, CH), 2.75-2.70 (m, 2H, CH), 2.55 (d, J = 11.5 Hz, 2H, NHCH); 13C NMR 
(100.6 MHz, CDCl3) δ 172.9 (C=O), 148.9 (ipso-Ar), 133.8 (ipso-Ar), 131.7 (ipso-Ar), 
129.6 (ipso-Ar), 129.1 (Ar), 128.6 (Ar), 127.0 (Ar), 126.2 (Ar), 125.8 (Ar), 122.2 (Ar), 
119.1 (Ar), 110.9 (Ar), 67.8 (NCH), 62.6 (CHCO), 55.4 (C), 51.8 (NHCH), 37.4 
(NCH2), 29.2 (CH2); HRMS (ESI) m/z calcd for C38H32N4O2 (M + H)+ 577.2598, found 
577.2600 (−0.4 ppm error). 307 was recrystallised from EtOAc to obtain an X-ray 
crystal structure. CCDC 1506359 contains the supplementary crystallographic data. 
Lab Book Reference: SC5/44 
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(1'S*,2S*)-2-(1H-Pyrrol-2-yl)-5',6'-dihydro-2'H-spiro[indoline-3,1'-pyrrolo[2,1-
a]isoquinolin]-3'(10b'H)-one 308 
 
308 
A flask was charged with spiroindolenine syn-267 (100 mg, 0.35 mmol) and pyrrole 
(218 µL, 3.15 mmol). AcOH (2.5 mL) was added and the reaction was stirred for 16 h. 
Sat. NaHCO3(aq) (10 mL) and CH2Cl2 (10 mL) were carefully added to the reaction and 
the layers were separated. The aqueous layer was extracted with CH2Cl2 (2 x 10 mL) 
and the combined organics were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica using EtOAc as eluent gave the spirocyclic product 308 (107 mg, 86%) as a 
yellow solid, mp 234-236 °C; RF (EtOAc) 0.25; IR (ATR) 3326 (NH), 3180, 2927, 2851, 
1655 (C=O), 1607, 1484, 1467, 1249, 969, 729 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
10.89 (s, 1H, NH), 7.32 (d, J = 7.5 Hz, 1H, Ar), 7.10-6.98 (m, 3H, Ar), 6.79 (ddd, J = 
7.5, 7.5, 1.0 Hz, 1H, Ar), 6.75-6.73 (m, 1H, Ar), 6.46 (d, J = 7.5 Hz, 1H, Ar), 6.43 (d, J 
= 7.5 Hz, 1H, Ar), 6.26 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.18 (d, J = 2.5 Hz, 1H, NH), 
6.07-6.05 (m, 1H, Ar), 6.03-6.02 (m, 1H, Ar), 5.42 (d, J = 2.5 Hz, 1H, NHCHAr), 5.08 
(s, 1H, NCH), 4.15 (ddd, J = 12.5, 5.0, 2.5 Hz, 1H, NCHAHB, 3.00-2.93 (m, 1H, 
NCHAHB), 2.89-2.74 (m, 2H, CHEHF), 2.31 (d, J = 16.5 Hz, 1H, CHCHDC(O)), 1.88 (d, 
J = 16.5 Hz, 1H, CHCHDC(O)); 13C NMR (100.6 MHz, DMSO-d6) δ 170.1 (C=O), 
150.2 (ipso-Ar), 134.9 (ipso-Ar), 134.0 (ipso-Ar), 131.3 (ipso-Ar), 130.6 (ipso-Ar), 
128.9 (Ar), 127.7 (Ar), 126.3 (Ar), 126.2 (Ar), 125.8 (Ar), 122.3 (Ar), 117.6 (Ar), 117.1 
(Ar), 108.4 (Ar), 107.5 (Ar), 106.3 (Ar), 64.0 (NHCHAr), 63.7 (NCH), 57.1 (C), 43.0 
(CH2C(O)), 36.5 (NCH2), 29.0 (CH2); HRMS (ESI) m/z calcd for C23H21N3O (M + H)+ 
356.1757, found 356.1746 (3.3 ppm error).  
Lab Book Reference: SC5/28 
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5.3.3. Chapter 4 
Ethyl 2-(1H-indol-3-yl)acetate 363 
 
363 
Acid 215 (3.00 g, 17.13 mmol) was added to a stirred solution of EtOH (150 mL) and 
conc. H2SO4(aq) (3 mL) at rt and the resulting solution was heated and stirred at reflux 
for 3 h. The reaction mixture was allowed to cool to room temperature and the solvent 
was evaporated under reduced pressure. The residue was diluted with water (30 mL) and 
taken to pH 10 with 1 M NaOH(aq). The reaction mixture was extracted into CH2Cl2 (3 x 
50 mL) and the combined organics were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the ester 363 (3.41 g, 97%) as a yellow oil, 1H NMR (400 
MHz, CDCl3) δ 8.11 (br s, 1H, NH), 7.64 (d, J = 8.0 Hz, 1H, Ar), 7.35 (d, J = 8.0 Hz, 
1H, Ar), 7.21 (ddd, J = 8.0, 8.0, 1.0 Hz, 1H, Ar), 7.16-7.13 (m, 2H, Ar), 4.18 (q, J = 7.0 
Hz, 2H, OCH2CH3), 3.78 (d, J = 1.0 Hz, 2H, CH2), 1.27 (t, J = 7.0 Hz, 3H, OCH2CH3); 
13C NMR (100.6 MHz, CDCl3) δ 172.1 (C=O), 136.1 (ipso-Ar), 127.2 (ipso-Ar), 123.0 
(Ar), 122.1 (Ar), 119.6 (Ar), 118.9 (Ar), 111.1 (Ar), 108.6 (ipso-Ar), 60.8 (OCH2), 31.4 
(CH2C(O)), 14.2 (CH3); HRMS (ESI) m/z calcd for C12H13NO2 (M + H)+ 204.1019, 
found 204.1022 (−1.5 ppm error). Spectroscopic data consistent with those reported in 
the literature.210 
Lab Book Reference: SC5/67 
 
 
 
 
 
N
H
O
OEt
 238 
Ethyl 2-(2-iodo-1H-indol-3-yl)acetate 364 
 
364 
A solution of iodine (1.25 g, 4.92 mmol) in THF (10 mL) was carefully added to a 
solution of AgOTf (1.64 g, 6.40 mmol) and indole 363 (1.00 g, 4.92 mmol) in THF (24 
mL) at rt. The resulting suspension was stirred at rt for 10 min and sat. Na2S2O3(aq) (10 
mL) was added. The reaction mixture was extracted into EtOAc (3 x 50 mL) and the 
combined organics were dried (MgSO4), filtered and evaporated under reduced pressure 
to give the crude product. Purification by flash column chromatography on silica using 
hexane-EtOAc (8:1 then 6:1) gave the iodinated indole 364 (1.25 g, 77%) as an orange 
oil, RF (6:1 hexane-EtOAc) 0.25; 1H NMR (400 MHz, CDCl3) δ 8.19 (br s, 1H, NH), 
7.56-7.54 (m, 1H, Ar), 7.28-7.25 (m, 1H, Ar), 7.15-7.08 (m, 2H, Ar), 4.17 (q, J = 7.0 
Hz, 2H, OCH2CH3), 3.72 (s, 2H, CH2), 1.27 (t, J = 7.0 Hz, 3H, OCH2CH3); 13C NMR 
(100.6 MHz, CDCl3) δ 171.1 (C=O), 138.7 (ipso-Ar), 127.4 (ipso-Ar), 122.4 (Ar), 120.1 
(Ar), 118.2 (Ar), 115.2 (ipso-Ar), 110.4 (Ar), 79.8 (ipso-Ar), 61.0 (OCH2CH3), 33.1 
(CH2C(O)), 14.2 (CH3). Spectroscopic data consistent with those reported in the 
literature.174 
Lab Book Reference: SC6/9 
 
Ethyl 2-(2-vinyl-1H-indol-3-yl)acetate 366 
 
366 
Vinyl boronic acid pinacol ester 365 (815 µL, 4.81 mmol), LiCl (313 mg, 7.40 mmol) 
and Na2CO3 (980 mg, 9.25 mmol) were added to a stirred solution of indole 364 (1.22 g, 
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3.70 mmol) in a mixture of toluene (8 mL), ethanol (8 mL) and water (5.7 mL) at rt. The 
reaction flask was purged three times with Ar and Pd(PPh3)4 (214 mg, 0.19 mmol) was 
added at rt. The reaction flask was purged again with Ar and the resulting suspension 
was heated and stirred at 80 °C for 18 h. The reaction was allowed to cool and was 
poured into water (50 mL). The reaction mixture was extracted into EtOAc (3 x 100 
mL) and the combined organics were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica using hexane-EtOAc (6:1 then 5:1) as eluent gave the vinyl 
substituted indole 366 (570 mg, 67%) as a yellow oil, RF (6:1 hexane-EtOAc) 0.30; IR 
(ATR) 3341 (NH), 3056, 2980, 2932, 1714 (C=O), 1461, 1368, 1304, 1158, 1027, 736 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.44 (br s, 1H, NH), 7.69-7.66 (m, 1H, Ar), 7.28-
7.22 (m, 2H, Ar), 7.18 (ddd, J = 8.0, 6.5, 1.5 Hz, 1H, Ar), 6.90 (dd, J = 17.5, 11.5 Hz, 
1H, CH=CH2), 5.54 (d, J = 17.5 Hz, 1H, CH=CHtransHcis), 5.31 (d, J = 11.5 Hz, 1H, 
CH=CHtransHcis), 4.22 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.87 (s, 2H, CH2), 1.31 (t, J = 7.0 
Hz, 3H, OCH2CH3); 13C NMR (100.6 MHz, CDCl3) δ 171.8 (C=O), 136.0 (ipso-Ar), 
133.5 (ipso-Ar), 128.4 (ipso-Ar), 125.1 (CH=CH2), 123.0 (Ar), 119.7 (Ar), 119.0 (Ar), 
112.4 (CH=CH2), 110.7 (Ar), 107.7 (ipso-Ar), 60.9 (OCH2CH3), 30.3 (CH2C(O)), 14.1 
(CH3). Spectroscopic data consistent with those reported in the literature.211  
Lab Book Reference: SC6/12 
 
Methyl 2-(1H-indol-3-yl)acetate 367 
 
367 
Acetyl chloride (10 mL, 140.6 mmol) was added to a solution of the indole acid 215 
(3.00 g, 17.13 mmol) in MeOH (150 mL) at rt. The resulting solution was stirred for 20 
h and the volatiles were removed under reduced pressure. Sat. NaHCO3(aq) (200 mL) 
was added to the residue and the mixture was extracted into CH2Cl2 (3 x 100 mL). The 
combined organics were dried (MgSO4), filtered and evaporated under reduced pressure 
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to give the indole ester 367 (3.07 g, 94%) as an orange oil, 1H NMR (400 MHz, CDCl3) 
δ 8.12 (br s, 1H, NH), 7.63 (d, J = 8.0 Hz, 1H, Ar), 7.35 (d, J = 8.0 Hz, 1H, Ar), 7.22 
(ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 7.18-7.13 (m, 2H, Ar), 3.80 (d, J = 1.0 Hz, 2H, CH2), 
3.72 (s, 3H, OCH3); 13C NMR (100.6 MHz, CDCl3) δ 172.5 (C=O), 136.1 (ipso-Ar), 
127.2 (ipso-Ar), 123.0 (Ar), 122.2 (Ar), 119.7 (Ar), 118.8 (Ar), 111.2 (Ar), 108.4 (ipso-
Ar), 52.0 (OCH3), 31.1 (CH2C(O)); HRMS (ESI) m/z calcd for C11H11NO2 (M + Na)+ 
212.0682, found 212.0692 (−4.8 ppm error). Spectroscopic data consistent with those 
reported in the literature.212 
Lab Book Reference: SC7/59 
 
Methyl 2-(2-iodo-1H-indol-3-yl)acetate 368 
 
368 
A solution of iodine (4.03 g, 15.86 mmol) in THF (34 mL) was carefully added to a 
solution of AgOTf (5.93 g, 20.62 mmol) and indole 367 (3.00 g, 15.86 mmol) in THF 
(78 mL) at rt. The resulting suspension was stirred at rt for 15 min and sat. Na2S2O3(aq) 
(100 mL) was added. The reaction mixture was extracted into EtOAc (3 x 100 mL) and 
the combined organics were dried (MgSO4), filtered and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica using hexane-EtOAc (8:1 then 6:1) gave the iodinated indole 368 (4.08 g, 81%) as 
a pale orange oil, RF (6:1 hexane-EtOAc) 0.20; 1H NMR (400 MHz, CDCl3) δ 8.13 (br 
s, 1H, NH), 7.55-7.53 (m, 1H, Ar), 7.31 (m, 1H, Ar), 7.16-7.08 (m, 2H, Ar), 3.74 (s, 2H, 
CH2), 3.70 (s, 3H, OCH3); 13C NMR (100.6 MHz, CDCl3) δ 171.6 (C=O), 138.8 (ipso-
Ar), 127.5 (ipso-Ar), 122.6 (Ar), 120.3 (Ar), 118.3 (Ar), 115.2 (ipso-Ar), 110.5 (Ar), 
79.7 (ipso-Ar), 52.2 (OCH3), 33.0 (CH2); HRMS (ESI) m/z calcd for C11H10INO2 (M + 
Na)+ 337.9648, found 337.9664 (−4.5 ppm error). Spectroscopic data consistent with 
those reported in the literature.213 
Lab Book Reference: SC7/38 
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(E)-Methyl 2-(2-(prop-1-en-1-yl)-1H-indol-3-yl)acetate 370 
 
370 
1-Propenyl boronic acid pinacol ester 369 (1.01 g, 6.00 mmol), LiCl (390 mg, 9.22 
mmol) and Na2CO3 (1.22 g, 11.53 mmol) were added to a stirred solution of indole 368 
(1.45 g, 4.61 mmol) in a mixture of toluene (10 mL), ethanol (10 mL) and water (7 mL) 
at rt. The reaction flask was purged three times with Ar and Pd(PPh3)4 (265 mg, 0.23 
mmol) was added at rt. The reaction flask was purged again with Ar and the resulting 
suspension was heated and stirred at 80 °C for 18 h. The reaction was allowed to cool 
and was poured into water (100 mL). The reaction mixture was extracted into EtOAc (3 
x 200 mL) and the combined organics were dried (MgSO4), filtered and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica using hexane-EtOAc (8:1) as eluent gave the 1-propenyl 
substituted indole 370 (643 mg, 60%) as a yellow solid, mp 100-102 °C (lit.214 115 °C); 
RF (8:1 hexane-EtOAc) 0.20; IR (ATR) 3347 (NH), 3023, 2957, 2913, 1721, 1700, 
1437, 1328, 1210, 1169, 947, 733 cm−1; 1H NMR (400 MHz, CDCl3) δ 8.08 (br s, 1H, 
NH), 7.56 (d, J = 8.0 Hz, 1H, Ar), 7.27 (d, J = 8.0 Hz, 1H, Ar), 7.16 (ddd, J = 7.5, 7.5, 
1.0 Hz, 1H, Ar), 7.10 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H, Ar), 6.54 (dq, J = 16.0, 1.5 Hz, 1H, 
CH=CHCH3), 6.04, (dq, J = 16.0, 6.5 Hz, 1H, CH=CHCH3), 3.77 (s, 2H, CH2), 3.67 (s, 
3H, OCH3), 1.94 (dd, J = 6.5, 1.5 Hz, 3H, CH=CHCH3); 13C NMR (100.6 MHz, CDCl3) 
δ 172.2 (C=O), 135.8 (ipso-Ar), 133.7 (ipso-Ar), 128.7 (ipso-Ar), 125.4 (CH=CHCH3), 
122.6 (Ar), 119.78 (CH=CHCH3), 119.75 (Ar), 118.7 (Ar), 110.4 (Ar), 105.9 (ipso-Ar), 
52.0 (OCH3), 30.1 (CH2), 18.8 (CH=CHCH3); HRMS (ESI) m/z calcd for C14H15NO2 
(M + H)+ 230.1176, found 230.1172 (+1.4 ppm error). Spectroscopic data consistent 
with those reported in the literature.214 
Lab Book Reference: SC7/78 
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(E)-2-(2-(Prop-1-en-1-yl)-1H-indol-3-yl)acetic acid 371 
 
371 
2 M NaOH(aq) (7 mL) was added to a stirred solution of indole ester 370 (320 mg, 1.40 
mmol) in MeOH (14 mL) at rt. The reaction was stirred for 4 h and the solvent was 
evaporated under reduced pressure. The residue was diluted with water (5 mL) and the 
solution was acidified with 6 M HCl(aq) until an orange precipitate was observed. The 
precipitate was filtered to give the acid 371 (288 mg, 95%) as an orange solid, mp 145-
147 °C; IR (ATR) 3424 (NH), 3039, 2913, 2676, 2571, 1695 (C=O), 1460, 1433, 1416, 
1304, 1240, 950, 743 cm−1; 1H NMR (400 MHz, CDCl3) δ 8.05 (br s, 1H, NH), 7.35 
(dd, J = 7.5, 0.5 Hz, 1H, Ar), 7.28-7.26 (m, 1H, Ar), 7.16 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H, 
Ar), 7.09 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H, Ar), 6.51 (dq, J = 16.0, 1.5 Hz, 1H, 
CH=CHCH3), 6.05 (dq, J = 16.0, 6.5 Hz, 1H, CH=CHCH3), 3.77 (s, 2H, CH2), 1.94 (dd, 
J = 6.5, 1.5 Hz, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 177.1 (C=O), 135.8 (ipso-
Ar), 133.9 (ipso-Ar), 128.6 (ipso-Ar), 125.7 (CH=CHCH3), 122.7 (Ar), 119.9 (Ar), 
119.6 (CH=CHCH3), 118.7 (Ar), 110.5 (Ar), 105.2 (ipso-Ar), 29.8 (CH2), 18.8 (CH3); 
HRMS (ESI) m/z calcd for C13H13NO2 (M + H)+ 216.1019, found 216.1025 (−2.6 ppm 
error). 
Lab Book Reference: SC7/83 
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2-(2-Iodo-1H-indol-3-yl)acetic acid 354 
 
354 
2 M NaOH(aq) (2.40 mL) was added to a stirred solution of indole ester 368 (150 mg, 
0.48 mmol) in MeOH (4.8 mL) at rt. The reaction was stirred for 2 h and the solvent was 
evaporated under reduced pressure. The residue was diluted with water (5 mL) and the 
solution was taken to pH 4 by addition of 6 M HCl(aq) until a white precipitate was 
observed. The mixture was extracted into EtOAc (3 x 30 mL) and the combined 
organics dried (MgSO4), filtered were evaporated under reduced pressure to give the 
acid 354 (127 mg, 88%) as an off-white solid, mp 81-85 °C; IR (ATR) 3397 (NH), 
2896, 1691 (C=O), 1446, 1408, 1393, 1227, 1199, 742 cm-1; 1H NMR (400 MHz, 
DMSO-d6) δ 12.27 (br s, 1H, OH), 11.55 (s, 1H, NH), 7.45 (d, J = 8.0 Hz, 1H, Ar), 7.29 
(d, J = 8.0 Hz, 1H, Ar), 7.04 (td, J = 7.5, 7.5, 1.5 Hz, 1H, Ar), 6.97 (td, J = 7.5, 7.5, 1.0 
Hz, 1H, Ar), 3.57 (s, 2H, CH2); 13C NMR (100.6 MHz, DMSO-d6) δ 172.3 (C=O), 
138.6 (ipso-Ar), 127.4 (ipso-Ar), 121.3 (Ar), 119.0 (Ar), 117.9 (Ar), 113.9 (ipso-Ar), 
110.6 (Ar), 82.9 (ipso-Ar), 32.5 (CH2); HRMS (ESI) m/z calcd for C10H8INO2 (M + 
Na)+ 323.9492, found 323.9488 (1.2 ppm error). 
Lab Book Reference: SC7/43 
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3-Allyl-3-ethylpiperidin-2-one 376 
 
376 
Trifluoroacetic acid (10 mL) was added to a stirred solution of Boc-protected lactam 
372 (2.00 g, 7.48 mmol) in CH2Cl2 (10 mL) and the resulting solution was stirred at rt 
for 1 h. The volatiles were evaporated under reduced pressure and sat. NaHCO3(aq) (50 
mL) was added. The mixture was extracted into CH2Cl2 (3 x 50 mL) and the combined 
organics were dried (MgSO4), filtered and the solvent evaporated under reduced 
pressure to give the lactam 376 (1.20 g, 96%) as a yellow oil, 1H NMR (400 MHz, 
CDCl3) δ 6.31 (br s, 1H, NH), 5.81-5.71 (m, 1H, CH=CH2), 5.07-5.02 (m, 2H, 
CH=CH2), 3.23 (ddd, J = 6.0, 6.0, 2.5 Hz, 2H, NCH2), 2.46 (dddd, J = 13.5, 6.5, 1.0, 1.0 
Hz, 1H, CHAHBC=C), 2.16 (dd, J = 13.5, 8.0 Hz, 1H, CHAHBC=C), 1.78-1.65 (m, 5H, 
CHAHBCH3, 2 x CH2), 1.47 (dq, J = 14.0, 7.5 Hz, 1H, CHAHBCH3), 0.87 (t, J = 7.5 Hz, 
3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 176.9 (C=O), 134.6 (CH=CH2), 117.8 
(CH=CH2), 44.7 (NCH2), 42.7 (C), 42.6 (CH2C=C), 31.0 (CH2CH3), 28.5 (CH2) 19.6 
(CH2), 8.6 (CH3); HRMS (ESI) m/z calcd for C10H17NO (M + H)+ 168.1383, found 
168.1384 (−0.6 ppm error). Spectroscopic data consistent with those reported in the 
literature.215 
Lab Book Reference: SC7/36 
 
tert-Butyl 3-ethyl-2-oxopiperidine-1-carboxylate 378 
 
378 
n-BuLi (2.5 M in hexanes, 26.6 mL, 66.66 mmol) was added to a stirred solution of δ-
valerolactam 379 in THF (25 mL) at −78 °C under Ar. The resulting solution was stirred 
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at 0 °C for 30 min, then EtI (2.43 mL, 30.26 mmol) was slowly added and the resulting 
cloudy mixture was stirred for 20 min. Boc2O (6.60 g, 30.26 mmol) was added and the 
resulting mixture was stirred for 30 min at 0 °C before sat. NH4Cl(aq) (100 mL) was 
added and the reaction was allowed to warm to room temp. The reaction mixture was 
extracted with Et2O (3 x 100 mL) and the combined organics were dried (MgSO4), 
filtered and evaporated under reduced pressure to give the crude product. Purification by 
flash column chromatography on silica using hexane-EtOAc (95:5 then 90:10) as eluent 
gave the ethyl substituted lactam 378 (5.09 g, 74%) as a pale yellow oil, RF (9:1 hexane-
EtOAc) 0.20; IR (ATR) 1968, 2941, 2875, 1769 (C=O), 1713 (C=O), 1458, 1367, 1296, 
1252, 1151 cm−1; 1H NMR (400 MHz, CDCl3) δ 3.73 (ddd, J = 13.0, 7.5, 5.0 Hz, 1H, 
NCH), 3.62-3.55 (m, 1H, NCH), 2.35-2.27 (m, 1H, CH), 2.04-1.75 (m, 4H, 3 x CH, 
CHAHB), 1.52 (s, 9H, C(CH3)3), 1.52-1.46 (m, 2H, CHAHB, CH), 0.95 (t, J = 7.5 Hz, 3H, 
CH3); 13C NMR (100.6 MHz, CDCl3) δ 174.3 (C=O), 153.1 (C=O), 82.6 (C), 45.7 (CH), 
45.1 (NCH2), 28.0 (C(CH3)3), 25.4 (CH2), 24.0 (CH2), 21.7 (CH2), 11.5 (CH3); HRMS 
(ESI) m/z calcd for C12H21NO3 (M + Na)+ 250.1414, found 250.1419 (−2.1 ppm error). 
Lab Book Reference: SC7/63 
 
3-Ethylpiperidin-2-one 387 
 
387 
Lactam 378 (523 mg, 2.30 mmol) was added to a solution of trifluoroacetic acid (5 mL) 
and CH2Cl2 (5 mL) at rt and the resulting solution was stirred for 1 h. The volatiles were 
removed under reduced pressure and sat. K2CO3(aq) (20 mL) was added to the resulting 
residue. The mixture was extracted into Et2O (3 x 50 mL) and the combined organics 
were dried (MgSO4), filtered and evaporated under reduced pressure to give the 
deprotected lactam 387 (273 mg, 93%) as a pale yellow oil, 1H NMR (400 MHz, 
CDCl3) δ 7.16 (br s, 1H, NH), 3.27-3.16 (m, 2H, NCH2), 2.17-2.10 (m, 1H, CH), 1.92-
1.75 (m, 3H, CHAHB, CH2), 1.68-1.58 (m, 1H, CH), 1.52-1.41 (m, 2H, CHAHB, CH), 
0.88 (t, J = 7.5 Hz, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 175.4 (C=O), 42.1 
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(NCH2), 42.0 (CH), 25.2 (CH2), 24.2 (CH2), 21.1 (CH2), 11.2 (CH3); HRMS (ESI) m/z 
calcd for C7H14NO (M + H)+ 128.1070, found 128.1072 (−2.0 ppm error). Spectroscopic 
data consistent with those reported in the literature.216 
Lab Book Reference: SC5/74 
 
Ethyl 5-((tert-butoxycarbonyl)amino)pentanoate 382 
 
382 
n-BuLi (2.04 M in hexanes, 0.27 mL, 0.55 mmol) was added to a solution of 
diisopropylamine (0.077 mL, 0.55 mmol) in THF at −78 °C under Ar. The resulting 
solution was stirred for 1 h at 0 °C and then cooled to −78 °C and N-Boc piperidone 288 
(100 mg, 0.50 mmol) was added. The resulting solution was stirred at 0 °C for 30 min 
and ethyl formate (121 µL, 1.50 mmol) was added. The reaction was allowed to warm to 
room temperature and stirred for 20 h. AcOH (2 mL) was added and the reaction was 
poured into sat. NaHCO3(aq) (10 mL). The reaction mixture was extracted into EtOAc (3 
x 20 mL) and the combined organics were dried (MgSO4), filtered and the solvent 
evaporated under reduced pressure to give the crude product. Purification by column 
chromatography on silica using hexane-EtOAc (4:1) as eluent gave the unwanted side-
product 382 (16 mg, 13%) as a colourless oil, RF (4:1 hexane-EtOAc) 0.30; IR (ATR) 
3375 (NH), 2978, 2934, 1713 (C=O), 1694 (C=O), 1520, 1454, 1366, 1248, 2267, 1032 
cm-1; 1H NMR (400 MHz, CDCl3) δ 4.57 (br s, 1H, NH), 4.12 (q, J = 7.0 Hz, 2H, 
OCH2CH3), 3.12 (td, J = 6.5, 6.5 Hz, 2H, NCH2), 2.31 (t, J = 7.5 Hz, 2H, C(O)CH2), 
1.68-1.60 (m, 2H, CH2), 1.54-1.45 (m, 2H, CH2), 1.43 (s, 9H, C(CH3)3), 1.24 (t, J = 7.0 
Hz, 3H, OCH2CH3); 13C NMR (100.6 MHz, CDCl3) δ 173.5 (C=O), 155.9 (C=O), 79.1 
(C), 60.3 (OCH2CH3), 40.1 (NCH2), 33.8 (CH2), 29.5 (CH2), 28.4 (C(CH3)3), 22.1 
(CH2), 14.2 (OCH2CH3); HRMS (ESI) m/z calcd for C12H23NO4 (M + Na)+ 268.1519, 
found 268.1512 (+2.7 ppm error). 
Lab Book Reference: SC5/59 
N
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N-tert-Butoxycarbonyl(4-formylhexyl)-carbamic acid ethyl ester 385 and ethyl 5-
((tert-butoxycarbonyl)amino)-2-ethylpentanoate 386 
    
385     386 
LHMDS (1 M in THF, 1.14 mL, 1.14 mmol) was added to a stirred solution ethyl-
susbstituted lactam 378 (200 mg, 0.88 mmol) in THF (10 mL) at −78 °C under Ar. The 
resulting mixture was stirred at −78 °C for 90 min and then ethyl formate (78 µL, 0.97 
mmol) was added. The reaction mixture was stirred at −78 °C for 2 h and then allowed 
to warm to rt and stirred for 3 h. Sat. NH4Cl(aq)  (20 mL) was added and the reaction 
mixture was extracted into Et2O (3 x 20 mL) and the combined organics were dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica using hexane-EtOAc (95:5 then 
90:10 then 85:15) as eluent gave the unwanted byproducts 385 (104 mg, 39%) and 386 
(27 mg, 11%). 
 
Aldehyde 385, pale yellow oil; RF (9:1 hexane-EtOAc) 0.20; IR (ATR) 2965, 2937, 
1731 (C=O), 1705 (C=O), 1688 (C=O), 1459, 1396, 1340, 1140, 1029, 777 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 9.14 (s, 1H, CHO), 4.12 (q, J = 7.0 Hz, 2H, OCH2CH3), 3.55 
(t, J = 7.0 Hz, 2H, NCH2), 2.28-2.21 (m, 1H, CH), 1.65-1.36 (m, 8H, 4 x CH2), 1.52 (s, 
9H, C(CH3)3), 1.24 (t, J = 7.0 Hz, 3H, OCH2CH3), 0.86 (t, J = 7.0 Hz, 3H, CH3); 13C 
NMR (100.6 MHz, CDCl3) δ 175.8 (C=O), 163.0 (CHO), 152.5 (C=O), 83.9 (C(CH3)3), 
60.1 (OCH2CH3), 46.8 (CH), 40.3 (NCH2), 29.0 (CH2), 28.0 (C(CH3)3), 26.1 (CH2), 
25.3 (CH2), 14.3 (OCH2CH3), 11.6 (CH3); HRMS (ESI) m/z calcd for C15H27NO5 (M + 
Na)+ 324.1781, found 324.1769 (+3.9 ppm error). 
 
Ester 386, pale yellow oil; RF (9:1 hexane-EtOAc) 0.10; IR (ATR) 3376 (NH), 2967, 
2934, 2881, 1712 (C=O), 1694 (C=O), 1517, 1457, 1366, 1249, 1165, 1027, 778 cm-1; 
1H NMR (400 MHz, CDCl3) δ 4.53 (br s, 1H, NH), 4.13 (q, J = 7.0 Hz, 2H, OCH2CH3), 
3.12-3.07 (m, 2H, NCH2), 2.29-2.22 (m, 1H, CH), 1.67-1.36 (m, 8H, 4 x CH2), 1.42 (s, 
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9H, C(CH3)3), 1.25 (t, J = 7.0 Hz, 3H, OCH2CH3), 0.88 (t, J = 7.0 Hz, 3H, CH3); 13C 
NMR (100.6 MHz, CDCl3) δ 176.0 (C=O), 155.9 (C=O), 79.0 (C(CH3)3), 60.1 
(OCH2CH3), 46.9 (CH), 40.3 (NCH2), 29.0 (CH2), 28.4 (C(CH3)3), 27.9 (CH2), 25.5 
(CH2), 14.3 (OCH2CH3), 11.7 (CH3); HRMS (ESI) m/z calcd for C14H27NO4 (M + Na)+ 
296.1832, found 296.1830 (+0.8 ppm error). 
Lab Book Reference: SC5/66 
 
1-tert-Butyl 3-methyl 2-oxopiperidine-1,3-dicarboxylate 389 
 
389 
LHMDS (1 M in THF, 0.7 mL, 0.70 mmol) was added to a stirred solution of N-Boc 
piperidone 288 (108 mg, 0.54 mmol) in THF (5 mL) at −78 °C under Ar. The resulting 
mixture was stirred at −78 °C for 1 h and then methyl chloroformate (46 µL, 0.59 mmol) 
was added. The reaction mixture was stirred for 90 min and then sat. NH4Cl(aq)  (10 mL) 
was added. The reaction mixture was extracted into Et2O (3 x 10 mL) and the combined 
organics were dried (MgSO4), filtered and evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica using hexane-
EtOAc (4:1) as eluent gave the ester substituted lactam 389 (123 mg, 88%) as a pale 
yellow oil, RF (4:1 hexane-EtOAc) 0.30; 1H NMR (400 MHz, CDCl3) δ 3.76 (s, 3H, 
OCH3), 3.69-3.66 (m, 2H, NCH2), 3.52 (dd, J = 9.0, 7.0 Hz, 1H, CHC(O)), 2.22-2.04 
(m, 2H, CH), 2.01-1.92 (m, 1H, CH), 1.87-1.76 (m, 1H, CH), 1.52 (s, 9H, C(CH3)3); 13C 
NMR (100.6 MHz, CDCl3) δ 170.3 (C=O), 167.5 (C=O), 152.6 (C=O), 83.4 (C(CH3)3), 
52.6 (OCH3), 51.3 (CH), 45.8 (NCH2), 27.9 (C(CH3)3), 24.1 (CH2), 21.0 (CH2); HRMS 
(ESI) m/z calcd for C12H19NO5 (M + Na)+ 280.1155, found 280.1159 (−1.1 ppm error). 
Spectroscopic data consistent with those reported in the literature.217 
Lab Book Reference: SC5/64 
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1-tert-Butyl 3-methyl 3-ethyl-2-oxopiperidine-1,3-dicarboxylate 390 and tert-butyl 
5-ethyl-6-((methoxycarbonyl)oxy)-3,4-dihydropyridine-1(2H)-carboxylate 391 
     
390      391 
LHMDS (1 M in THF, 19.16 mL, 19.16 mmol) was slowly added to a stirred solution of 
lactam 378 (3.35 g, 14.8 mmol) in THF (30 mL) at −78 °C under Ar. The resulting 
solution was stirred at −78 °C for 30 min and then methyl cyanoformate (1.17 mL, 
14.74 mmol) was added. The resulting mixture was allowed to warm to rt and stirred for 
16 h. Sat. NaHCO3(aq) (200 mL) was added and the reaction was extracted into CH2Cl2 
(4 x 200 mL) and the combined organics were dried (MgSO4), filtered and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica using hexane-EtOAc (90:10) as eluent gave ester substituted 
lactam 390 (360 mg, 59%) as a colourless oil, RF (9:1 Hexane-EtOAc) 0.10; IR (ATR) 
2976, 2881, 1771 (C=O), 1718 (C=O), 1457, 1368, 1248, 1278, 1149 cm−1; 1H NMR 
(400 MHz, CDCl3) δ 3.72 (s, 3H, OCH3), 3.72-3.65 (m, 1H, NCH), 3.57-3.51 (m, 1H, 
NCH), 2.29 (dddd, J = 13.5, 6.0, 6.0, 0.5 Hz, 1H, CH), 1.98-1.92 (m, 2H, CH2), 1.90-
1.79 (m, 2H, CH), 1.76-1.69 (m, 1H, CH), 1.50 (s, 9H, C(CH3)3), 0.90 (t, J = 7.5 Hz, 
3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 172.6 (C=O), 170.5 (C=O), 152.9 (C=O), 
82.9 (C), 56.9 (C), 52.6 (OCH3), 45.5 (NCH2), 29.0 (CH2), 28.7 (CH2), 27.9 (C(CH3)3), 
20.0 (CH2), 8.9 (CH3); HRMS (ESI) m/z calcd for C14H23NO5 (M + Na)+ 308.1468, 
found 308.1460 (+2.7 ppm error). 
Lab Book Reference: SC7/14 
 
LHMDS (1 M in THF, 2.86 mL, 2.86mmol) was slowly added to a stirred solution of 
lactam 378 (500 mg, 2.20 mmol) in THF (20 mL) at −78 °C under Ar. The resulting 
solution was stirred at −78 °C for 90 min and then methyl chloroformate (187 µL, 2.42 
mmol) was added and the resulting mixture was stirred for 2 h. The reaction was 
allowed to warm to room temperature and sat. NH4Cl(aq) (30 mL) was added. The 
reaction was extracted into Et2O (3 x 50 mL) and the combined organics were dried 
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(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica using hexane-EtOAc (90:10) as 
eluent gave lactam 390 (112 mg, 17%) as a colourless oil and unwanted byproduct 391 
(355 mg, 56%) as a pale yellow oil, RF (9:1 Hexane-EtOAc) 0.20; IR (ATR) 2976, 
2941, 1768 (C=O), 1713 (C=O), 1442, 1368, 1256, 1235, 902 cm−1; 1H NMR (400 
MHz, CDCl3) δ 3.84 (s, 3H, OCH3), 3.58-3.56 (m, 2H, NCH2), 2.14 (dd, J = 7.0, 7.0 Hz, 
2H, CH2), 2.01 (q, J = 7.5 Hz, CH2CH3), 1.82 -1.76 (m, 2H, CH2), 1.45 (s, 9H, 
C(CH3)3), 0.99 (t, J = 7.5 Hz, 3H, CH2CH3); 13C NMR (100.6 MHz, CDCl3) δ 153.2 
(C=O), 152.9 (C=O), 135.3 (C), 115.0 (C), 81.2 (C(CH3)3), 55.1 (OCH3), 45.1 (NCH2), 
28.1 (C(CH3)3), 25.3 (CH2), 23.5 (CH2), 23.0 (CH2), 12.1 (CH3); HRMS (ESI) m/z calcd 
for C14H23NO5 (M + Na)+ 308.1468, found 308.1466 (+0.9 ppm error). 
Lab Book Reference: SC 5/65 
 
Methyl 3-ethyl-2-oxopiperidine-3-carboxylate 394 
 
394 
Lactam 390 (445 mg, 1.56 mmol) was added to a solution of trifluoroacetic acid (5 mL) 
and CH2Cl2 (5 mL) at rt and the resulting solution was stirred for 1 h. The volatiles were 
removed under reduced pressure and sat. NaHCO3(aq) (50 mL) was added to the resulting 
residue. The mixture was extracted into CH2Cl2 (3 x 50 mL) and the combined organics 
were dried (MgSO4), filtered and evaporated under reduced pressure to give the 
deprotected lactam 394 (279 mg, 96%) as a pale yellow solid, mp 58-60 °C, RF (EtOAc-
hexane 2:1) 0.20; 1H NMR (400 MHz, CDCl3) δ 6.63 (br s, 1H, NH), 3.72 (s, 3H, 
OCH3), 3.38-3.25 (m, 2H, CH), 2.19-2.13 (m, 1H, CH), 2.05-1.89 (m, 2H, CH2), 1.88-
1.75 (m, 3H, CH), 0.93 (3H, t, J = 7.5 Hz, CH3); 13C NMR (100.6 MHz, CDCl3) δ 173.5 
(C=O), 171.0 (C=O), 54.1 (C), 52.4 (OCH3), 42.3 (NCH2), 28.9 (CH2), 28.4 (CH2), 19.6 
(CH2), 8.9 (CH3); HRMS (ESI) m/z calcd for C9H15NO3 (M + H)+ 186.1125, found 
186.1122 (+1.6 ppm error). Spectroscopic data consistent with those reported in the 
literature.191 
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Lab Book Reference: SC6/20 
 
Methyl 3-ethyl-3,4,5,6-tetrahydropyridine-3-carboxylate 396 
 
    390        393   396 
NaBH4 (453 mg, 11.99 mmol) was added to a stirred solution of Boc-protected lactam 
390 (1.71 g, 5.99 mmol) in MeOH (20 mL) at 0 °C and the resulting reaction mixture 
was stirred for 18 h at rt. The volatiles were removed under reduced pressure and the 
residue was taken up in water (100 mL) and the resulting solution was extracted into 
CH2Cl2 (3 x 100 mL) and the combined organics were dried (MgSO4), filtered and 
evaporated under reduced pressure to give the crude hemiaminal 393 (1.54 g) as a pale 
yellow oil, 1H NMR (400 MHz, CDCl3) 1:2.3 ratio of diastereoisomers δ 6.00 (br s, 1H, 
CHOH), 5.74 (br s, 2.3H, CHOH), 3.85-3.81 (m, 3.3H, OH), 3.72 (s, 6.9H, CO2CH3), 
3.6 (s, 3H, CO2CH3), 3.09-3.01 (m, 3.3H, NCH), 2.07-1.99 (m, 3.3H, NCH), 1.70-1.49 
(m, 19.8H, 3 x CH2), 1.46 (s, 29.7H, C(CH3)3), 0.82 (t, J = 7.5 Hz, 3H, CH3), 0.77 (t, J = 
7.5 Hz, 6.9H, CH3). The crude hemiaminal 393 (1.54 g, 5.35 mmol) was taken up in a 
solution of TFA (7 mL) and CH2Cl2 (7 mL) and the resulting solution was stirred at rt 
for 1 h. The volatiles were evaporated under reduced pressure and sat. NaHCO3(aq) (100 
mL) was added to the residue. The mixture was extracted into CH2Cl2 (100 mL) and the 
two layers were separated. The aqueous layer was extracted into CH2Cl2 (2 x 100 mL) 
and the combined organics were dried (MgSO4) and evaporated under reduced pressure 
to give the crude product. Purification by flash column chromatography on silica using 
EtOAc as eluent gave the imine 396 (427 mg, 47%) as a colourless oil. 
Lab Book Reference: SC7/19 
 
The crude hemiaminal 393 (170 mg, 0.59 mmol) was taken up in a solution of TFA (5 
mL) and CH2Cl2 (5 mL) and the resulting solution was stirred at rt for 30 min. The 
volatiles were evaporated under reduced pressure and sat. NaHCO3(aq) (20 mL) was 
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added to the residue. The mixture was extracted into CH2Cl2 (3 x 20 mL) and the 
combined organics were dried (MgSO4), filtered and evaporated under reduced pressure 
to give the imine 396 (87 mg, 87%) as a colourless oil. 
Lab Book Reference: SC6/8 
 
Colourless oil; RF (EtOAc) 0.25; IR (ATR) 2936, 1858, 1729 (C=O), 1682, 1650 
(C=N), 1448, 1434, 1239, 1169, 1197, 1131, 1106 cm−1; 1H NMR (400 MHz, CDCl3) δ 
7.77 (br d, J = 1.0 Hz, 1H, N=CH), 3.72 (dd, J = 1.0, 1.0 Hz, 3H, CO2CH3), 3.71-3.63 
(m, 1H, NCH), 3.49-3.41 (m, 1H, NCH), 2.48-2.22 (m, 1H, CH), 1.91-1.81 (m, 1H, 
CH), 1.70-1.61 (m, 2H, 2 x CH), 1.60-1.50 (m, 1H, CH), 1.48-1.41 (m, 1H, CH), 0.89 
(tdd, J = 7.5, 1.0, 1.0 Hz, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 173.5 (C=O), 
162.6 (N=CH), 52.1 (OCH3), 49.5 (NCH2), 49.0 (C), 30.5 (CH2), 26.4 (CH2), 8.5 (CH3); 
HRMS (ESI) m/z calcd for C9H15NO2 (M + H)+ 170.1176, found 170.1172 (+2.3 ppm 
error). 
 
3-Ethyl-3-(hydroxymethyl)piperidin-2-one 395 
 
395 
LiBH4 (4 M in THF, 2.82 mL, 11.27 mmol) was added to a solution of lactam 394 (696 
mg, 3.76 mmol) in THF (20 mL) at 0 °C under Ar and the reaction mixture was stirred 
at rt for 2 h. The reaction was cooled to 0 °C and NH4Cl (100 mL) was carefully added. 
The reaction mixture was extracted into CH2Cl2 (3 x 10 mL) and the combined organics 
were dried (MgSO4), filtered and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica using EtOAc-MeOH 
(90:10) as eluent gave the alcohol 395 (170 mg, 28%) as an off-white solid. 
Lab Book Reference: SC6/28 
 
HN
O
OH
 253 
Lithium tri-tert-butoxyaluminiumhydride (150 mg, 0.59 mmol) was added to a stirred 
solution of lactam 394 (50 mg, 0.27 mmol) in THF (3 mL) at rt under Ar. The reaction 
was heated and stirred at 60 °C for 16 h. Another portion of lithium tri-tert-
butoxyaluminiumhydride (150 mg, 0.59 mmol) was added and the reaction was stirred 
at 60 °C for 72 h. The reaction was allowed to cool to rt and EtOAc (5 mL) was slowly 
added. Water (5 mL) was added and an excess of sat. Na2SO4(aq) was added and stirred 
for 30 min. The reaction mixture was filtered and the filtrate was evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica using EtOAc-MeOH (95:5) as eluent gave the alcohol 395 (19 
mg, 45%) as an off white solid.  
Lab Book Reference: SC7/34 
 
Off-white solid, mp 64-66 °C (lit.218 91-93 °C); 1H NMR (400 MHz, CDCl3) δ 6.60 (br 
s, 1H, NH), 3.93 (dd, J = 8.5, 2.0 Hz, 1H, OH), 3.55-3.47 (m, 2H, CH2OH), 3.26 (ddd, J 
= 7.0, 5.0, 2.0 Hz, 2H, NCH2), 1.87-1.67 (m, 5H, CH2CH3, CH), 1.47 (ddd, J = 13.0, 
10.0, 3.5 Hz, 1H, CH), 0.88 (t, J = 7.5 Hz, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 
178.5 (C=O), 67.3 (CH2OH), 45.1 (C), 42.2 (NCH2), 26.7 (CH2), 26.4 (CH2), 19.3 
(CH2), 7.8 (CH3); HRMS (ESI) m/z calcd for C8H15NO2 (M + H)+ 158.1176, found 
158.1174 (+0.7 ppm error). Spectroscopic data consistent with those reported in the 
literature.191 
 
3-Ethyl-2-oxopiperidine-3-carbaldehyde 388 
 
388 
Dess-Martin periodinane (890 mg, 2.10 mmol) was added to a stirred solution of alcohol 
395 (165 mg, 1.05 mmol) in CH2Cl2 (6 mL) at rt for 2.5 h. Sat. Na2SO4(aq) (20 mL) and 
sat. NaHCO3(aq) (20 mL) were added and the resulting mixture was stirred for 30 min at 
rt. The reaction mixture was extracted into CH2Cl2 (3 x 20 mL) and the combined 
organics were dried (MgSO4), filtered and evaporated under reduced pressure to give the 
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crude product. Purification by flash column chromatography on silica using EtOAc as 
eluent gave aldehyde 388 (97 mg, 60%) as an off-white solid 
Lab Book Reference: SC7/3  
 
LiAlH4 (516 mg, 13.61 mmol) was added to a stirred solution of lactam 394 (840 mg, 
4.54 mmol) in Et2O (50 mL) at −78 °C under Ar. The resulting mixture was stirred for 1 
h and EtOAc (10 mL) was added, followed by water (5 mL) and dried by adding an 
excess of MgSO4. The reaction mixture was filtered and the filtrate was evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica using EtOAc-MeOH (100:0 then 95:5) as eluent gave the 
aldehyde 388 (350 mg, 49%) as an off-white solid, together with alcohol 395 as an off-
white solid (230 mg, 32%) and an unseparated mixture of ester 394 (92 mg, 11%) and 
aldehyde 388 (28 mg, 4%). 
Lab Book Reference: SC7/56  
 
LiAlH4 (239 mg, 2.11 mmol) was added to a stirred solution of lactam 394 (390 mg, 
2.11 mmol) in Et2O (10 mL) at −40 °C under Ar. The resulting mixture was stirred for 1 
h and EtOAc (100 mL) was added, followed by water (10 mL). A saturated solution of 
Rochelle salt was added and the reaction mixture stirred for 18 h. The reaction mixture 
was extracted into EtOAc (3 x 100 mL) and the combined organics were dried (Na2SO4) 
and evaporated under reduced pressure to give the crude product containing a 1:6.5:6.5 
mixture of ester 394, aldehyde 388 and alcohol 395. The crude product was taken up in 
CH2Cl2 (9 mL) and Dess-Martin periodinane (594 mg, 2.80 mmol) was added at rt. The 
resulting mixture was stirred for 1 h and then sat. NaHCO3(aq) (50 mL) and Na2S2O3(aq) 
(50 mL) were added and the resulting mixture was stirred at rt for 30 min. The reaction 
mixture was extracted into CH2Cl2 (3 x 100 mL) and the combined organics were dried 
(MgSO4), filtered and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica using EtOAc-hexane (3:1) as 
eluent gave the aldehyde 388 (80 mg, 24 %) over two steps, as an off-white solid. 
Lab Book Reference: SC7/71 and SC7/72 
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Off-white solid, mp 59-61 °C (lit.218 63-65 °C); RF (EtOAc) 0.3; 1H NMR (400 MHz, 
CDCl3) δ 9.64 (d, J = 1.0 Hz, 1H, CHO), 7.08 (br s, 1H NH), 3.29-3.26 (m, 2H, NCH2), 
2.26 (ddd, J = 13.5, 6.0, 2.5 Hz, 1H, CH), 2.00 (dq, J = 14.0, 7.0 Hz, 1H, CHAHB), 1.83 
(dq, J = 14.0, 7.0 Hz, 1H, CHAHB), 1.73-1.55 (m, 3H, CH), 0.88 (t, J = 7.0 Hz, 3H, 
CH3); 13C NMR (100.6 MHz, CDCl3) δ 201.3 (C=O), 171.2 (C=O), 58.8 (C), 42.3 
(NCH2), 27.1 (CH2), 24.0 (CH2), 20.1 (CH2), 8.1 (CH3); HRMS (ESI) m/z calcd for 
C8H13NO2 (M + H)+ 178.0838, found 178.0839 (−0.1 ppm error). Spectroscopic data 
consistent with those reported in the literature.218 
 
3-Ethyl-3-vinylpiperidin-2-one 397 
 
397 
n-BuLi (2.5 M in hexanes, 0.34 mL, 0.84 mmol) was slowly added to a stirred solution 
of methyltriphenylphosphonium bromide (300 mg, 0.84 mmol) in THF (2 mL) at 0 °C 
and the resulting mixture was stirred for 20 min. A solution of aldehyde 388 (87 mg, 
0.56 mmol) in THF (1 mL) was added dropwise to the ylide mixture and stirred for 20 
min at 0 °C. The reaction mixture was allowed to warm to rt and stirred for 30 min at rt, 
then heated and stirred at reflux for 1 h. The reaction mixture was allowed to cool to rt 
and sat. NH4Cl(aq) (50 mL) was added. The mixture was extracted into CH2Cl2 (3 x 50 
mL) and the combined organics were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica using EtOAc as eluent gave an inseparable 1:1 mixture of 
alkene 397 (28 mg, 32% by 1H NMR spectroscopy) and triphenylphosphine oxide as an 
off-white solid, RF (EtOAc) 0.30; 1H NMR (400 MHz, CDCl3) δ 6.50 (br s, 1H NH), 
5.82 (dd, J = 17.5, 11.0 Hz, 1H, CH=CHAHB), 5.09 (dd, J = 11.0, 1.0 Hz, CH=CHAHB), 
5.05 (dd, J = 17.5, 1.0 Hz, CH=CHAHB), 3.22-3.19 (m, 2H, NCH2), 1.83-1.66 (m, 5H, 4 
x CH, CHAHB), 1.57 (dq, J = 14.0, 7.5 Hz, 1H, CHAHB), 0.81 (t, J = 7.5 Hz, 3H, CH3); 
13C NMR (100.6 MHz, CDCl3) δ 175.1 (C=O), 141.9 (CH=CH2), 114.1 (CH=CH2), 48.8 
(C), 42.6 (NCH2), 31.0 (CH2), 28.4 (CH2), 19.0 (CH2), 8.3 (CH3); HRMS (ESI) m/z 
HN
O
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calcd for C9H15NO (M + H)+ 176.1046, found 176.1048 (−1.3 ppm error). The mixture 
was taken on crude to the subsequent step. 
Lab Book Reference: SC7/7 
 
tert-Butyl 3-ethyl-2-oxo-3-vinylpiperidine-1-carboxylate 374 
 
374 
Boc2O (412 mg, 1.89 mmol), DMAP (23 mg, 0.19 mmol) and Et3N (263 µL, 1.89 
mmol) were added to a mixture of triphenylphosphine oxide 398 and lactam 397 (62 
mg, 0.40 mmol of lactam 397) in CH2Cl2 (8 mL) at rt. The reaction mixture was stirred 
at rt for 18 h and then the volatiles were removed under reduced pressure. Purification 
by flash column chromatography on silica using EtOAc-hexane (9:1 then EtOAc) as 
eluent gave the Boc-protected lactam 374 (89 mg, 89%) as a yellow oil, RF (9:1 hexane-
EtOAc) 0.3; IR (ATR) 2922, 2855, 1717 (C=O), 1590, 1397, 1271, 1102, 1012 cm−1; 1H 
NMR (400 MHz, CDCl3) δ 5.84 (dd, J = 17.5, 11.0 Hz, 1H, CH=CH2), 5.15 (d, J = 11.0 
Hz, 1H, CH=CHAHB), 5.07 (d, J = 17.5 Hz, 1H, CH=CHAHB), 3.67-3.61 (m, 1H, NCH), 
3.53-3.47 (m, 1H, NCH), 1.84-1.75 (m, 5H, CHAHB, 4 x CH), 1.64 (dq, J = 14.0, 7.5 Hz, 
1H, CHAHB), 1.48 (s, 9H, C(CH3)3), 0.83 (s, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 
174.8 (C=O), 153.7 (C=O), 141.6 (CH=CH2), 114.7 (CH=CH2), 82.4 (C(CH3)3), 51.6 
(C), 46.9 (NCH2), 31.6 (CH2), 29.2 (CH2), 27.9 (C(CH3)3), 19.5 (CH2), 8.3 (CH3); 
HRMS (ESI) m/z calcd for C14H23NO3 (M + Na)+ 276.1570, found 276.1562 (+2.9 ppm 
error). 
Lab Book Reference: SC7/62 
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5-Ethyl-5-vinyl-2,3,4,5-tetrahydropyridine 351 
 
374   399   351 
NaBH4 (39 mg, 1.04 mmol) was added to a stirred solution of Boc-protected lactam 374 
(66 mg, 0.26 mmol) in MeOH (3 mL) at 0 °C and the resulting reaction mixture was 
stirred for 18 h at rt. The volatiles were removed under reduced pressure and the residue 
was taken up in water (20 mL) and the resulting solution was extracted into CH2Cl2 (3 x 
20 mL) and the combined organics were dried (MgSO4), filtered and evaporated under 
reduced pressure to give the hemiaminal 399 with a 1:1 mixture of diastereoisomers (by 
1H NMR spectroscopy). Diagnostic signals for diastereoisomers: 1H NMR (400 MHz, 
CDCl3) 1:1 mixture of diastereoisomers δ 5.73 (dd, J = 17.5, 11.0 Hz, 1H, HC=CHAHB), 
5.51 (dd, J = 18.0, 11.5 Hz, 1H, HC=CHAHB), 5.24 (d, J = 11.0 Hz, 1H, HC=CHAHB), 
5.16 (d, J = 11.5 Hz, 1H, HC=CHAHB), 5.06 (d, J = 17.5 Hz, 1H, HC=CHAHB), 5.00 
(dd, J = 18.0, 1.0 Hz, 1H, HC=CHAHB), 0.82 (t, J = 7.5 Hz, 3H, CH3), 0.73 (t, J = 7.5 
Hz, 3H, CH3). The crude hemiaminal 399 was taken up in a solution of TFA (3 mL) and 
CH2Cl2 (3 mL) at rt and stirred for 1 h. The volatiles were removed under reduced 
pressure and sat. NaHCO3(aq) (20 mL) was added to the residue. The reaction mixture 
was extracted into CH2Cl2 (10 mL) and the two layers were separated. The aqueous 
layer was extracted into CH2Cl2 (2 x 10 mL) and the combined organics were dried 
(MgSO4) and evaporated under reduced pressure to give the imine 351 (30 mg, 80%) as 
a yellow oil; IR (ATR) 2961, 2925, 2864, 1779, 1731, 1668, 1448, 1199, 1173, 1136, 
933, 797, 721, 705 cm−1; 1H NMR (400 MHz, CDCl3) δ 8.55 (s, 1H, C=NH), 5.71 (dd, J 
= 18.0, 11.0 Hz, 1H, CH=CH2), 5.42 (d, J = 11.0 Hz, 1H, CH=CHAHB), 5.01 (d, J = 
18.0 Hz, 1H, CH=CHAHB), 3.85 (dddd, J = 17.0, 3.5, 3.5, 1.5 Hz, 1H, NCH), 3.65 
(dddd, J = 17.0, 9.5, 5.5, 2.5 Hz, 1H, NCH), 2.04-1.84 (m, 3H, CH), 1.80-1.70 (m, 3H, 
CH2CH3, CH), 1.00 (t, J = 7.5 Hz, 3H, CH3); 13C NMR (100.6 MHz, CDCl3) δ 180.7 
(C=N), 137.0 (CH=CH2), 119.4 (CH=CH2), 45.1 (NCH2), 44.9 (C), 30.6 (CH2), 26.6 
(CH2), 16.6 (CH2), 7.6 (CH3); HRMS (ESI) m/z calcd for C9H15N (M + H)+ 138.1277, 
found 138.1284 (−4.6 ppm error). 
Lab Book Reference: SC7/76 and 7/77 
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& Spirocycles
From Heteroaromatic Acids and Imines to Azaspirocycles:
Stereoselective Synthesis and 3D Shape Analysis
Sarah J. Chambers, Graeme Coulthard, William P. Unsworth, Peter O’Brien, and
Richard J. K. Taylor*[a]
Abstract: Heteroaromatic carboxylic acids have been di-
rectly coupled with imines using propylphosphonic anhy-
dride (T3P) and NEt(iPr)2 to form azaspirocycles via inter-
mediate N-acyliminium ions. Spirocyclic indolenines (3H-
indoles), azaindolenines, 2H-pyrroles and 3H-pyrroles were
all accessed using this metal-free approach. The reactions
typically proceed with high diastereoselectivity and 3D
shape analysis confirms that the products formed occupy
areas of chemical space that are under-represented in ex-
isting drugs and high throughput screening libraries.
In recent years, the biological evaluation of under-explored re-
gions of chemical space has attracted significant attention in
the search for new pharmaceutical lead compounds. In particu-
lar, rigid, three-dimensional scaffolds have been targeted, as
they are generally poorly represented in current drugs and
screening libraries.[1] With this in mind, functionalised spirocy-
cles are of much current interest and efficient methods to gen-
erate such compounds are of high value.[1,2]
In this paper, the formation and 3D shape analysis of spiro-
cyclic indolenines and related azaspirocycles are described. Spi-
rocyclic indolenines (also known as 3H-indoles)[3] are important
scaffolds in their own right, being present in a number of bio-
active natural products, and also since they serve as precursors
to other privileged heterocycles including b-carbolines,[4] ox-
indoles[5] and indolines.[6] The most common synthetic strat-
egies currently used to generate spirocyclic indolenines are
shown in Figure 1A. Interrupted Fisher-indole reactions (1!
4)[7] and intramolecular imine condensation routes (2!4)[8]
have each been well used over the years, whereas dearomatis-
ing spirocyclisation reactions (3!4)[9] are of particular current
interest[10] and underpin the approach described herein.
Our new, connective method is based on the coupling of ar-
omatic carboxylic acids 5 with imines 6 to form reactive N-acyl-
iminium ions 7[11, 12] in situ, that can then be intercepted by in-
tramolecular nucleophilic attack, exemplified in Figure 1B by
the formation of spirocyclic indolenines 8.[13] The high electro-
philicity of the N-acyliminium ion intermediate is a key design
feature, as it means sufficiently mild conditions can be used to
the allow the products to be isolated, without competing 1,2-
migration and dimerisation/trimerisation reactions taking
place.[3] Herein we report the successful implementation of this
strategy, which allows indoles and other simple, electron-rich
aromatics to be converted into complex azaspirocycles, in
a one-pot, metal-free, stereoselective process. Furthermore, 3D
shape analysis,[1b,14] using the principal moments of inertia (PMI)
method,[15] shows that most of the products formed occupy in-
teresting and under-exploited regions of “3D chemical space”.
To explore the viability of this new approach, the reaction
between 2-methyl-3-indole acetic acid 5a and imine 6a was
first examined (Scheme 1), by stirring these compounds in the
presence of NEt(iPr)2 and propylphosphonic anhydride (T3P) in
THF at RT. Pleasingly, this led to the formation of the expected
spirocycle as a mixture of diastereoisomers (8a :9a, 11:1),
through a process that is conceptually similar to an interrupted
Pictet–Spenger reaction.[16] The diastereomeric products were
partially separable by column chromatography, and isolated in
92% overall yield (Scheme 1). The stereochemistry of the
major diastereoisomer 8a was confirmed by X-ray crystallog-
raphy (Figure 2, see later).[17] Following a temperature and solv-
ent screen (see the Supporting Information), a range of other
2-methyl indole acetic acid derivatives (5b–5 f)[18] were also
coupled with imine 6a under the optimised conditions; substi-
Figure 1. Previous and new strategies for spirocyclic indolenine synthesis.
[a] S. J. Chambers, Dr. G. Coulthard, Dr. W. P. Unsworth, Prof. P. O’Brien,
Prof. R. J. K. Taylor
Department of Chemistry, University of York, York (UK)
E-mail : richard.taylor@york.ac.uk
Supporting information and ORCID from the author for this article are
available on the WWW under http://dx.doi.org/10.1002/chem.201600823.
⌫ 2016 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of the Creative Commons At-
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tution on all positions of the indole ring was examined and
the desired spirocyclic indolenines were formed in good to ex-
cellent overall yield (8/9b–f, 81–96%). The diastereoselectivity
was universally high (d.r. 6:1–13:1), with the same major dia-
stereoisomer being formed in all cases.[19]
Indole acetic acid itself (5g) was also compatible with the
standard procedure, furnishing spirocycles 8g/9g in good
yield (Scheme 2), demonstrating that substitution on the
indole 2-position is not a requirement, which is pleasing given
the propensity for related compounds to undergo 1,2-migra-
tion reactions.[20] Phenyl substitution at the 2-position (acid
5h) was also well-tolerated, with spirocycles 8h/9h being
formed in good yield, and interestingly the major product in
this case was 9h (confirmed by X-ray crystallography, Figure 2),
which shows opposite diastereoselectivity to the previous ex-
amples.[17] Finally, six-membered ring spirocyclic lactams 8 i/9 i
were formed in good overall yield, using higher homologue 5 i.
A plausible explanation for the observed diastereoselectivi-
ties is depicted in Figure 3, using the reaction of indole 5a and
imine 6a as an example. The reaction is thought to proceed
through activation of the carboxylic acid with T3P, followed by
N-acylation to generate a reactive N-acyliminium ion 7a. As-
suming that this is correct, the stereoselectivity is then deter-
mined by the facial selectivity of the nucleophilic attack onto
the N-acyliminium ion (7a!8a/9a). In A, the benzenoid rings
of the imine and indole components appear to be relatively
close together in space and look well-suited to experience
a stabilising p-stacking interaction, whereas in B, this interac-
tion is absent, and replaced by a potentially destabilising steric
clash between the imine and the indole 2-methyl group. These
transition-state models also offer a plausible explanation for
the switch in stereoselectivity in products 8h/9h ; in this case,
as the indole 2-position is substituted with a phenyl group
rather than a methyl, a stabilising p-stacking interaction now
appears to be viable in model B. The reactions are believed to
be under kinetic control, based on the fact that re-subjecting
a purified sample of spirocycle 8a to the optimised reaction
conditions led to no change in the d.r. , indicating that the spi-
rocyclisation is not reversible in this case.
The scope of the reaction with respect to the imine coupling
partner was examined next, with the imines used (6b–6g)[21]
shown in Figure 4 and spirocyclisation results in Scheme 3. Di-
methoxy-substituted imine 6b successfully gave the expected
products 8 j and 9 j in moderate diastereoselectivity. Tetra-sub-
stitution around the aromatic ring of the imine did not hinder
the reaction as 2,5-dibromo-3,4-dimethoxy-substituted sub-
strate 6c gave products 8k and 9k in good yield and diaste-
Scheme 1. Spirocyclisation with 2-methyl 3-indole acetic acid derivatives. For
full experimental details, see the Supporting Information; major diastereo-
isomer is shown, d.r. values based on 1H NMR analysis before chromatog-
raphy; yields obtained following column chromatography.
Figure 2. X-ray images for spirocycles 8a (left) and 9h (right).
Scheme 2. Additional acid substrates in the spirocyclisation with imine 6a ;
for full experimental details see the Supporting Information.
Figure 3. Stereochemical model for the spirocyclisation of indole acetic acid
derivatives with imine 6a.
Chem. Eur. J. 2016, 22, 6496 – 6500 www.chemeurj.org ⌫ 2016 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim6497
Communication
 260 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
reoselectivity. Thiophene- and pyrrole-fused imines 6d and 6e
were also suitable substrates, as was benzylated imine 6 f, all
forming the expected spirocycles 8 l/9 l–8n/9n with generally
good diastereoselectivity and in good yield. Acyclic imines,
which are often avoided in related methods based on N-acyl-
iminium ion chemistry due to their tendency to hydrolyse,[22]
are also well-tolerated, with spirocyclic products 8o/9o and
8p/9p each isolated in good overall yields. The major diaste-
reoisomer formed in each case was assigned based on 1H NMR
spectroscopy,[19] and in the case of spirocycles 8n and 8o, con-
firmed by X-ray crystallography (Scheme 3).[17]
Preliminary work also confirms that this method can be ex-
tended to other heterocyclic systems. Aza-indoles are impor-
tant structures in medicinal chemistry[23] and pleasingly we
found that aza-indoleacetic acid 10[18b] reacted with imine 6a
under the usual conditions to give the spirocyclic product 11
in excellent yield as a single diastereoisomer (Scheme 4), with
the stereoselectivity seemingly being consistent with the anal-
ogous indole examples. Dearomatising via the 2-position of
pyrroles 12 and 13[24] is also possible;[25] on these systems, only
a small amount of the desired product was formed when the
standard conditions were used, but by switching the reaction
solvent to CHCl3 and increasing the temperature to 70 8C, spi-
rocycles 14 and 15 were each formed in good yield, with good
to excellent diastereoselectivity. In the phenyl-substituted case,
the major diastereoisomer 15 was separable by chromatog-
raphy and X-ray crystallography was used to assign the
configuration depicted.[17,26] Finally, this same modified set of
conditions was used to form spirocycle 17 through the reac-
tion of pyrrole 16 with imine 6a ; this example is noteworthy,
given that 3H-pyrroles are known to be unstable and their syn-
thesis is a considerable challenge using existing methods.[27]
The dearomatisation reactions described allow access to a di-
verse array of spirocyclic scaffolds, and the products formed
are well primed to undergo further transformations, allowing
additional structural diversity to be introduced or the proper-
ties of the compounds to be tuned. This is exemplified using
spirocycles 8a and 8g (Scheme 5), and it is likely that similar
processes (and many more) will be broadly applicable across
the other spirocyclic products described in this paper. For ex-
ample, indolenines 8a and 8g were both reduced to indolines
18 and 19 respectively by sodium borohydride in refluxing
methanol. In the case of product 18, the reduction was com-
pletely diastereoselective, with the hydride source approaching
Figure 4. Imines 6b–6g.
Scheme 3. Spirocyclisation with imines 6b–g. For full experimental details,
see the Supporting Information; major diastereoisomer shown, d.r. values
based on 1H NMR analysis before chromatography; yields obtained following
column chromatography. [a] Reaction performed at 90 8C in toluene for
18 h; [b] reaction performed at 70 8C in THF for 1 h.
Scheme 4. Other heterocycles in the spirocyclisation; for full experimental
details see the Supporting Information.
Scheme 5. Modification of spirocycles 8a and 8g.
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the indolenine from the less sterically hindered side (i.e. , away
from the two benzenoid rings, verified by X-ray crystallog-
raphy).[17] Indolenines 18 and 19 could also be reduced further,
forming products 20 and 21, upon reaction with lithium alu-
minium hydride in refluxing THF. Products with complementary
relative stereochemistry to indoline 18 could also be obtained
through the addition of carbon-based nucleophiles; products
22 and 23 were formed, again with complete diastereoselectiv-
ity, through the addition of pyrrole and methyl magnesium
bromide respectively to indolenine 8g.[28]
Finally, the principal moments of inertia (PMI) method[1b,14]
was used in order to characterise the 3D shape of the azaspiro-
cycles produced.[29] The PMI method utilises the molecular me-
chanics-generated lowest-energy conformation and the nor-
malized principal moments of inertia ratios, NPR1 and NPR2,
are displayed on a triangular plot, with the three vertices corre-
sponding to rod-, disc- and spherical-shaped molecules. A PMI
plot containing the major diastereoisomeric forms of all of the
azaspirocyclic products synthesised during the course of our
study is shown in Figure 5. As this plot highlights, 88% (22 out
of 25, compounds 8a–g, 8 i–p, 9h, 14, 15, 17–21, 23) of the
new azaspirocycles occupy the highlighted ‘3D region’ (blue
triangle) and have values of (NPR1+NPR2)>1.2. These 3D
shape properties are in stark contrast to the majority of current
drugs, most of which lie close to the rod-disc axis. For exam-
ple, PMI analysis of 1439 FDA-approved small molecule
drugs[30] shows that just 23% are found within the (NPR1+
NPR2)>1.2 area (see the Supporting Information), and most
drug-screening libraries have a similar shape distribution.[31]
Hence, these results are significant, in view of the current inter-
est in the synthesis of compounds that populate under-ex-
plored regions of chemical space, especially spherical areas
(e.g. , azaspirocycles 8b, 8c, 8e, 8n, 8p, 9h, 11), in pharma-
ceutical lead-identification programs.
In conclusion, a new, metal-free, connective method for the
synthesis of a range of 3D spirocyclic scaffolds has been re-
ported, starting from far simpler 2D building blocks. The reac-
tions proceeded in moderate to excellent yields and are diaste-
reoselective, with the major diastereoisomers isolable in good
overall yield in the majority of cases. This study focused pre-
dominantly on the synthesis of spirocyclic indolenines, but the
successful results obtained using azaindoleacetic acid, as well
as 2- and 3-substituted pyrrole acetic acids, indicate that the
process is much more general. 3D shape analysis indicates that
a high percentage of the compounds generated in this study
occupy underexplored regions of chemical space, and the abili-
ty to modify the scaffolds further has also been demonstrated,
meaning that their desirable spatial and physicochemical prop-
erties can be further tuned. Future applications in the genera-
tion of medicinally relevant scaffolds/lead compounds and nat-
ural products are anticipated, and the development of asym-
metric variants of these reactions will also be explored.[32]
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Figure 5. PMI analysis of spirocycles 8a–g, 8 i–p, 9h, 14, 15, 17–21 and 23.
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Abbreviations 
Ac  Acetyl 
Ar  Argon 
Ar (in NMR) Aromatic proton signal 
aq.   Aqueous 
Boc  t-butoxycarbonyl 
br  Broad 
Bu  Butyl 
CHARMm Chemistry at Harvard macromolecular mechanics 
COSY  Correlation spectroscopy 
cm−1  Wavenumber 
δ  Chemical shift 
d  Doublet  
DABCO 1,4-diazabicyclo[2.2.2]octane 
DEPT  Distortionless enhancement by polarisation transfer 
DBU  1,8-Diazabicycloundec-7-ene 
DIA  Direct Imine Acylation 
DIBAL-H Diisobutylaluminium hydride 
DIPEA N,N-Diisopropylethylamine 
DMP  Dess-Martin periodinane 
dr  Diastereomeric ratio 
ee  Enantiomeric excess 
eq.  Equivalents 
ESI  Electrospray ionisation 
Et  Ethyl 
Et2O  Diethyl ether 
g  Gram(s) 
h  Hour(s) 
[H]  Reduction 
HMBC Heteronuclear multiple bond correlation 
HRMS  High resolution mass spectrometry 
HSQC  Heteronuclear single quantum coherence 
Hz  Hertz 
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IR  Infra-red 
J  Coupling constant in Hz 
LDA  Lithium diisopropylamide 
LHMDS Lithium bis(trimethylsilyl)amide 
lit.   Literature 
µL  Microlitres 
m  Multiplet 
M  Molar 
M+  Molecular ion 
Me  Methyl 
mg  Milligram(s) 
MHz  Megahertz 
min  Minutes(s) 
mL  Millilitre(s) 
mmol  Millimole(s) 
mp  Melting point 
Ms  Methanesulfonyl 
MS  Molecular sieves (4Å) 
MW  Microwave irradiation 
m/z  Mass to charge ratio 
nAChRs Nicotinic acetylcholine receptors 
NBS  N-Bromosuccinimide 
NMR  Nuclear Magnetic Resonance 
Petrol  Petroleum ether (fraction which boils at 40-60 °C) 
Ph  Phenyl 
PMI  Principle moment of inertia 
ppm  Parts per million 
q  Quartet  
RF  Retention factor 
RMSD  Root mean square deviation 
rt  Room temperature 
s  Singlet 
sat.   Saturated 
SMILES simplified molecular input line entry specification 
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t  Triplet 
T3P  Propylphosphonic anhydride 
TBAF  Tetrabutylammonium fluoride 
TBME  tert-Butyl methyl ether 
TBDMS tert-Butyldimethylsilyl 
Tf  Trifluoromethanesulfonyl 
TFA  Trifluoroacetic acid 
THF  Tetrahydrofuran 
TMEDA N,N, N’,N’-tetramethylethylenediamine 
Ts  p-Toluenesulfonyl 
PPA  Polyphosphoric acid 
Py  Pyridine 
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